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Summary 
 
Heart failure (HF) is a major health concern internationally and associated with considerable 
mortality and morbidity. Patients with HF are at risk of sudden cardiac death (SCD). Most 
SCD is caused by ventricular tachyarrhythmic events (VTE) that can be treated with an 
implantable cardioverter-defibrillator (ICD). Identifying patients at risk of VTE remains a 
clinical challenge.   
 
Microvolt T-wave alternans (MTWA) examines beat-to-beat fluctuations in the morphology of 
the electrocardiographic T-wave. The presence of significant alternans is thought to reflect 
dynamic instability of repolarisation and be mechanistically linked to VTE.  MTWA testing 
can be performed clinically using a commercially available system. Patients must be in sinus 
rhythm and the heart rate is increased up to a maximum of 110 beats per minute by using sub 
maximal treadmill exercise. Observational studies in highly selected populations have 
suggested that MTWA testing may be used as a non-invasive tool for identifying patients at 
risk of VTE who, by implication, may benefit from primary prevention ICD therapy. However, 
to date, no study has investigated the use of MTWA testing in a real-life population of patients 
with HF.  
 
The main aims of this study were to evaluate the applicability of MTWA testing in an 
unselected cohort of patients recently hospitalised with decompensated HF and determine the 
prevalence and incremental prognostic value of this test.   
 
Of 2361 patients with suspected decompensated HF screened for inclusion in the study, 1003 
were recruited. Of those recruited, 648 patients attended the study visit for MTWA testing one 
month following hospital discharge. The most common reason for failing to attend the study 
visit was refusal to participate; other reasons were deteriorating health and death before the 
study visit appointment.  
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The mean age of those returning for MTWA testing was 71 years (SD 11) and 58% were male. 
Of 648 patients who completed the study visit, 330 (51%) were eligible for MTWA testing. 
Almost half were ineligible for MTWA testing due to atrial fibrillation (AF), pacemaker-
dependency or physical inability to undertake the treadmill test. AF accounted for three-
quarters of those who were ineligible in this study, i.e. 38% of all patients. Although only a 
small proportion of patients (7%) overall were ineligible because of physical inability to 
attempt the sub-maximal treadmill test, this is an underestimate of this problem as many 
patients simply did not attend for the test because of poor health. 
 
Many of the characteristics of the ineligible patients in this study suggested they had a poor 
prognosis, including the highest log (BNP) concentration. BNP is also an independent 
predictor of sudden cardiac death, suggesting that the patients at the highest arrhythmic risk 
may in fact not be eligible for MTWA testing. These findings suggest the utility of the MTWA 
test as a means of detecting those at highest risk of sudden death is likely to be limited as 
many such patients are ineligible for the test. Patients ineligible for MTWA testing were older 
than patients eligible for testing and a higher proportion had a history of pre-admission heart 
failure. Ineligible patients also had more evidence of persisting or advanced heart failure, with 
a higher proportion having NYHA functional class III or IV symptoms and a greater frequency 
of peripheral oedema. Those ineligible for MTWA testing also had a greater prevalence of 
renal dysfunction, liver enzyme abnormalities, hyperuricaemia and lymphopenia.  
 
The clinical data collected at the study visit was analysed according to whether patients had 
HF with preserved ejection fraction (HF-PEF) or reduced ejection fraction (HF-REF). The 
majority of clinical characteristics were similar between the two groups although there were 
some notable differences. Patients with HF-PEF were older, more likely to be female, more 
likely to have hypertension and less likely to have had a myocardial infarction (MI), in 
comparison to those with HF-REF. These findings are consistent with previous studies of HF-
PEF. Prescribing of HF pharmacological therapies was greater amongst patients with HF-REF. 
Patients with HF-REF had median BNP concentrations almost twice that of those with HF-
PEF, both on admission to hospital and at the study visit.  
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Of 330 patients who underwent MTWA treadmill testing, 100 (30%) were positive, 78 (24%) 
were negative and 152 (46%) were indeterminate (unable to be classified as positive or 
negative). The majority of indeterminate tests (75%) occurred because of failure to achieve the 
target heart rate due to chronotropic incompetence, secondary to beta-blocker therapy, or 
physical limitations. There were more abnormal clinical characteristics associated with an 
indeterminate result, than a positive or negative result. Patients with an indeterminate result 
were older and more likely to have a history of HF, diabetes, AF, anaemia and renal 
dysfunction, as well as a higher log (BNP). Patients with positive and indeterminate MTWA 
tests were quite different, in terms of clinical characteristics, questioning the contemporary 
way of classifying these results as ‘non-negative’.  
 
The mean follow-up was 18 months (SD 8.1) and 131 deaths occurred during this period. 
There were proportionately more deaths amongst the patients ineligible for MTWA testing 
than those eligible. There was no significant difference in mortality rates between patients 
with HF-PEF and HF-REF. There was no significant difference in crude all-cause mortality 
rates between the three MTWA groups. Unexpectedly, patients with negative and 
indeterminate results had proportionately similar mortality rates whilst those with positive 
results had proportionately fewest events overall. MTWA was analysed in the accepted way of 
‘non-negative’ (positive and indeterminate) and negative, but this did not alter the results. 
Indeed, the very different mortality for those patients with positive and indeterminate results 
challenges the use of this ‘non-negative’ classification.  
 
MTWA had no incremental prognostic value when added to a multivariable model containing 
the strongest predictors of mortality in this study. The independent predictors of all-cause 
mortality following stepwise multivariable modelling were; lower body mass index, New 
York Heart Association class III-IV, previous myocardial infarction, elevated BNP 
concentration and elevated troponin levels.  
 
In summary, MTWA treadmill-testing was not widely applicable in typical patients with HF 
and failed to predict mortality risk. At present MTWA cannot be endorsed as a tool for 
improving risk stratification in HF.   
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1.1 Epidemiology and pathophysiology of heart failure 
 
1.1.1 Definition of heart failure 
 
Heart failure (HF) is the clinical syndrome that occurs when the ventricle fails to properly fill 
with or eject blood. It commonly presents with symptoms of breathlessness and fatigue and 
clinical signs of fluid retention. Depending on the timing of symptoms and signs, HF may 
present in one of three ways; acute ‘de novo’ HF, chronic HF or acute decompensation of 
chronic HF. Acute ‘de novo’ HF may present as acute pulmonary oedema or cardiogenic 
shock, often in the context of an acute coronary syndrome. 
 
1.1.2 Global burden of heart failure 
 
HF is a significant public health problem internationally. In Europe the overall prevalence is 
2-3% (1). The prevalence of HF correlates with age and increases exponentially, rising to 10-
20% for septuagenarians. Younger patients with HF are more likely to be men with reduced 
systolic function secondary to myocardial infarction, predominantly because coronary heart 
disease occurs earlier in men. On the other hand, elderly patients with HF are more likely to be 
women with HF with preserved systolic function, secondary to established hypertension (2). 
Overall the prevalence of HF is rising, particularly in developed countries as life expectancy 
improves. Thus the burden this health problem has on society is increasing. The incidence of 
HF is also age-related. In the United Kingdom (UK), a population-based study found that the 
majority of new diagnoses of HF occur in the elderly with an incidence rate of 0.2 cases per 
1000 population per year for 45-55 year olds, rising to 11.6 in those 85 years and over (3). In 
this study the incidence was greater in males and the median age at presentation was 76 years. 
 
The financial burden of HF is huge and growing. The cause of this is multifactorial and 
includes the increasing prevalence of HF, an ageing population, a rising rate of hospital 
admissions for HF and the availability of expensive therapies that are revolutionising 
treatment of this condition. The implications for healthcare systems are substantial. Between 
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1-2% of the National Health Service (NHS) budget is spent on HF (4), whilst in the United 
States a recent estimate for annual expenditure for HF was 27.9 billion dollars (5). In the UK, 
HF accounts for around 5% of all hospital admissions (3) and readmission rates are high, 
almost one-third of patients hospitalised with HF may be readmitted within one year of 
discharge (6). Unsurprisingly, hospitalisation costs account for the majority of the budget 
spent on HF. 
 
1.1.3 Aetiology of heart failure 
 
HF may result from a broad spectrum of structural or functional cardiac and non-cardiac 
disorders and is often the end-stage of many forms of cardiovascular disease. The common 
causes of HF and their clinical presentations are outlined in Table 1-1. Causes of HF can be 
categorised into disorders of the pericardium, myocardium, endocardium or great vessels. 
Myocardial disorders are the most common causes of HF and are often classified according to 
ejection fraction (EF), namely HF with reduced ejection fraction (HF-REF) or HF with 
preserved ejection fraction (HF-PEF). HF-PEF is discussed in more detail below (section 
1.1.5). HF-REF is also commonly classed as ischaemic or non-ischaemic HF. Common causes 
of non-ischaemic HF-REF include hypertension, valvular heart disease, arrhythmias, alcohol 
and dilated cardiomyopathy. The cardiomyopathies are a collection of myocardial diseases 
that are often, but not exclusively, familial in which the diagnosis can only be made after the 
exclusion of other causes of heart failure. The different types of cardiomyopathy are 
hypertrophic, dilated, restrictive, arrhythmogenic right ventricular and unclassified (7). 
Hypertension is also a common cause of HF-PEF. Other causes of HF-PEF include 
hypertrophic, restrictive and infiltrative cardiomyopathies. HF-PEF often occurs in association 
with atrial fibrillation (AF). Other causes of HF are presented in Table 1-2.   
 
Aetiology and risk factors for HF exhibit geographical variation. Coronary heart disease is 
undoubtedly the most common cause of HF in developed countries, accounting for 
approximately 70% of cases (8). Hypertension is the next commonest cause in Western 
countries, followed by valvular heart disease (particularly degenerative) and cardiomyopathies. 
Arrhythmias and alcohol are also frequent precursors of HF in developed countries. In 
 34 
Africans and African Americans, hypertension is a common cause of HF (9), whilst in South 
America Chagas disease is often implicated (10). In developing countries, rheumatic valvular 
heart disease and nutritional deficiencies are more common causes of HF (11). 
 
Coronary heart disease has not always been the commonest cause of HF in Western societies. 
Hypertension was the most common cause in the original Framingham study (12). However 
the proportion of cases of HF caused by hypertension has decreased over the follow-up period, 
whilst those attributed to coronary heart disease have risen. The reasons for the changing 
aetiology of HF are likely multifactorial and include improvements in survival after a 
myocardial infarction (13) as well as increasing accessibility to techniques for diagnosing 
coronary heart disease. Hypertension may be responsible for fewer cases of HF owing to 
pharmacological advances in antihypertensive therapy preventing the longer term 
complications such as HF (14). 
 
Table 1-1: Common causes of heart failure and their common modes of presentation 
 
Cause Examples of presentations 
Coronary heart disease Myocardial infarction 
Chronic ischaemia 
Arrhythmias 
Hypertension Heart failure with preserved systolic function 
‘Burnt out’ hypertensive cardiomyopathy 
Malignant hypertension with acute pulmonary oedema 
Valvular heart disease Degenerative 
Rheumatic fever 
Endocarditis 
Congenital valve disease  
Arrhythmias Atrial fibrillation 
Cardiomyopathies Idiopathic 
Alcohol 
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Table 1-2: Other causes of heart failure and their modes of presentation 
 
Cause Examples of presentations 
Cardiomyopathies Familial 
Peripartum 
Toxins (cocaine, iron, copper) 
Congenital heart disease Corrected transposition of great arteries 
Repaired tetralogy of Fallot 
Ebstein’s anomaly 
Infective Viral myocarditis 
Chagas disease 
Human immunodeficiency virus 
Lyme disease 
Iatrogenic Anthracyclines 
Abstruzimab 
Steroids 
Infiltrative Amyloid 
Sarcoid 
Neoplastic 
Storage disorders Haemachromatosis 
Fabry disease 
Glycogen storage diseases 
Endomyocardial disease Radiotherapy 
Endomyocardial fibrosis 
Carcinoid 
Pericardial disease Calcification 
Infiltrative 
Metabolic Endocrine (e.g. acromegaly, thyroid disease) 
Nutritional (e.g. deficiency of thiamine, selenium) 
Autoimmune (e.g. scleroderma) 
Neuromuscular disease Friedreich’s ataxia 
Muscular dystrophy 
High-output Anaemia 
Thyrotoxicosis 
Arteriovenous fistulae 
Paget’s disease 
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1.1.4 Diagnosis of heart failure 
 
The Heart Failure Association of the European Society of Cardiology (ESC) specify that three 
diagnostic criteria must be met in order to make the diagnosis of HF (1). Firstly, the patient 
must experience symptoms characteristic of this condition. These include breathlessness, 
fatigue and ankle swelling. Secondly the patient should have clinical signs indicative of HF, 
including amongst others; tachypnoea, tachycardia, raised jugular venous pressure, pulmonary 
crepitations, pleural effusions and peripheral oedema. Finally, there must be objective 
evidence of structural or functional cardiac disease. This may be verified by evidence of 
cardiomegaly, a third heart sound, echocardiographic abnormalities or a raised natriuretic 
peptide level.  
 
1.1.5 Heart failure with preserved ejection fraction 
 
Myocardial disorders account for the vast majority of cases of HF, caused by either systolic or 
diastolic dysfunction. Systolic dysfunction leads to a low left ventricular ejection fraction 
(LVEF). Diastolic dysfunction impairs left ventricular (LV) distensibility, filling and 
relaxation, irrespective of LVEF. Yet, patients with HF are often subdivided according to their 
EF; HF-REF or HF-PEF. One possible explanation for this is because of the difficulties 
measuring diastolic dysfunction. HF-PEF diagnosed solely by LVEF may encompass patients 
without diastolic dysfunction. Indeed, the major clinical trials of pharmacological therapy in 
HF-PEF enrolled patients solely on the basis of an echocardiographically assessed LVEF (15-
17). HF-REF may also include patients with diastolic dysfunction. Unlike HF-REF, HF-PEF 
remains a diagnosis of exclusion. Non-cardiac causes of signs and symptoms of HF must be 
excluded before HF-PEF can be accurately diagnosed.  
 
The LVEF cut-off criterion for HF-PEF varies in different guidelines and studies. A recent 
ESC consensus statement includes more than just LVEF in the diagnostic criteria of HF-PEF 
(18). In addition to the presence of signs or symptoms of HF and normal or mild LVSD, these 
guidelines recommend that there should be evidence of diastolic dysfunction, obtained 
invasively or non-invasively. Normal or mild LVSD is defined as LVEF > 50% (18). 
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HF-PEF and HF-REF may be considered as two ends of a spectrum. Both lead to reductions in 
exercise tolerance and activation of neurohormonal systems with different myocardial 
remodelling processes.  HF-PEF is recognised as a precursor to HF-REF in several causes of 
HF, for example hypertension and the cardiomyopathies. Epidemiological studies have 
revealed that as many as 50% of HF patients with acute decompensation have HF-PEF (19-23). 
HF-PEF is the principal cause of HF in the elderly and in women (23;24). Although previously 
considered to have a more favourable prognosis than HF-REF, HF-PEF is now considered to 
be associated with significant mortality risk. The mortality rates of HF-PEF vary between 
clinical studies. This variation may be explained by the heterogeneity of the populations 
studied and the diagnostic criteria used for HF-PEF. Recent large population studies have 
reported one year mortality rates of 22% and 29% in patients with HF-PEF (19;23), 
comparable to one year mortality rates of 21% observed in a recent local study (25). Yet, 
despite the poor prognosis associated with this condition, treatment of HF-PEF remains 
challenging and largely symptomatic based. This is in stark contrast to HF-REF, for which a 
large evidence-base exists. 
 
1.1.6 Treatment of heart failure 
 
The treatment of HF-REF consists of pharmacological, device and surgical therapy. Advances 
in pharmacological therapy over the last three decades have significantly improved the 
prognosis for many patients with HF-REF. The first step of managing HF-REF should involve 
initiating diuretic therapy and an angiotensin-converting enzyme (ACE) inhibitor. There is a 
large evidence-base for the use of ACE inhibitors in HF-REF for improving both mortality and 
morbidity (26;27). For patients hospitalised with decompensated HF, an ACE inhibitor should 
be initiated prior to discharge from hospital. Patients intolerant of ACE inhibitors may be 
prescribed an angiotensin-receptor blocker (ARB) (28). All patients with HF-REF should also 
be treated with a beta-blocker, unless contraindicated. There is significant evidence of 
improved mortality and morbidity with the use of beta-blockers in addition to ACE inhibitor 
therapy (29-31). Patients hospitalised with decompensated HF may be commenced on beta-
blocker therapy prior to discharge, once they are stable and euvolaemic (31). Following ACE 
inhibitor and beta-blocker therapy, patients with HF-REF and persistent symptoms should be 
started on an aldosterone antagonist (32;33). 
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The introduction of device therapy, in the form of the implantable cardioverter defibrillator 
(ICD) and, more recently, cardiac synchronisation therapy (CRT), has revolutionised the 
treatment of HF-REF. ICDs have been demonstrated to reduce the risk of sudden cardiac death 
in patients with HF-REF. The majority of evidence for this comes from trials involving 
patients with coronary heart disease (34-36) although there is evidence of survival benefit in 
patients with non-ischaemic HF-REF (37). CRT with pacemaker function (CRT-P) should be 
considered for patients with moderate-severe HF (New York Heart Association [NYHA] III-
IV) with left ventricular ejection fraction (LVEF) ≤ 35% and QRS duration ≥ 120ms that 
remain symptomatic despite optimal medical therapy (38). Patients who fulfil criteria for 
CRT-P and who have a life expectancy exceeding 1 year should be considered for CRT-D (39). 
Patients with mild HF (NYHA I-II, LVEF ≤ 30% and QRS duration ≥ 130ms) (40) and those 
with mild-moderate HF (NYHA II-III, LVEF ≤ 30% and QRS duration ≥ 120ms) (41) should 
also now be considered for CRT-D. 
 
Surgical treatment for advanced HF-REF is available in the form of cardiac transplantation, 
ventricular assist devices and artificial hearts. These are therapies of limited resource, for 
financial and availability reasons, and therefore must be targeted to those at highest risk of 
dying and greatest potential for benefit. Patients with HF, LVEF ≤ 35% and coronary artery 
disease amenable to coronary artery bypass grafting (CABG) may be considered for CABG, 
although a recent trial showed no difference in all-cause mortality compared with medical 
therapy alone (42). 
 
The evidence-base for the treatment of HF-PEF is less clear. Diuretics are used for 
symptomatic control and fluid balance. There is evidence that ARBs reduce hospital 
admissions in patients with HF and preserved systolic function (15). However there is no 
evidence of mortality benefit with modulation of the renin angiotensin system (15-17). Results 
are awaited for the effect of aldosterone antagonist therapy in HF-PEF (43). 
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1.1.7 Prognosis in heart failure 
 
Although advances in the modalities of treatment have greatly improved the prognosis for 
patients with HF, the outlook for many remains poor. The mortality rate is high and 
comparable with rates seen in many common cancers (44). Around 50% of patients with heart 
failure will be dead at 4 years (1). The morbidity and mortality associated with hospitalisation 
for HF is dire; 40% of patients will be readmitted or dead within 1 year (1). The mortality rate 
for new cases of HF admitted to hospital is highest within the first few weeks with a 30 day 
mortality rate approximately 10-20% (2). 
 
1.2 Prognostication in heart failure 
 
1.2.1 Importance of assessing prognosis 
 
Determining whether a patient with HF is at high risk of mortality is important for several 
reasons.  Optimal tolerated doses of evidence-based medical therapies are indicated regardless 
of risk status. However, other therapies for which there are limited resources, such as ICDs, 
CRT and cardiac transplantation should be targeted to those at highest risk of dying and 
greatest chance of benefit.  Those at particularly high risk of dying can be considered for 
appropriate end-of life care.  Benefits can also come from identifying those at low risk of 
dying.  Patients at lower risk could be reassured that invasive therapies (e.g. ICDs or 
transplantation) are unlikely to be in their interests.   
 
Accurate assessments of prognosis can also confer economic benefits. This is particularly 
important given the financial burden associated with HF. The majority of this expenditure is 
incurred in the provision of inpatient care. Identifying low risk patients in hospital may allow 
appropriate early discharge, thus improving hospital efficiency and targeting intensive 
monitoring and longer hospital stays to high risk patients. Furthermore, identifying patients at 
high risk of admission or readmission to hospital might allow targeted interventions to lower 
hospitalisation rates.   
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A universal approach to defining prognosis in HF is complicated for several reasons. HF is a 
clinical syndrome with a range of aetiologies and mechanisms and is associated with both 
reduced and preserved LV systolic function. Patients with HF often have co-morbidities which 
also influence prognosis. For these reasons, many individual predictors of morbidity and 
mortality do not have independent predictive power when incorporated into multivariable 
models. Moreover, patients with HF face competing risks of progressive pump failure and 
sudden cardiac death (SCD). Thus predicting prognosis for patients with HF is extremely 
challenging. 
 
Yet despite the recognised importance of prognostication in HF, accurate determination of 
individual risk within this large and heterogeneous population is a major challenge. It has 
recently been demonstrated that physicians often fail to accurately predict mortality for 
patients with advanced HF (45).  
 
1.2.2 Traditional predictors of prognosis in heart failure 
 
Many individual markers have been associated with an increased risk of mortality and 
morbidity in HF. These include a spectrum of demographic data, past medical history, 
physical examination findings, comorbidity, aetiology of HF, electrocardiographic parameters, 
echocardiographic variables, exercise-related parameters, laboratory blood results and 
haemodynamic variables.  Some of these markers, for example the natriuretic peptides, have 
been identified to be independently predictive in comprehensive multivariable analyses 
undertaken in large cohorts of HF patients. However, many markers have limited prognostic 
ability having been identified in small cohorts after only univariate or limited multivariable 
analyses. Few markers have been evaluated in the prediction of cause-specific death. The 
established prognostic markers in HF are displayed in Table 1-3. 
 
The use of individual risk markers in isolation has limited prognostic utility. The absence or 
presence of a single risk marker does not necessarily convey a good or bad prognosis. Multiple 
individual risk markers may be present in any given patient. Combining these to predict an 
individual’s prognosis is a challenge that has not yet been adequately met. 
 41 
Table 1-3: Established prognostic markers in heart failure 
 
Category Prognostic Marker 
Demographics Age 
Male sex 
Comorbidity Coronary artery disease 
Resuscitated sudden cardiac death  
Chronic renal failure 
Diabetes mellitus 
Anaemia 
Chronic obstructive pulmonary disease 
Clinical parameters Low blood pressure  
Increasing heart rate 
NYHA class III-IV 
Prior HF hospitalisation 
Laboratory tests B-type natriuretic peptides 
Sodium 
Creatinine/Urea/eGFR 
Haemoglobin 
Electrophysiological QRS duration 
Imaging LVEF 
LV end-diastolic dimensions 
Haemodynamics Peak VO2 
6 minute walk test 
 
eGFR = estimated glomerular filtration rate; VO2 = oxygen consumption 
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1.2.3 The B-type natriuretic peptides 
 
The natriuretic peptides consist of a group of 4 hormones (A, B, C and D). The principal 
role of these hormones is to regulate sodium and water homeostasis via natriuresis, diuresis 
and vasodilatation. The B-type natriuretic peptides (BNPs) have been most widely studied 
in HF and their name derives from the site of origin of their discovery - porcine brain (46). 
However it has since become apparent that the major secretory source of these 
neurohormones in humans is the left ventricle (LV). ProBNP is the precursor from which 
the biologically active BNP and inactive N-terminal-proBNP (NT-proBNP) are derived. 
ProBNP is produced predominantly by ventricular myocytes, and to a lesser extent in the 
atria, and synthesis increases in response to stretch and dilatation of the LV. The biological 
half-life of BNP is approximately 20 minutes whilst NT-proBNP, partially excreted by the 
kidneys, has a half-life of between 1-2 hours. In addition to natriuresis, diuresis and 
vasodilatation, the physiological actions of BNP also include inhibition of the sympathetic 
and renin-angiotensin-aldosterone systems and reduction in myocardial fibrosis and 
vascular smooth muscle proliferation.  
 
Over the last 5-10 years, BNP and NT-proBNP have increasingly been used in HF for 
diagnostic and prognostic purposes. One of the strengths of this test as a diagnostic tool is 
its high negative predictive value (47). Clinical use of this biomarker has been endorsed by 
the ESC guidelines for HF and features in the diagnostic pathway. These guidelines state 
that a diagnosis of chronic HF is unlikely in untreated patients with normal BNP or NT-
proBNP levels (1).  
 
In recent years, BNP has become established as a powerful predictor of prognosis in 
chronic HF, independent of many other markers of risk. Independent prognostic power for 
mortality has been demonstrated across the HF spectrum encompassing asymptomatic 
LVSD (48), mild to moderate severity (49;50) and advanced HF (51). It has also been 
demonstrated that patients with BNP levels that decrease significantly have a more 
favourable prognosis. On the other hand, elevated BNP levels that fail to fall or rise over 
serial measurements confer highest mortality risk (52). Studies evaluating the link between 
BNP and prognosis have largely concentrated on all-cause mortality or cardiac mortality, 
incorporating both modes of death in HF; pump failure and SCD. However, one study has 
established BNP to be the only independent predictor of SCD in chronic HF in a 
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multivariable analysis including systolic blood pressure (SBP), LVEF, NYHA, coronary 
heart disease, diabetes, heart rate and HF medications (53). 
 
BNP and NT-proBNP have also been demonstrated to be beneficial in the diagnosis of 
acute HF. These biomarkers have high negative predictive values for patients presenting to 
Accident and Emergency departments with breathlessness (54-56). The diagnostic 
accuracy of BNP has incremental benefit, after multivariable adjustment for standard 
clinical variables, in the identification of patients with acute HF (55). Akin to its role in 
chronic HF, BNP has also been shown to be a powerful determinant of prognosis in acute 
HF (57). BNP levels that rise during an admission with acute HF are predictive of an 
increased risk of both mortality and readmission with decompensated HF (58). Moreover, 
one study found a high pre-discharge BNP to be the only significant variable for predicting 
risk of death or readmission with HF. This followed multivariable adjustment including 
clinical variables, echocardiographic parameters and percentage change in BNP levels 
during admission (59). 
 
BNP and NT-proBNP are simple, non-invasive biomarkers with powerful prognostic 
utility in HF, independent of many established predictors of risk. The BNPs should be 
incorporated into the management of all patients with HF to guide prognostication. 
 
1.2.4 Cardiac troponin 
 
Cardiac troponins are emerging as potentially powerful biomarkers for prognostication in 
HF. Troponin is a complex of three integrated proteins (troponin C, troponin I and troponin 
T), integral to muscle contraction and relaxation and under the regulation of intracellular 
calcium concentration (60). Cardiac troponin I and troponin T are cardiac specific, levels 
are not raised following noncardiac injury or disease. Cardiac troponin has become 
established as the gold standard biomarker for the diagnosis of acute myocardial infarction 
(61). Acute myocardial ischaemia and necrosis destroys the myocyte structure, resulting in 
large elevations of the troponin proteins in the bloodstream. Modern troponin assays are 
able to detect small elevations in cardiac troponin, representative of minor myocardial 
injury in acute coronary syndromes. These biomarkers provide prognostic information and 
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are used in the risk stratification process for patients with an acute coronary syndrome (62-
64).  
Troponin elevation reflects myocardial damage but is not indicative of a specific 
pathological process. Elevated levels of troponin are detectable in the absence of 
myocardial ischaemia in a wide range of clinical conditions, including HF. The majority of 
cardiac troponin is located within the complex involved in the contractile process with the 
remainder existing in the cytoplasm. The mechanisms of nonischaemic troponin elevations 
are unclear but are probably related to disruption of the cell membrane and release of 
cytoplasmic troponin, leading to small rises of troponin concentration in the bloodstream. 
Possible mechanisms in HF include; ongoing myocyte necrosis in ischaemic LVSD (65), 
cellular stretch in dilated cardiomyopathy (66-68), ventricular remodelling (69) and 
chronic activation of the neuroendocrine and inflammatory pathways (70). 
 
Several studies over the last decade have identified an elevated troponin in 10-50% of 
patients with chronic HF (71-73). Troponin elevation in patients with stable HF may reflect 
pathophysiological mechanisms such as continual ‘cytosolic leakage’. Elevation of this 
biomarker has been linked with adverse clinical outcomes, including mortality, 
hospitalisation with HF and cardiac transplantation (71-75). A multimarker approach with 
BNP and other established biomarkers has recently been shown to improve risk 
stratification in two modest-sized studies of patients with advanced HF (71;75). Only one 
study published to date has included troponin in a prognostic risk score for chronic HF (76). 
This large study stratified patients into risk categories using ten non-invasive variables, 
including troponin and NT-proBNP. A high score corresponded with a four-fold risk of the 
primary outcome of cardiac mortality. This risk tool is yet to be validated in an external 
cohort to determine its applicability to a general HF population.  
 
More recently, troponin elevation has been identified in patients with acute decompensated 
HF. Unsurprisingly, these studies have found high proportions of patients to have raised 
troponin levels in the decompensated state (69;70;77-82). Elevation of troponin has also 
been linked to adverse clinical events in these studies. Although many of these studies 
have evaluated the incremental prognostic value of an elevated troponin, albeit some in 
limited multivariable analyses, the incorporation of troponin into a prognostic risk tool is 
currently lacking for acute HF.  
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Troponin elevation is common in chronic and acute HF, the prognostic significance of 
which is emerging. Many studies to date have evaluated the impact of a raised troponin in 
univariate or limited multivariable analyses. More recent analyses have shown an 
incremental prognostic value for troponin over the natriuretic peptides. No studies have 
evaluated the significance of elevated troponin in prediction of cause-specific death in HF. 
The combination of troponin with other established biomarkers in the form of a prognostic 
scoring tool may improve risk stratification in HF. 
 
1.2.5 Rationale for improving prognostication 
 
There remains a real need for improving prognostication in order to improve the 
management of patients with heart failure. This is essential in an era in which complex 
therapies are improving outcomes but are limited by resources and financial restraints. 
Accurate targeting of these therapies is required to optimise their use.  An accurate means 
of predicting an individual’s risk will facilitate the efficient allocation of therapies and 
provide physicians with an objective assessment of their patient’s prognosis. The latter 
may enable medical staff to have more honest and informative discussions with their 
patients regarding prognosis. In a wider sense, improving risk assessment in HF may 
further knowledge of the pathophysiology of this condition. Identification of novel 
biomarkers and determining the combinations of variables which identify those at greatest 
risk are likely to provide avenues for further research and new targets for potential 
therapeutic intervention. 
 
1.2.6 Identifying cause-specific mortality in heart failure 
 
Many established and novel biomarkers are predictive of an increased risk of all-cause 
mortality. Few biomarkers have demonstrated a capability to determine cause-specific 
mortality. This is particularly relevant in HF where many deaths may be attributed to SCD 
caused by ventricular tachyarrhythmic events (VTE) and better selection of candidates for 
primary prevention ICD devices is warranted. Many guidelines advocate the use of LVEF 
to select candidates who would most benefit from device implantation (1;83;84), as this 
was what gated the clinical trials inclusion criteria. However, in the largest randomised 
controlled trial evaluating primary prevention ICD therapy in patients with reduced LVEF 
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HF, 79% of patients in the ICD arm did not use their device (37). Moreover the absolute 
risk reduction in the group randomised to ICD therapy was modest at 7.2% over 5 years 
follow-up. Although this landmark study clearly demonstrated the mortality benefit 
associated with reducing SCD in HF, it also highlighted the limitation of LVEF in isolation 
for identifying those at risk of SCD. 
 
Other non-invasive tests have been scrutinised as potential biomarkers for predicting the 
risk of SCD in HF. These include electrocardiographic parameters, markers of autonomic 
dysfunction, imaging modalities and serum biomarkers.  
 
A prolonged QRS duration is associated with a poor prognosis in patients with HF and is 
currently part of the selection criteria for implantation of CRT devices (83;84). However, 
patients with HF and a normal QRS duration remain at high risk of SCD (37;85). This 
highlights the difficulty of using QRS duration as a tool for predicting risk and ICD 
requirement. The presence of nonsustained arrhythmias does not predict risk of SCD in HF 
(86). Markers of ventricular repolarisation, such as QT dispersion, QT dynamics (ratio of 
QT to RR interval) and QT interval rate dependence have been linked to increased risk of 
arrhythmias. Many of these markers have been predictive for all-cause mortality rather 
than SCD or have been predictive for SCD after limited multivariable analyses and in 
patients on sub-optimal medical therapy (87). Other electrophysiological markers, such as 
signal-averaged electrocardiogram (ECG), are also limited predictors of SCD due to their 
low sensitivity (88).  Markers of autonomic dysfunction, such as baroreflex sensitivity and 
heart rate variability, have limited clinical utility due to their low sensitivity (88). The 
clinical utility of BNP as an independent predictor of SCD in chronic HF has already been 
discussed in section 1.2.3. Markers of collagen turnover, such as procollagen type 1 
aminoterminal peptide (PINP) and PIIINP have been demonstrated to be elevated in HF 
and may have a role in predicting SCD (89). The role of nuclear imaging with single-
photon emission computed tomography (SPECT) is expanding in HF and may be used to 
risk stratify patients for SCD in the future (90).  
 
Microvolt T-wave alternans (MTWA) has recently been proposed as a potential tool for 
identifying patients at risk of sudden cardiac death and assisting in the selection of patients 
for primary prevention ICD therapy.  
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1.3 Microvolt T-wave alternans in heart failure 
 
1.3.1 Definition and clinical application 
 
T-wave alternans describes beat-to-beat fluctuations in the morphology of the 
electrocardiographic T-wave. Experimentally, it has been suggested that T-wave alternans 
is caused by cellular repolarisation alternans, which can cause dynamic instability in 
cardiac repolarisation and has been mechanistically linked to a predisposition to ventricular 
arrhythmias (91). Repolarisation alternans is thought to be due to action potential duration 
alternans and abnormal intracellular calcium handling (92). Repolarisation alternans 
normally develops in a concordant way with all myocytes alternating in phase. The 
presence of repolarisation alternans may cause arrhythmias if discordant repolarisation 
alternans develops. In early clinical studies, MTWA during atrial pacing was associated 
with ventricular arrhythmia (93). MTWA testing is now performed clinically using a 
commercially available system (CH2000 or HearTwave II, Cambridge Heart, Bedford, 
Mass). MTWA testing is undertaken using proprietary low-noise ECG electrodes. Patients 
must be in sinus rhythm and the heart rate is increased up to a maximum of 110 beats per 
minute (bpm) by using sub maximal treadmill exercise. A series of beats recorded at a 
stable heart rate are lined up and the amplitude of each T-wave at the same time with 
respect to the QRS complex is plotted. These data then undergo spectral analysis using fast 
Fourier transformation, a computer mathematical process that transforms a waveform into 
the components of its frequency spectrum. This determines the magnitude, at the microvolt 
level, of T-wave fluctuations occurring on alternate beats. If sufficient alternans is 
sustained at heart rates <110 bpm, the test is classified as positive. Absence of alternans 
activity at 110 bpm constitutes a negative test. Alternans is a heart rate dependent 
phenomenon and the presence of alternans at heart rates >110 bpm is considered normal. A 
test that satisfies neither set of criteria is classified as indeterminate. An indeterminate test 
may occur when analysis is not possible due to artifact, ectopic beats, nonsustained 
alternans or inability to raise the heart rate to 110 bpm. The latter may occur either due to 
chronotropic incompetence or if the patient is physically incapable of exercising long 
enough to raise their heart rate. The computer system generates a report and an automatic 
classification of the MTWA results. MTWA tests are reported as positive, negative or 
indeterminate. Patients in AF are ineligible for MTWA testing by the spectral method as 
unequal R-R intervals confound the frequency analysis. MTWA can also be determined 
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with time-domain methods, which are applicable to AF and Holter data. This method has 
been evaluated during pacing (94), in patients undergoing routine exercise tolerance testing  
(95) and in post myocardial infarction studies (96;97), but at present no prospective data 
are available regarding the prognostic value of Holter-based MTWA testing in patients 
with HF. 
 
1.3.2 Predictive value of microvolt T-wave alternans  
 
The published studies that have assessed the predictive value of MTWA testing during 
exercise are summarised in Table 1-4. 
 
1.3.2.1 Known or suspected arrhythmia 
 
In a population of 313 patients referred for cardiac electrophysiological study (EPS), a 
positive MTWA test predicted the primary endpoint of VTE (VTE: SCD, ventricular 
fibrillation [VF], sustained ventricular tachycardia [VT] or appropriate ICD therapy) better 
than EPS (relative risk [RR] 10.9 vs.7.1) (98). However, this was a heterogeneous 
population; some patients were referred for EPS because of prior cardiac arrest, while 
others were undergoing assessment of supraventricular tachycardia.  
 
1.3.2.2 Myocardial infarction 
 
Three studies have investigated the prognostic utility of MTWA following myocardial 
infarction (MI) regardless of LVEF. Only one has suggested that MTWA may predict SCD.  
This study enrolled 850 consecutive patients who underwent MTWA testing after MI 
(mean 2.7 months post-MI). A positive MTWA test predicted SCD or resuscitated VF, 
although the event rate was only 3% in this population (99). The proportion of patients 
prescribed a beta-blocker was low (30%). Two other studies have suggested that MTWA is 
not prognostically useful in this population. In one, 140 consecutive patients were 
investigated in the first 30 days following MI. Only three endpoints, death or VTE, 
occurred over 15 months of follow-up (100). A positive MTWA test did not predict events 
in this low-risk population. The second study examined the predictive value of MTWA for 
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all-cause mortality in patients early after MI (mean 8 days post-MI) (101). Of 323 
consecutive patients, only 56 (17%) had a positive MTWA result.  None of the 26 deaths 
occurred in this group. Notably, these patients were receiving optimal medical therapy, 
including a beta-blocker in 97%, at the time of MTWA testing.  
 
In a cohort of 1041 patients with preserved LVEF after MI (mean 48 days post-MI), a 
positive MTWA test did predict VTE, although the number of endpoints was extremely 
low over a long period of follow-up (18 over 34 months) (102).  
 
Two small studies have enrolled patients meeting Multicenter Automatic Defibrillator 
Implantation Trial (MADIT)-II entry criteria (previous MI, LVEF ≤ 30% and no history of 
ventricular arrhythmia) from other cohorts. In 129 such patients, none of the twelve who 
experienced SCD or resuscitated VF had a negative MTWA result (103). In a subgroup 
analysis of a larger study, 177 patients meeting MADIT-II criteria were studied. MTWA 
tests were classified as abnormal (positive or indeterminate) in 68% and normal (negative) 
in 32% (85). The hazard ratio (HR) associated with an abnormal test was 4.8 (95% 
Confidence Interval [CI]: 1.1-20.7), but this was only adjusted for QRS duration, and 
therefore does not reflect incremental prognostic value. 
 
Results from two larger studies were published after my study commenced. The Microvolt 
T-Wave AlternanS Testing for Risk Stratification of Post MI Patients (MASTER) study 
(104) study examined MTWA in 575 MADIT-II-indicated ICD-treated patients. MTWA 
tests were classified as non-negative (positive 51% and indeterminate 12%) and negative 
(37%). After multivariable adjustment (including age, LVEF, beta-blocker medications, 
QRS duration and NYHA class), a non-negative MTWA result did not predict VTE. The 
Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction 
(CARISMA) study (105) examined MTWA in 312 patients. Patients were tested six weeks 
post-MI, all had LVEF ≤ 40% and all received an implantable ECG loop-recorder. In 
addition to MTWA testing, heart rate variability measures, signal-averaged ECG and 
electrophysiological studies were also performed. MTWA was not predictive of the 
primary endpoint of VF/VT, all-cause mortality or cardiac death. The strongest predictors 
of the primary endpoint were measures of heart rate variability. MTWA does not appear to 
have clinical benefit early after MI in patients with LVSD.  
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The evidence for the use of MTWA in the risk stratification of patients post-MI is not 
robust. The negative predictive value (NPV) may be high in selected patients, but the 
results are conflicting in more representative cohorts. 
  
1.3.2.3 Ischaemic left ventricular systolic dysfunction 
 
Three studies have examined the prognostic value of MTWA in patients with ischaemic 
LVSD. The first performed MTWA testing in 144 non-consecutive patients referred for 
EPS (106). The cohort was separated into primary (n = 88) and secondary (n = 56) 
prevention subgroups and 111 patients received an ICD, because of a prior history or 
induction of sustained ventricular arrhythmia. A positive MTWA test did not predict the 
primary endpoint, death or VTE, in the primary prevention subgroup.  
 
The second study evaluated 768 consecutive patients with coronary heart disease and 
LVSD (107). The authors analysed positive and indeterminate tests together and separately, 
addressed cause-specific death as a secondary endpoint, and performed a more extensive 
multivariable analysis than previous studies. However, the follow-up was relatively short 
(mean 18±10 months) and the event rate (n=99) was low for this type of population, 
limiting the power of the study. A non-negative MTWA test independently predicted all-
cause mortality (HR 2.24; 95% CI, 1.34 to 3.75) and arrhythmic mortality (HR 2.29; 95% 
CI, 1.0 to 5.24) in the whole population. However, when positive and indeterminate results 
were analysed separately, positive results failed to predict arrhythmic mortality, whereas 
indeterminate results predicted both all-cause and arrhythmic death. Therefore, 
indeterminate rather than positive tests accounted for the majority of the predictive value 
for arrhythmia in this study, which contradicts the proposition that MTWA identifies a 
specific proarrhythmic substrate. 
 
The Alternans Before Cardioverter Defibrillator (ABCD) study published results as my 
study was closing (108). This interventional study recruited 566 patients with ischaemic 
LVSD and nonsustained VT and compared the ability of MTWA and EPS to predict VTE. 
The 1-year event rate was lowest (2.3%) when both tests were negative and highest (11.1%) 
when both were positive. The event rate was intermediate and similar when only 1 test was 
positive (MTWA positive, 6.5%; EPS positive, 7.8%). However, the 1-year event rate was 
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highest when MTWA was indeterminate and EPS was positive (14.8%). Use of an ICD 
(shock or pacing) accounted for the majority of end points (85%). However, ICD 
implantation was not compulsory if both tests were normal, and so patients in this group 
(n=99) may have been less likely to reach an end point. Moreover, because ICD therapies 
occur more frequently than SCD in patients without ICDs, a significant proportion of the 
end points in this study may have been attributable to non clinical arrhythmias. 
 
1.3.2.4 Left ventricular systolic dysfunction irrespective of aetiology 
 
One study recruited 549 patients with LVSD and no history of sustained ventricular 
arrhythmia, including patients with both ischaemic (n = 267) and non-ischaemic (n = 282) 
cardiomyopathy (109). The primary endpoint was a composite of death and VTE.  Over 20 
months, there were 2 deaths and 2 ICD discharges in the normal (negative) MTWA group 
(n = 189) compared with 38 deaths and 9 ICD discharges in the abnormal (positive or 
indeterminate) MTWA group (n = 360). The proportion with an ICD in each group was the 
same. After multivariable adjustment, an abnormal MTWA test was associated with an 
increased risk of VTE.  
 
Results were published from an electrophysiological MTWA study shortly after my study 
began. This study investigated the predictive value of MTWA in patients with both 
ischaemic and nonischaemic cardiomyopathy, referred for EPS for evaluation of non-
sustained VT and/or syncope (110). MTWA was performed during atrial pacing at the time 
of EPS. Over 38 months, the primary endpoint of arrhythmia-free survival (defined as 
freedom from death or sustained ventricular arrhythmias) was higher in MTWA negative 
patients (88%) than MTWA non-negative patients (66%). However, the two-year event 
rate for death or sustained ventricular arrhythmias was 19% among the MTWA negative 
patients. This suggests MTWA alone may be insufficient for identifying a low-risk 
population who, by implication, do not need ICD implantation.  
 
1.3.2.5 Nonischaemic left ventricular systolic dysfunction  
 
Three studies have examined the prognostic utility of MTWA in non-ischaemic 
cardiomyopathy. The first study performed MTWA testing in 104 patients and found that a 
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positive MTWA test was independently associated with VTE (111). However, this study 
has many limitations. The actual number of endpoints was very small (n=12), as was the 
sample size, limiting the multivariable analysis. Many screened patients were ineligible 
because of AF, but no information was given regarding the number or characteristics of the 
patients screened. No patient was prescribed an ACE inhibitor or beta-blocker prior to 
entry into the study and thus MTWA testing was carried out on sub-optimal medical 
therapy.  The mean NYHA functional class was less than II and more than half of the 
patients were not prescribed a diuretic, suggesting the majority had asymptomatic LVSD, 
not symptomatic heart failure. The second recruited 137 patients and compared MTWA 
with other arrhythmic markers (112). A positive MTWA test was the only independent 
predictor of VTE after a mean of 14 months follow-up.  This study again has many 
limitations.  The multivariable model did not include age or LVEF. The cohort included 
patients with an ICD (27%), mostly for prior sustained ventricular arrhythmia, and 11 of 18 
endpoints occurred in those patients. This restricts extrapolation of these results to a 
primary prevention population. The third and largest study (n = 263) excluded patients 
with prior VF/VT and had a longer duration of follow-up (52 months) (113). In this study a 
positive MTWA test was not associated with the occurrence of VTE.  In this study an 
indeterminate test was associated with the primary outcome on univariate analysis.  
 
The available evidence suggests that MTWA is not a reliable indicator of arrhythmia in 
patients with non-ischaemic LVSD.  There appears to be little to recommend a strategy of 
using MTWA in this population to determine which patients should or should not have an 
ICD.   
 
1.3.2.6 Symptomatic heart failure with low left ventricular ejection fraction 
 
The evidence for the prognostic utility of MTWA in LVSD cannot simply be extrapolated 
to patients with symptomatic chronic HF, which is a clinically distinct entity. When my 
study began, only three small studies (n=73, n=46, n=107) had assessed the predictive 
value of MTWA testing in patients with HF-REF (114-116). On initial review these studies 
suggest that MTWA predicts clinical outcome in this population. However, they do have 
several limitations beyond their size.  
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The first study selected 73 patients with NYHA II chronic HF after excluding those with 
LVEF ≤ 20% “because of high risk of death”. An additional 17 patients with indeterminate 
results were excluded, leaving a small and highly selected group in which a positive 
MTWA test was associated with an increased risk of VTE over 17 months (114). In 
another study, of 46 patients with NYHA II-III chronic HF, MTWA predicted cardiac 
death (n=7) but not SCD (n=1) (115). In the third study, of 107 patients with chronic HF, 
none of the 13 end points occurred in MTWA-negative patients and MTWA was the only 
independent predictor of VTE (116). However, this multivariable analysis included only 7 
arrhythmia markers. 
 
These studies are small, appear to be highly selected, and lack proper multivariable 
adjustment. Their limited relevance to real-life populations with chronic HF is exemplified 
by the mean ages of the patients enrolled (64 years, 59 years, and 56 years, respectively). 
The average age of unselected HF populations is 75 years (117). This evidence certainly 
does not support the routine use of MTWA testing to risk stratify patients with chronic HF. 
 
Results were published from two larger studies of MTWA in chronic HF after my study 
began. The Microvolt T-Wave Alternans in Patients with Heart Failure (ALPHA) study 
recruited 446 patients with non-ischaemic cardiomyopathy (LVEF ≤ 40%) and stable 
NYHA II-III chronic HF on optimal medical therapy (118). A non-negative MTWA test 
was associated with an increased risk of cardiac death or VTE over 18 - 24 months. 
However, these patients were older, more symptomatic, and had lower mean LVEF, 
imbalances that highlight the need for careful multivariable adjustment in such studies. In 
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) T-wave alternans sub-study, 
MTWA testing was performed in 490 patients with LVEF ≤ 35% and NYHA II-III chronic 
HF (119). In this study 41% of tests were indeterminate and over 35 months there was no 
difference in the rate of VTE between MTWA groups for patients who received either ICD 
or placebo. These studies are larger than those published to date and their contradictory 
results means that doubt remains regarding the value of MTWA for predicting arrhythmic 
risk in chronic HF. 
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Table 1-4: Published observational studies of MTWA exercise testing 
 
MTWA result (%) Primary end-point Predictive value Study N Mean age 
(yrs) 
Mean LVEF 
(%) 
Prior 
VTE (%) 
BB stopped 
pre-MTWA 
Pos Indet Neg Event Mean FU 
(mths)  
N RR/HR 
(95% CI) 
PPV 
(%) 
NPV 
(%) 
Suspected arrhythmia 
Gold (98) 313 56 44 19 >24 hrs 31 24§ 45 VTE‡ 10 22 RR 10.9 NA NA 
Post-MI 
Ikeda (99) 850 63 NA 0 NA 36 13§ 51 SCD/    
VF 
25 25 RR† 5.9 
(1.6-21) 
7 99 
Schwab (100) 140 60 56 0 1 dose 20 27§ 53 Death/ 
VTE 
15 3 NS 4 97 
Tapanainen (101) 323 62 45 0 No 17 38 45 ACM 14 26 NS 0 99 
Ikeda (102) 1041 64 55 0 No 17 9 74 VTE 32 18 19.7† 9 99 
Post-MI LVSD 
Hohnloser (103) 129 63 26 0 NA 60 13 27 SCD/    
VF 
17 12 RR 5.5 13 100 
Chow (104) 575 65 24 0 NA 51 12 37 VTE 25 70 NS NA NA 
Bloomfield (85) 177 61 23 0 No 27 41 32 ACM 20 20 HR 4.8    
(1.1-20) 
NA NA 
Huikuri (105) 312 65 35 0 NA NA NA NA VF/VT 22 25 NS NA NA 
LVSD (ischaemic) 
Rashba (106) 144 64 28 39 >24hr 49 25 26 ACM/ 
VTE‡ 
17 50 HR 2.2† 
(1.1-4.7) 
40 84 
Chow (107) 768 ~67 ~27 0 >24hr 46 21 33 ACM 18 99 HR 2.2† 
(1.3-3.8) 
15 92 
Costantini (108) 566 65 28 0 >24hr 46 25 26 SCD/  
ICD 
19 65 HR 2.1 9 95 
LVSD (ischaemic and nonischaemic) 
Bloomfield (109) 549 56 25 0 No 29 35 36 ACM/ 
VTE‡ 
20 51 HR 6.5† 
(2.4-18) 
13 98 
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MTWA result (%) Primary end-point Predictive value Study N Mean age 
(yrs) 
Mean LVEF 
(%) 
Prior 
VTE (%) 
BB stopped 
pre-MTWA 
Pos Indet Neg Event Mean FU 
(mths)  
N RR/HR 
(95% CI) 
PPV 
(%) 
NPV 
(%) 
LVSD (nonischaemic) 
Kitamura (111) 104 52 41 0 NA 44 20§ 36 VTE 21 12 RR 8.9†    
(2-34) 
38 95 
Hohnloser (112) 137 55 29 20 NA 48 27§ 25 VTE‡ 14 18 RR 3.4† 22 94 
Grimm (113) 263 ~49 ~30 0 >24hr 52 21 27 VTE 52 38 NS 13 90 
Chronic HF and LVSD 
Baravelli (114) 73 64 36 10 >48hr 41 23§ 36 VTE‡ 17 8 ∞ 24 100 
Sarzi (115) 46 59 29 0 NA 52 20§ 28 Cardiac 
death 
19 7 NA 30 100 
Klingenheben (116) 107 56 28 0 NA 49 20 31 VTE 14 13 ∞ 21 100 
Gold (119) 490 59 24 0 >24hr 37 41 22 SCD/ 
VTE‡ 
30 75 NS NA NA 
Chronic HF and nonischaemic LVSD 
Salerno-Uriarte (118) 446 59 29.5 0 No 45 20 35 Cardiac 
death/  
VTE 
19 33 3.98 9 97 
 
 
N = number; BB = beta-blocker; Pos = positive; Indet = indeterminate; Neg = negative; FU = follow-up; RR = relative risk; HR = hazard ratio; CI = 
confidence interval; PPV = positive predictive value; NPV = negative predictive value; hr = hours; NA = not applicable; NS = not significant; ICD = 
appropriate ICD discharge; † = multivariable HR/RR; ‡ = VTE including ICD discharges; § = excluded from predictive analyses; ∞ = infinity 
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1.3.3 Unresolved issues in Microvolt T-wave alternans testing 
 
1.3.3.1 Does MTWA have incremental prognostic value?  
 
There are, at present, few data regarding the true incremental prognostic value of MTWA 
testing, due to the lack of detailed multivariable analysis undertaken in the studies to date. 
The parameters that have been included in these limited multivariable analyses are 
displayed in Table 1-5. A number of powerful predictors of outcome in chronic HF have 
been identified including BNP, as outlined in section 1.2.3. BNP has also been found to be 
an independent predictor of SCD (53). The prognostic value of MTWA testing has not 
been compared with that of BNP. It is certainly conceivable that a low BNP could confer 
as good a prognosis as a negative MTWA test. If this were the case, then the cost and small 
risk to the patient associated with MTWA testing would be unjustified. Although BNP may 
be considered unsuitable for risk stratification because concentrations may vary over short 
periods of time, there is no evidence regarding the reproducibility of MTWA results over 
timescales greater than a few hours (120). MTWA testing should be investigated as an 
independent predictor of outcome over and above already established indicators in chronic 
HF. 
 
1.3.3.2 Atrial fibrillation  
 
MTWA exercise testing cannot be performed in patients with AF.  Only 2 studies have 
reported the proportion of screened patients ineligible due to AF [23% (113) and 22% 
(118)]. In the MADIT-II study 9% of patients had AF (36), and in populations with chronic 
HF approximately 25-30% have concurrent AF (121).  If sufficient evidence was obtained 
to allow MTWA to be used to identify appropriate candidates for ICD therapy in 
populations with sinus rhythm, alternative strategies will have to be found for the large 
population ineligible for testing. Other methods of MTWA analysis, which may be 
applicable to patients with AF, are available, but there are as yet no published data 
regarding their prognostic value.   
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Table 1-5: Parameters included in MTWA observational studies multivariable analyses 
 
 
 Age Gender LVEF NYHA class BNP β-Blocker ACE 
inhibitor 
QRS 
duration 
Suspected arrhythmia 
Gold (98) √ √ √ x x x x x 
Post-MI 
Ikeda (99) √ √ √ x x √ x x 
Tapanainen (101) √ √ √ √ x x x √ 
Ikeda (102) √ √ √ x x √ x x 
Post-MI LVSD 
Bloomfield (85) x x x x x x x √ 
LVSD (ischaemic) 
Rashba (106) √ √ √ √ x x x x 
Chow (107) √ √ √ x x √ √ √ 
LVSD (ischaemic and nonischaemic) 
Bloomfield (109) √ √ √ √ x x x x 
LVSD (nonischaemic) 
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 Age Gender LVEF NYHA class BNP β-Blocker ACE 
inhibitor 
QRS 
duration 
Kitamura (111) x x √ x x x x x 
Hohnloser (112) x x √ x x x x √ 
Grimm (113) √ √ √ √ x √ √ x 
Chronic HF and LVSD 
Baravelli (114) √ √ √ x x x x x 
Klingenheben (116) x x √ x x x x x 
Chronic HF and nonischaemic LVSD 
Salerno-Uriarte (118) √ √ √ √ x √ √ √ 
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1.3.3.3 Inability to exercise 
 
One post-MI study reported that 15% of 379 consecutive patients in sinus rhythm could not 
exercise due to co-morbidity or physical frailty (101). Although a positive MTWA test did 
not predict all-cause mortality, inability to perform the exercise test was found to be an 
independent predictor of death (RR 5.62; 95% CI, 1.76 to 15.99). Implementation of a risk 
stratification tool which requires exercise is likely to be problematic in populations such as 
chronic HF and LVSD, where the incidence of frailty and co-morbidity is high.   
 
1.3.3.4 Medical therapy 
 
Pharmacological therapy can reduce SCD. Yet optimal medical therapy was mandatory 
inclusion criteria in only one of the studies described. Less than half of patients were 
prescribed a beta-blocker in one post-MI study (99) and two chronic HF studies (115;116). 
Most studies have discontinued beta-blockers for at least 24 hours, to facilitate elevation in 
heart rate and reduce indeterminate tests. This practice is not suitable for many HF patients, 
but whether beta-blocker continuation would then prevent a significant portion of patients 
achieving the heart rate required for a valid test is uncertain but clearly important. Aside 
from the impact on heart rate, there is also evidence that acute beta-blockade reduces the 
magnitude of MTWA, potentially converting a positive to a negative test (122). Omission 
of beta-blockers may not only reduce the number of indeterminate tests but may also 
increase the number of positive tests. I believe that MTWA testing is only clinically 
valuable, if shown to be independently predictive of outcome in patients on optimal 
tolerated medical therapy, including a beta-blocker. 
 
1.3.3.5 Indeterminate MTWA results  
 
MTWA tests are classified as indeterminate in the following circumstances: if there is 
significant noise or ventricular ectopy; if alternans is unsustained; or if the patient is able to 
exercise but cannot attain a heart rate of 110bpm for one minute. In early studies, 
indeterminate MTWA tests were believed to be of no significance to arrhythmic events and 
were excluded from predictive analyses. However, in a study of 177 patients post-MI, 
indeterminate MTWA tests accounted for the majority of non-negative tests. The authors 
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grouped indeterminate and positive tests together as abnormal (85), which has now become 
common practice in MTWA studies. Table 1-6 shows outcomes in MTWA positive and 
indeterminate groups from studies which have examined all-cause mortality. For each 
study, mortality was higher in the MTWA indeterminate group than in the MTWA positive 
group.  Clearly, an indeterminate test result indicates a poor prognosis, but the nature of 
this risk is unclear. Only one study, in patients with ischaemic LVSD, enrolled a 
sufficiently large cohort to examine cause-specific mortality (Table 1-7). Indeterminate 
tests accounted for 159 of 514 non-negative MTWA tests and an indeterminate test 
predicted both arrhythmic and non-arrhythmic death, whereas a positive test only predicted 
all-cause mortality (107). Moreover, in another study, the rate of major arrhythmic events 
was higher in the indeterminate group (24%) than either the MTWA positive (13%) or 
negative (10%) groups (113).  
 
This suggests that an indeterminate test may actually predict both non-arrhythmic and 
arrhythmic risk. While this may seem counter-intuitive, it is possible that patients with 
unsustained alternans or ectopy on exercise are prone to ventricular arrhythmia. Recent 
analyses of indeterminate tests concluded that such patients were at high risk, distinct from 
the tests categorised as indeterminate due to noise, artifact or a sharp rise in heart rate 
(123;124). This suggests that the classification of MTWA tests may require re-evaluation 
and the prognostic value of MTWA may be improved by reclassification of indeterminate 
tests.  
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Table 1-6:  Distribution of all-cause mortality rates per MTWA result 
 
All-cause mortality, % Study Number Population Mean FU (months) 
Positive Indeterminate Negative 
Chow (107) 768 Ischaemic LVSD 18 12 21 8 
Bloomfield (85)  177 Ischaemic LVSD 2-year mortality rate 14.5 20.1 3.8 
Bloomfield (109)  549 LVSD 2-year event rate 
(mortality & ICD 
discharges) 
12.3  
(5 ICD discharges) 
17.8  
(4 ICD discharges) 
2.4  
(2 ICD discharges) 
Tapanainen (101)  323 Post-MI 14 0 15 <1 
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Table 1-7: Adjusted comparisons of mortality per MTWA result in 768 patients with ischaemic cardiomyopathy (107) 
 
MTWA Result  
Non-negative (n=514) Positive (n=355) Indeterminate (n=159) 
All deaths HR (95% CI) 2.24 (1.34 – 3.75) 2.08 (1.18 – 3.66) 2.78 (1.55 – 4.99) 
Arrhythmic deaths HR (95% CI) 2.29 (1.00 – 5.24) NS 3.62 (1.44 – 9.13) 
Nonarrhythmic deaths HR (95% CI) NS NS 2.47 (1.17 – 5.22) 
 
CI = confidence interval; HR = hazard ratio; NS = not significant  
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1.3.4 Extrapolation to primary prevention ICD therapy 
 
There has been much speculation that MTWA could improve risk stratification for the primary 
prevention of SCD, including patients with HF. It has been argued that the current evidence 
regarding the favourable prognosis conferred by a negative test is sufficient to justify using 
MTWA to identify a subgroup of primary prevention ICD candidates who would not benefit 
(85;125). This could reduce the number of primary prevention implants and thereby reduce the 
cost of therapy. 
 
However, the current evidence is lacking in many respects. Most of the studies are limited by 
small sample size or by low event rates, which reduces power, and there is a lack of detailed 
multivariable analysis. We cannot, at present, extrapolate the prevalence data for a negative 
test to unselected populations, because the proportion of patients who would be ineligible for 
testing because of AF, demand ventricular pacing or an inability to exercise is unknown. In 
addition, a high NPV has only been demonstrated over relatively short time scales, and 
because the arrhythmic substrate changes over time it is likely that serial MTWA testing 
would be required. This is difficult to address when little is known regarding reproducibility of 
this test. The corollary of not implanting in MTWA negative patients would be to implant in 
all non-negative patients, including those with indeterminate tests. Given the lack of proven 
incremental prognostic value of MTWA and the conflicting results in some studies, there are 
serious doubts regarding the benefit of this strategy.  
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1.4 Aims of this study 
 
MTWA has been proposed as a novel method of predicting risk of sudden cardiac death and 
recommended as a solution to the conundrum of decision making for ICD implantation. Yet as 
outlined above, there are many gaps in the literature surrounding MTWA and HF. The clinical 
utility of MTWA testing in HF remains to be fully evaluated. The proportion of patients 
eligible for MTWA testing in a representative HF population is unknown, but clearly has 
major implications for the widespread use of MTWA testing. The tolerability of the exercise 
protocol and the prevalence of determinate MTWA results have not been assessed 
prospectively in such a population. In particular, the prevalence of abnormal MTWA results in 
patients with HF and preserved LVEF is not known. Little is known about the clinical 
characteristics associated with a specific MTWA result. The incremental predictive value of 
MTWA over LVEF in an unselected HF population has yet to be conclusively demonstrated. 
The incremental value of MTWA over other prognostic markers such as BNP has not been 
assessed in any type of HF. In particular, patients with HF-PEF have not been studied. It is 
necessary to have this information before considering implementing MTWA as a routine 
clinical tool.  
 
This study intends to provide a comprehensive evaluation of the use of MTWA in patients 
with HF and evaluate if this test will improve risk stratification for these patients. The 
hypotheses of the study of MTWA are twofold.  
 
Firstly, in an unselected population of patients recently hospitalised for HF, the presence of an 
abnormal MTWA test (positive or indeterminate) provides prognostic information over and 
above that obtained from clinical data, LVEF or natriuretic peptide levels in the prediction of 
all-cause mortality, SCD and cardiovascular death.  
 
Secondly, not withstanding the first hypothesis, the inability or ineligibility to perform an 
MTWA test will identify a group of patients at highest risk of all-cause mortality, SCD and 
cardiovascular death. 
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This aims of this study are: 
 
1. Define eligibility for MTWA testing in a cohort of patients with stable HF. 
2. Determine the prevalence of positive, negative and indeterminate results in a 
representative, well-defined population of patients with HF on optimal medical therapy, 
accounting for aetiology and LVEF.  
3. Determine the tolerability of the exercise protocol in patients with HF. 
4. Describe the clinical characteristics associated with a specific MTWA result.  
5. Examine the predictive value of MTWA testing for all-cause mortality, SCD and 
cardiovascular mortality in HF.  
6. Clarify the incremental prognostic utility of MTWA by evaluating MTWA alongside 
established predictors of mortality, including BNP, and more novel biomarkers, such 
as cardiac troponin.  
7. Describe the characteristics and outcomes of those ineligible for MTWA testing. 
 
Ultimately this study endeavours to determine if MTWA testing has a role in the risk 
stratification of patients with HF. 
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CHAPTER TWO 
 
METHODS 
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2.1 Introduction 
 
This chapter will explain the methods behind this prospective observational study.  The study 
design, patient identification methods, and data collection techniques will be illustrated. 
Application of the MTWA test to this cohort will be described. The methods of collecting and 
storing data will be outlined, and the statistical analyses used will be described. An overview 
of the study design is presented in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Outline of the study design 
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2.2 The hospitalised heart failure cohort 
 
2.2.1 Patient population and recruitment 
 
All patients were recruited from the Royal and Western Infirmaries in Glasgow, and the Royal 
Alexandra Hospital in Paisley. The Royal Infirmary in Glasgow is a city hospital covering a 
catchment area of over 250,000 for the north and east of Glasgow. The Western Infirmary 
covers north-west Glasgow, with a catchment area of approximately 250,000. The Royal 
Alexandra Hospital is a district general hospital with a large catchment area, approximately 
200,000 from Renfrewshire and also serving areas as far away as Oban and Argyll.  
 
Patients recruited into this study were admitted to these hospitals by self referral to the 
Accident and Emergency Department or referral from their General Practitioner. All patients 
recruited were admitted to the Medical Receiving Units, Coronary Care Units or directly to 
general medical wards. Near-consecutive admissions were screened daily in both Glasgow 
hospitals between 1st December 2006 and 10th January 2009, and in the Royal Alexandra 
Hospital in Paisley from 22nd April 2008 to 10th January 2009. Recruitment of patients from 
the third site, the Royal Alexandra Hospital, began after it became apparent that a significant 
proportion of enrolled patients failed to return for the follow-up study visit and that additional 
recruitment was needed to achieve an adequate number of patients attending the follow-up 
visit.  
   
Identifying potential study patients 
 
All admissions to the three hospitals were screened for evidence of decompensated HF 
(appendix I, page 326). This involved reviewing the case records for all new admissions for 
documentation of the following:  
• Symptoms and clinical signs of HF  
• Radiological evidence suggestive of HF 
• Clinical response to intravenous diuretics 
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Symptoms of HF included shortness of breath and peripheral oedema. Clinical signs of HF 
included a raised jugular venous pressure (JVP), lung crepitations and pitting peripheral 
oedema. Radiological evidence of HF included cardiomegaly (defined as a cardiothoracic ratio 
>0.5) and signs of pulmonary oedema. The latter comprised vascular redistribution (upper lobe 
venous diversion), raised pulmonary pressure (Kerley B lines), pulmonary venous congestion 
(interstitial or alveolar oedema) and pleural effusions. A clinical response to intravenous 
diuretics was defined as an improvement in the signs of HF (documented in the case notes) or 
a symptomatic improvement (reported by the patient).  
 
Inclusion criteria 
 
Patients were invited to participate in the study if they met all of the following criteria: 
• Primary reason for admission to hospital was decompensated HF 
• Symptoms and signs of HF plus radiological evidence of HF or clinical response to 
intravenous diuretics 
• No exclusion criteria (see below) 
 
Exclusion criteria 
 
Patients were not approached for participation if they met any of the following exclusion 
criteria: 
• Cognitive impairment 
• Serious concurrent systemic disease resulting in reduced life expectancy (such as 
advanced malignancy) 
• Acute coronary syndromes complicated by pulmonary oedema 
• Geographical or social factors making participation or follow-up impractical  
 
Recruitment into the study involved a two stage consent process (see below). Written 
information was provided for both stages (appendices II, page 327, and III, page 329).  
Patients who agreed to participate in the study provided written informed consent for both 
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stages (appendix IV, page 334). Copies of the consent form were given to the patient and filed 
in their medical case records. The study was approved by the Local Research Ethics 
Committee. 
 
Consent - Stage One 
 
Stage one involved providing informed consent to blood sampling to measure plasma BNP 
concentration. Information for medical staff explaining the BNP test was placed in the 
patient’s case notes (appendix V, page 336). The BNP test result was available within 24 
hours. All patients were informed the following day of their result. Those with a BNP level 
within the normal reference range, below the ESC guidelines “rule-out” threshold for HF 
(<100pg/ml) (1), were not recruited into stage two. No further participation in the study was 
asked of these patients. Patients providing consent at this stage also gave permission to be 
“flagged” for follow-up with Information Services Division (ISD) of NHS Scotland, allowing 
identification of deaths and readmissions to hospital. 
 
Thus, all patients enrolled in the study fulfilled the three ESC diagnostic criteria for HF (1). 
All enrolled patients had both symptoms and signs of HF, the first and second criteria of these 
guidelines. The third criteria requires evidence of structural or functional cardiac disease, 
namely; evidence of cardiomegaly, a third heart sound, echocardiographic abnormalities or a 
raised natriuretic peptide level. Thus, an elevated BNP concentration satisfied the third criteria 
of these guidelines.  
 
Consent – Stage Two 
 
This involved obtaining consent from patients with an elevated BNP concentration to 
participate in the follow-up study visit. The study visit was scheduled for approximately 4-6 
weeks after the patients were discharged from hospital. Details of the study visit were 
provided verbally and by written means. A letter explaining the study was issued to every 
participant’s general practitioner and filed in the patient’s case notes (appendix VI, page 337). 
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An appointment card was issued to each patient prior to their discharge from hospital, 
detailing the date and location of the study visit (appendix VII, page 339). 
  
2.2.2 Data collection 
 
Every patient recruited into the study had an extensive amount of clinical data collected during 
their hospital admission. This was contained in a case record form (appendix VIII, pages 340-
355). Each patient was allocated a unique and anonymous study identification number. 
Completing the case record form involved a forty-five minute consultation with each patient 
during their hospital admission. Data were obtained by a thorough review of the patient’s 
medical case notes as well as a clinical assessment of each patient. The latter comprised taking 
a detailed account of their medical history and examining their cardiovascular system. Other 
methods of obtaining data included searching hospital database systems for echocardiography, 
coronary angiography and radiological reports.  
 
The types of data recorded were chosen for several reasons. A precise record of the past 
medical history and results of any previous angiography allowed accurate determination of the 
aetiology of HF. Data used in recently validated models of mortality prediction in HF (126) 
were collected, both from hospitalisation and study visit, to evaluate the incremental 
prognostic value of MTWA to these models.  
 
Data were recorded under the following headings; demographics, clinical HF assessment, past 
medical history and family medical history. Medications prescribed pre-admission and heart 
failure medical therapy administered during the first 24 hours of admission were noted. ECG 
results, chest X-ray (CXR) findings and echocardiogram analysis pre- and during admission 
were also recorded. Finally, results from blood tests carried out on admission to hospital were 
noted.  
 
Demographic data included date of birth, gender and race. Dates of admission, recruitment and 
discharge, or death in hospital, were recorded. 
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The clinical HF assessment included a detailed history recording the presence or absence of 
typical symptoms of HF prior to admission. An assessment of symptom severity in the days 
prior to admission was made using the NYHA classification system, an established objective 
method of recording HF symptom status (Table 2-1). This classification system relates 
symptoms to activities of daily life and allows an assessment of quality of life. This 
classification is also commonly used by medical professionals to guide therapeutic decisions.  
If the patient already had an established diagnosis of chronic HF in their medical case notes, 
this was recorded as a previous history of HF. For those with a history of HF, the duration was 
documented and whether or not there had been a previous hospitalisation for HF. This 
information has prognostic relevance in HF (126). The clinical HF assessment also included a 
clinical examination. This examination involved: the vital signs on admission, the presence or 
absence of common signs of HF and a complete cardiovascular system examination. The 
severity of the HF clinical examination findings were summarised by assigning each patient a 
Killip score (Table 2-2).  In addition to the clinical examination, every patient had their weight, 
height and waist measurement recorded whilst in hospital.  
 
Table 2-1: New York Heart Association (NYHA) classification of heart failure 
 
NYHA Class 
 
Patient Symptoms 
I No limitation of physical activity. Ordinary physical activity does not 
cause undue fatigue, palpitations or breathlessness. 
II Mild limitation of physical activity. Comfortable at rest or with mild 
exertion but ordinary activity results in fatigue, palpitations or 
breathlessness. 
III Marked limitation of physical activity. Comfortable at rest but any 
ordinary activity causes fatigue, palpitations or breathlessness. 
IV Symptoms of HF at rest and any physical activity cause exacerbation 
of symptoms. 
 
 73 
Table 2-2: Killip classification of heart failure 
 
Killip Score 
 
Description of Signs 
I No clinical signs of heart failure. 
II Basal lung crepitations, S3 gallop rhythm, elevated jugular venous 
pressure. 
III Frank pulmonary oedema. 
IV Cardiogenic shock – hypotension and evidence of peripheral 
vasoconstriction. 
 
 
Every patient in this study had a 12-lead ECG performed during their hospital admission. ECG 
abnormalities occur frequently in patients with HF. This is particularly evident in LVSD 
(127;128). The ECG can also allude to the primary aetiology, for example previous 
myocardial infarction (MI). Arrhythmias can be the cause or effect of decompensated HF and 
may also be evident on the 12-lead ECG. There are many other ECG abnormalities suggestive 
of potential causes of HF (1). The ECG can also confer prognostic information in HF. AF and 
bundle branch block have been shown to be independent predictors of mortality in the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 
study (126). Left bundle branch block (LBBB) has been demonstrated to be an independent 
predictor of sudden cardiac death, as well as all-cause mortality, in the Italian Network 
Congestive HF registry (129). Specific ECG parameters were recorded in each patient’s case 
record form (appendix VIII, page 352). These included rhythm, QRS duration and the QT 
interval corrected for heart rate (QTc). QTc was calculated using Bazett’s formula (130). The 
presence or absence of the following parameters were also recorded; bundle branch block, 
paced rhythm, pathological Q waves, left ventricular hypertrophy (LVH) and ischaemic ST 
depression. LVH was defined using the Sokolow and Lyon criteria (S V1 + R V5 or V6 > 35 
mm) (131).  
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The CXR frequently assists in the diagnosis of acute HF, although a normal CXR does not 
exclude this diagnosis. The majority of patients enrolled in this study had a CXR performed on 
admission to hospital. The presence of radiological signs suggestive of HF, as detailed in the 
ESC HF guidelines (1), were recorded in the case record form (appendix VIII, page 352). 
These radiological signs were outlined earlier in Section 2.2.1. Cardiomegaly has prognostic 
significance in HF and has been shown to be predictive of all-cause mortality (126), as well as 
sudden death (132).  
 
Echocardiography is an established investigation in patients with suspected HF. It enables a 
non-invasive assessment of pericardial, myocardial and valvular function. LV systolic function, 
as measured by ejection fraction, is an independent predictor of mortality in patients with HF 
(126). Many patients in the study had an echocardiogram performed prior to enrolment in this 
study. Data from this was recorded in the case record form (appendix VIII, page 353). If 
multiple echocardiograms had previously been performed, data from the most recent one was 
recorded. If an echocardiogram was performed during the index hospital admission then these 
data were also recorded in the case record form. Often patients were discharged from hospital 
with an appointment for an early outpatient echocardiogram; in these instances the data from 
these scans were also obtained. Specific information from the echocardiogram report was 
recorded. The LV internal dimension in diastole was recorded and whether or not the ventricle 
was dilated. The presence or absence of LVSD and LVH was noted. LVSD was recorded as 
documented on the report; mild, mild to moderate, moderate, moderate to severe or severe. 
This classification system is a subjective measure of dysfunction. Unfortunately LVEF is not 
routinely calculated. The presence of absence of valvular heart disease was recorded. The 
valve type and lesion (stenosis or incompetence) was recorded as well as the severity, using 
the same classification system as that of LVSD.  
 
2.2.3 Biochemical and haematological tests 
 
Blood sampling is informative in heart failure. It provides prognostic information and can 
assist with determining the aetiology of HF and reason for decompensation. Many routine 
laboratory investigations are recommended in the evaluation of patients with HF (1). 
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All patients had the following blood tests taken during hospitalisation; BNP, urea and 
electrolytes (U&E), liver function tests (LFT) and full blood count (FBC). The majority of 
patients had troponin I measured. The results of the following blood tests were also recorded 
in the case record form if they were carried out during the hospital admission; thyroid function 
(TFT), glycosylated haemoglobin (HBA1c), urate, phosphate, C-reactive protein (CRP), 
glucose and lipid profile. All routine biochemical and haematological tests were performed at 
the time of admission and analysed in the hospital biochemistry and haematology laboratories 
within four hours of venesection.  
 
Plasma BNP was an essential test in this study, an elevated level being mandatory for 
recruitment to stage two of the study. Blood sampling for BNP was performed within 24 hours 
of admission to hospital. Blood samples were collected in potassium ethylene diamine tetra 
acetic acid (EDTA) tubes and sent to the department of biochemistry at Gartnavel General 
Hospital in Glasgow for testing. Results were available on the same day of sampling. Plasma 
BNP was measured using the Architect Assay (Abbott Laboratories, Abbott Park, IL, USA). 
The Architect Assay has a range 0-5000 pg/ml. BNP values exceeding 5000pg/ml are recorded 
as >5000pg/ml. The cut-off for BNP in this study was 100 pg/ml and patients with values 
<100pg/ml were not recruited into stage two. This level was determined by consideration of 
several factors. Firstly, work carried out previously on a local healthy population identified the 
95th percentile at 67.6pg/ml for those aged 70 years and over (133). Abbott Laboratories 
evaluated their assay in non-hospitalised patients with renal disease, diabetes mellitus, chronic 
obstructive pulmonary disease and hypertension. In non-HF patients over 75 years old, mean 
and median values were 31pg/ml and 67pg/ml, respectively. Furthermore, 83.3% of these 
patients had results <100pg/ml. A previous study of the utility of BNP in diagnosing HF in the 
emergency setting also used 100pg/ml as the cut-off level (55). This yielded a diagnostic 
accuracy of 83%, with 90% sensitivity and 76% specificity, for differentiating HF from other 
causes of breathlessness. Finally, according to ESC guidelines, a diagnosis of HF is unlikely 
for patients presenting to hospital with breathlessness and a BNP level <100pg/ml (1). 
 
Cardiac troponin is commonly measured in patients admitted to hospital with decompensated 
HF. This was of particular interest in our study to evaluate the prognostic significance of this 
novel biomarker in HF. In the Royal and Western Infirmaries troponin I is measured using the 
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Architect assay (Abbott Laboratories, Abbott Park, IL, USA).  This assay reports negative 
results as <0.04ng/ml, the level that achieves 10% coefficient of variance. Elevated troponin I 
results are reported as ≥ 0.04ng/ml. In the Royal Alexandra Hospital troponin T is measured 
using the Roche assay (Roche Diagnostics, Basel, Switzerland). This assay reports negative 
results as <0.05ng/ml the level that achieves 10% coefficient of variance. Elevated troponin T 
results are reported as ≥ 0.05ng/ml. 
 
All patients had U&E measured on admission. Serum creatinine concentration alone is a poor 
indicator of renal function (134). Thus, renal function was assessed by estimation of the 
glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) 
equations (135). The MDRD equations have been validated in patients with severe chronic HF 
(136). The four-variable MDRD equation was calculated for all patients. This formula 
calculates eGFR as follows: 
eGFR (ml/min/1.73m2) = 32788 x (Serum Creatinine in µmol/l)-1.154 x (Age)-0.203 x [1.210 if 
Black] x [0.742 if Female] 
 
Renal function, represented by eGFR concentration, was then classified using the National 
Kidney Foundation classification (137). This guideline classifies renal function as normal if 
the eGFR is ≥ 90 ml/min/1.73m2. Mild renal impairment is eGFR 60 - < 90 ml/min/1.73m2. 
Moderate and severe renal impairment are defined as eGFR of ≥ 30 – 59 ml/min/1.73m2 and < 
30 ml/min/1.73m2, respectively.  
 
All patients had a FBC measured on admission. This haematological test includes several 
parameters that are useful in HF. These are haemoglobin, white blood cell (WBC) count, 
lymphocytes and red cell distribution width (RDW). Anaemia may be a cause or a 
consequence of HF and has prognostic importance regardless of systolic function (138). In this 
study, anaemia was defined according to the World Health Organization (WHO) criteria (139). 
These criteria define anaemia as a haemoglobin < 12g/dl in women and < 13g/dl in men. A 
raised total WBC count may indicate infection as a cause of decompensated HF.  
Lymphopenia is common in HF (138). Red cell distribution width is a novel prognostic 
marker in patients with chronic HF (140). 
 77 
 2.3 The post-discharge heart failure cohort 
 
2.3.1 Study visit 
 
All enrolled patients were invited to attend the British Heart Foundation (BHF) Glasgow 
Cardiovascular Research Centre to complete the follow-up study visit. This visit was arranged 
approximately 4-6 weeks after the patients were discharged from hospital. All surviving 
patients were telephoned one week prior to their allocated appointment to confirm attendance 
for study visit and organise taxi transport to the BHF Glasgow Cardiovascular Research 
Centre. The local online patient record database was checked prior to telephoning patients to 
ensure they were still alive. The study visits took place between 17th January 2007 and 12th 
March 2009. 
 
2.3.2 Data collection 
 
Every patient had a second case record form completed for their study visit using the same 
unique, anonymous study identification number allocated during their hospital admission 
(appendix IX, pages 356-368). Data collected in hospital were updated and recorded. This 
included current HF symptom status and current medications. New medical conditions were 
noted. Further admissions to hospital with HF, since enrolment in this study, were documented. 
Routine physiological measurements, body composition measurements and a cardiovascular 
system examination were performed for all patients. A 12-lead ECG was recorded and the 
same parameters described in section 2.2.2 were noted.  The aetiology of HF was detailed for 
every patient. Biochemical and haematological blood tests results, LVEF by echocardiography 
and MTWA results, were also recorded in the case record form (appendix IX). The reasons 
patients failed to attend the study visit were noted. These were recorded as; refusal to attend, 
unable to attend due to deteriorating health, or deceased. If the patient was deceased, the date 
of the death was obtained from the local online patient record database.  
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2.3.3 Aetiology of heart failure 
 
The primary aetiology of HF was recorded for all enrolled patients. Contributing aetiologies 
were also noted. The primary aetiology was defined as “ischaemic” if there was evidence of 
prior myocardial infarction, coronary revascularisation or angiographically significant 
coronary artery disease. Significant coronary artery disease was defined as >50% stenosis in at 
least one major epicardial coronary artery branch. “Non-ischaemic” aetiology was assumed 
only when significant coronary artery disease had been excluded by angiography. Patients 
who did not fit into either group were deemed to have “unknown” aetiology. Patients with 
non-ischaemic aetiology of HF were categorised into one of the following categories; 
idiopathic dilated cardiomyopathy, hypertension, alcohol or valvular heart disease. Valvular 
heart disease was only considered causative if at least moderate in severity. Patients with a 
non-ischaemic cause who did not fit into one of the aforementioned categories were classified 
as ‘other’ and the specific cause recorded. Assigning the aetiology of HF was performed at the 
time of the study visit, rather than during the hospital visit. This allowed use of information 
from investigations performed after recruitment, and improved the chances of determining the 
primary aetiology. For example, investigations like coronary angiography may have been 
performed late in the hospital admission or following discharge from hospital. Results of 
angiograms were obtained by interrogation of the local angiography database.  
 
Other aetiologies potentially contributing to HF were also recorded for all patients. These 
largely fell into the following categories; valvular heart disease, diabetes mellitus, atrial 
fibrillation, hypertension and alcohol. Valvular heart disease was only considered a potential 
contributor if the severity was at least moderate. The valve(s) involved were also recorded. 
Atrial fibrillation was only considered a contributing aetiology if persistent or permanent. The 
aetiology of HF was also recorded for patients who did not complete the study visit.  
 
2.3.4 Biochemical and haematological tests 
 
Several biochemical and haematological tests were performed at the study visit. The blood 
tests were selected either because they are already established biomarkers in HF or to 
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potentially allow identification of new variables that may be prognostically important in HF.   
The blood tests carried out at the study visit included all the laboratory parameters that were 
part of the final multivariable model for cardiovascular death or chronic heart failure 
hospitalisation for the CHARM cohort (126). These are red cell distribution width, bilirubin, 
lymphocytes, urate, glycosylated haemoglobin, haemoglobin, creatinine and phosphate. This 
would allow testing of the CHARM model in this cohort. In addition to the aforementioned 
tests the following biochemical and haematological tests were performed at the study visit; 
BNP, troponin I, U&E, LFT, TFT, cholesterol profile and FBC. The same assays (section 
2.2.3) were used to measure BNP and troponin I. Renal function was assessed by eGFR in the 
same way as described earlier (section 2.2.3). 
 
2.3.5 Echocardiography 
 
All patients attending the study visit underwent echocardiographic assessment of LVEF using 
the biplane method of discs (modified Simpson’s rule). This method relies on accurate tracing 
of the endocardial borders to calculate left ventricular volume. Apical four-chamber and two-
chamber views were used. LVEF was then calculated from the left ventricular volumes 
recorded in systole and diastole. This would allow dichotomising of patients into HF-REF and 
HF-PEF groups. Images were recorded on an Acuson Sequoia C512 machine, the machine 
used for all studies in the BHF Glasgow Cardiovascular Research Centre. All images were 
recorded by myself. Patients were positioned in the left lateral decubitus position. The 
calculations of LVEF were carried out offline by a single operator, who is an accredited 
cardiac technician of the British Society of Echocardiography. The images were stored using 
the anonymous study identification number and the operator calculating the LVEFs was 
blinded to all patient details. HF-PEF was defined as LVEF > 50% (18). Simpson’s Biplane 
method cannot be used if the quality of echocardiographic images is sub-optimal, as this leads 
to poor identification of endocardial borders. This is usually due to patient body habitus or 
poor echocardiographic windows. In these cases, a qualitative assessment of overall left 
ventricular systolic function was made (reduced or preserved function).  
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2.3.6 Microvolt T-Wave Alternans  
 
2.3.6.1 Application of the Microvolt T-Wave Alternans test 
 
MTWA testing was performed on eligible patients using the commercially available 
HearTWaveTM system (Cambridge Heart) (Figure 2.2). This uses the spectral analysis method 
to measure the magnitude of MTWA at a threshold heart rate. Seven proprietary noise-
reducing electrodes (Figure 2.3) and seven standard electrodes were placed on the 
praecordium and limbs. The proprietary electrodes are designed to detect alternans, even in the 
presence of the noise that is usually present during exercise stress testing. Noise was further 
minimised by careful preparation of the skin using abrasive gel prior to electrode placement. 
Detailed ECG recordings were taken at rest, during exercise on the treadmill and in recovery 
(Figure 2.4). The treadmill exercise was tailored to produce a gradual elevation in heart rate. 
The test requires elevation of the heart rate to at least 110bpm for approximately 2-3 minutes. 
The HearTWaveTM system then analyses the data by measuring the amplitude of the 
corresponding points of 128 consecutive T waves (Figure 2.5) (141). Each T-wave is 
measured at the same time point relative to the start of the QRS complex. Beat-to-beat 
fluctuations in amplitude are plotted and fast Fourier transformation performed to quantify the 
variation in frequency (Figure 2.5) (141). The HearTWaveTM system provides an automatic 
interpretation of the test results, as positive, negative or indeterminate. Indeterminate results 
are most commonly due to an inability to raise the heart rate sufficiently (due to chronotropic 
incompetence or if the patient is physically incapable of exercising long enough to raise their 
heart rate), the presence of ventricular ectopy or excessive signal noise due to motion or 
respiration (141). Indeterminate tests due to noise may become determinate when re-tested 
immediately. There is evidence that indeterminate results due to noise are not prognostically 
significant (123) and for this reason, those patients with an indeterminate result due to 
excessive noise were re-tested once. Whether or not a patient was prescribed optimal HF 
therapy at the time of MTWA testing was also documented. Patients were not asked to 
discontinue beta-blockers prior to MTWA testing; previous studies have done this in order to 
improve the likelihood of a determinate test. A fundamental objective of this study was to 
determine the predictive role of MTWA testing while taking optimal individualised therapy. 
Overall the MTWA test takes less than 30 minutes to perform, including preparation time. 
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Figure 2.2: HearTWaveTM system (Cambridge Heart) 
 
 
 
 
Figure 2.3:  Proprietary ECG electrodes 
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Figure 2.4: MTWA testing in the BHF Glasgow Cardiovascular Research Centre 
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Fast Fourier transformation   
  
 
 
 
 
 
 
Figure 2.5: Spectral method of measuring T-wave alternans (141) 
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2.3.6.2 Microvolt T-Wave Alternans Prevalence Study 
 
Eligibility for MTWA testing was recorded for all patients attending the study visit. Reasons 
for ineligibility were documented (AF, demand ventricular pacing or inability to exercise). 
Differences in clinical characteristics according to eligibility for MTWA testing were analysed. 
Potential eligibility for MTWA treadmill testing was recorded for patients who did not attend 
and was derived from clinical data collected during the hospital admission. This was to enable 
an assessment of whether or not the patients attending the study visit were representative of an 
unselected cohort of patients with HF.  
 
The results of MTWA testing and the prevalence of positive, negative and indeterminate 
results in our study population were recorded. The reasons for an indeterminate test were 
outlined. The functional capacity of the patients was recorded. This included a description of 
the reason for terminating exercise, duration of exercise and metabolic equivalent values 
(METs) expended. This would allow an evaluation of the practicality of MTWA testing in 
patients with HF. For patients unable to exercise, MTWA testing at rest was described.  
 
All automated computer-generated MTWA test results were reviewed by myself and 
subsequently interpreted by a single clinician (Dr Rachel Myles) experienced in reviewing 
MTWA reports. The clinician was blinded to both the patient details and the automated 
computer-generated result. This would enable an assessment of the correlation between the 
automatic result and a clinician’s interpretation. 
 
Differences in the clinical characteristics between the three MTWA groups were analysed to 
determine the clinical associates of a particular MTWA result. Particular attention was paid to 
LVEF, aetiology of HF (ischaemic or non-ischaemic), QRS duration, BNP levels, as well as 
many clinical and demographic variables. 
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2.3.6.3 Microvolt T-Wave Alternans Prognostic Study 
 
The prognostic value of MTWA testing was examined after a period of follow-up (section 2.5). 
The statistical analysis of the prognostic study is described later (section 2.6). The incremental 
prognostic value of MTWA over established predictors of outcome in HF was determined. 
These included LVEF, BNP, clinical variables and biochemical and haematological indices. 
These analyses were carried out in all patients completing MTWA testing. 
 
2.4 Database Construction 
 
All paper copies of the hospital and study visit case record forms were kept in a locked filing 
system at the BHF Glasgow Cardiovascular Research Centre. An electronic database was 
created in the Robertson Centre for Biostatistics at the University of Glasgow to store these 
data. Data were manually entered into the electronic database and verified by two independent 
database managers working in the Robertson Centre. No patient identifying material was 
entered into the electronic database; patients were anonymised and identified by their unique 
study identification number. All data were subject to manual and prespecified electronic data 
validation checks which resulted in the production of a large number of queries. All queries 
were rectified and data appropriately amended in the central database. This robust system 
ensured quality control of the data processed. 
 
2.5 Long-Term Follow Up 
 
All enrolled patients consented to be “flagged” with the Information Services Division (ISD) 
of the Scottish Health Service. This allowed mortality follow-up data to be obtained. Patient 
identifying information was sent to ISD for all patients once recruitment was complete. ISD 
linked the study database to information on in-hospital and out-of hospital deaths, held by the 
General Register Office for Scotland. The database was also linked to the Scottish Morbidity 
Register which provides details of dates and causes of hospital readmission. Data on cause, 
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location and date of death were obtained. ISD classifies causes of death using the WHO 
International Classification of Diseases (ICD-10) coding system.  
 
The final follow-up visit was 12th March 2009. Linkage data were requested in January 2010. 
Data provided by ISD has a lag time of approximately six months. Thus, survival time was 
calculated from the date of attendance at the study visit until death or censoring at 31st July 
2009. 
 
2.6 Statistical methodology  
 
2.6.1 Statistical Analyses  
 
Statistical Package for the Social Sciences (SPSS) (version 18) software was used for basic 
statistical analyses. S-Plus (version 8.1) was used for analysis of variance (ANOVA), 
Student’s t-test, χ2 test logistic regression and mortality analyses.   
 
Inter-group comparisons were made for continuous variables using ANOVA F-test (for 
comparisons involving more than 2 groups) and Student’s t-test (for 2 group comparisons), 
and for categorical variables using χ2 test. Logistic regression analysis was used to identify 
predictors of each MTWA result. A probability value of p<0.1 was used for selecting variables 
for the logistic regression analyses. A probability value of p<0.05 was considered significant 
for all other analyses. All continuous variables were transformed as appropriate to normalize 
their distributions. 
 
Survival time was calculated from the date of attendance at the study visit until death or 
censoring at 31st July 2009. Kaplan-Meier survival curves were constructed to illustrate 
survival of the patients according to MTWA result. Curves were compared using the log rank 
test. The incremental prognostic value of MTWA testing was evaluated using Cox 
proportional hazard models. A three stage prognostic model (Table 2-3) was used with 
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variable selection based on the clinical model derived by the CHARM investigators (126). 
Stage one, the basic model, incorporated the strongest predictors of outcome from the 
CHARM model in a multivariable Cox proportional hazard model. Stage two included the 
variables from stage one plus routine haematological and biochemical variables predictive of 
outcome in the subsequent CHARM analyses (140;142). Stage three included the variables 
from stages one and two plus the novel biomarkers BNP and troponin I. For the multivariable 
models variables were removed using backwards elimination, removing the largest p values 
first until all p values were significant (< 0.05). Finally, the MTWA result was added to each 
of the three stages to assess for incremental prognostic value.  
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Table 2-3: Three stage model for evaluating the incremental prognostic value of MTWA 
 
Stage Variables 
1 Age 
Ejection fraction 
Diabetes – insulin treated 
BMI (kg/m2) 
Sex (Female) 
NYHA class III and IV 
Bundle branch block 
Cardiomegaly 
SBP 
Diagnosis of chronic HF over 2 years ago  
Previous myocardial infarction  
Dependent oedema  
Heart rate 
AF  
2 eGFR 
RDW 
Bilirubin 
Haemoglobin 
Lymphocytes 
Urate 
Phosphate 
Glycosylated haemoglobin 
3 BNP 
Troponin I 
 
BMI = body mass index; RDW = red cell distribution width 
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2.6.2 Power Calculation 
 
It was assumed that if 600 subjects were recalled for MTWA testing then 400 would actually 
undergo evaluation, after excluding those ineligible for testing. Based on recent studies 
(107;109), it was assumed that these would split one third MTWA negative and two thirds 
MTWA non-negative (positive or indeterminate). Power calculations were based on the all-
cause mortality data estimating the hazard ratio of MTWA (non-negative / negative) with 
adjustment for other prognostic factors. Assuming crude 1 year mortality rates of 21% in the 
preserved ejection fraction group and 32% in the reduced ejection fraction group, as observed 
in a recent study in Glasgow (25), the study would have 84% power at the 5% level of 
significance to detect a MTWA non-negative/ MTWA negative hazard ratio of 1.78.  
 
2.6.3 Defining events and outcomes 
 
The primary outcome measure of this study was all-cause mortality. Secondary outcome 
measures of interest were (i) SCD or resuscitated cardiac arrest, and (ii) cardiovascular death 
(excluding sudden). All outcome data were obtained from linkage data provided by ISD. 
Causes of death were classified according to the ICD-10 classification as documented on the 
death certificates. Causes of death were not adjudicated. Although the secondary outcome 
measures were of interest in this study, it was recognised at study conception that, due to the 
limitations of the ISD data, only all-cause mortality would be a robust and definitive outcome. 
 
All-cause mortality was defined as death from any cause. Cardiac transplantation was also 
censored as death. Much has been written on the problems of defining and identifying SCD, 
particularly in patients with HF (143;144). Not all sudden deaths are arrhythmic, and not all 
arrhythmic deaths are sudden. The majority of SCD occurs outside hospital, and is commonly 
certified as acute myocardial infarction. A small proportion of patients undergo a resuscitation 
attempt by the ambulance service, while others may suffer sudden and unexpected death 
during their hospital admission. Some classification systems, such as that proposed by Hinkle 
and Thaler (145), require detailed information to be obtained from relatives or medical 
attendants on the exact sequence of events immediately prior to death. Such an approach was 
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beyond the scope of this study. A recent clinical trial in patients with acute HF defined SCD as 
death occurring unexpectedly in a previously stable patient and including any of the following 
deaths: (i) witnessed and instantaneous without new or worsening symptoms and also in the 
absence of progressive circulatory failure lasting for 1 hour or more, (ii) witnessed within 1 
hour of the onset of new or worsening symptoms unless a cause other than cardiac is obvious, 
(iii) death witnessed and attributed to an identified arrhythmia, (iv) death during an attempted 
resuscitation for cardiac arrest or death within 24 hours of resuscitation, or without gaining 
consciousness, from cardiac arrest in the absence of pre-existing circulatory failure or other 
causes of death, and (v) unwitnessed death in the absence of pre-existing progressive 
circulatory failure or other causes of death, only where the stability of the patient in the week 
prior to death was known (146). Clinical trials are supported by endpoint adjudication 
committees who are provided with detailed information regarding deaths, allowing the clinical 
expertise of the committee to appropriately adjudicate the cause of deaths. Some MTWA 
studies have included SCD as a clinical endpoint (103;104;111-115;119). These studies have 
defined SCD as death within an hour of symptom onset or during sleep without another 
identifiable cause.  
 
The detailed information and infrastructure required for adjudicating sudden cardiac death, as 
outlined above, was not available for this study. Thus, a pragmatic definition of SCD for this 
study was adopted as being: (i) death occurring outside hospital and certified as due to acute 
MI, (ii) death certified as cardiac arrest (ICD-10 code I46) or (iii) death certified as VF (ICD-
10 code I490) or VT (ICD-10 code I472).  
 
The secondary outcome ‘SCD or resuscitated cardiac arrest’ therefore included successful in- 
and out-of-hospital resuscitations of cardiac arrest (ICD-10 code I460), in addition to SCD as 
defined above. Information regarding appropriate ICD discharges for documented ventricular 
arrhythmia is not provided by ICD-10 codes and was therefore unavailable and not included in 
outcome measures for this study. Cardiovascular death (excluding sudden) was defined as 
death from any cardiovascular disease (ICD-10 codes I00-I99) and not meeting the criteria for 
sudden cardiac death, as outlined above. The latter was included to evaluate if MTWA was 
predictive of general cardiovascular mortality, rather than arrhythmic mortality. 
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3.1 Introduction 
 
This chapter will outline the recruitment of patients into the study and detail the reasons for 
exclusion from participation. The main focus of this chapter is to describe in detail the clinical 
characteristics of the hospitalised patients recruited into the study. This will include basic 
demographic details, signs and symptoms prior to admission, medical history, medications 
prescribed pre-admission, medical therapies administered during the first 24 hours after 
admission and examination findings. Electrocardiographic, radiological, blood test and 
echocardiographic results will also be described.   
 
3.2 Results 
 
3.2.1 Selection of study cohort 
 
An overview of the patients screened for participation in the study and the subsequent 
involvement of recruited patients in the follow-up study visit is shown in Figure 3.1. 
Recruitment into the study took place between 1.12.06 and 10.01.09 at the Royal and Western 
Infirmaries in Glasgow and between 22.04.08 and 10.01.09 at the Royal Alexandra Hospital in 
Paisley. During these periods, 2361 patients admitted with suspected decompensated HF were 
screened for participation in the study. A total of 1003 patients were recruited; the breakdown 
per hospital and rate of recruitment is displayed in Figure 3.2. Recruitment stopped once the 
600th patient had completed the study visit. This was the original target number of patients 
(section 2.6.2, page 89). 
 
More than half (n=1358) of all patients with suspected decompensated HF were excluded from 
recruitment. Figure 3.3 illustrates the reasons for exclusion.  The most common reason was 
readmission of patients already enrolled in the study, confirming the high readmission rates 
that occur for patients with HF. The next most common reasons for exclusion were cognitive 
impairment and a normal BNP level (<100pg/ml). Analysis per hospital revealed consistency 
for most reasons of exclusion (Figure 3.3). Notable exceptions to this were the following 
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categories; BNP level <100pg/ml, pulmonary oedema secondary to ACS (acute coronary 
syndrome) and refusal to take part in the study. A greater proportion of patients screened in 
Glasgow Royal Infirmary had a normal BNP level than the other two hospitals. This may be 
due to variation in operator screening techniques at the three hospitals. Alternatively, more 
patients with suspected HF may have been admitted to Glasgow Royal Infirmary. The 
proportions of patients excluded due to pulmonary oedema secondary to ACS were similar at 
the two Glasgow hospitals but lower at the Royal Alexandra Hospital. The reasons for this are 
unclear but may reflect less frequent screening at the Royal Alexandra Hospital or variations 
in investigator screening technique at that site. Finally, considerable variation in the number of 
patients who refused to take part in the study was observed across all three sites. The reasons 
for this are likely multifactorial and may include the communication skills of the investigators 
at each hospital, the patients response to whether a doctor or research nurse approached them 
and the distance the patient would have to travel for the follow-up visit. The majority of 
patients in the category ‘Other’ would have required ambulance transportation to the study 
visit. This included nursing home residents, patients dependent on domiciliary oxygen and 
those who were housebound.  Patients who subsequently had alternative diagnoses and 
explanations for an elevated BNP, such as pulmonary embolism, were also included in the 
category ‘Other’. 
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Figure 3.1: Overview of all the patients screened from the three hospitals and final 
composition of the recruited study cohort 
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Figure 3.2: Recruitment into the study; overall and per hospital. This figure details the rate of recruitment at each of the 3 hospitals, from 1st 
December 2006 for Royal and Western Infirmaries in Glasgow (GRI and WIG, respectively) and from the 22nd April 2008 from the Royal 
Alexandra Hospital (RAH). Recruitment finished on 10th January 2009.  
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Figure 3.3: Breakdown of the major reasons for exclusion from recruitment into the 
study, per hospital.  
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3.2.2 Demographics  
 
The demographics of the hospitalised cohort are displayed in Table 3-1. The majority of 
patients were male (53%). The mean (SD) age was 73 years (10.5), with a wide overall range 
from 19 to 99 years. Almost half of the cohort was more than 75 years old. The vast majority 
of patients were Caucasian (98.7%).  The mean (SD) duration of admission was 12 days (14), 
with a wide overall range from 1-141 days. Many patients died during the index admission 
(6.8%).  
 
Table 3-1: Demographics of the hospitalised cohort 
  
 
Variable n (%), mean (SD) or median [IQR] 
Male 532 (53.0) 
Female 471 (47.0) 
Mean age (years)  73 (10.5) 
Median age (years)  74 [67-81] 
Age range 18 – 99 
≥ 75 years old 458 (45.7) 
Race 
     Caucasian 
     Black 
     South Asian 
     Oriental 
 
990 (98.7) 
2 (0.2) 
10 (1.0) 
1 (0.1) 
Mean duration of admission (days)  12 (14) 
Median duration of admission (days)  8 [5-14] 
Death during index admission 68 (6.8) 
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3.2.3 History of heart failure 
 
Many patients hospitalised with decompensated HF have a history of chronic HF and previous 
hospital admissions. In this study, almost half of the patients had a history of chronic HF. The 
majority of these patients had previous hospitalisations with decompensated HF (76.5%). 
Most patients with a history of HF had this diagnosis established more than two years before 
enrolment into this study (71.4%).  
 
Various healthcare professionals were involved in the care of those patients with a history of 
HF (Figure 3.4). The majority of these patients had regular cardiology follow-up, attending 
either general cardiology clinics (50.5%) or HF specialist clinics (22.1%). A small proportion 
of patients were looked after by a general physician (14.4%), whilst a similar proportion was 
cared for by their general practitioner alone (13.0%). Many patients were also under the care 
of HF liaison nurse services (22.3%). 
 
 
 
 
 
Figure 3.4: Healthcare professionals involved in the management of patients with a 
diagnosis of HF prior to recruitment into the study 
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3.2.4 Symptoms prior to admission 
 
Symptoms of decompensated HF in the days prior to admission were recorded for every 
patient. Each patient was asked if they had experienced any of the following symptoms: 
paroxysmal nocturnal dyspnoea, orthopnoea, ankle swelling, palpitations, wheeze and chest 
pain. Table 3-2 displays the frequencies of these symptoms. Orthopnoea and ankle swelling 
were the commonest symptoms, affecting more than two-thirds of the cohort. Most patients 
had NYHA functional class III symptoms at the time of admission (59.2%).  Similar 
proportions of patients had NYHA functional classes II or IV symptoms (22.4% and 18.4%, 
respectively). More than half of all patients recruited had a history of angina.  
 
Table 3-2: Symptoms of heart failure prior to admission  
 
 
Symptoms Number of patients % of cohort (n=1003) 
NYHA Class    
                        II 
                        III 
                        IV 
 
225 
594 
184 
 
22.4 
59.2 
18.4 
Paroxysmal nocturnal dyspnoea 484 48.3 
Orthopnoea 761 75.9 
Ankle swelling 698 69.6 
Palpitations 204 20.3 
Wheeze 291 29.0 
History of angina 
                      Current angina 
548 
296 
54.6 
29.5 
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3.2.5 Medical history 
 
Table 3-3 shows the common cardiovascular conditions and their prevalences in the 
hospitalised cohort. The risk factors for cardiovascular disease are displayed in Table 3-4.  
 
Coronary heart disease is the commonest cause of HF. Of 1003 patients enrolled in the study, 
443 patients (44.2%) had a history of a previously reported MI. Many patients had evidence of 
significant coronary artery disease on angiography (defined as at least 50% stenosis in at least 
1 major epicardial artery). The results of coronary angiograms performed prior to enrolment in 
the study are displayed in Figure 3.5. Percutaneous coronary intervention (PCI) had been 
performed in 122 patients (12.2%) and 170 patients (17.0%) had previous coronary artery 
bypass grafting (CABG), at the time of enrolment.  
 
Hypertension is a frequent cause of HF, particularly in elderly patients, and was particularly 
common in this study with almost two-thirds of the cohort treated for hypertension prior to 
recruitment. A significant proportion had hypercholesterolemia (36.0%). Cerebrovascular 
disease, defined as a cerebrovascular accident (CVA) or transient ischaemic attack (TIA), was 
also common (23.0%). 
 
Atrial fibrillation (AF) is a common comorbidity in HF, especially in this study. Over half of 
all patients had a history of AF (53.5%), with the majority of these patients experiencing 
permanent AF (28.5%). Few patients had a past history of AF but were in sinus rhythm at the 
time of recruitment (3.2%). A similar proportion of patients had paroxysmal AF (11.2%) or 
persistent AF (10.7%). 
 
Arrhythmias are a common cause of morbidity and mortality in HF. Of 1003 enrolled patients, 
108 patients (10.8%) had documented evidence of a prior arrhythmia. A similar proportion of 
patients had a history of syncope (12.2%). The documented arrhythmias included 
supraventricular tachycardia (SVT) (1.7%) ventricular tachycardia (VT) (2.6%), ventricular 
fibrillation (VF) (1.6%), sick sinus syndrome (SSS) (1.7%) and atrioventricular (AV) block 
 101 
(3.2%). Of the small number of patients with a documented history of VT, the majority was 
nonsustained VT (73.1%). Of the patients with a history of AV block; the majority had either 
second or third degree (40.6% and 43.8%, respectively). The low prevalence of first-degree 
AV block may simply reflect this arrhythmia not being recorded in the medical case-notes.  
 
Only 5 patients (0.5%) had a primary prevention ICD and 8 patients (0.8%) a secondary 
prevention ICD. Conventional pacemakers were more common (6.1%), but few patients had 
cardiac resynchronisation therapy with a defibrillator device (CRT-D) (0.5%). No patients had 
cardiac resynchronisation therapy without a defibrillator device (CRT-P) at the time of 
enrolment into the study. 
  
Many patients had a history of valvular heart disease (44.3%). A subset of these patients had a 
history of rheumatic valvular heart disease (7.2%) or a valve replacement prior to enrolment 
into the study (8.0%).  
 
Diabetes mellitus is an established risk factor for coronary heart disease and has recently 
emerged as a risk factor for HF. Almost one third of the cohort had a history of diabetes 
mellitus (31.2%). This was managed in the following ways; dietary modification alone (5.8%), 
oral hypoglycaemic therapy (14.4%), insulin (8.0%), and oral hypoglycaemic and insulin 
combination therapy (3.1%).  
 
Alcohol is another important risk factor for HF and the majority of patients in this study 
acknowledged alcohol consumption prior to admission (62.0%). Of these patients, few 
admitted to alcohol intake in excess of the recommended safe limits (7.0%). A similar 
proportion of patients admitted to a previous history of alcohol excess (9.6%) and almost half 
of the cohort consumed alcohol within the recommended limits (45.5%). Few patients 
admitted to a past history of alcohol excess but drank within recommended limits at the time 
of admission (1.1%). 
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Over two-thirds of the cohort reported a history of cigarette smoking, the majority being ex-
smokers. Of the ex-smokers, most had stopped smoking more than 12 months before 
recruitment into the study. Approximately one fifth of the cohort were cigarette smokers prior 
to admission. 
 
A family history of cardiac disease was recorded for every patient enrolled in the study. The 
majority had no family history (61.0%). Around one third of the cohort described details of a 
family history of coronary heart disease, with few patients aware of family members with a 
diagnosis of a cardiomyopathy (0.7%). A small proportion could give an account of family 
members having a history of cardiac disease but did not know the specific diagnoses (5.1%).  
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Medical condition Number of patients % of cohort (n=1003) 
MI 443 44.2 
Angiographic CAD 323 /436 74.1 
PCI 122 12.2 
CABG 170 17.0 
Cerebrovascular disease (TIA/CVA)  231 23.0 
Atrial fibrillation 
          Past 
          Paroxysmal 
          Persistent 
          Permanent 
 
32 
112 
107 
286 
 
3.2 
11.2 
10.7 
28.5 
Prior arrhythmia  
          SVT 
          SSS 
          1st degree AV block 
          2nd degree AV block 
          3rd degree AV block 
          Sustained VT 
          Nonsustained VT 
          VF 
 
17 
17 
5 
13 
14 
7 
19 
16 
 
1.7 
1.7 
0.5 
1.3 
1.4 
0.7 
1.9 
1.6 
Conventional pacemaker  61 6.1 
CRT-D 5 0.5 
Primary prevention ICD 5 0.5 
Secondary prevention ICD 8 0.8 
Valvular heart disease 444 44.3 
Rheumatic heart disease 72 7.2 
Valve replacement 80 8.0 
Peripheral arterial disease 180 18.0 
 
CAD = coronary artery disease (defined as > 50% stenosis in ≥ 1 major epicardial vessel, 
denominator is number of patients who had an angiogram) 
Table 3-3: Common cardiovascular conditions present in the hospitalised cohort 
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Table 3-4: Prevalence of major risk factors for cardiovascular disease in the hospitalised 
cohort 
 
Cardiovascular risk factor Number of patients % of cohort (n=1003) 
Treated hypertension 660 65.8 
Hypercholesterolemia 361 36.0 
Diabetes mellitus 
    Diet controlled 
    Oral therapy  
    Insulin 
    Oral therapy & insulin 
313 
58 
144 
80 
31 
31.2 
5.8 
14.4 
8.0 
3.1 
Smoking history 
    Ex-smoker >1 year 
    Ex-smoker <1 year 
    Current smoker 
 
427 
46 
208 
 
42.6 
4.6 
20.7 
Alcohol history 
    Within recommended limits 
    Previous or current excess  
 
456 
166 
 
45.5 
16.6 
Family history of cardiac disease 
    No history 
    Unknown cardiac conditions 
    Coronary heart disease 
    Cardiomyopathy 
 
612 
51 
333 
7 
 
61.0 
5.1 
33.2 
0.7 
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Figure 3.5: Coronary angiography results for the hospitalised cohort. This figure 
displays the results of angiograms performed prior to recruitment into the study. 
 
 
Table 3-5 shows the common non-cardiovascular medical comorbidities and their prevalences 
in the hospitalised cohort. Chronic obstructive pulmonary disease (COPD), anaemia and 
depression are common comorbidities with HF. In particular, HF and COPD often coexist and 
almost one-third of the cohort had a diagnosis of COPD at the time of enrolment into the study. 
Anaemia has also been demonstrated to be frequently present in HF. Anaemia, as defined by 
the WHO criteria (139), affected almost half of the hospitalised cohort. A significant 
proportion of patients with HF have depression. This was observed in this study with one fifth 
of all patients having a history of depression and the majority of these patients were 
experiencing ongoing symptoms prior to their admission to hospital. Weight loss is associated 
with a poor prognosis in HF. Involuntary weight loss, defined as a loss of at least 5% of body 
weight, was experienced prior to admission in a significant proportion of the hospitalised 
cohort. Other common comorbidities recorded in the hospitalised cohort are displayed in 
Table 3-5. Finally, only 12 patients (1%) had no significant medical history at the time of 
recruitment into the study. This was defined as no cardiovascular disease, cardiovascular risk 
factor or other medical comorbidity. 
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Table 3-5: Frequencies of common non-cardiovascular medical comorbidities in the 
hospitalised cohort 
 
Medical condition Number of patients % of cohort (n=1003) 
Depression  
         Current  
208 
139 
20.7 
13.9 
Cancer 
         Previous 
         Current 
 
121 
24 
 
12.1 
2.4 
COPD 297 29.6 
Asthma 48 4.8 
Anaemia 454 45.3 
Hypothyroidism 102 10.2 
Hyperthyroidism 22 2.2 
Osteoarthritis 255 25.4 
Rheumatoid arthritis 35 3.5 
Connective tissue disease 20 2.0 
Neuropathy 58 5.8 
Urinary incontinence 112 11.2 
Involuntary weight loss  
(≥ 5% body weight) 
164 16.4 
 
3.2.6 Medications pre-admission 
 
Table 3-6 displays the frequencies of prescribing of HF medications prior to admission. More 
than two-thirds of the cohort was prescribed diuretics prior to admission. This was more than 
the number of patients with an established previous diagnosis of HF. This may be explained 
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by General Practitioners suspecting a diagnosis of HF in the weeks preceding admission, and 
initiating diuretic therapy. Half of the cohort was prescribed an ACE inhibitor prior to 
admission, with almost the same proportion of patients prescribed a beta blocker. Fewer 
patients were prescribed an ARB or an aldosterone blocker prior to admission.  
 
Table 3-6: Frequency of heart failure medication prescribing prior to admission to 
hospital 
 
 
Heart failure medication Number of patients  % of cohort (n=1003) 
Diuretics 696 69.4 
Furosemide & other loop diuretics 641 63.9 
ACE inhibitor 507 50.6 
ARB 140 14.0 
ACE or ARB 613  61.1 
ACE and ARB 34 3.4 
Beta-blocker 478 47.7 
Aldosterone blocker 66 6.6 
Digoxin 167 16.7 
 
 
Table 3-7 outlines the frequencies of prescribing of other common cardiovascular medications. 
A large proportion of patients were taking statins and aspirin prior to admission, reflective of 
the high prevalence of coronary heart disease in this cohort. A significant number of patients 
were prescribed calcium channel blockers, warfarin, oral hypoglycaemic agents or long-acting 
nitrates. Smaller proportions of patients were taking digoxin, nicorandil, clopidogrel, insulin 
or anti-arrhythmic medications. 
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Table 3-7: Frequency of cardiovascular medication use prior to admission to hospital 
 
Cardiovascular medication Number of patients  % of cohort (n=1003) 
Statins 657 65.5 
Aspirin 543 54.1 
Clopidogrel 118 11.8 
Aspirin or clopidogrel 602 60.0 
Calcium channel blockers 272 27.1 
Warfarin 264 26.3 
Oral hypoglycaemic agents 244 24.3 
Long-acting nitrates 196 19.5 
Nicorandil 147 14.7 
Insulin 109 10.9 
Anti-arrhythmic 38 3.8 
 
Many patients were taking non-cardiovascular medications prior to their admission to hospital, 
reflective of the many comorbidities associated with HF (Table 3-8). Almost 40% of the 
cohort was prescribed proton pump inhibitors. A significant number of patients were 
prescribed bronchial inhalers, consistent with the high prevalence of chronic obstructive 
airways disease in this cohort. Few patients were prescribed non-steroidal anti-inflammatory 
drugs (NSAIDs). 
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Table 3-8: Frequency of non-cardiovascular medication use prior to admission to 
hospital 
 
Non-cardiovascular medication Number of patients  % of cohort (n=1003) 
Proton pump inhibitors 396 39.5 
Inhalers 283 28.2 
Antidepressants 146 14.6 
Ferrous sulphate 105 10.5 
Allopurinol 76 7.6 
Alendronate  58 5.8 
Vitamins (B1 & B-complex)  54 5.4 
NSAIDs 37 3.7 
Antihistamines 30 3.0 
H2-receptor antagonists 26 2.6 
Incontinence meds 20 2.0 
 
3.2.7 Heart failure medical therapy during first 24 hours of admission 
 
The medical therapy administered during the first 24 hours of admission was recorded for 
every patient in the study (Table 3-9). Medical therapies prescribed beyond the first 24 hours 
of hospitalisation and on discharge from hospital were not recorded. Medications prescribed 
on discharge from hospital were likely similar to the medical therapy recorded at the follow-up 
study visit, albeit smaller doses of HF therapies may have been prescribed on discharge. 
 
Nearly all patients in the study were treated with diuretics immediately on admission to 
hospital. The most commonly used diuretic was furosemide (95.7%). Of the patients treated 
with furosemide on admission, the majority were given this medication intravenously (71.2%).  
More than half of the patients treated with intravenous furosemide received this more than 
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once during their admission. Almost one quarter of the cohort received oral diuretic therapy on 
admission to hospital.  
 
A small number of patients were treated with intravenous nitrates (8.9%) or inotropes (1.7%) 
on admission to hospital. Most patients receiving these therapies are critically unwell.  
Approaching such patients for consent to participate in a research study could be ethically 
inappropriate. This may explain why few patients treated with these therapies were enrolled in 
this study. 
 
Table 3-9: Heart failure medications administered during the first 24 hours of 
hospitalisation  
 
Heart failure therapy Number of 
patients  
% of cohort (n=1003) 
Diuretics 975 97.2 
Furosemide 960 95.7 
              i) Intravenous furosemide  
                 Single dose 
                 Regular 
714 
333 
381 
71.2 
33.2 
38.0 
              ii) Oral furosemide 247 24.6 
Intravenous nitrate 89 8.9 
Inotropes (dopamine or dobutamine)  17 1.7 
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3.2.8 Clinical examination findings on admission 
 
3.2.8.1 Routine physiological measurements  
 
Routine physiological measurements were recorded for all patients enrolled in the study 
(Table 3-10). The first recording on arrival to hospital was used. The mean pulse rate was 90 
bpm, with approximately one-third of patients having a tachycardia on admission (defined as 
pulse >100 bpm). Of those patients with a tachycardia on admission, almost half were in AF 
on their admission ECG. The majority of patients had a pulse between 60-100 bpm on arrival 
to hospital, with few patients having a bradycardia (defined as pulse <60 bpm). The mean 
(standard deviation [SD]) blood pressure was 136/76 mmHg (27.3/18.0), with an elevated 
pulse pressure of 60mmHg. Many patients had a systolic blood pressure (SBP) greater than 
140 mmHg (41.8%), with a significant proportion of these patients having stage 2 
hypertension (defined as SBP ≥ 160 mmHg) on admission (16.4%).  Few patients had systolic 
hypotension (defined as SBP <90 mmHg) on admission. Over one fifth of patients presented 
with diastolic hypertension (defined as diastolic blood pressure [DBP] ≥ 90 mmHg). A similar 
proportion of patients presented with diastolic hypotension (defined as DBP <60 mmHg). The 
mean temperature was 36.5°C with the majority of patients having a temperature within the 
normal range (defined as 36.1-37.8°C). The mean respiratory rate was slightly elevated and 
most patients were tachypnoeic (defined as respiratory rate ≥ 20 breaths per minute) on 
admission to hospital (66.2%). The median oxygen saturation (SpO2) on admission to hospital 
was 96%. Almost one third of all patients had SpO2 recordings less than 95% on admission to 
hospital. 
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Table 3-10: Physiological measurements on admission to hospital.  
 
Variable n (%), mean (SD) or median [IQR] Units 
Mean pulse rate 90 (24.2) bpm 
Median pulse rate 86 [71-105] bpm 
Pulse rate > 100 324 (32.3) bpm 
Pulse rate > 100 & AF on ECG 149/324 (46) bpm 
Pulse rate < 60 67 (6.7) bpm 
Mean SBP 135.6 (27.3) mmHg 
Median SBP  134 [115-152] mmHg 
SBP > 140 419 (41.8) mmHg 
SBP ≥ 160 164 (16.4) mmHg 
SBP < 90 27 (2.7) mmHg 
Mean DBP 76.1 (18.0) mmHg 
Median DBP 75 [63-88] mmHg 
DBP ≥ 90 228 (22.7) mmHg 
DBP < 60 215 (21.4) mmHg 
Mean pulse pressure 59.5 (21.3) mmHg 
Median pulse pressure 56 (45-71) mmHg 
Mean temperature 36.5 (0.7) ° Celsius 
Median temperature  36.6 [36.1-36.9] ° Celsius 
Temperature < 36.1 254 (25.3) ° Celsius 
Temperature > 37.8 35 (3.5) ° Celsius 
Mean respiratory rate 22 (5.1) breaths / min 
Median respiratory rate  20 [18-24] breaths / min 
Respiratory rate ≤ 12 3 (0.3) breaths / min 
Respiratory rate ≥ 20 664 (66.2) breaths / min 
Mean SpO2 95 (4.2) % 
Median SpO2 96 [94-97] % 
SpO2 < 95% 314 (31.3) % 
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3.2.8.2 Body mass index and waist circumference measurements 
 
Table 3-11 displays the body composition measurements recorded on admission to hospital. 
Height, waist and weight measurements were recorded for all patients enrolled into the study. 
Body mass index (BMI) was calculated from these measurements. Over two-thirds of all 
patients were either overweight or obese on admission (defined as BMI 25-30 kg/m2 or >30 
kg/m2, respectively). Few patients were underweight on admission (defined as BMI <18.5 
kg/m2). In terms of waist circumference, over half of all patients had a waist circumference 
exceeding the sex-specific recommendations (defined as ≥ 102 cm in men and ≥ 88 cm in 
women). Approximately one quarter of patients had a waist circumference below the sex-
specific recommendations (defined as <94 cm in men and <80 in women).  
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Measurement n (%), mean (SD) or median [IQR] Units 
Mean height 163.5 (10.4) cm 
Median height  163.0 [156-171] cm 
Mean height (men) 170.2 (8.1) cm 
Mean height (women) 155.9 (7.2) cm 
Mean weight 77.7 (20.4) kg 
Median weight  75.0 [63-89] kg 
Mean weight (men) 84.4 (20) kg 
Mean weight (women) 70.2 (18.3) kg 
Mean BMI  29.0 (6.9) kg/m2 
Median BMI 27.8 [24.1-32.8] kg/m2 
Mean BMI (men) 29.1 (6.5) kg/m2 
Mean BMI (women) 28.9 (7.3) kg/m2 
BMI calculation missing 10 (1.0) - 
BMI < 18.5 (underweight) 23 (2.3) kg/m2 
BMI 18.5–24.9 (normal weight) 285 (28.7) kg/m2 
BMI 25–30 (overweight) 307 (30.9) kg/m2 
BMI >30 (obese) 378 (38.1) kg/m2 
Mean waist 98.7 (17.1) cm 
Median waist  97.0 [87-109] cm 
Waist measurement missing 31 (3.1) - 
Waist < 94 males; < 80 females 240 (24.7) cm 
Waist 94–102 males; 80–88 females 195 (20.1) cm 
Waist ≥ 102 males; ≥ 88 females 537 (55.2) cm 
 
Table 3-11: BMI and waist circumference measurements on admission to hospital 
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3.2.8.3 Cardiovascular examination signs 
 
A full cardiovascular examination was performed for all patients enrolled into the study (Table 
3-12). The cardiovascular signs on examination were consistent with expected findings for 
patients with decompensated HF. The majority of patients had a raised jugular venous pressure 
(JVP), pulmonary crackles and peripheral oedema. Almost one quarter of patients had a 
palpable displaced apex beat. Nearly all patients were in Killip class II or III. The small 
number of patients in Killip class IV likely reflects the high mortality associated with this 
clinical state, and the unsuitability of approaching such unstable patients for inclusion in a 
research study. The small number of patients with a third heart sound is unexpected for a 
cohort of patients with decompensated HF. One explanation may be the variation in an 
individual’s ability to detect and record this clinical sign. Furthermore, this sign may have 
been no longer present by the time of enrolment if the patient had already received HF 
treatment. More than one-third of all patients recruited had a detectable murmur recorded, 
consistent with the notable prevalence of valvular heart disease. 
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Table 3-12: Cardiovascular examination findings on admission to hospital 
 
Clinical Sign Number of patients % of cohort (n=1003) 
Elevated JVP (>4cm) 680 67.8 
JVP not elevated 210 20.9 
JVP not seen 113 11.3 
Palpable apex 661 65.9 
Displaced apex 241 24.0 
Third heart sound 66 6.6 
Murmur 367 36.6 
Pulmonary crackles (any) 942 93.9 
Pulmonary crackles – basal only 706 70.4 
Pulmonary crackles – mid-zones 223 22.2 
Pulmonary crackles - apices 13 1.3 
Pleural effusion(s) 150 15.0 
Peripheral oedema (any) 725 72.3 
Peripheral oedema – ankle 715 71.3 
Peripheral oedema – knee 295 29.4 
Peripheral oedema – thigh 97 9.7 
Peripheral oedema – sacrum 45 4.5 
Peripheral oedema – abdomen 19 1.9 
Ascites 40 4.0 
Carotid bruit 38 3.8 
Killip class I 46 4.6 
Killip class II 706 70.4 
Killip class III 247 24.6 
Killip class IV 4 0.4 
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3.2.9 Electrocardiography 
 
A 12-lead ECG was performed routinely on admission to hospital for the majority of patients 
in this study. This was usually performed as part of the work-up to determine the cause of 
decompensated HF, for example ischaemia or arrhythmias, or to investigate possible 
consequences of the decompensation, for example arrhythmias. The first ECG performed 
during the admission was analysed, the parameters and their frequencies are shown in Table 3-
13. More than half of all patients were in sinus rhythm. A significant number of patients were 
in AF (41.3%). A small proportion was in a paced rhythm (4.3%). More than one fifth of 
patients had ECG evidence of LVH. A quarter of patients had a bundle branch block, the 
majority being LBBB.  The mean (SD) QRS duration for the hospitalised cohort was 109ms 
(27.8), within normal limits. A prolonged QRS duration (defined as greater than 120ms) was 
evident in almost one third of patients, many of these having a major prolongation (defined as 
>150ms). The mean (SD) corrected QT (QTc) interval for the whole cohort was 448ms (39.8), 
slightly higher than the upper limit of normal (defined as 440ms). 
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Table 3-13: Admission ECG findings and their frequencies within the cohort  
 
Variable n (%), mean (SD) or median [IQR] Units 
Sinus rhythm 549 (54.7) - 
AF 414 (41.3) - 
Paced rhythm 43 (4.3) - 
LBBB 190 (18.9) - 
RBBB 69 (6.9) - 
Pathological Q waves 62 (6.2) - 
LVH 214 (21.3) - 
Ischaemic ST depression 42 (4.2) - 
Mean QRS duration 109 (27.8) ms 
Median QRS duration  102 [88-126] ms 
QRS duration >120 296 (29.5) - 
QRS duration 120 – 150 184 (18.3) - 
QRS duration >150 112 (11.2) - 
Mean QTc interval 448 (39.9) ms 
Median QTc interval (IQR) 447 [422-471] ms 
QTc interval <440 417 (41.6) - 
QTc interval ≥ 440 585 (58.3) - 
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3.2.10 Chest X-Ray 
 
Of 1003 patients in the study, 1000 patients had a CXR performed on admission to hospital. 
The findings are displayed in Figure 3.6. The majority of patients had radiological evidence of 
cardiomegaly (70.5%). Similar proportions of patients had signs of pulmonary oedema 
reported on CXR, namely upper lobe venous diversion (68.5%) and alveolar oedema (73.8%). 
Over half of patients (54.2%) had evidence of pulmonary congestion in the form of interstitial 
oedema. Pleural effusions were also a common radiological finding, reported in a third of the 
cohort. 
 
 
 
 
 
 
Figure 3.6: Radiological findings on the admission CXR for the hospitalised cohort 
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3.2.11 Echocardiography  
 
3.2.11.1 Previous echocardiographic findings 
 
An echocardiogram was performed prior to hospitalisation in 761 patients (Table 3-14). The 
majority of these scans were performed more than a year before the admission, thus a repeat 
study was performed in many of these cases. The previous echocardiographic findings 
revealed many abnormalities. Many patients had a dilated LV or LVH (29.5% and 43.3%, 
respectively). LVEF is not calculated on a routine echocardiogram. More than half had LVSD 
(55.3%), the majority of which was at least moderate in severity. Almost half of patients with 
a previous echocardiogram had preserved LV systolic function (44.7%). Many patients had at 
least moderate valvular heart disease. This included aortic stenosis (AS), aortic regurgitation 
(AR), mitral stenosis (MS), mitral regurgitation (MR) or tricuspid regurgitation (TR). 
 
Table 3-14: Echocardiographic findings for the 761 patients with an echocardiogram 
performed prior to enrolment in the study 
 
Echocardiographic parameter Number of patients % of cohort (n=761) 
Dilated LV 223 29.3 
LVH 327 43.0 
Preserved LV systolic function 340 44.7 
Mild LVSD 128 16.8 
Moderate LVSD 161 21.2 
Severe LVSD 131 17.2 
At least moderate AS 53 7.0 
At least moderate AR 25 3.3 
At least moderate MS 13 1.7 
At least moderate MR 147 19.3 
At least moderate TR 66 8.7 
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3.2.11.2 Current echocardiographic findings  
 
An echocardiogram was performed after enrolment into the study for 727 patients (Table 3-
15). The majority of these were carried out during the index admission (81.2%), with the 
remainder being performed in the weeks following discharge from hospital. The predominant 
reason an echocardiogram was not performed following enrolment in the study was that the 
scan had been performed recently. The proportions of patients with a dilated LV or LVH were 
similar to the previous echocardiographic studies (35.5% and 43.1%, respectively). LVEF was 
not calculated routinely on the current echocardiograms, thus preventing dichotomisation of 
patients into HF-REF or HF-PEF groups. A qualitative assessment of LVSD was recorded as 
documented on the echocardiogram report; mild, mild to moderate, moderate, moderate to 
severe or severe. Figure 3.7 displays the distribution of severity of LVSD. The majority of 
patients had LVSD (65.9%), proportionately more than the previous echocardiogram findings. 
The high prevalence of LVSD is an expected finding in a cohort of patients with 
decompensated HF. Many of those with preserved LV systolic function may have had 
diastolic dysfunction. Unfortunately, parameters of diastolic dysfunction were not routinely 
recorded. The proportions of patients with significant valvular heart disease (defined as at least 
moderate in severity) were similar to those in the previous echocardiogram studies. The 
exception to this was higher proportions of MR and TR, possibly due to more patients having 
functional MR and TR in the decompensated state. 
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Table 3-15: Current echocardiographic findings for the 727 patients with an 
echocardiogram performed after enrolment in the study 
 
Echocardiographic parameter Number of Patients Percentage of cohort 
(n=727) 
Dilated LV 258 35.5 
LVH 313 43.1 
Preserved LV systolic function 249 34.3 
LVSD 479 65.9 
At least moderate AS 57 7.8 
At least moderate AR 29 4.0 
At least moderate MS 14 1.9 
At least moderate MR 211 29.0 
At least moderate TR 116 16.0 
 
 
 
 
 
Figure 3.7: Distribution of LV systolic function for the 727 patients with an 
echocardiogram performed after enrolment in the study 
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3.2.12 Haematology 
 
All patients enrolled in the study had a full blood count performed routinely on admission to 
hospital; the results are displayed in Table 3-16. The mean haemoglobin for the hospitalised 
patients was 12.1g/dl. More than half of all patients were anaemic by WHO standards (defined 
as haemoglobin <12g/dl for females and <13g/dl for males) and many of these met criteria for 
severe anaemia (defined as haemoglobin <11.5g/dl for both sexes). The mean WBC count for 
the whole cohort was within normal limits, with almost a quarter of patients having a raised 
count. The mean lymphocyte count for the cohort was within normal limits but over one-fifth 
of patients had a low lymphocyte count (<1 x109/l). The mean RDW concentration was 15.4%, 
higher than the upper limit of normal (defined as >15%). 
 
Table 3-16: Full blood count profile on admission for all patients (n=1003) 
 
FBC parameter n (%), mean (SD) or  
median [IQR] 
Units 
Mean WBC count 9.4 (3.7) x109/l 
Median WBC count  8.7 [6.9-10.9] x109/l 
WBC count >11 250 (24.9) - 
Mean haemoglobin 12.1 (2.2) g/dl 
Median haemoglobin  12.1 [10.6-13.6] g/dl 
Haemoglobin <13 males; <12 females 568 (56.6) - 
Haemoglobin <11.5 398 (39.7) - 
Mean RDW 15.4 (2.3) % 
Median RDW  15 [13.9-16.3] % 
RDW >15 503 (50.2) - 
Mean lymphocytes 1.64 (1.37) x109/l 
Median lymphocytes  1.4 [1.0-1.88] x109/l 
Lymphocytes <1 236 (23.5) - 
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3.2.13 Biochemistry 
 
There was considerable variation in the number of biochemical tests performed for each 
patient during their admission, as displayed in Table 3-17. The results of the biochemical tests 
are shown in Tables 3-18-20. All patients had BNP measured within 24 hours of admission to 
hospital, an elevated result being mandatory for inclusion in the study. All patients had U&E 
measured on admission to hospital. The majority of patients had troponin I, LFT, CRP, 
phosphate and glucose measured routinely during their hospital stay. Approximately half of 
the cohort had their cholesterol level checked. A small proportion of patients had TFT, urate 
and HbA1c measured.  
 
Table 3-17: Frequencies of biochemical tests performed in the hospitalised cohort 
 
Biochemical test Number of patients  % of cohort 
(n=1003) 
BNP 1003 100 
U&E 1003 100 
LFT 998 99.5 
CRP 983 98.0 
Glucose 945 94.2 
Phosphate 892 88.9 
Troponin*  875 87.2 
TFT 706 70.4 
Lipid profile 527 52.5 
HbA1c 85 8.5 
Urate 48 4.8 
 
* Troponin I measured at Royal and Western Infirmaries, troponin T measured at Royal 
Alexandra Hospital 
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The BNP and U&E results are displayed in Table 3-18. The median BNP for the hospitalised 
cohort was significantly raised at 880pg/ml [IQR 394-1811]. A small proportion of the cohort 
had a major elevation of BNP, exceeding the upper limit of the assay (>5000pg/ml). The 
distribution of BNP results for the entire cohort is displayed in Figure 3.8. The mean sodium 
and potassium levels for the whole cohort were within the normal ranges (138mmol/l and 
4.2mmol/l, respectively). Many patients were hyponatraemic (defined as sodium <135mmol/l) 
on admission (17.9%). The majority of patients had an elevated urea concentration (defined as 
≥ 7.5mmol/l) on admission (62.3%). The mean creatinine level was elevated at 122µmol/l. 
eGFR was calculated using the 4-variable MDRD formula, as outlined in Chapter 2. The mean 
eGFR for the entire cohort was reduced at 55.6 ml/min/1.73m2. Only 5.5% of patients had a 
normal eGFR (defined as >90 ml/min/1.73m2). The distribution of GFR per 30 ml/min/1.73m2 
is shown in Figure 3.9. 
  
Table 3-18: BNP and renal function results on admission for all patients (n=1003) 
 
Biochemical Test n (%), mean (SD) or median [IQR] Units 
Mean BNP 1308 (1234) pg/ml 
Median BNP  880 [394-1812] pg/ml 
BNP >5000 32 (3.2) pg/ml 
Mean sodium  137.8 (4.5) mmol/l 
Median sodium  138 [136-141] mmol/l 
Sodium <135 179 (17.8) mmol/l 
Mean potassium 4.2 (0.6) mmol/l 
Median potassium  4.1 [3.8-4.5] mmol/l 
Mean urea 10.1 (5.8) mmol/l 
Median urea  8.6 [6.3-11.8] mmol/l 
Urea ≥ 7.5 625 (62.3) mmol/l 
Mean creatinine 121.7 (54.0) µmol/l 
Median creatinine  109 [87-138] µmol/l 
Mean eGFR 55.6 (21.1) ml/min/1.73m2 
Median eGFR  54.5 [40.8-68.5] ml/min/1.73m2 
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Figure 3.8: Distribution of BNP levels for all enrolled patients 
 
 
 
 
 
Figure 3.9: Distribution of eGFR on admission for all enrolled patients   
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Most patients enrolled in the study had LFT measured during their admission (Table 3-19). 
The mean bilirubin level was within normal limits. Almost one fifth of patients had an 
elevated bilirubin (defined as >22 µmol/l). The mean concentration of liver enzymes aspartate 
transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase were within the 
local reference ranges. The mean gamma glutamyl transpeptidase (GGT) was elevated at 
86.6U/l, the upper limit of normal being 55U/l. The mean albumin level was at the lower end 
of the normal range at 35.5g/l and over one-third of patients had hypoalbuminaemia (defined 
as <35g/l). 
 
Table 3-19: Liver function tests during hospital admission for 998 patients  
 
Biochemical Test n (%), mean (SD) or median [IQR] Units 
Mean Bilirubin 15.8 (11.9) µmol/l 
Median bilirubin  13.0 [8-19] µmol/l 
Bilirubin ≥ 22 182 (18.2) U/l 
Mean AST 35.8 (49.5) U/l 
Median AST  25.0 [19-36] U/l 
Mean ALT  33.7 (57.3) U/l 
Median ALT  20.0 [14-32] U/l 
Mean GGT 86.6 (94.7) U/l 
Median GGT  57.0 [32-103] U/l 
Mean Alkaline Phosphatase 109.0 (58.5) U/l 
Median Alkaline Phosphatase 95.0 [75-123] U/l 
Mean albumin 35.5 (4.5) g/l 
Median albumin  36.0 [33-39] g/l 
Albumin <35 369 (37.0) g/l 
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The remaining biochemical tests recorded during the admission for subsets of the cohort are 
shown in Table 3-20. The mean CRP was significantly raised at 28.4mg/l and three-quarters of 
patients had an elevated CRP level (defined as ≥ 6mg/l). Of 901 patients recruited from the 
Royal and Western Infirmaries, 844 patients had troponin I measured. More than half of these 
patients had an elevated result (defined by the local biochemistry laboratory as ≥ 0.04 µg/l). 
Of 102 patients recruited from the Royal Alexandra Hospital, 31 had troponin T measured and 
approximately one quarter of these patients had an elevated result (defined by the local 
biochemistry laboratory as ≥ 0.05 µg/l). The mean phosphate, thyroid stimulating hormone 
(TSH), thyroxine (T4), urate, cholesterol and HbA1c levels were within normal reference 
ranges.  
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Table 3-20: Other biochemical tests measured during the hospital admission  
 
Biochemical Test n (%), mean (SD) or median [IQR] Units 
Mean CRP 28.4 (42.5) mg/l 
Median CRP  14.0 [6-31] mg/l 
CRP ≥ 6 743 (75.6) mg/l 
Mean glucose 8.0 (4.6) mmol/l 
Median glucose  6.6 [5.6-8.5] mmol/l 
Troponin I ≥ 0.04 465 (55.1) µg/l 
Troponin T ≥ 0.05 8 (25.8) µg/l 
Mean phosphate 1.21 (0.32) mmol/l 
Median phosphate  1.16 [1.03-1.33] mmol/l 
Mean TSH 2.54 (3.2) mU/l 
Median TSH  1.7 [1-2.8] mU/l 
Mean T4 15.3 (4.0) pmol/l 
Median T4  15 [13-17] mmol/l 
Mean cholesterol 4.1 (1.1) mmol/l 
Median cholesterol  3.9 [3.2-4.7] mmol/l 
Mean HbA1c 7.7 (1.9) % 
Median HbA1c  7.4 [6-8.9] % 
Mean urate 0.47 (0.16) mmol/l 
Median urate  0.49 [0.36-0.57] mmol/l 
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3.2.14 Aetiology of heart failure 
 
The primary aetiologies of heart failure for the entire hospitalised cohort are displayed in 
Table 3-21. Coronary heart disease was the primary aetiology for the majority of patients. 
Over 40% of the entire cohort had documented evidence of a prior MI. Approximately one-
third of patients had angiographic evidence of coronary heart disease (defined as >50% 
stenosis in at least one major epicardial vessel). Over a third of patients had an ‘unknown’ 
primary aetiology of HF. These were patients with no previous MI or angiogram performed by 
the time of aetiology assessment. The non-ischaemic primary causes of HF are also displayed 
in Table 3-21. A non-ischaemic primary aetiology was only assigned when ischaemia had 
been excluded (no previous MI and coronary angiography demonstrating no significant 
stenoses) and no other clear causes of HF were present.  The majority of non-ischaemic causes 
were valvular heart disease. As outlined in the methods, valvular heart disease was only 
considered causative if it was at least moderate in severity. The cardiomyopathies were the 
primary cause of HF for a small number of patients (see Table 3-21). Few patients had 
hypertension and alcohol as the primary reason for their HF. It is likely that more patients had 
hypertension, alcohol or valvular heart disease as the primary cause of HF. However if these 
patients had not had coronary angiography, to exclude ischaemia as the cause, then the 
primary aetiology was classified ‘unknown’. In these instances all potential causes were 
recorded as ‘contributing aetiologies’, as detailed in the following paragraph.  
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Table 3-21: Primary aetiology of heart failure for the hospitalised cohort 
 
Primary Aetiology Number of 
patients 
% of cohort 
(n=1003) 
Ischaemic  
     a) Definite previous MI 
     b) Angiographic evidence  
        (>50% stenosis in ≥ 1 vessel) 
544 
447 
324 
54.2 
44.6 
32.3 
Non-ischaemic 114 11.4 
     Valvular 60 6.0 
     Cardiomyopathies 
         a) Idiopathic dilated cardiomyopathy 
         b) Hypertrophic cardiomyopathy 
         c) Peripartum cardiomyopathy 
         d) Restrictive cardiomyopathy 
26 
17 
4 
3 
2 
2.6 
1.7 
0.4 
0.3 
0.2 
     Hypertension 16 1.6 
     Alcohol 12 1.2 
Unknown (no previous MI or angiography) 345 34.4 
 
Regardless of whether or not the patient had a primary aetiology assigned, the presence of any 
potential contributing aetiologies were also documented, the results are shown in Table 3-22. 
Two-thirds of all patients had hypertension as a contributing cause of HF. Almost 40% of the 
entire cohort had valvular heart disease as a contributing cause of HF. The majority of these 
were mitral regurgitation, many cases being functional regurgitation secondary to LVSD 
rather than primary valve disease. Aortic stenosis was also a significant contributing cause for 
many patients. AF was a potential contributing cause of HF when persistent or permanent in 
duration, this applied to almost half of the entire cohort. Epidemiological studies have recently 
demonstrated an increased risk of HF amongst patients with diabetes. In this study the 
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prevalence of diabetes was high, affecting almost a third of all patients. Excess alcohol 
consumption was also a significant contributor, in at least 16% of all patients. A small 
proportion of the cohort had other contributing causes of HF identified, including; previous 
chemotherapy, thyrotoxicosis and long-term right ventricular pacing.   
 
Table 3-22: Potential contributing aetiologies of heart failure in the hospitalised cohort  
 
Contributing aetiology Number of patients % of cohort (n=1003) 
Hypertension 663 66.1 
Valvular heart disease 396 39.5 
Atrial fibrillation 445 44.4 
Diabetes mellitus 314 31.3 
Alcohol 166 16.6 
Other 68 6.8 
 
3.3 Summary 
 
This chapter outlined the process of recruitment and described in detail the clinical 
characteristics from the hospital admission for the cohort of patients hospitalised with 
decompensated HF. Of 2361 patients with suspected decompensated HF screened for 
inclusion in the study, 1003 patients were recruited. The mean age was 73 years, consistent 
with established epidemiological studies of HF. The majority of patients were male. A 
significant proportion of the cohort was elderly with multiple medical co-morbidity and 
polypharmacy. Only 1% of the entire cohort had no known medical conditions prior to 
enrolment into the study, reflecting the high levels of co-morbidity associated with HF. 
Survivors were discharged from hospital after approximately 12 days.  
 
Almost half of the cohort had a prior diagnosis of HF. Three-quarters of these patients had 
experienced a previous hospitalisation with decompensated HF, highlighting the high rates of 
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hospitalisation associated with this condition. The primary aetiology of HF was ischaemia for 
the majority of patients, but over one-third had an unknown primary aetiology. The majority 
of patients were already taking oral diuretics prior to admission. Many were already prescribed 
HF disease-modifying therapies. Nearly all of the patients recruited into the study received 
diuretic therapy on admission to hospital, approximately three-quarters of the cohort received 
this therapy intravenously. Less than 3% of all patients in the study were not treated with 
diuretic therapy on admission to hospital, most likely reflecting younger patients presenting 
with progressive pump failure rather than fluid overload. Most physiological measurements 
were stable on admission, indicative of the inability of more unstable patients to be 
approached to consent to participate in the study. The majority of patients had a raised JVP, 
lung crepitations, peripheral oedema and were in Killip class II.  
 
There were a significant number of patients in AF on admission to hospital and many had left 
bundle branch block on their ECG. The presence of radiological signs of pulmonary oedema 
was common on the admission CXR. Most patients had an echocardiogram performed 
following enrolment into the study. This revealed LVSD for the majority of cases. Routine 
blood sampling on admission to hospital revealed many biochemical and haematological 
abnormalities in this cohort. All patients had an elevated BNP, an essential component of the 
study inclusion criteria, and the median was significantly elevated. More than half of all 
patients were anaemic by WHO criteria, almost two-thirds had an elevated serum urea 
concentration and >90% had a reduction in their GFR. More than half of all patients with 
troponin I measured on admission to hospital had an elevated result. 
 
In summary the hospitalised cohort was made up of 1003 patients, the majority of whom were 
elderly with multiple medical co-morbidity and LVSD.  
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 CHAPTER FOUR 
 
CLINICAL CHARACTERISTICS OF  
HOSPITALISED COHORT STRATIFIED BY  
STUDY VISIT ATTENDANCE 
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4.1 Introduction  
 
This chapter will compare the clinical characteristics of the hospital cohort of patients 
according to whether or not they attended the post-discharge study visit. The data described 
will be similar to the previous chapter but stratified by subsequent attendance at the study visit 
or not. Non-attendance will be subdivided into the reasons for failure to complete the study 
visit. The data described will comprise basic demographic details, symptoms prior to 
admission, medical history, medications pre-admission and during the first 24 hours of 
admission, and examination findings on admission. Electrocardiographic, radiological, blood 
test and echocardiographic results will also be stratified by attendance at the study visit. The 
main aim of this chapter will be to ascertain whether or not there were any major clinical 
differences in the cohort of patients who returned to complete the study visit compared to 
those who did not attend. Ultimately, these comparisons will allow an objective assessment of 
whether or not the patients returning for the study visit were truly representative of the entire 
cohort. 
 
4.2 Comparison of hospital data for study visit attendees and non-attendees 
 
4.2.1 Outcome of hospitalised cohort 
  
Of 1003 patients enrolled in the study, 648 patients (64.6%) completed the study visit. The 
reasons why the remaining patients failed to attend are outlined in Figure 4.1. The most 
common reason for failure to attend the study visit was refusal to participate, 167 patients 
(16.7%) withdrew from the study for this reason following discharge from hospital. 115 
patients (11.5%) died prior to the study visit appointment. More than half of these deaths, 68 
deaths (59.1%), occurred during the index admission. The remaining 47 deaths (40.9% of 
deaths) occurred after discharge from hospital and before the study visit. Finally, 73 patients 
(7.3%) were unable to attend the study visit appointment because of deterioration in their 
health.  
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For the remainder of this chapter patients who completed the post-discharge study visit will be 
referred to as ‘attendees’ and those who withdrew from participating in the study visit will be 
referred to as ‘withdrawn’. Patients who failed to complete the study visit because of 
deterioration in their health will be referred to as ‘deteriorating health’ and those who died 
before their study visit appointment will be referred to as ‘deceased’ or ‘died before the study 
visit’. 
 
 
 
 
 
Figure 4.1: Overview of the 1003 patients recruited into the study and the breakdown 
of reasons for failure to attend the study visit 
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4.2.2 Demographics 
 
Table 4-1 shows the demographics of the hospitalised cohort, stratified by whether or not they 
subsequently attended the study visit. Attendees had proportionately more male patients than 
the other three groups, whilst patients who died before the study visit had more female patients 
than the other three groups (p=0.00015).  
 
Patients attending the study visit were younger than the other three groups (p<0.0001), with 
fewest patients over 75 years of age (p<0.0001). Patients with deteriorating health had the 
highest mean age, with almost three-quarters of this group over 75 years of age. 
 
The average length of hospitalisation was significantly longer for patients with deteriorating 
health and those who died before their study visit appointment (p<0.0001).  
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Table 4-1: Basic demographics of the hospitalised cohort, stratified by whether or not they subsequently attended the study visit. Data are 
expressed as number (%), mean (SD) or median [IQR]. 
 
Variable  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall  
(n=1003) 
p value* 
Male 
 
377 
(58.2) 
73 
(43.7) 
35 
(48.0) 
47 
(40.9) 
532 
(53.0) 
0.00015 
Age (years)  70.8 
(10.6) 
77.1 
(8.2) 
80.0 
(8.0) 
75.1 
(10.3) 
73.0 
(10.5) 
<0.0001 
≥ 75 years of age 232 
(35.8) 
107 
(64.1) 
54 
(74.0) 
65 
(56.5) 
458 
(45.7) 
<0.0001 
Mean duration of admission (days) 9.7 
(8.1) 
10.3 
(10.3) 
21.9 
(23.4) 
20.9 
(23.8) 
11.9 
(13.6) 
<0.0001 
Median duration of admission (days) 7 
[4-12] 
7 
[5-12] 
13 
[8-31] 
13 
[6-24.5] 
8 
[5-14] 
<0.0001 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
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4.2.3 History of heart failure 
 
A history of HF was defined as a previous admission with decompensated HF or a 
diagnosis of HF established in an outpatient clinic. Almost half of the overall cohort had a 
history of HF prior to enrolment in this study. A history of HF was more common amongst 
patients with deteriorating health and those who were deceased (p=0.00047) [Table 4-2]. 
Consequently, more patients who subsequently attended the study visit or withdrew from 
participation were de novo presentations of HF at the time of enrolment in this study. The 
proportion of patients with a diagnosis of chronic HF for more than 2 years was similar in 
all four groups. The proportion of patients with a previous hospital admission with 
decompensated HF did not significantly differ between the groups, although the proportion 
was greatest for those who died before the study visit. 
  
 
 Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
p value* 
1 283 
(43.7) 
69 
(41.3) 
44 
(60.3) 
69 
(60.0) 
465 
(46.4) 
0.00047 
2 203 
(71.7) 
45 
(65.2) 
33 
(75.0) 
51 
(73.9) 
332 / 465 
(71.4) 
0.62 
3 216 
(76.3) 
48 
(69.6) 
33 
(75.0) 
58 
(84.1) 
355 / 465 
(76.3) 
0.31 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference 
between the four groups. 
 
1 = Previous diagnosis of heart failure 
2 = Diagnosis of heart failure > 2 years ago 
3 = Previous admission with decompensated heart failure 
Table 4-2: History of heart failure, stratified by study visit attendance. Data are 
expressed as number (%). 
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4.2.4 Heart failure symptoms prior to admission 
 
The presence of HF symptoms prior to hospitalisation varied between the four groups, as 
displayed in Table 4-3.  
 
Severity of HF symptoms, as defined by the NYHA classes, differed between the groups 
(p=0.00067). Those who attended the study visit or withdrew from participation had more 
patients with milder HF symptoms (NYHA class II) than the other two groups. The 
prevalence of moderate HF symptoms (NYHA class III) was similar amongst all four 
groups. Those who died prior to the study visit had the greatest proportion of patients with 
severe HF symptoms (NYHA class IV).  
 
Patients who died before the study visit were more likely to experience paroxysmal 
nocturnal dyspnoea (PND) (p=0.022).  
 
Ankle swelling affected the majority of all patients, although was more common amongst 
patients with deteriorating health and those who died before the study visit (p<0.0001).  
 
There was no significant difference between the four groups in the prevalence of the 
following symptoms; orthopnoea, palpitations, wheeze and angina. 
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Symptom Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating health 
(n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
p value* 
NYHA    II                              
               III 
               IV 
160 (24.7) 
374 (57.7) 
114 (17.6) 
42 (25.1) 
104 (62.3) 
21 (12.6) 
13 (17.8) 
47 (64.4) 
13 (17.8) 
11 (9.6) 
69 (60.0) 
35 (30.4) 
225 (22.4) 
594 (59.2) 
184 (18.3) 
0.00067 
PND 311 (48.0) 69 (41.3) 35 (47.9) 69 (60.0) 484 (48.3) 0.022 
Orthopnoea 488 (75.3) 121 (72.5) 54 (74.0) 98 (85.2) 761 (75.9) 0.078 
Ankle swelling 412 (63.6) 126 (75.4) 61 (83.6) 99 (86.1) 698 (69.6) <0.0001 
Palpitations 146 (22.5) 25 (15.0) 14 (19.2) 19 (16.5) 204 (20.3) 0.11 
Wheeze 189 (29.2) 43 (25.7) 24 (32.9) 35 (30.4) 291 (29.0) 0.68 
Angina 356 (54.9) 86 (51.5) 40 (54.8) 66 (57.4) 548 (54.6) 0.79 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
Table 4-3: Heart failure symptom status prior to admission, stratified by study visit participation. Data are expressed as number (%).       
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4.2.5 Medical history 
 
The prevalences of common medical comorbidities varied between the groups (Table 4-4).  
A history of a previously reported MI was similar in all four groups, affecting a large 
proportion of all patients.  On the other hand, the prevalence of major angiographic 
coronary heart disease differed between the groups (p=0.012). This was defined as 
previous angiographic evidence of at least 50% stenosis in at least 1 major epicardial 
vessel. Angiographic coronary heart disease was more prevalent amongst patients who 
withdrew and those with deteriorating health. A higher proportion of attendees had 
undergone PCI compared to the non-attendees, a difference of borderline statistical 
significance (p=0.057). 
 
AF was proportionately more common amongst patients who withdrew from the study visit 
or had deteriorating health (p=0.045). Surprisingly, the lowest prevalence of AF was 
amongst the patients who died before the study visit.  
 
Patients with deteriorating health or death before the study visit were more likely to have 
experienced major weight loss in the 6 months prior to enrolment in the study (p=0.019).  
 
A history of cancer was more common in those with deteriorating health than the other 
three groups (p=0.0034). Surprisingly, there were similar proportions of this comorbidity 
amongst attendees and patients who died before the study visit. 
 
Peripheral arterial disease was most common amongst patients who died before the study 
visit and least common amongst attendees (p=0.041). One possible explanation for the 
higher prevalence of this condition amongst patients who withdrew or cited deteriorating 
health as the reason for non-attendance may be the MTWA treadmill test. Patients 
experiencing pain from walking due to peripheral arterial disease may have been more 
inclined to withdraw from participation in the study visit.  
 
Hypothyroidism was most common amongst patients with deteriorating health and least 
common amongst attendees, although this was of borderline statistical significance 
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(p=0.051). Those who subsequently died or withdrew from the study visit had similar 
proportions of patients affected by this condition.  
 
Osteoarthritis was more common in patients with deteriorating health, affecting over 40% 
of this group (p=0.0062). Although fewer patients in the other three groups suffered from 
osteoarthritis, it was still common and affected around a quarter of these patients. Physical 
disabilities may have been a reason why many patients withdrew from participation 
because of difficulties travelling to the study visit or anxiety regarding the treadmill test.  
 
Patients who did not complete the study visit due to deteriorating health or death were 
more likely to be anaemic (p<0.0001). However this comorbidity was common in the 
overall cohort and many patients in all four groups met the WHO criteria for the diagnosis 
of anaemia.  
 
Urinary incontinence was more prevalent amongst patients who failed to complete the 
study visit, irrespective of cause (p=0.0016). Those unable to attend due to declining health 
were most likely to suffer from this comorbidity.  
 
There was no difference between the groups in the prevalence of the following medical 
conditions; hypertension, cerebrovascular disease (as defined by prior TIA or CVA), prior 
arrhythmia, diabetes mellitus, depression, COPD, asthma, hyperthyroidism and rheumatoid 
arthritis.  
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Condition Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
MI 278 (42.9) 70 (41.9) 39 (53.4) 56 (48.7) 443 (44.2) 0.23 
Angiographic CAD 224 / 307 (73.0) 48 / 59 (81.4) 15 / 19 (78.9) 36 / 51 (70.6) 323 / 436 (74.1) 0.012 
PCI 92 (14.2) 16 (9.6) 6 (8.2) 8 (7.0) 122 (12.2) 0.057 
CABG 112 (17.3) 27 (16.2) 9 (12.3) 22 (19.1) 170 (16.9) 0.65 
Hypertension 420 (64.8) 116 (69.5) 49 (67.1) 75 (65.2) 660 (65.8) 0.72 
TIA/CVA 146 (22.5) 36 (21.6) 25 (34.2) 24 (20.9) 231 (23.0) 0.12 
History of AF 344 (53.1) 95 (56.9) 43 (58.9) 55 (47.8) 537 (53.5) 0.045 
Prior arrhythmia 53 (8.2) 15 (9.0) 6 (8.2) 9 (7.8) 83 (8.3) 0.99 
Diabetes  203 (31.3) 48 (28.7) 25 (34.2) 37 (32.2) 313 (31.2) 0.84 
Weight loss† 94 (14.5) 26 (15.6) 19 (26.0) 26 (22.6) 165 (16.5) 0.019 
Depression 137 (21.1) 31 (18.6) 17 (23.3) 23 (20.0) 208 (20.7) 0.83 
History of cancer 87 (13.4) 28 (16.8) 15 (20.5) 15 (13.0) 145 (14.5) 0.0034 
Table 4-4: Prevalence of common medical conditions, stratified by study visit attendance. Data are expressed as number (%). 
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Condition Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
COPD 181 (27.9) 50 (29.9) 23 (31.5) 43 (37.4) 297 (29.6) 0.23 
PAD 104 (16.0) 30 (18.0) 15 (20.5) 31 (27.0) 180 (17.9) 0.041 
Asthma 34 (5.2) 7 (4.2) 2 (2.7) 5 (4.3) 48 (4.8) 0.76 
Hypothyroidism 55 (8.5) 20 (12.0) 13 (17.8) 14 (12.2) 102 (10.2) 0.051 
Hyperthyroidism 12 (1.9) 6 (3.6) 1 (1.4) 3 (2.6) 22 (2.2) 0.53 
RA 18 (2.8) 5 (3.0) 5 (6.8) 7 (6.1) 35 (3.5) 0.12 
OA 154 (23.8) 43 (25.7) 31 (42.5) 27 (23.5) 255 (25.4) 0.0062 
Anaemia 276 (42.6) 64 (38.3) 46 (63.0) 68 (59.1) 454 (45.3) <0.0001 
Urinary incontinence 58 (9.0) 21 (12.6) 17 (23.3) 16 (13.9) 112 (11.2) 0.0016 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
CAD = coronary artery disease (defined as > 50% stenosis in ≥ 1 major epicardial vessel, denominator is number of patients who had an angiogram); OA 
= osteoarthritis; PAD = peripheral arterial disease; RA = rheumatoid arthritis 
 † >5% body weight in previous 6 months  
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4.2.6 Cardiovascular medications pre-admission 
 
The pre-admission use of certain cardiovascular medications varied between the four 
groups (Table 4-5). The majority of these differences were in HF medications. The 
majority of patients in all groups were prescribed a diuretic. However, patients with 
deteriorating health and those who died before the study visit were most likely to be taking 
diuretics prior to the index admission (p=0.027).  
 
Patients attending the study visit were more likely to be prescribed beta-blockers before 
hospitalisation (p=0.0018). Patients who died before the study visit and those with 
deteriorating health had fewest patients on this drug. The use of ACE inhibitors was 
similar in all 4 groups.  
 
In comparison to ACE inhibitors and beta-blockers, the overall number of patients 
prescribed ARBs pre-admission was small. Only 14% of the entire cohort was prescribed 
ARBs before the index admission. Patients who withdrew from the study visit were most 
likely to be prescribed ARBs whilst those with deteriorating health or death had fewest 
patients prescribed this drug (p=0.025). The overall prescribing of aldosterone antagonists 
prior to admission was also small. However, the use of this medication was most common 
amongst those who died before the study visit (p=0.029). 
 
Although there was no statistically significant difference between the groups in the 
proportion of patients prescribed aspirin, there was a trend towards more prescribing 
amongst the group who died before the study visit (p=0.057). Two-thirds of deceased 
patients were prescribed aspirin compared to approximately half of patients in the other 
three groups. Statin prescribing was more common amongst attendees and least common 
amongst patients who did not attend the study visit due to deteriorating health (p=0.043). 
 
The use of the following medications was similar in all four groups; digoxin, clopidogrel, 
warfarin, nicorandil, calcium channel blockers, anti-arrhythmic therapies, long-acting 
nitrates and non-statin lipid lowering agents. 
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Medication Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating health  
(n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
p value* 
Diuretics 432 (66.7) 117 (70.1) 57 (78.1) 90 (78.3) 696 (69.4) 0.027 
Beta-blockers 337 (52.0) 71 (42.5) 26 (35.6) 44 (38.3) 478 (47.7) 0.0018 
ACE inhibitors 340 (52.5) 74 (44.3) 33 (45.2) 60 (52.2) 507 (50.5) 0.21 
ARBs 92 (14.2) 32 (19.2) 4 (5.5) 12 (10.4) 140 (14.0) 0.025 
Aldosterone antagonists 36 (5.6) 10 (6.0) 5 (6.8) 15 (13.0) 66 (6.6) 0.029 
Aspirin 341 (52.6) 87 (52.1) 39 (53.4) 76 (66.1) 543 (54.1) 0.057 
Clopidogrel 82 (12.7) 16 (9.6) 9 (12.3) 11 (9.6) 118 (11.8) 0.61 
Aspirin or clopidogrel 382 (59.0) 99 (59.3) 42 (57.5) 79 (68.7) 602 (60.0) 0.13 
Digoxin 104 (16.0) 27 (16.2) 15 (20.5) 22 (19.1) 168 (16.7) 0.68 
Warfarin 186 (28.7) 39 (23.4) 16 (21.9) 23 (20.0) 264 (26.3) 0.12 
Nicorandil 90 (13.9) 26 (15.6) 15 (20.5) 16 (13.9) 147 (14.7) 0.48 
Calcium channel blockers 166 (25.6) 58 (34.7) 17 (23.3) 31 (27.0) 272 (27.1) 0.1 
Anti-arrhythmic 22 (3.4) 8 (4.8) 3 (4.1) 5 (4.3) 38 (3.8) 0.84 
Long-acting nitrates 120 (18.5) 29 (17.4) 19 (26.0) 28 (24.3) 196 (19.5) 0.21 
Statin 443 (68.4) 101 (60.5) 40 (54.8) 73 (63.5) 657 (65.5) 0.043 
Other lipid lowering agents 16 (2.5) 9 (5.4) 2 (2.7) 7 (6.1) 34 (3.4) 0.095 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
Table 4-5: Prevalence of cardiovascular medication prescribing pre-admission, stratified by study visit attendance. Data are expressed as 
number (%). 
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4.2.7 Heart failure medical therapy during first 24 hours of admission 
 
The pharmacological treatment of HF during the first 24 hours of admission is shown in 
Table 4-6. More than 95% of the overall cohort was prescribed furosemide on admission. 
The use of furosemide and loop diuretics was similar in all four groups.  
 
The use of intravenous nitrate therapy during the first 24 hours of admission differed 
between the groups of patients. Those who died before the study visit were most likely to 
be treated with intravenous nitrate therapy, more than double the prescribing rate of the 
other three groups (p=0.0055).  
 
Few patients were prescribed inotrope therapy (dobutamine or dopamine). However the 
use of this therapy was more common amongst those who died before the study visit 
(p<0.0001). 
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* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
 
 
 
Table 4-6: Heart failure medical therapy during the first 24 hours of admission, stratified by study visit attendance. Data are expressed as 
number (%). 
Medication Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
p value* 
Furosemide 615 (94.9) 161 (96.4) 71 (97.3) 113 (98.3) 960 (95.7) 0.33 
Other loop diuretic 28 (4.3) 5 (3.0) 3 (4.1) 9 (7.8) 45 (4.5) 0.27 
Intravenous nitrate 54 (8.3) 10 (6.0) 5 (6.8) 20 (17.4) 89 (8.9) 0.0055 
Inotrope  
(dobutamine or dopamine) 
5 (0.8) 0 (0) 3 (4.1) 9 (7.8) 17 (1.7) <0.0001 
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4.2.8 Clinical examination findings on admission 
 
4.2.8.1 Routine physiological measurements 
 
There were several differences between the four groups of patients in the routine 
physiological measurements recorded on admission to hospital (Table 4-7). Patients who 
died before the study visit had lower SBP than the other three groups (p<0.0001). When 
the range of SBP was divided into 5 cut-off points there were other differences between the 
groups (p<0.0001). Patients who did not attend the study visit because of death or 
deteriorating health had proportionately more patients in the lower two categories of SBP 
(<80mmHg and 80-100mmHg). Attendees and those who withdrew from participating had 
more patients in the middle categories of SBP (100-140mmHg and 140-180mmHg). 
 
Patients who did not attend the study visit because of death or deteriorating health had 
lower DBP than the other two groups (p<0.0001). Attendees had a similar DBP to those 
who withdrew from the study visit. When the range of DBP was divided into three cut-off 
points, other differences existed between the groups (p=0.00013). Patients who 
subsequently did not participate in the study visit because of deteriorating health or death 
had proportionately more patients with DBP <65mmHg. In contrast, attendees and those 
who withdrew from the study visit had proportionately more patients with diastolic 
hypertension (defined as ≥ 90mmHg). 
 
The first peripheral SpO2 reading, on either air or oxygen, was recorded for every patient 
enrolled in the study. Patients who subsequently did not participate in the study visit 
because of deteriorating health or death had a lower SpO2 reading on air than the other two 
groups of patients (p<0.0001). Unsurprisingly, there was no difference between the groups 
for patients with an initial SpO2 reading on oxygen.  
 
There were no differences between the groups of patients in the following physiological 
parameters; mean heart rate, temperature and respiratory rate. 
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Table 4-7: Routine physiological measurements on admission to hospital, stratified by study visit attendance. Data are expressed as number (%) 
or mean (SD).  
 
Physiological 
measurement (units) 
Attendee (n=648) Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased (n=115) Overall (n=1003) p value* 
Heart rate (bpm) 89 (25) 90 (25) 89 (21) 92 (22) 90 (24) 0.68 
SBP (mmHg) 137 (27) 139 (29) 134 (27) 122 (26) 136 (27) <0.0001 
SBP levels (mmHg) 
    < 80 
     80-100 
     100-140 
     140-180 
    ≥ 180 
 
0 (0) 
41 (6.3) 
312 (48.2) 
250 (38.6) 
45 (6.9) 
 
0 (0) 
9 (5.4) 
83 (49.7) 
56 (33.5) 
19 (11.4) 
 
0 (0) 
6 (8.2) 
41 (56.2) 
19 (26.0) 
7 (9.6) 
 
3 (2.6) 
17 (14.8) 
72 (62.6) 
18 (15.7) 
5 (4.3) 
 
3 (0.3) 
73 (7.3) 
508 (50.6) 
343 (34.2) 
76 (7.6) 
<0.0001 
DBP (mmHg) 78 (18) 76 (19) 73 (17) 69 (16) 76 (18) <0.0001 
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Physiological 
measurement (units) 
Attendee (n=648) Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased (n=115) Overall (n=1003) p value* 
DBP levels (mmHg) 
     < 65 
      65-90 
     ≥ 90 
 
157 (24.2) 
329 (50.8) 
162 (25.0) 
 
43 (25.7) 
82 (49.1) 
42 (25.2) 
 
30 (41.1) 
28 (38.4) 
15 (20.5) 
 
42 (36.5) 
64 (55.7) 
9 (7.8) 
 
272 (27.1) 
503 (50.2) 
228 (22.7) 
0.00013 
Pulse pressure (mmHg) 59.6 (20.6) 62.4 (22.7) 61.6 (21.7) 52.6 (21.8) 59.4 (21.3) 0.0012 
Temperature (°C) 36.5 (0.6) 36.5 (0.7) 36.6 (0.6) 36.5 (0.8) 36.5 (0.7) 0.4 
Respiratory rate (breaths 
per min) 
22 (5.1) 21 (5.4) 22 (4.9) 23 (4.9) 22 (5.1) 0.16 
SpO2 on air (%) † 95 (3.8) 95 (2.9) 93 (5.6) 93 (6.0) 95 (4.2) <0.0001 
SpO2 on oxygen (%)† 96 (4.1) 95 (4.5) 96 (4.1) 96 (4.1) 96 (4.2) 0.37 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
† SpO2 measurement as per first recording on observation chart on air or oxygen 
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4.2.8.2 Body mass index and waist circumference measurements 
 
BMI and waist circumference measurements recorded on admission to hospital differed 
between the four groups (Tables 4-8 to 4-10). For the male patients, attendees and those 
who withdrew from the study visit were taller than the patients in the other two groups 
(p=0.0036).  Attendees and patients who withdrew from the study visit were also heavier 
than the other two groups (p=0.0017). A similar trend was seen amongst the female 
patients, although the difference was not statistically significant for weight. 
 
Consequently the BMI differed between the four groups, with male attendees having a 
larger BMI than men in the other three groups (p=0.0029). There was no significant 
difference between the four groups in the mean BMI for the female patients. Interestingly 
the mean BMI for all four groups, regardless of sex, was in the pre-obese range. BMI 
levels were analysed in the categories that are used clinically; underweight (<18.5), ideal 
weight (18.5-25), pre-obese / overweight (>25-30) and obese (≥ 30).  The proportions of 
patients in each of the BMI categories differed. Those who died before the study visit had 
more underweight patients than the other three groups, particularly amongst the female 
patients. Attendees had most obese patients whilst those who died before the study visit 
had the fewest.  
 
Attendees had the largest waist circumference of all four groups, over 7cm greater than the 
mean circumference of patients who died before the study visit (p<0.0001). Waist 
circumference was analysed in the sex-specific categories that are used clinically; low 
waist circumference (<94cm for men and <80cm for women), normal waist circumference 
(94-102cm for men and 80-88cm for women) and high waist circumference (>102cm for 
men and >88cm for women). The proportions in each of the categories differed between 
the four groups (p=0.0056).  Attendees had most patients with high waist circumference 
and fewest patients with low waist circumference. Patients who withdrew from the study 
visit or died before the study visit had the greatest proportion of patients with low waist 
circumference. 
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Measurement (units) Attendee 
(n=377) 
Withdrawn 
(n=73) 
Deteriorating 
health (n=35) 
Deceased 
(n=47) 
Overall 
(n=532) 
 
p value* 
Missing value 0 1 4 1 6 - 
Height (cm) 170.0 (8) 172.8 (7.6) 167.0 (9.3) 169.1 (7.3) 170.2 (8.1) 0.0036 
Weight (kg) 86.2 (20.3) 83.3 (19.7) 77.7 (20.7) 76.0 (13.3) 84.4 (20.0) 0.0017 
BMI (kg/m2) 29.8 (6.7) 27.9 (6.6) 27.7 (5.8) 26.7 (4.9) 29.1 (6.5) 0.0029 
BMI levels  <18.5 
                      18.5-25 
                      25-30 
                      >30 
1 (0.3) 
88 (23.3) 
133 (35.3) 
155 (41.1) 
3 (4.2) 
22 (30.5) 
26 (36.1) 
21 (29.2) 
1 (3.3) 
9 (29.0) 
9 (29.0) 
12 (38.7) 
2 (4.4) 
14 (30.4) 
19 (41.3) 
11 (23.9) 
7 (1.3) 
133 (25.3) 
187 (35.6) 
199 (37.8) 
0.023 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
 
Table 4-8: BMI and waist circumference measurements for men on admission to hospital, stratified by study visit attendance. Data are 
expressed as number (%) or mean (SD). 
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Measurement (units) Attendee 
(n=271) 
Withdrawn 
(n=94) 
Deteriorating 
health (n=38) 
Deceased 
(n=68) 
Overall 
(n=471) 
 
p value* 
Missing value 0 4 0 0 4 - 
Height (cm) 155.8 (6.4) 157.9 (6.5) 154.7 (7.0) 154.8 (10.0) 155.9 (7.2) 0.023 
Weight (kg) 71.6 (18.4) 69.6 (17.2) 67.1 (18.7) 67.3 (18.6) 70.2 (18.3) 0.21 
BMI (kg/m2) 29.5 (7.3) 27.7 (6.7) 28.2 (8.2) 28.2 (7.7) 28.9 (7.3) 0.17 
BMI levels  <18.5 
                      18.5-25 
                      25-30 
                      >30 
6 (2.2) 
79 (29.2) 
74 (27.3) 
112 (41.3) 
3 (3.3) 
37 (41.1) 
21 (23.3) 
29 (32.3) 
0 (0) 
19 (50.0) 
5 (13.2) 
14 (36.8) 
7 (10.3) 
17 (25.0) 
20 (29.4) 
24 (35.3) 
16 (3.4) 
152 (32.6) 
120 (25.7) 
179 (38.3) 
0.0037 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
Table 4-9: BMI and waist circumference measurements for women on admission to hospital, stratified by study visit attendance. Data are 
expressed as number (%) or mean (SD). 
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Table 4-10: Waist circumference measurements on admission to hospital, stratified by study visit attendance. Data are expressed as mean (SD) 
or number (%). 
 
 
 
Measurement (units) Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Missing value 0 20 8 3 31 - 
Waist (cm) 100.7 (17.0) 95.1 (17.5) 96.5 (16.5) 93.4 (15.5) 98.7 (17.1) <0.0001 
Waist levels  <94 M / <80 F 
                      94-102 M / 80-88 F 
                      >102 M / >88 F 
137 (21.1) 
134 (20.7) 
377 (58.2) 
50 (34.0) 
24 (16.3) 
73 (49.7) 
16 (24.6) 
18 (27.7) 
31 (47.7) 
37 (33.0) 
19 (17.0) 
56 (50.0) 
240 (24.7) 
195 (20.1) 
537 (55.2) 
0.0056 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
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4.2.8.3 Clinical signs of heart failure 
 
There were several differences between the four groups of patients in the signs of HF 
recorded on admission to hospital. The results are displayed in Table 4-11.  
 
Few patients had an audible third heart sound. However, the prevalence of this clinical sign 
was more common amongst patients who died before the study visit than the other three 
groups (p=0.037). The level of pulmonary oedema differed between the groups (p=0.0019). 
Few patients in all four groups had no crackles auscultated. The absence of pulmonary 
crackles was more common amongst attendees and patients who withdrew from the study 
visit. These groups also had more patients with only basal crackles whilst those unable to 
participate in the study visit due to deteriorating health or death had more patients with 
crackles extending to the mid-zones and apices. The presence of a pleural effusion 
(unilateral or bilateral) showed a similar pattern to pulmonary crackles, although the 
prevalence was much less in all four groups and the difference less striking (p=0.042).   
 
Peripheral oedema was a common clinical sign, affecting the majority of patients in all 
groups. However, there were differences between the four groups in the proportions of 
patients with peripheral oedema (p=<0.0001). Patients who died before the study visit or 
had deteriorating health had more patients with peripheral oedema, than the other two 
groups. The level of peripheral oedema also differed between the groups. Those unable to 
complete the study visit due to death or deteriorating health had proportionately more 
patients with oedema at all levels (ankle, knee, thigh, sacrum and abdomen), than the other 
two groups.  
 
Few patients in the overall cohort had ascites. There was no significant difference between 
the groups in the presence of this clinical sign, although it was proportionately more 
common amongst those who died before the study visit.  
 
The majority of patients in all four groups were in Killip class II. The proportions in each 
of the four Killip classes differed between the groups (p<0.0001). Patients who died before 
the study visit were more likely to be in class III and IV, than the other three groups.  
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Clinical sign Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Third heart sound  42 (6.5) 8 (4.8) 2 (2.7) 14 (12.2) 66 (6.6) 0.037 
Pulmonary crackles   
      None 
      Basal 
      Middle 
      Apex 
 
42 (6.5) 
468 (72.2) 
130 (20.1) 
8 (1.2) 
 
12 (7.2) 
124 (74.3) 
30 (17.9) 
1 (0.6) 
 
3 (4.1) 
50 (68.5) 
18 (24.7) 
2 (2.7) 
 
4 (3.5) 
64 (55.7) 
45 (39.1) 
2 (1.7) 
 
61 (6.1) 
706 (70.4) 
223 (22.2) 
13 (1.3) 
0.0019 
Pleural effusion 
      None 
      Right 
      Left 
      Bilateral 
 
568 (87.6) 
24 (3.7) 
14 (2.2) 
42 (6.5) 
 
139 (83.2) 
8 (4.8) 
4 (2.4) 
16 (9.6) 
 
60 (82.2) 
6 (8.2) 
3 (4.1) 
4 (5.5) 
 
86 (74.8) 
9 (7.8) 
4 (3.5) 
16 (13.9) 
 
853 (85.0) 
47 (4.7) 
25 (2.5) 
78 (7.8) 
0.042 
Peripheral oedema (any) 436 (67.3) 129 (77.2) 62 (84.9) 98 (85.2) 725 (72.3) <0.0001 
Table 4-11: Clinical signs of heart failure on admission to hospital, stratified by study visit attendance. Data are expressed as number (%) or 
mean (SD). 
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Clinical sign Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Peripheral oedema – ankle 432 (66.7) 127 (76.1) 61 (83.6) 95 (82.6) 715 (71.3) <0.0001 
Peripheral oedema – knee 155 (23.9) 48 (28.7) 35 (48.0) 57 (49.6) 295 (29.4) <0.0001 
Peripheral oedema – thigh 49 (7.6) 12 (7.2) 15 (20.6) 21 (18.3) 97 (9.7) <0.0001 
Peripheral oedema – sacrum 25 (3.9) 4 (2.4) 8 (11.0) 8 (7.0) 45 (4.5) 0.011 
Peripheral oedema – abdomen 10 (1.5) 1 (0.6) 2 (2.7) 6 (5.2) 19 (1.9) 0.029 
Ascites 26 (4.0) 4 (2.4) 1 (1.4) 9 (7.8) 40 (4.0) 0.077 
Killip class  
      I 
      II 
      III 
      IV 
 
39 (6.0) 
464 (71.6) 
144 (22.2) 
1 (0.2) 
 
6 (3.6) 
132 (79.0) 
29 (17.4) 
0 (0) 
 
1 (1.4) 
52 (71.2) 
19 (26.0) 
1 (1.4) 
 
0 (0) 
61 (53.0) 
51 (44.4) 
3 (2.6) 
 
46 (4.6) 
709 (70.7) 
243  (24.2) 
5 (0.5) 
<0.0001 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
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4.2.9 Electrocardiography 
 
There were few differences between the four groups of patients in the electrocardiographic 
(ECG) parameters recorded on admission to hospital, as displayed in Table 4-12. The 
parameters that differed between the groups were; sinus rhythm, LBBB and prolonged 
QRS. There were no differences between the four groups for the following parameters; AF, 
paced rhythm, LVH, ischaemic ST depression, mean QRS duration, mean QTc interval and 
proportion with prolonged QTc.  
 
Patients who died before the study visit and attendees were more likely to be in sinus 
rhythm than the other two groups (p=0.009). Less than half of patients who did not 
complete the study visit because of deteriorating health or withdrawal from participation 
were in sinus rhythm on admission.  
 
LBBB was present on almost a fifth of the admission ECGs of all patients enrolled in the 
study. This ECG abnormality was more common amongst patients who died before the 
study visit (p=0.012). Patients who attended the study visit or were unable to because of 
deteriorating health had similar percentages of LBBB. Those who withdrew from 
participating in the study visit had fewest patients with this ECG abnormality.  
 
The prevalence of a prolonged QRS differed between the four groups (p=0.024). The 
prevalence of a QRS duration 120-150ms amongst the four groups exhibited a similar 
pattern to that of LBBB. However a more prolonged QRS duration (>150ms) was more 
common amongst those with deteriorating health than the other three groups. Attendees 
and patients who died before the study visit had similar proportions with a QRS duration 
>150ms whilst those that withdrew from participation had fewest patients with this ECG 
abnormality. 
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Table 4-12: Electrocardiographic parameters on admission to hospital, stratified by study visit attendance. Data are number (%) or mean (SD). 
 
ECG parameter (units) Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Sinus rhythm 368 (56.8) 74 (44.3) 36 (49.3) 71 (61.7) 549 (54.7) 0.009 
AF 258 (39.8) 81 (48.5) 34 (46.6) 41 (35.7) 414 (41.3) 0.089 
LBBB 124 (19.1) 19 (11.4) 15 (20.5) 32 (27.8) 190 (18.9) 0.012 
Paced 28 (4.3) 9 (5.4) 4 (5.5) 2 (1.7) 43 (4.3) 0.46 
LVH 127 (19.6) 37 (22.2) 16 (21.9) 34 (29.6) 214 (21.3) 0.11 
Ischaemic ST depression 29 (4.5) 3 (1.8) 4 (5.5) 6 (5.2) 42 (4.2) 0.37 
Mean QRS (ms) 109.9 (27.9) 104.2 (26.2) 112.9 (31.9) 111.2 (26.4) 109.3 (27.8) 0.055 
QRS duration >120 
QRS duration 120-150  
QRS duration  >150 
193 (29.8) 
121 (18.7) 
72 (11.1) 
34 (20.4) 
22 (13.2) 
12 (7.2) 
27 (37.0) 
13 (17.8) 
14 (19.2) 
42 (36.5) 
28 (24.3) 
14 (12.2) 
296 (29.5) 
184 (18.3) 
112 (11.2) 
0.024 
Mean QTc (ms) 449.4 (39.7) 448.2 (36.4) 444.3 (40.9) 439.7 (43.9) 447.7 (39.8) 0.097 
QTc ≥440 388 (59.9) 96 (57.5) 39 (53.4) 62 (53.9) 585 (58.3) 0.51 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
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4.2.10 Chest X-Ray 
 
Radiological features of pulmonary oedema differed between the four groups of patients, 
as shown in Table 4-13.  
 
Many patients enrolled in the study had cardiomegaly present on their admission CXR, 
defined as a cardiothoracic ratio >50%. Patients with deteriorating health or who died 
before the study visit were more likely to have cardiomegaly on their CXR than the other 
two groups, albeit with only a trend towards statistical significance (p=0.056).  Patients 
who withdrew from the study visit had fewest patients with this radiological sign.  
 
The presence of alveolar oedema was more common in patients who died before the study 
visit (p<0.0001). Patients attending the study visit and those with deteriorating health had 
similar proportions with this radiological sign. Those who withdrew from the study visit 
had fewest patients with alveolar oedema. 
 
Patients with deteriorating health or who died before the study visit were most likely to 
have a unilateral pleural effusion (p=0.0054). Bilateral pleural effusions were more 
common amongst those who died before the study visit, than the other three groups of 
patients.  
 
Although there was no statistically significant difference between the groups in the 
proportions of patients with upper lobe venous diversion or interstitial oedema, there was a 
trend towards a greater prevalence of both of these parameters amongst patients who died 
before the study visit.  
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Parameter  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
CXR performed  646 (99.7) 166 (99.4) 73 (100) 115 (100) 1000 (99.7) - 
Cardiomegaly 463 (71.7) 103 (62.0) 54 (74.0) 85 (73.9) 705 (70.5) 0.056 
Upper lobe venous diversion 433 (67.0) 112 (67.5) 48 (65.8) 91 (79.1) 684 (68.4) 0.068 
Interstitial oedema 350 (54.2) 81 (48.8) 37 (50.7) 73 (63.5) 541 (54.1) 0.089 
Alveolar oedema 165 (25.5) 31 (18.7) 20 (27.4) 49 (42.6) 265 (26.5) <0.0001 
Pleural effusion 
      None 
      Left 
      Right  
      Bilateral 
 
455 (70.5) 
55 (8.5) 
35 (5.4) 
101 (15.6) 
 
112 (67.5) 
15 (9.0) 
7 (4.2) 
32 (19.3) 
 
42 (57.5) 
10 (13.7) 
6 (8.2) 
15 (20.6) 
 
58 (50.4) 
15 (13.0) 
8 (7.0) 
34 (29.6) 
 
667 (66.7) 
95 (9.5) 
56 (5.6) 
182 (18.2) 
0.0054 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
Table 4-13: CXR parameters on admission to hospital, stratified by study visit attendance. Data are expressed as number (%). 
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4.2.11 Echocardiography 
 
The majority of all patients had an echocardiogram performed after enrolment into the 
study (Table 4-14). Most of these echocardiograms were carried out during the index 
admission (81.2%), with the remainder being performed in the early weeks following 
discharge from hospital. The main reason for not performing echocardiography for the 
remaining 276 patients was that it had already been done.  
 
Patients who died before the study visit were less likely to have an echocardiogram 
performed after enrolment, than the other three groups (p=0.0012). Most recorded 
echocardiographic parameters did not differ between the four groups. However a dilated 
LV was more common amongst patients who attended the study visit (p=0.0014). The 
prevalence of this abnormality was similar in the other three groups. 
 
The presence of LVH and LVSD was similar in all four groups. As reported in chapter 3 
(section 3.2.11.2), LVEF was not calculated routinely on the current echocardiograms, thus 
preventing dichotomisation of patients into HF-REF or HF-PEF groups. The majority of 
valvular abnormalities did not differ between the four groups. There was a trend towards 
AS being more common in patients who died before the study visit (p=0.064). MR and TR 
were the commonest recorded valvular abnormalities in all four groups of patients, likely 
reflecting functional rather than structural valve disease. The presence of TR was greatest 
amongst those who died before the study visit (0.044).  
 165
 
Parameter  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Echo after enrolment 487 (75.2) 116 (69.5) 57 (78.1) 67 (58.3) 727 (72.5) 0.0012 
Dilated LV 197 (40.5) 29 (25.0) 16 (28.1) 16 (23.9) 258 (35.5) 0.0014 
LVH 197 (40.5) 58 (50.0) 29 (50.9) 28 (41.8) 312 (42.9) 0.12 
LVSD 340 (69.8) 62 (53.4) 34 (59.6) 42 (62.7) 478 (65.7) 0.14 
At least moderate AS 31 (6.4) 15 (12.9) 4 (7.0) 7 (10.4) 57 (7.8) 0.064 
At least moderate AR 20 (4.1) 3 (2.6) 2 (3.5) 4 (6.0) 29 (4.0) 0.23 
At least moderate MS 8 (1.6) 4 (3.4) 1 (1.8) 1 (1.5) 14 (1.9) 0.95 
At least moderate MR 147 (30.2) 29 (25.0) 16 (28.1) 19 (28.4) 211 (29.0) 0.75 
At least moderate TR 66 (13.6) 20 (17.2) 11 (19.3) 19 (28.4) 116 (16.0) 0.044 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
Table 4-14: Echocardiographic parameters following enrolment, stratified by study visit attendance. Data are expressed as number (%).  
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4.2.12 Haematology 
 
All patients enrolled in the study had a full blood count performed routinely on admission 
to hospital. The results of the individual parameters of the FBC, stratified by study visit 
attendance, are displayed in Table 4.15.  
 
Patients unable to complete the study visit due to deteriorating health or death had a lower 
haemoglobin level than those who completed the study visit or withdrew from participation 
(p=0.0028). Moreover, patients with deteriorating health or who died before the study visit 
were more likely to be anaemic by WHO criteria (defined as haemoglobin <12g/dl for 
females and <13g/dl for males).  
 
Half of all patients had an elevated RDW concentration with the mean value for all four 
groups above the normal range (>15%). However, RDW level was highest in patients who 
died before the study visit (p=0.00024).  
 
Lymphocyte concentration displayed a similar pattern between the four groups to that of 
haemoglobin. Patients unable to complete the study visit due to deteriorating health or 
death had a lower lymphocyte concentration than those who completed the study visit or 
withdrew from participation (p=0.0032). Many patients in all four groups were 
lymphopenic on admission to hospital, but this was more common amongst those unable to 
complete the study visit due to deteriorating health or death (p<0.0001).   
 
Total WBC count and platelet concentration was similar in all four groups. 
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Parameter  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
WBC count (x109/l) 9.3 (3.7) 9.2 (3.4) 9.2 (4.0) 9.8 (4.1) 9.4 (3.7) 0.62 
Haemoglobin (g/dl) 12.3 (2.2) 12.0 (2.1) 11.5 (2.0) 11.7 (2.2) 12.1 (2.2) 0.0028 
Haemoglobin <13 males, <12 females 337 (52.0) 101 (60.5) 53 (72.6) 77 (67.0) 568 (56.6) 0.00025 
RDW % 15.2 (2.1) 15.6 (2.5)  15.9 (3.2) 16.1 (2.6) 15.4 (2.3) 0.00024 
RDW ≥ 15 % 305 (47.1) 91 (54.5) 35 (47.9) 72 (62.6) 503 (50.1) 0.045 
Platelets (x109/l) 244.7 (90.0) 249.0 (89.7) 257.1 (109.0) 237.7 (97.6) 245.5 (91.7) 0.52 
Lymphocytes (x109/l) 1.8 (1.6) 1.5 (0.9) 1.3 (0.8) 1.4 (1.0) 1.6 (1.4) 0.0032 
Lymphocytes <1 x109/l 122 (18.8) 44 (26.3) 22 (30.1) 48 (41.7) 236 (23.5) <0.0001 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
Table 4-15: Full blood count parameters on admission, stratified by study visit attendance. Data are expressed as mean (SD) or number (%). 
 168 
4.2.13 Biochemistry 
 
Many biochemical laboratory tests were performed on admission to hospital. All patients 
had BNP and U&E measured. The majority of patients also had LFT and CRP measured. 
Most patients recruited from Glasgow Royal Infirmary and Western Infirmary Glasgow 
had troponin I measured.  The results of these tests, as stratified by study visit attendance, 
are presented in Tables 4-16 to 4-20. 
 
BNP testing was part of the study protocol, a raised BNP (>100pg/ml) being mandatory for 
enrolment in the study. BNP concentration was highest amongst patients who died before 
the study visit (p<0.0001). Those who completed the study visit or withdrew from 
participation had the lowest levels. 
 
Troponin I was raised (defined as ≥ 0.04µg/l) on admission to hospital for more than half 
of all patients recruited from Western and Royal Infirmaries. Those who died before the 
study visit were more likely to have an elevation of this biomarker than the other three 
groups (p<0.0001). Patients who attended the study visit had fewest patients with a raised 
troponin I.  Of 102 patients recruited from the Royal Alexandra Hospital, 31 had troponin 
T measured and only 8 patients had an elevation of this biomarker (defined as ≥ 0.05µg/l). 
There was no difference between the 4 groups in the proportions of patients with a raised 
troponin T. 
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Parameter  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Mean BNP (pg/ml) 1197 (1154) 1173 (1136) 1296 (1095) 2142 (1550) 1308 (1234) <0.0001 
Median BNP (pg/ml) 788  
[366-1582] 
774 
[351-1438] 
967 
[577-1609] 
1762  
[856-3176] 
880  
[394-1812] 
<0.0001 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
 
 
Parameter  Attendee 
(n=561) 
Withdrawn 
(n=125) 
Deteriorating health 
(n=57) 
Deceased 
(n=101) 
Overall 
(n=844) 
p value* 
Troponin I ≥ 0.04 µg/l 280  
(49.9) 
69 
(55.2) 
35  
(61.4) 
81  
(80.2) 
465  
(55.1) 
<0.0001 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the four groups. 
Table 4-16: BNP levels on admission, stratified by study visit attendance. Data are mean (SD) or median [IQR]. 
Table 4-17: Troponin I levels on admission for Glasgow Royal Infirmary and Western Infirmary patients who had troponin I measured, 
stratified by study visit attendance. Data are expressed as number (%). 
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U&E were measured on admission for all patients enrolled in the study. Nearly all the 
parameters differed between the four groups of patients (Table 4-18).  Patients who died 
before the study visit or had deteriorating health had lower sodium concentrations than the 
other two groups (p<0.0001). Hyponatraemia (defined as sodium <135mmol/l) was more 
common amongst those who died before the study visit, than the other three groups 
(p=0.0019). Patients attending the study visit had fewest patients with this biochemical 
abnormality, almost half the prevalence of those who died before the study visit.  
 
The majority of patients in each of the four groups had an elevated urea concentration. 
Patients who died before the study visit had higher concentrations than the other three 
groups (p<0.0001). Patients with deteriorating health and those who died before the study 
visit had proportionately more patients with an elevation above the normal range (defined 
as >7.5mmol/l) [p<0.0001].  
 
Creatinine concentration also differed between the four groups. Consistent with the 
findings regarding serum urea, the highest concentrations of creatinine were amongst those 
who failed to complete the study visit due to deteriorating health or death (p=0.00035).  
 
eGFR was calculated for all patients using the four-variable MDRD formula, as outlined in 
Chapter 2. This formula uses age, sex, race and creatinine to calculate the eGFR and 
provides a more accurate assessment of renal function than urea or creatinine alone. 
Consistent with the results of urea and creatinine concentrations, eGFR was lower in those 
who died before the study visit or had deteriorating health than the other two groups 
(p<0.0001). Although the majority of patients in all four groups had renal dysfunction 
(defined as eGFR <60ml/min/1.73m2), this was more common in patients who died before 
the study visit or had deteriorating health. Severe renal dysfunction (defined as eGFR 
<30ml/min/1.73m2) was more common amongst those who died before the study visit 
(p<0.0001). 
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Parameter  Attendee 
(n=648) 
Withdrawn 
(n=167) 
Deteriorating 
health (n=73) 
Deceased 
(n=115) 
Overall 
(n=1003) 
 
p value* 
Sodium (mmol/l) 138.3 (4.3) 137.3 (4.1) 136.8 (5.2) 136.4 (5.5) 137.8 (4.5) <0.0001 
Sodium < 135mmol/l 98 (15.1) 31 (18.6) 16 (21.9) 34 (29.6) 179 (17.8) 0.0019 
Potassium (mmol/l) 4.2 (0.6) 4.2 (0.5) 4.2 (0.6) 4.2 (0.7) 4.2 (0.6) 0.35 
Urea (mmol/l) 9.4 (5.4) 10.2 (5.7) 11.6 (5.6) 13.2 (6.9) 10.1 (5.8) <0.0001 
Urea ≥ 7.5 mmol/l 368 (56.8) 108 (64.7) 58 (79.5) 91 (79.1) 625 (62.3) <0.0001 
Creatinine (µmol/l) 105.5  
[86.0-135.0] 
107 
[85.5-136.5] 
115  
[94.0-155.0] 
120  
[91.5-162.0] 
109 
[87.0-138.0] 
0.00035 
eGFR (ml/min/1.73m2) 58.0 (20.4) 54.0 (21.8) 50.2 (19.5) 47.9 (22.5) 55.6 (21.1) <0.0001 
eGFR levels (ml/min/1.73m2) 
<30 
30-60 
60-90 
≥ 90 
 
55 (8.5) 
310 (47.8) 
244 (37.7) 
39 (6.0) 
 
22 (13.2) 
85 (50.9) 
51 (30.5) 
9 (5.4) 
 
8 (11) 
45 (61.6) 
18 (24.7) 
2 (2.7) 
 
27 (23.5) 
59 (51.3) 
24 (20.8) 
5 (4.4) 
 
112 (11.2) 
499 (49.7) 
337 (33.6) 
55 (5.5) 
 
 
<0.0001 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
Table 4-18: Renal function on admission for all patients, stratified by study visit attendance. Data are mean (SD), number (%) or median [IQR] 
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LFT were measured on admission for the majority of patients enrolled in the study. The 
results, stratified by study visit attendance, are displayed in Table 4-19.  
 
The proportion of patients with an elevated bilirubin concentration result (defined as 
>22µmol/l) differed between the four groups (p=0.036). Those who died before the study 
visit had more patients with a raised bilirubin concentration. Those with deteriorating 
health had, perhaps surprisingly, fewest patients with an elevated bilirubin with similar 
proportions for those who completed the study visit or withdrew from participation.  
 
Patients with deteriorating health had higher levels of alkaline phosphatase than the other 
three groups (p=0.00024). Patients attending the study visit had the lowest levels of this 
liver test. 
 
Albumin concentration was lowest amongst patients who died before the study visit than 
the other three groups (p<0.0001). Patients who withdrew from participating in the study 
visit had the highest levels of this biomarker. Those who died before the study visit had 
more patients with hypoalbuminaemia (defined as albumin <35g/l), whilst attendees and 
patients who withdrew from participating in the study visit had fewest patients with this 
abnormality (P<0.0001).  
 
AST, ALT and GGT concentrations were similar in all four groups. 
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* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
Table 4-19: Liver function parameters stratified by study visit attendance. Data are expressed as median [IQR], number (%) or mean (SD). 
Parameter  Attendee 
(n=646) 
Withdrawn 
(n=165) 
Deteriorating 
health (n=72) 
Deceased 
(n=115) 
Overall 
(n=998) 
p value* 
Bilirubin (µmol/l) 12.0 [8.0-19.0] 13.0 [9.0-19.0] 11.0 [8.0-16.0] 14.0 [9.5-23.0] 13.0 [8.0-19.0] 0.14 
Bilirubin ≥ 22 µmol/l 111 (17.2) 29 (17.6) 10 (13.9) 32 (27.8) 182 (18.2) 0.036 
AST (U/l) 25.0 [19.0-35.0] 25.5 [19.0-35.0] 24.0 [19.0-35.0] 28.5 [20.0-44.0] 25.0 [19.0-36.0] 0.17 
ALT (U/l) 21.0 [15.0-33.3] 19.5 [13.0-30.0] 18.0 [13.0-28.0] 21.0 [14.0-32.0] 20.0 [14.0-32.0] 0.33 
GGT (U/l) 59.0 [33.0-109.5] 51.0 [29.0-88.0] 59.0 [25.8-97.0] 55.0 [34.0-98.0] 57.0 [32.0-103.0] 0.39 
Alk Phos (U/l) 93.0 [73.0-121.0] 96.0 [78.0-122.0] 109.0 [87.3-141.3] 97.0 [77.0-136.5] 95.0 [75.0-123.0] 0.00024 
Albumin (g/l) 35.9 (4.2) 36.0 (4.5) 35.2 (5.2) 33.1 (5.0) 35.5 (4.5) <0.0001 
Albumin <35g/l 212 (32.8) 54 (32.7) 32 (44.4) 71 (61.7) 369 (37.0) <0.0001 
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The majority of all enrolled patients had CRP measured on admission to hospital, the 
results of which are shown in Table 4-20. Patients who died before the study visit or had 
deteriorating health had higher CRP levels than the other two groups (p=0.00027). The 
majority of patients in all four groups had a CRP level elevated above the normal reference 
range (defined as >6mg/l). There was a trend towards a greater proportion of patients with 
an elevated CRP in the group who died before the study visit, although the difference was 
not statistically significant (p=0.057). 
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Parameter  Attendee 
(n=638) 
Withdrawn 
(n=160) 
Deteriorating 
health (n=71) 
Deceased 
(n=114) 
Overall 
(n=983) 
p value* 
CRP (mg/l) 12.0 
[5.5-27.8] 
15.0 
[6.2-30.8] 
18.0 
[5.5-44.0] 
19.5 
[9.2-41.8] 
14.0 
[6.0-31.0] 
0.00027 
CRP ≥ 6mg/l 471 
(73.8) 
124 
(77.5) 
51 
(71.8) 
97 
(85.1) 
743 
(75.6) 
0.057 
 
* Inter-group comparisons using ANOVA F test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the four groups. 
 
 
Table 4-20: CRP results, stratified by study visit attendance. Data are expressed as median [IQR] or number (%). 
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4.3 Summary 
 
Chapter 4 has compared the clinical characteristics of the patients in hospital according to 
whether or not they subsequently completed the study visit. Many differences in the clinical 
characteristics between these four groups of patients have been described. The attendees were 
more likely to be younger and male. Both attendees and those who withdrew from the study 
visit contained patients with milder symptoms, in terms of NYHA class, and significantly 
shorter durations of hospitalisation. The groups of patients who died or had deteriorating 
health preventing subsequent attendance at the study visit had more patients with a previous 
diagnosis of HF. 
 
There was a high prevalence of medical comorbidity amongst patients in all groups, regardless 
of subsequent attendance at the study visit. The majority of common medical conditions did 
not differ in prevalence between the four groups.  Peripheral arterial disease and weight loss 
were more common amongst those who died before the study visit or had deteriorating health. 
There was a high prevalence of anaemia in all four groups but this was significantly higher 
amongst those who died before the study visit or had deteriorating health. This is reflective of 
anaemia being a predictor of poor prognosis in HF. A history of cancer was more prevalent 
amongst patients with deteriorating health, perhaps a reason for subsequent non-attendance at 
the study visit. Certain physically disabling conditions, such as peripheral arterial disease, 
osteoarthritis and urinary incontinence, were also more prevalent in non-attendees. This may 
be reflective of the burden of attending an additional clinic and the apprehension of attempting 
the MTWA treadmill test. The prescribing of certain HF medications prior to hospitalisation 
differed between the groups. More patients who did not attend the study visit due to 
deteriorating health or death were prescribed diuretics, most likely explained by the higher 
prevalence of a previous diagnosis of HF amongst these groups. More patients who 
subsequently attended the study visit were prescribed beta-blockers prior to their admission; 
this may reflect the prognostic benefit of these therapies. The use of intravenous nitrates or 
inotrope therapy on admission was greatest amongst patients who died before the study visit, 
an expected finding given that patients necessitating these medications are usually critically 
unwell.  
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Patients who did not attend the study visit because of deteriorating health or death had more 
adverse clinical signs on admission to hospital. These signs included systolic and diastolic 
hypotension, and lower peripheral oxygen saturations. Men who did not attend the study visit 
because of deteriorating health or death had a lower average weight than those who attended 
or withdrew from the study visit. Men and women who died before the study visit had the 
largest proportion of patients in the underweight category whilst those who attended the study 
visit had the highest proportion of patients in the obese category, evidence of the reverse 
epidemiology paradox in HF. Clinical signs of fluid overload on admission were also greater 
amongst those with subsequent deteriorating health or death preventing study visit attendance.  
 
There were differences between the four groups in the routine clinical investigations 
performed on admission to hospital. Patients who subsequently died had the highest 
proportion of LBBB present on the admission ECG, consistent with this parameter being a 
marker of poor prognosis. Those with deteriorating health or death had the highest prevalence 
of some radiological features of HF, including cardiomegaly and pleural effusions. Perhaps 
surprisingly, the proportion of patients with a dilated LV on current echocardiogram was 
greatest amongst the group of attendees. There were no other differences in echocardiographic 
parameters between the four groups, including LVSD. There were several differences between 
the four groups in haematological and biochemical parameters recorded on admission to 
hospital. Many of these parameters are established markers of adverse outcome in HF, 
abnormalities of which were proportionately more common in the groups who failed to attend 
the study visit due to deteriorating health or death. These parameters included haemoglobin, 
RDW, lymphocytes, BNP, troponin, sodium, urea, creatinine, eGFR, albumin and CRP. The 
majority of these parameters were also abnormal amongst patients in the groups who attended 
or withdrew from participating, but to a lesser extent than the other two groups.  
 
In summary, patients attending the study visit were similar, in terms of clinical characteristics 
during hospitalisation, to the group of patients who withdrew from participating in the study 
visit. Both of these groups contained patients with proportionately fewer markers of an 
adverse prognosis in heart failure, than the patients in the groups who failed to complete the 
study visit due to deteriorating health or death.   
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CHAPTER FIVE 
 
CLINICAL CHARACTERISTICS  
OF  
POST-DISCHARGE COHORT 
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5.1 Introduction  
 
This chapter will describe the cohort of patients who completed the study visit at the BHF 
Glasgow Cardiovascular Research Centre; the post-discharge cohort. The main focus of this 
chapter will be a detailed description of the clinical characteristics of the patients who 
completed the study visit. This will be an update of the data recorded from the hospital 
admission. This data will comprise current HF symptomatology and status, current prescribed 
medications, physiological and body composition measurements, and cardiovascular 
examination findings. ECG findings, LVEF by echocardiography and blood test results will 
also be presented.  
 
5.2 Results 
 
5.2.1 Composition of post-discharge cohort 
 
Of 1003 patients enrolled in the study, 648 patients attended the BHF Glasgow Cardiovascular 
Research Centre approximately 4-6 weeks following discharge from hospital. This represented 
64.6% of the original hospitalised cohort. The reasons the remaining 35.4% failed to attend 
were outlined in Figure 4.1 (page 136).  
 
5.2.2 Demographics  
 
The demographics of the patients who completed the study visit are displayed in Table 5-1. 
Compared to the results for the overall hospitalised cohort, the post-discharge cohort 
contained more men (58.2% versus 53.0%), the mean age was slightly younger (70.8 versus 
73.0) and a smaller proportion of patients were over 75 years of age (35.8% versus 45.7%). 
For those attending the study visit the average duration of hospitalisation was 2 days shorter. 
Over 40% of patients completing the study visit had a previous diagnosis of HF, prior to 
enrolment in this study. Only 6.8% of the post-discharge cohort been readmitted to hospital 
with decompensated HF since the index admission. 
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Table 5-1: Demographics of the post-discharge cohort.  
 
Variable  n (%), mean (SD) or  
median [IQR] 
Male 377 (58.2) 
Female 271 (41.8) 
Mean age (years)  70.8 (10.6) 
Median age (years)  71.6 [64.7 -78.0] 
Age range 18 – 96 
≥ 75 years of age 232 (35.8) 
Mean duration of admission (days) 9.7 (8.1) 
Median duration of admission (days) 7 [4-12] 
Diagnosis of HF prior to enrolment 283 (43.7) 
Readmission with HF since enrolment 44 (6.8) 
 
5.2.3 Symptoms of heart failure 
 
Current HF symptoms were recorded for each patient attending the study visit (Table 5-2). 
The majority of patients experienced an overall improvement in their HF symptom status since 
discharge from hospital, with only 10% of patients experiencing deterioration. Almost two-
thirds of all patients were NYHA class II, with less than one-third of patients NYHA class III. 
Few patients were NYHA class I or IV. This contrasts with the hospital admission where the 
majority of the study visit attendees were NYHA class III (Table 4-3, page 141). Fewer 
patients experienced nocturnal symptoms by the time of their study visit (Table 4-3, page 141). 
Approximately one quarter of patients had symptoms of orthopnoea, whilst three-quarters of 
the study visit attendees had this symptom during hospitalisation. Only 12% of attendees had 
symptoms of PND, whilst almost half of the same patients had this symptom during 
hospitalisation. Over a quarter of patients had symptoms of ankle swelling at the time of the 
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study visit, compared with almost two-thirds during hospital admission. Almost a quarter of 
patients had symptoms of palpitations and wheeze, similar proportions to hospitalisation.  
 
Table 5-2: Current heart failure symptoms  
 
Symptom Number of patients % of cohort (n=648) 
Overall deterioration since discharge 70 10.8 
NYHA Class 
                      I 
                      II 
                      III 
                      IV 
 
25 
409 
207 
7 
 
3.9 
63.1 
31.9 
1.1 
PND 79 12.2 
Orthopnoea 163 25.2 
Ankle swelling 185 28.5 
Palpitations 157 24.2 
Wheeze 153 23.6 
 
5.2.4 Common medical comorbidity 
 
Table 5-3 displays the prevalences of common medical comorbidities in the post-discharge 
cohort. There was a high prevalence of coronary heart disease. Over 40% of the cohort had 
documented evidence of a previous MI and many had previously undergone PCI or CABG. 
Hypertension was the commonest medical comorbidity, affecting almost two-thirds of patients. 
AF was also extremely prevalent, affecting over half of the patients. Anaemia was another 
common condition amongst the post-discharge cohort, as were diabetes mellitus and COPD. 
Other common conditions and their prevalences are shown in Table 5-3. 
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Table 5-3: Prevalences of common medical conditions  
 
Condition Number of patients % of cohort (n=648) 
MI 278 42.9 
History of angina 356 54.9 
Angiographic CAD 224 / 307 73.0 
PCI 92 14.2 
CABG 112 17.3 
Hypertension 420 64.8 
TIA/CVA 146 22.5 
History of AF 344 53.1 
Prosthetic heart valve 50 7.7 
Pacemaker 41 6.3 
Prior arrhythmia 53 8.2 
Diabetes mellitus 203 31.3 
Anaemia 276 42.6 
Depression 137 21.1 
History of cancer 87 13.4 
COPD 181 27.9 
Peripheral arterial disease 104 16.0 
Osteoarthritis 154 23.8 
 
CAD = coronary artery disease (defined as > 50% stenosis in ≥ 1 major epicardial vessel, 
denominator is number of patients who had an angiogram) 
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5.2.5 Medications  
 
Table 5-4 displays the frequencies of HF medication prescribing for patients attending the 
study visit. The data are presented for the overall post-discharge cohort and dichotomised by 
LVEF. This is because the evidence base for HF treatment is largely confined to HF-REF. The 
significant differences in clinical characteristics, including medications, between the patients 
with HF-REF and HF-PEF are described later in this chapter (section 5.2.12). 
 
Almost all patients were prescribed diuretic therapy at the time of study visit, the 
overwhelming majority being furosemide or an alternative loop diuretic. More than 70% of 
patients with HF-REF were prescribed an ACE inhibitor, with almost 20% having this therapy 
initiated since recruitment into the study. Over two-thirds of the post-discharge cohort with 
HF-REF was prescribed a beta-blocker, with 17.5% having this therapy initiated since 
recruitment into the study. ARB prescribing was less common, with few patients in the post-
discharge cohort having these drugs prescribed since recruitment. Similar proportions were 
prescribed an aldosterone receptor blocker, the majority of which was initiated since 
recruitment into the study. Of those with HF-REF, 60% were prescribed the combination of 
either an ACE inhibitor or an ARB and a beta-blocker. Various combinations of the other HF 
disease-modifying therapies (ACE inhibitor, beta-blocker, ARB and aldosterone blocker) were 
prescribed in small proportions of the post-discharge cohort (Table 5-4). Proportionately more 
patients with HF-PEF were prescribed digoxin, than patients with HF-REF. 
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Table 5-4: Frequency of heart failure medication prescribing in the post-discharge 
cohort at the study visit, overall and stratified according to LVEF. Data are expressed as 
number (%) 
 
Heart failure medication HF-PEF 
(n=127) 
HF-REF 
(n=521) 
Overall  
(n=648) 
Diuretics 116 (91.3) 505 (96.9) 621 (95.8) 
Furosemide / loop diuretics 114 (89.8) 498 (95.6) 612 (94.4) 
ACE inhibitor* 72 (56.7) 384 (73.7) 456 (70.4) 
ACE inhibitor since recruitment  18 (14.2) 98 (18.8) 116 (17.9) 
Beta-blocker* 70 (55.1) 360 (69.1) 430 (66.4) 
Beta-blocker since recruitment 2 (1.6) 91 (17.5) 93 (14.4) 
ARB* 12 (9.4) 70 (13.4) 82 (12.7) 
ARB since recruitment 3 (2.4) 7 (1.3) 10 (1.5) 
Aldosterone blocker* 12 (9.4) 73 (14.0) 85 (13.1) 
Aldosterone blocker since recruitment 4 (3.1) 45 (8.6) 49 (7.6) 
ACE inhibitor or ARB 79 (62.2) 435 (83.5) 514 (79.3) 
ACE inhibitor or ARB & Beta-blocker 43 (33.9) 314 (60.3) 357 (55.1) 
ACE inhibitor and ARB & Beta-blocker 4 (3.1) 14 (2.7) 18 (2.8) 
ACE inhibitor & Beta-blocker & 
Aldosterone blocker 
4 (3.1) 46 (8.8) 50 (7.7) 
ARB & Beta-blocker & Aldosterone blocker 0 (0) 2 (0.4) 2 (0.3) 
ACE inhibitor or ARB & Beta-blocker & 
Aldosterone blocker 
4 (3.1) 48 (9.2) 52 (8) 
Digoxin 37 (29.1) 126 (24.2) 163 (25.2) 
 
* = total number of patients prescribed this medication, including those since recruitment  
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The frequencies of prescribing of other cardiovascular medications in the post-discharge 
cohort are outlined in Table 5-5. The prescribing rates of these medications were similar to 
pre-admission (Table 4-5, page 147). Statin therapy was prescribed for almost three-quarters 
of the post-discharge cohort. Over half of the cohort was prescribed aspirin, with almost one 
fifth prescribed clopidogrel and 10% prescribed dual antiplatelet therapy. Almost 40% of 
patients were warfarinised, reflecting the high prevalence of AF in the post-discharge cohort. 
Many patients were prescribed anti-anginal therapies (calcium channel blockers, long-acting 
nitrates and nicorandil) and diabetic medications, as outlined in Table 5-5. Anti-arrhythmic 
therapy was prescribed in a minority of patients. 
 
Table 5-5: Frequency of cardiovascular medication prescribing in the post-discharge 
cohort at the study visit 
 
Cardiovascular medication Number of patients % of cohort (n=648) 
Statin 477 73.6 
Aspirin 362 55.9 
Clopidogrel 115 17.7 
Aspirin or clopidogrel 409 63.1 
Warfarin 253 39.0 
Calcium channel blocker 117 18.1 
Anti-arrhythmic 35 5.4 
Long-acting nitrates 112 17.3 
Nicorandil 97 15.0 
Oral hypoglycaemic agents 157 24.2 
Insulin 66 10.2 
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The frequencies of prescribing of other common non-cardiovascular medications in the post-
discharge cohort are outlined in Table 5-6. Over a quarter of all patients were prescribed 
bronchial inhaler therapies. A considerable proportion of patients were prescribed 
antidepressant medications.  
 
Table 5-6: Frequency of prescribing of common non-cardiovascular medications in the 
post-discharge cohort 
 
Non-cardiovascular medication Number of patients % of cohort (n=648) 
Bronchial inhalers 172 26.5 
Antidepressants 94 14.5 
Vitamins (B1 & B complex) 39 6.0 
NSAIDs 30 4.6 
Antihistamines 21 3.2 
Incontinence meds 16 2.5 
 
5.2.6 Clinical examination 
 
5.2.6.1 Routine physiological measurements 
 
Routine physiological measurements were recorded for all patients attending the study visit 
(Table 5-7). In contrast to the recordings from the hospital admission (Table 4-7, page 151), 
fewer patients had abnormal physiological measurements. The mean pulse was lower at 77.1 
beats per minute (bpm), with only 50 patients (7.7%) having a tachycardia (defined as a pulse 
greater than 100 bpm). Of those patients with a tachycardia at the study visit, over half were in 
AF on their study visit ECG. Of 648 patients, 84 patients (13%) were bradycardic (defined as 
a pulse less than 60 bpm), likely reflective of treatment with beta-blockers. The mean blood 
pressure was normal at 131 / 68 mmHg. Over one third of patients had a SBP greater than 140 
mmHg, with only 22 patients (3.4%) having severe hypertension (defined as SBP greater than 
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180 mmHg). During hospitalisation, 45 study visit attendees (6.9%) had severe hypertension 
(Table 4-7, page 151). Only 43 patients (6.6%) had systolic hypotension (defined as SBP less 
than 90 mmHg) at the study visit. Only 34 patients (5.2%) met criteria for diastolic 
hypertension (defined as DBP greater than 90 mmHg), in contrast to a quarter of the same 
patients during hospitalisation (Table 4-7, page 154). A significant proportion of the cohort 
(42.6%) had diastolic hypotension (defined as DBP less than 60 mmHg). The mean 
temperature, respiratory rate and SpO2 were normal.  
 
5.2.6.2 Body mass index and waist circumference measurements 
 
Height, waist and weight measurements were recorded for all patients attending the study visit. 
BMI was calculated from these measurements. The results are displayed in Table 5-8. Over 
three-quarters of the post-discharge cohort lost weight from the hospital admission (Table 4-8, 
page 154) to the study visit. These declines in weight are most likely due to successful diuresis 
and establishing euvolaemic status after the decompensated episode in hospital. Despite this, 
most of the post-discharge patients were still overweight with an average BMI of 28.7 kg/m2. 
Over two-thirds of all patients were either overweight or obese (defined as BMI 25-30 kg/m2 
or >30 kg/m2, respectively). Less than one-third of the post-discharge cohort was normal 
weight (defined as BMI 18.5-24.9 kg/m2). Only 16 patients (2.5%) were underweight (defined 
as BMI < 18.5 kg/m2). Over half of patients had a waist circumference exceeding the sex-
specific recommendations (defined as 94–102 cm in men and 80–88 cm in women). More than 
one-quarter of patients had a waist circumference below the sex-specific recommendations 
(defined as < 94 cm in men and < 80 in women).  
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Table 5-7: Physiological findings in the post-discharge cohort, recorded at the study visit.  
 
Variable Mean (SD), median [IQR] 
or n (%) 
Units 
Mean HR  77.1 (15.5) bpm 
Median HR 76 [67-88] bpm 
HR > 100 50 (7.7) bpm 
HR > 100 & AF on study visit ECG 27/50 (54) bpm 
HR < 60 84 (13.0) bpm 
HR < 50 12 (1.9) bpm 
Mean SBP 131 (23.5) mmHg 
Median SBP 129 [114-145] mmHg 
SBP > 140 225 (34.7) mmHg 
SBP ≥ 180 22 (3.4) mmHg 
SBP < 90 43 (6.6) mmHg 
Mean DBP 67.8 (13.2) mmHg 
Median DBP 67 [58-77] mmHg 
DBP ≥ 90 34 (5.2) mmHg 
DBP < 60 276 (42.6) mmHg 
Mean pulse pressure 63.2 (23.6) mmHg 
Median pulse pressure 56 [45-71] mmHg 
Mean temperature  36.2 (0.6) ° Celsius 
Median temperature  36.2 [35.9-36.5] ° Celsius 
Mean respiratory rate  19.1 (3.5) breaths /  min 
Median respiratory rate  18 [17-20] breaths / min 
Mean SpO2  97.5 (2.8) % 
Median SpO2   98 [96-99] % 
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Table 5-8: BMI and waist circumference measurements at the study visit.  
 
Measurement Mean (SD), median [IQR] or n 
(%) 
Units 
Mean height 163.9 (10.2) cm 
Median height  164 [156.8-171] cm 
Mean height (men) 169.9 (8.0) cm 
Mean height (women) 155.6 (6.5) cm 
Mean weight 77.5 (20.3) kg 
Median weight  75 [63-88.5] kg 
Mean weight (men) 83.3 (19.6) kg 
Mean weight (women) 69.4 (18.4) kg 
Study visit weight <  hospital weight  503 (77.6) - 
Mean BMI 28.7 (6.7) kg/m2 
Median BMI  27.6 [24.1-32.5] kg/m2 
Mean BMI (men) 28.8 (6.3) kg/m2 
Mean BMI (women) 28.6 (7.3) kg/m2 
BMI < 18.5 (underweight) 16 (2.5) kg/m2 
BMI 18.5 – 24.9 (normal weight) 189 (29.2) kg/m2 
BMI 25 – 30 (overweight) 218 (33.6) kg/m2 
BMI > 30 (obese) 225 (34.7) kg/m2 
Mean waist 97.5 (17.0) cm 
Median waist  97 [87-107] cm 
Waist < 94 M; < 80 F 186 (28.7) cm 
Waist 94 – 102 M; 80 – 88 F 125 (19.3) cm 
Waist ≥ 102 M; ≥ 88 F 337 (52.0) cm 
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5.2.6.3 Cardiovascular examination signs 
 
A full cardiovascular examination was performed for all patients attending the study visit 
(Table 5-9). Few patients had a raised JVP, an expected finding in a cohort of patients with 
stable HF. Three quarters of patients had palpable apices and over a third of these were 
displaced. Detection of a third heart sound was less common at the study visit than during the 
hospital admission for the post-discharge cohort (Table 4-11, page 158), also an expected 
finding in a cohort of patients with stable HF. Only a quarter of the post-discharge cohort had 
pulmonary crackles on examination, the vast majority of which were confined to the lung 
bases. More than 90% of the post-discharge cohort had at least basal pulmonary crackles on 
admission to hospital (Table 4-11, page 158). Few patients had clinical signs of a pleural 
effusion (uni- or bilateral) at the study visit. Over a third of the post-discharge cohort had 
ankle oedema, with few patients having oedema extending beyond the ankles. A significant 
proportion of the post-discharge cohort had complete resolution of peripheral oedema, by the 
time of their study visit. Few patients had clinical evidence of ascites at the study visit. 
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Table 5-9:  Cardiovascular examination findings at the study visit 
 
Clinical sign Number of patients % of cohort (n=648) 
Elevated JVP (>4cm) 67 10.3 
JVP not elevated 505 77.9 
JVP not seen 77 11.9 
Palpable apex 494 76.2 
Displaced apex 178 27.5 
Third heart sound 6 0.9 
Murmur 288 44.4 
Pulmonary crackles (any) 168 25.9 
Pulmonary crackles – basal only 162 25.0 
Pulmonary crackles – mid-zones 6 0.9 
Pulmonary crackles – apices 0 0 
Complete resolution of pulmonary 
crackles from hospitalisation 
440 67.9 
Pleural effusion(s) 17 2.6 
Peripheral oedema – ankle 238 36.7 
Peripheral oedema – knee 43 6.6 
Peripheral oedema – thigh 6 0.9 
Peripheral oedema – sacrum 1 0.2 
Peripheral oedema – abdomen 0 0 
Complete resolution of peripheral 
oedema from hospitalisation 
234 36.1 
Ascites 6 0.9 
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5.2.7 Electrocardiography 
 
All patients had a 12-lead ECG performed at the study visit; the results are displayed in Table 
5-10. Of 648 patients attending the study visit, 379 patients were in sinus rhythm. Over one 
third of the patients were in AF.  Only 34 patients (5.2%) were in a paced rhythm. A 
significant number of patients had ECG evidence of LVH (n=107, 16.5%). Over a quarter of 
patients had evidence of a bundle branch block on ECG, with 142 patients having LBBB 
(21.9%).  The mean QRS duration for the post-discharge cohort was within normal limits at 
112ms. A prolonged QRS duration (defined as >120ms) was common and evident in almost 
one-third of patients, with 81 patients (12.5%) having a major prolongation (defined as 
>150ms). The mean QTc interval for the post-discharge cohort was at the upper limit of the 
normal range and approximately half of the cohort had a prolonged QTc (defined as >440ms). 
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Table 5-10: ECG parameters at the study visit.  
 
ECG parameter n (%), mean (SD) or median [IQR] Units 
Sinus Rhythm 379 (58.5) - 
AF 240 (37.0) - 
Paced rhythm 34 (5.2) - 
LBBB 142 (21.9) - 
RBBB 34 (5.2) - 
Pathological Q waves 61 (9.4) - 
LVH 107 (16.5) - 
Ischaemic ST depression 13 (2.0) - 
Mean QRS duration 111.7 (27.5) ms 
Median QRS duration  104 [90-126] ms 
QRS duration ≥ 120 206 (31.8) - 
QRS duration 120 -150 125 (19.3) - 
QRS duration > 150 81 (12.5) - 
Mean QTc interval 439.4 (33.0) ms 
Median QTc interval  439 [414.8-462] ms 
QTc interval <440 326 (50.3) - 
QTc interval ≥440 322 (49.7) - 
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5.2.8 Ejection fraction by echocardiography 
 
All patients had a focused echocardiogram performed at the study visit to calculate LVEF. Of 
648 patients attending the study visit, 622 patients (96.0%) had echocardiographic images of 
satisfactory quality to enable LVEF to be calculated using Simpson’s biplane method. The 
mean (SD) LVEF was 40.2% (12.2). The median [IQR] LVEF was also 40% [32-48]. The 
minimum LVEF was 11% and the maximum 70%. The distribution of LVEF is shown in 
Figure 5-1. One fifth of the post-discharge cohort had severe LVSD (defined as LVEF <30%). 
Approximately one fifth had preserved left ventricular systolic function (defined as LVEF ≥ 
50%). For the 26 patients whose echocardiographic images were inadequate to calculate an 
ejection fraction by Simpson’s method, an estimate of whether left ventricular systolic 
function was reduced or preserved was made. Of these patients with an incalculable LVEF by 
Simpson’s method, 18 patients were estimated to have reduced left ventricular systolic 
function. 
 
Figure 5-1: Distribution of LVEF at the study visit for 622 patients with calculable EF by 
Simpson’s biplane method 
 195 
5.2.9 Haematology 
 
Table 5-11 displays the full blood count results for the post-discharge cohort. The mean WBC 
count was within normal limits, with only 54 patients (8.3%) having a raised count. The mean 
(SD) haemoglobin was 12.5g/dl (2.0). Almost half of the post-discharge cohort were anaemic, 
by WHO standards (defined as haemoglobin <12g/dl for females and <13g/dl for males). The 
mean lymphocyte count for the cohort was within normal limits and 79 patients (12.2%) had a 
low lymphocyte count (<1 x109/l). Over half of the cohort had an elevated RDW (defined as 
RDW ≥ 15%). 
 
Table 5-11: Full blood count profile for the post-discharge cohort at the study visit 
 
Parameter Mean (SD), median [IQR] or n (%) Units 
Mean WBC count 7.9 (2.4) x109/l 
Median WBC count  7.6 [6.3-9.3] x109/l 
WBC count >11 54 (8.3) - 
Mean haemoglobin 12.5 (2.0) g/dl 
Median haemoglobin  12.4 [11.3-13.7] g/dl 
Haemoglobin <13 M; <12 F 318 (49.1) - 
Mean RDW 15.6 (2.5) % 
Median RDW (IQR) 15.0 [14-16.3] % 
RDW ≥ 15 333 (51.4) - 
Mean lymphocytes 1.9 (1.3) x109/l 
Median lymphocytes  1.8 [1.3-2.3] x109/l 
Lymphocytes <1 79 (12.2) - 
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5.2.10 Biochemistry 
 
All post-discharge patients attending the study visit had the following biochemical blood tests 
performed; BNP, troponin I, U&E, LFT, TFT, HBA1c, phosphate and urate.  
 
The BNP and troponin I results are displayed in Table 5-12. The distribution of BNP results 
for the post-discharge cohort is displayed in Figure 5.2. The distribution of BNP was skewed 
and logarithmic (log) transformation of BNP was performed.  The median BNP concentration 
was 395.5pg/ml [201.8-806.3].  This was considerably lower than the median BNP for the 
hospitalised cohort (880pg/ml, [394-1811]). As expected, there was a decline in BNP level for 
most patients from hospitalisation to the study visit. The median fall in BNP was 240.5pg/ml. 
Only 1 patient attending the study visit had a BNP in excess of the upper limit of the assay 
(>5000pg/ml), compared to 32 patients in the hospitalised cohort. Less than a quarter of the 
post-discharge cohort had an elevated troponin I (defined as ≥ 0.04 µg/l). Half of the post-
discharge cohort had an elevated troponin I during the hospital admission (Table 4-17, page 
169).  
 
Table 5-12: BNP and troponin I results for the post-discharge cohort at the study visit 
 
Parameter Mean (SD), median [IQR] or n 
(%) 
Units 
Mean BNP 671.8 (775.9) pg/ml 
Median BNP 395.5 [201.8-806.3] pg/ml 
BNP >5000  1 (0.2) pg/ml 
Log (BNP) 5.9 (1.1) - 
Mean ∆ BNP – hospital to study visit 525.2 (970.1) pg/ml 
Median ∆ BNP – hospital to study visit 240.5 [17.8-771.3] pg/ml 
Troponin I ≥ 0.04  116 (17.9) µg/l 
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Figure 5.2: Distribution of BNP levels at the study visit 
 
 
All patients had renal function measured at the study visit (Table 5-13). The mean sodium and 
potassium levels were within the normal ranges. Only 56 patients (8.6%) were hyponatraemic 
(defined as sodium <135mmol/l), approximately half the number of patients hyponatraemic 
during hospitalisation (Table 4-18, page 171). The mean urea concentration was raised at 
9.8mmol/l and 390 patients (60.2%) had an elevated urea concentration (defined as urea ≥ 
7.5mmol/l), similar to the proportion of this cohort with an elevated urea concentration during 
hospitalisation. The median creatinine concentration was 108µmol/l. The mean eGFR for the 
entire cohort was reduced at 56.7 ml/min/1.73m2. Only 25 patients (3.9%) had a normal eGFR 
(defined as eGFR ≥ 90 ml/min/1.73m2), fewer patients than during hospitalisation (Table 4-18, 
page 171). The distribution of GFR per 30 ml/min/1.73m2 is shown in Figure 5.3.  
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Table 5-13: Renal function results for the post-discharge cohort at the study visit.  
 
Parameter Mean (SD), median [IQR] or n (%) Units 
Mean sodium 139.2 (3.4) mmol/l 
Median sodium 140 [137.8-141.3] mmol/l 
Sodium <135 56 (8.6) mmol/l 
Mean potassium 4.0 (0.5) mmol/l 
Median potassium  4.0 [3.7-4.3] mmol/l 
Mean urea 9.8 (5.1) mmol/l 
Median urea  8.3 [6.3-11.7] mmol/l 
Urea ≥ 7.5 390 (60.2) mmol/l 
Mean creatinine 117.8 (44.0) µmol/l 
Median creatinine  108 [89-132] µmol/l 
Mean eGFR  56.7 (19.3) ml/min/1.73m2 
Median eGFR  55.4 [42.9-69.5] ml/min/1.73m2 
 
 
 
Figure 5.3: Distribution of eGFR for the post-discharge cohort 
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All patients had LFT measured at the study visit (Table 5-14). The mean bilirubin level was 
within the normal range. Only 55 patients (8.5%) had an elevated bilirubin (defined as >22 
µmol/l). This was half the number of patients, in the post-discharge cohort, with a raised 
bilirubin in the decompensated state (Table 4-19, page 173). The mean AST, ALT and 
alkaline phosphatase levels were within the normal ranges. The mean GGT was elevated at 
77.9U/l, the upper limit of normal is 55U/l. The mean albumin level was within the normal 
range at 38.7g/l, higher than the mean for the same patients during hospitalisation (Table 4-19, 
page 173). Only 86 patients (13.3%) were hypoalbuminaemic (defined as <35g/l), almost a 
third of the number of patients with this biochemical abnormality during hospital admission 
(Table 4-19, page 173). 
 
The mean thyroid function, HbA1c, phosphate and urate levels were within the normal 
reference ranges. These results are displayed in Table 5-15. 
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Table 5-14: LFT results for the post-discharge cohort at the study visit.  
 
Parameter Mean (SD), median [IQR] or n (%) Units 
Mean bilirubin 11.6 (7.9) µmol/l 
Median bilirubin  9 [7-13] µmol/l 
Bilirubin ≥  22 55 (8.5) U/l 
Mean AST 25.8 (41.3) U/l 
Median AST  21 [17-27] U/l 
Mean ALT  23.5 (49.0) U/l 
Median ALT  18 [13-25] U/l 
Mean GGT 77.9 (94.3) U/l 
Median GGT 45 [28-88.3] U/l 
Mean Alk Phos 104.6 (56.6) U/l 
Median Alk Phos  92 [74-118] U/l 
Mean albumin 38.7 (4.0) g/l 
Median albumin  39 [36-41] g/l 
Albumin <35 86 (13.3) g/l 
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Table 5-15: Other biochemical tests recorded at study visit for the post-discharge cohort.  
 
Parameter Mean (SD), median [IQR] or number (%) Units 
Mean TSH 2.3 (3.5) mU/l 
Median TSH  1.6 [0.9-2.4] mU/l 
Mean T4 14.3 (3.0) pmol/l 
Median T4  14.0 [13.0-16.0] pmol/l 
Mean HbA1c  6.3 (1.3) % 
Median HbA1c 5.9 [5.6-6.7] % 
Mean phosphate 1.16 (0.22) mmol/l 
Median phosphate 1.16 [1.01-1.29] mmol/l 
Mean urate 0.47 (0.14) mmol/l 
Median urate 0.46 [0.37-0.55] mmol/l 
Mean cholesterol (total) 4.3 (1.3) mmol/l 
Median cholesterol (total) 4.1 [3.4-4.9] mmol/l 
Mean HDL  1.1 (0.4) mmol/l 
Median HDL 1.1 [0.9-1.4] mmol/l 
 
5.2.11 Aetiology of heart failure  
 
The primary aetiologies of HF for the post-discharge cohort are displayed in Table 5-16. The 
primary aetiology for the majority of patients was ischaemic heart disease. Over 40% of the 
post-discharge cohort had documented evidence of a previously reported MI. More than one-
third of patients had angiographic evidence of coronary heart disease (defined as >50% 
stenosis in at least 1 major epicardial vessel). Almost one-third of patients had an ‘unknown’ 
primary aetiology of HF. These patients had no history of a MI or a coronary angiogram 
performed by the time of the study visit. The non-ischaemic primary causes of HF are also 
detailed in Table 5-16. A non-ischaemic primary aetiology was only assigned where ischaemia 
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had been excluded (no previous MI and coronary angiography demonstrating no lesions ≥ 
50% in ≥ 1 major epicardial artery).  The majority of non-ischaemic causes of HF were 
valvular heart disease. As outlined in the methods section, valvular heart disease was only 
considered causative if it was at least moderate in severity. The cardiomyopathies were the 
cause of HF for a small number of patients, as outlined in Table 5-16. Fewer patients had 
hypertension and alcohol as the primary reason for their HF. It is likely that more patients had 
hypertension, alcohol or valvular heart disease as the primary cause of their HF but in the 
absence of coronary angiography these patients were categorised as ‘unknown’ primary 
aetiology and any potential primary causes were recorded as ‘contributing aetiologies’, as 
detailed in the following paragraph.  
 
Table 5-16: Primary aetiology of heart failure for the post-discharge cohort 
 
Primary aetiology Number % of cohort (n=648) 
Ischaemic 
          a) Definite previous MI 
          b) Angiographic evidence  
             (>50% stenosis in ≥ 1 vessel) 
353 
278 
224 
 
54.5 
42.9 
34.6 
 
Non-ischaemic 91 14.0 
          Valvular 39 6.0 
          Cardiomyopathies 
               a) Idiopathic dilated cardiomyopathy 
               b) Hypertrophic cardiomyopathy 
               c) Peripartum cardiomyopathy 
               d) Restrictive cardiomyopathy 
25 
16 
4 
3 
2 
3.9 
2.5 
0.6 
0.5 
0.3 
          Hypertension 15 2.3 
          Alcohol 12 1.9 
Unknown (no previous MI or angiography) 204 31.5 
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The prevalences of contributing aetiologies are displayed in Table 5-17. Almost two-thirds of 
the post-discharge cohort had a history of hypertension as a contributing cause of HF. AF was 
recorded as a potential contributing cause of HF in cases where the arrhythmia was persistent 
or permanent in duration, this was the case in 44% of the entire cohort. More than one-third 
had valvular heart disease as a contributing cause of their HF. Many of these were functional 
MR. The prevalence of diabetes mellitus was high in the post-discharge cohort, affecting 
almost a third of all patients. Excess alcohol consumption was also a significant contributor, in 
at least 18% of all patients.  
 
Table 5-17: Contributing aetiologies of heart failure in the post-discharge cohort 
 
Contributing aetiology Number of patients Percentage of cohort 
(n=648) 
Hypertension 420 64.8 
Valvular heart disease 286 44.1 
AF 
(paroxysmal, persistent or permanent) 
319 49.2 
Diabetes mellitus 203 31.3 
Alcohol (previous or current excess) 119 18.4 
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5.2.12 Heart failure with reduced versus preserved ejection fraction (HF-REF v HF-PEF) 
 
Overall, the majority of the post-discharge cohort had HF-REF. Less than 20% had HF-PEF, 
defined as LVEF > 50% (Figure 5-4). The mean (SD) LVEF for patients with HF-REF was 
36.0% (9.4) and for patients with HF-PEF was 57.6% (5.1). All of the clinical characteristics 
of the post-discharge cohort, described in this chapter, were analysed according to LVEF to 
determine if there were significant differences in the characteristics of the patients with HF-
REF compared to those with HF-PEF. All characteristics with a significant difference (defined 
as a p-value <0.05) are presented in Tables 5-18 and 5-19.  
 
Figure 5.4: HF-PEF versus HF-REF for the post-discharge cohort 
 
 
Patients with HF-REF were younger (p=0.025), by an average of more than 2 years, and were 
more often men (p<0.0001) than those with HF-PEF. A diagnosis of HF prior to enrolment 
into this study was more common amongst those with HF-REF (p=0.00049), although there 
was no difference in HF symptoms between the two groups. Coronary heart disease was more 
common amongst those with HF-REF, with proportionately more of these patients having a 
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history of MI (p=0.00011), angina (p=0.0017), angiographic coronary heart disease (p=0.006), 
PCI (p=0.023) and CABG (p=0.0007). Hypertension was more common amongst those with 
HF-PEF (p=0.00054), whilst COPD tended to be more common amongst those with HF-PEF 
(p=0.06), compared with patients with HF-REF. The prevalences of the other medical 
comorbidities (outlined in Table 5-3) were similar between the two groups. 
 
The prescribing of diuretics (p=0.0047), ACE inhibitors (p=0.00017), beta-blockers (p=0.0028) 
and combinations of HF disease-modifying therapies was more common amongst patients 
with HF-REF (compared with patients with HF-PEF).  Calcium channel blockers prescribing 
were more common amongst patients with HF-PEF. The prescribing of other cardiovascular 
medications was similar between the two groups. 
 
There were few differences in clinical examination findings between the two groups. Patients 
with HF-PEF had higher SBP (p=0.006) and greater pulse pressure (p=0.0008), than those 
with HF-REF. There were no differences in the proportions of patients in sinus rhythm or AF, 
stratified by reduced or preserved LVEF. Among patients with HF-REF, LBBB was five times 
more common than in those with HF-PEF (p<0.0001). Median QRS duration was greater for 
patients with HF-REF (p<0.0001), and proportionately more HF-REF patients (than HF-PEF 
patients) had a prolonged QRS duration (p<0.0001).  Mean QTc interval was longer for 
patients with HF-REF (p=0.00043) and more HF-REF patients had prolonged QTc intervals 
(p<0.0001), compared with patients with HF-PEF. The prevalence of radiological pulmonary 
oedema during hospitalisation did not differ between the two groups. 
 
There were differences in biochemical and haematological findings between the two groups of 
patients. Patients with HF-REF had higher BNP concentrations during hospitalisation and at 
the study visit (both p<0.0001), with median values almost twice those of patients with HF-
PEF on both occasions. Patients with HF-REF also had higher urea concentrations (p=0.049), 
more hypoalbuminaemia (0.046) and lower HDL concentrations p=0.0042). Mean 
haemoglobin concentration was lower amongst patients with HF-PEF (p=0.0019), and 
consequently anaemia was more prevalent amongst those patients (p<0.0001).  
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Table 5-18: Demographics, medical history and current medications, stratified by LVEF 
(significant results only). Data are expressed as number (%) or mean (SD).  
 
 
Variable HF-PEF 
(n=127) 
HF-REF 
(n=521) 
Overall 
(n=648) 
p 
value* 
Male 50 (39.4) 327 (62.8) 377 (58.2) <0.0001 
Age 72.7 (9.2) 70.3 (10.9) 70.8 (10.6) 0.025 
Previous diagnosis HF 38 (29.9) 245 (47) 283 (43.7) 0.00049 
MI 38 (29.9) 255 (48.9) 293 (45.2) 0.00011 
History of angina 54 (42.5) 302 (58) 356 (54.9) 0.0017 
Angiographic CAD 26/44 (59) 199/262 (76) 225/307 (73) 0.006 
PCI 10 (7.9) 82 (15.7) 92 (14.2) 0.023 
CABG 9 (7.1) 103 (19.8) 112 (17.3) 0.0007 
Hypertension 99 (78) 321 (61.6) 420 (64.8) 0.00054 
Diuretics 116 (91.3) 505 (96.9) 621 (95.8) 0.0047 
ACE inhibitors 72 (56.7) 384 (73.7) 456 (70.4) 0.00017 
Beta-blockers 70 (55.1) 360 (69.1) 430 (66.4) 0.0028 
ACE inhibitor or ARB 79 (62.2) 435 (83.5) 514 (79.3) <0.0001 
ACE inhibitor or ARB & Beta-
blocker 
43 (33.9) 314 (60.3) 357 (55.1) <0.0001 
ACE inhibitor or ARB & Beta-
blocker & Aldosterone blocker 
4 (3.1) 48 (9.2) 52 (8) 0.038 
Calcium channel blockers 37 (29.1) 80 (15.4) 117 (18.1) 0.00029 
 
* Inter-group comparisons using Student’s t-test (continuous variables) and χ2 test (categorical 
variables), p value <0.05 indicates a significant difference between the two groups. 
CAD = coronary artery disease (defined as > 50% stenosis in ≥ 1 major epicardial vessel, 
denominator is number of patients who had an angiogram) 
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Table 5-19: Clinical examination, ECG and blood parameters, stratified by LVEF 
(significant results only). Data are expressed as number (%), mean (SD) or median 
[IQR].  
 
Variable HF-PEF 
(n=127) 
HF-REF 
(n=521) 
Overall 
(n=648) 
p 
value* 
SBP 136.1 (22) 129.8 (23.7) 131 (23.5) 0.006 
Pulse pressure 69.2 (23.3) 61.7 (22.2) 63.2 (22.6) 0.0008 
LBBB 7 (5.5) 135 (25.9) 142 (21.9) <0.0001 
QRS (ms) 92 [86-104] 110 [94-134] 104 [90-126] <0.0001 
QRS duration  
        ≥ 120 
        120-150 
         > 150 
 
11 (8.7) 
8 (6.3) 
3 (2.4) 
 
195 (37.4) 
117 (22.5) 
78 (15.0) 
 
206 (31.8) 
125 (19.3) 
81 (12.5) 
 
<0.0001 
QTc (ms) 430.2 (32.5) 441.6 (32.8) 439.4 (33.0) 0.00043 
QTc ≥ 440 43 (33.9) 279 (53.6) 322 (49.7) <0.0001 
BNP - hospital (pg/ml) 435 [240-952] 918 [407-1866] 788 [366-1582] <0.0001 
BNP - study visit (pg/ml) 237 [129-426] 453 [225-920] 396 [202-806] <0.0001 
Troponin I ≥ 0.04 µg/l 8 (6.3) 97 (18.6) 105 (16.2) 0.0011 
Urea (mmol/l) 9 (4.5) 9.9 (5.2) 9.8 (5.1) 0.049 
Albumin <35 (g/l) 10 (7.9) 76 (14.6) 86 (13.3) 0.046 
HDL (mmol/l) 1.2 (0.4) 1.1 (0.4) 1.1 (0.4) 0.0042 
Haemoglobin (g/dl) 12.1 (2) 12.7 (1.9) 12.5 (2) 0.0019 
Haemoglobin <13M; <12F 83 (65.4) 235 (45.1) 318 (49.1) <0.0001 
 
* Inter-group comparisons using Student’s t-test (continuous variables) and χ2 test (categorical 
variables), p value <0.05 indicates a significant difference between the two groups. 
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5.3 Discussion 
 
Chapter 5 has described the clinical data obtained from the study visit for the post-discharge 
cohort. The study visit occurred approximately 4-6 weeks after hospitalisation. The post-
discharge cohort comprised 648 patients of the original 1003 patients enrolled during 
hospitalisation. A significant proportion of the original cohort was deceased by 4-6 weeks, 
consistent with the high early mortality rate following hospitalisation for HF (147).  
 
The post-discharge cohort was, expectedly, a cohort of patients with stable HF. The majority 
of these patients were NYHA class II, having been NYHA class III at the time of hospital 
admission. The majority of patients experienced a reduction in weight from the hospital 
admission to study visit attendance, consistent with achieving euvolaemic status following 
their admission with decompensated HF. There was also an expected reduction in the numbers 
of patients with signs of fluid overload by the time of the study visit. The significance of 
worsening signs and symptoms of HF following an admission for HF and subsequent 
rehospitalisation and mortality has recently been recognised (148). 
 
The frequency of diuretic prescribing was high amongst the post-discharge cohort (> 95%), 
with modest prescribing of HF disease-modifying therapies (70% prescribed an ACE inhibitor; 
66% prescribed a beta-blocker).  
 
A large proportion of the post-discharge cohort was in AF at the time of the study visit (37%), 
consistent with the prevalence of 10-50% reported by clinical studies of AF in LVSD (149) 
and the recognition of AF as a common finding in patients with heart failure and preserved 
systolic function (150). Over a quarter of the post-discharge cohort had evidence of bundle 
branch block on the ECG performed at the study visit. The prevalence of this finding is similar 
to other chronic HF cohorts containing patients with both reduced and preserved systolic 
function (151). Many patients had electrocardiographic evidence of LVH, this prevalence is 
also similar to other chronic HF cohorts containing patients with both reduced and preserved 
systolic function (152). 
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The mean LVEF for the post-discharge cohort was 40%, consistent with the mean LVEF 
reported by other chronic HF cohorts containing patients with both reduced and preserved 
systolic function (121). Approximately one-fifth of the post-discharge cohort had preserved 
systolic function, defined as LVEF ≥ 50% (18).  
 
There was an improvement in most of the haematological and biochemical parameters 
measured in the post-discharge cohort, compared to measurements performed whilst in 
hospital. There was a significant reduction in BNP levels for the majority of the post-discharge 
cohort and a sizeable reduction in the proportion of the cohort with an elevated troponin 
concentration. The prognostic importance of persistent troponin elevation in both chronic HF 
and during admission for acute decompensated HF has been recently demonstrated (153;154). 
Fewer patients were hyponatraemic, hyperbilirubinaemic or hypoalbuminaemic, than during 
the hospital admission. The post-discharge cohort had similar proportions of patients with an 
elevated urea concentration and reduced eGFR, compared to the hospitalised cohort. Indeed, 
fewer patients had normal eGFR at the time of the study visit than on admission to hospital. 
Almost half of the post-discharge cohort was anaemic, similar to the prevalence of anaemia 
during the hospital admission.  
 
Ischaemic heart disease was the primary aetiology of HF for the majority of the post-discharge 
cohort, consistent with this being the commonest cause of HF in Western countries. However, 
almost one-third of patients had an ‘unknown’ primary aetiology of heart failure. 
 
When the clinical data of the post-discharge cohort were analysed according to whether the 
patients had HF-REF or HF-PEF, the majority of clinical characteristics were similar between 
the two groups. This is consistent with previous reports that patients with HF-PEF cannot be 
distinguished from those with HF-REF on the basis of symptoms and signs, CXR or ECG 
findings (19). However, there were some notable differences between the two groups. Patients 
with HF-PEF were older, more likely to be female, more likely to have hypertension and less 
likely to have had a MI, in comparison to those with HF-REF. These findings are consistent 
with previous studies of HF-PEF (22;24;155). Prescribing of recommended pharmacological 
treatments for HF was greater amongst patients with HF-REF, an unsurprising result given the 
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evidence-base for the use of these medications exists only for patients with HF-REF and no 
treatment is of proven benefit in HF-PEF. Prescribing of calcium channel blockers was more 
common amongst those with HF-PEF, perhaps reflecting the use of these agents as 
antihypertensive treatment. Apart from SBP and pulse pressure, there were no differences in 
clinical examination findings between the two groups. There were also no differences in the 
proportions in sinus rhythm or AF between the two groups. QRS duration and QTc interval 
were longer amongst patients with HF-REF. The majority of biochemical and haematological 
tests performed did not differ according to LVEF. However, the differences in BNP 
concentrations between the two groups, on admission to hospital and at the study visit, were 
striking. Patients with HF-REF had median BNP concentrations almost twice that of those 
with HF-PEF.  Previous studies in patients with decompensated HF have demonstrated similar 
findings (156). Anaemia was more common amongst those with HF-PEF, consistent with 
previous reports (23).   
 
In summary, many of the symptoms, signs and blood tests of the post-discharge cohort showed 
an expected improvement compared to data recorded during hospitalisation with 
decompensated HF. The post-discharge cohort still exhibited many abnormal clinical 
characteristics, many of which are consistent with prior findings published in chronic HF 
cohorts, and the majority of patients had HF-REF. 
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6.1 Introduction 
 
This chapter will describe the results of MTWA testing in the post-discharge cohort. The 
eligibility for MTWA testing will be described and the reasons for ineligibility outlined. The 
potential eligibility in the entire hospitalised cohort will also be outlined. This will 
demonstrate whether or not the post-discharge cohort was similar, in terms of eligibility for 
MTWA testing, to that of an unselected cohort of patients with HF. The clinical characteristics 
of the post-discharge cohort, described in chapter 5, will be stratified by eligibility for MTWA 
testing. This will determine if there were any significant differences in the clinical 
characteristics of the patients eligible for MTWA testing compared to those ineligible. The 
results of MTWA testing and the prevalence of positive, negative and indeterminate results 
will be described, including an outline of the reasons for an indeterminate test. The functional 
capacity of the patients will also be displayed including the reasons for terminating exercise, 
average duration of exercise and metabolic equivalent values (METs). This will allow an 
evaluation of the practicality of this test in HF patients. For patients unable to exercise, 
MTWA testing at rest will be described.  
 
6.2 Results 
 
6.2.1 Eligibility 
 
The spectral analysis method of MTWA testing is not suitable for all patients. It is mandatory 
that patients are in sinus rhythm, and able to perform sub maximal treadmill exercise in order 
to raise their heart rates to 110 beats per minute. Patients are ineligible for MTWA testing if 
they are in AF, continuously ventricular pacing (and therefore unable to produce a 
chronotropic response), or unable to perform sub maximal exercise on a treadmill. The reasons 
for the latter may be multifactorial and include physical incapabilities as well as medical 
contraindications, for example severe symptomatic aortic stenosis. Figure 6.1 illustrates the 
potential eligibility for MTWA testing in the hospitalised cohort. This includes the non-
attendees, as well as the post-discharge cohort. For the former, eligibility is based on clinical 
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data collected during hospitalisation and therefore may not be truly accurate. For example, a 
patient in AF whilst hospitalised with decompensated HF could have cardioverted to sinus 
rhythm before the study visit. Furthermore it is impossible to estimate the rhythm for non-
attendees with paroxysmal AF. Therefore, the rhythm during the index hospitalisation was 
used for determining potential eligibility for non-attendees. An accurate assessment of a 
patient’s ability to exercise is also difficult to establish during hospitalisation and is likely to 
be underrepresented in Figure 1. Thus, Figure 6.1 provides an approximate assessment of 
eligibility for MTWA testing for the hospitalised cohort. Of 1003 patients enrolled, 549 
patients (54.7%) were potentially eligible for MTWA testing. A large proportion was therefore 
ineligible. The most common reason for this was AF, affecting 364 patients (36.3%). Only 35 
patients (3.5%) were in a paced ventricular rhythm and 56 patients (5.6%) were unable to 
attempt exercise. An inability to attempt exercise included patients who were physically 
incapable as well as those with medical contraindications, for example severe aortic stenosis.  
 
Figure 6.1: Potential eligibility for MTWA testing in the hospitalised cohort 
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Eligibility for MTWA exercise testing at the study visit is displayed in Figure 6.2. Just over 
half of the attendees were eligible for MTWA exercise testing (50.9%). The proportion of 
patients eligible for MTWA testing was similar to the potential eligibility in the hospitalised 
cohort (50.9% versus 54.7%, respectively). The most common reason for ineligibility was AF, 
accounting for 242 patients (37.3%) attending the study visit. The remaining patients were 
ineligible for MTWA testing because of continuous ventricular pacing (5.1%) and inability to 
exercise (6.6%). The latter included patients who could not satisfactorily exercise on the 
treadmill as well as patients with a contra-indication to performing exercise, such as severe 
aortic stenosis. Satisfactory exercise was defined as an ability to walk on the treadmill for at 
least two minutes. Of all patients taking the MTWA test, 43 patients (6.6%) were unable to 
exercise, the majority of whom attempted exercise (n=26). Figure 6.3 displays the breakdown 
of reasons for being unable to exercise for two minutes. The reasons why exercise was not 
attempted in the remaining 17 patients are displayed in Figure 6.4. MTWA testing was 
performed at rest in all patients unable to exercise to assess if alternans activity was present at 
rest. In these cases, only a positive MTWA result could be included in the subsequent analyses 
– a negative result would not be possible without raising the heart rate to 110 beats per minute 
and these results could not be classified as indeterminate.  
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Figure 6.2: Eligibility for MTWA testing in 648 patients attending the study visit 
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Figure 6.3: Reasons for discontinuing exercise for 26 patients who attempted exercise but 
were unable to exercise for 2 minutes 
 
 
Figure 6.4: Reasons for not attempting exercise in 17 patients 
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6.2.2 Clinical characteristics stratified by MTWA eligibility 
 
All of the clinical characteristics of the post-discharge cohort, as described in the results 
section of chapter 5, were analysed according to eligibility for MTWA testing. Details of a 
previous history of HF, as outlined in section 4.2.3 of chapter 4, and medical history, as 
outlined in section 4.2.5 of chapter 4, were also included. Only statistically significant 
differences in clinical characteristics, between those eligible for the MTWA test and those 
ineligible for MTWA testing, are presented in Tables 6-1 to 6-3. A probability value of p<0.05 
was considered significant for statistical analyses. 
 
Table 6-1 displays the parameters that differed according to MTWA eligibility for the 
following characteristics; demographics, history of HF and current HF symptoms. Patients 
ineligible for MTWA testing were older (p<0.0001), by an average of approximately 4 years, 
and therefore a greater proportion were 75 years of age or older (p=0.046). There was no 
difference in gender between the two groups. A diagnosis of HF prior to the index admission 
to hospital was more common amongst patients ineligible for MTWA testing (p=0.00013). 
Duration of hospitalisation and readmission to hospital since recruitment were similar in both 
groups. Patients ineligible for MTWA testing were more symptomatic, in terms of NYHA 
functional class, with more patients in classes III and IV than those eligible for MTWA testing 
(0.015). Of the other symptoms of HF described in Section 5.2.3 of Chapter 5, ankle swelling 
differed between the two groups, a greater proportion of ineligible patients having this 
symptom at the study visit (p=0.00022). 
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Table 6-1: Demographics, history of heart failure and current heart failure symptoms for the post-discharge cohort, stratified by MTWA 
eligibility (significant results only). Data are expressed as number (%) or mean (SD). 
 
Parameter Ineligible (n=318) Eligible (n=330) Overall (n=648) p value* 
Demographics 
 
Male 179 (56.3) 198 (60.0) 377 (58.2) 0.34 
Age, years 72.7 (9.5) 68.8 (11.3) 70.8 (10.6) <0.0001 
Age ≥ 75  126 (39.6) 106 (32.1) 232 (35.8) 0.046 
History of HF 
 
Diagnosis of HF pre-hospitalisation 163 (51.3) 120 (36.4) 283 (43.7) 0.00013 
Diagnosis HF > 2 yrs 124 / 163 (76.1) 79 / 120 (65.8) 203 / 283 (71.7) 0.059 
Current HF symptoms 
 
NYHA           I-II 
                     III-IV 
197 (61.9) 
121 (38.1) 
237 (71.8) 
93 (28.2) 
434 (67.0) 
214 (33.0) 
0.015 
Current ankle swelling 112 (35.2) 73 (22.1) 185 (28.5) 0.00022 
 
* Inter-group comparisons using Student’s t-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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Table 6-2 displays the medical comorbidities and medications that differed according to 
MTWA eligibility. The prevalence of many cardiovascular conditions differed between the 
two groups of patients. More patients eligible for MTWA testing had a history of a 
previously reported MI, compared to ineligible patients (p=0.033). Similarly, more eligible 
patients had a history of angina (p=0.02). For those who had previously undergone 
coronary angiography, a greater proportion of eligible patients had evidence of significant 
coronary artery disease (defined as > 50% stenosis in at least 1 major epicardial vessel) 
(p=0.012). PCI was also more common amongst eligible patients (p=0.0031). 
 
Predictably, the proportion of patients with either past or present AF differed between the 
two groups of patients (p<0.0001). Over 90% of those ineligible for MTWA testing had a 
history of AF. The high prevalence of this arrhythmia is expected as it was the commonest 
reason for ineligibility in the post-discharge cohort. Almost one fifth of eligible patients 
had a history of past or paroxysmal AF – none were in AF at the time of the study visit, as 
this would have rendered them ineligible for MTWA testing. Previous or current valvular 
heart disease was more common amongst ineligible patients (p<0.0001). Furthermore the 
prevalence of a valve replacement was also greater amongst those ineligible for MTWA 
testing, although of borderline statistical significance (p=0.057).  
 
The number of patients with a pacemaker differed between the two groups, 34 (10.7%) of 
those ineligible compared with 7 eligible patients (2.1%) [p<0.0001]. This is unsurprising 
as the majority of patients with a pacemaker were continuously ventricular pacing, unable 
to produce a chronotropic response and thus ineligible for MTWA testing.  
 
The prescribing of HF disease-modifying medications was similar in the two groups. 
However there were many differences in the prescribing of other cardiovascular 
medications between the two groups of patients (Table 6-2). Unsurprisingly, there was 
greater prescribing of both digoxin (p<0.0001) and warfarin (p<0.0001) in the ineligible 
group, reflective of the higher proportions of AF amongst these patients. There was greater 
prescribing of both aspirin (p<0.0001) and clopidogrel (p=0.0057) amongst eligible 
patients, consistent with the higher proportions of MI and PCI amongst this group. The 
prescribing of anti-arrhythmic therapy was highest amongst eligible patients, possibly 
reflecting the ability of these medications to maintain sinus rhythm and thus eligibility for 
MTWA (p=0.0045).  
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Table 6-2: Medical comorbidity and medications for the post-discharge cohort, 
stratified by MTWA eligibility (significant results only). Data are number (%). 
 
Parameter Ineligible 
(n=318) 
Eligible 
(n=330) 
Overall  
(n=648) 
p value* 
Medical comorbidity 
 
MI 123 (38.7) 155 (47.0) 278 (42.9) 0.033 
History of angina 160 (50.3) 196 (59.4) 356 (54.9) 0.02 
Angiographic CAD  90 / 137 
(65.7) 
134 / 169 
(79.3) 
224 / 306 
(73.2) 
0.012 
PCI 32 (10.1) 60 (18.2) 92 (14.2) 0.0031 
AF (past or present) 288 (90.6) 84 (25.5) 372 (57.4) <0.0001 
Valvular heart disease 169 (53.1) 117 (35.5) 286 (44.1) <0.0001 
Valve replacement 31 (9.7) 19 (5.8) 50 (7.7) 0.057 
Pacemaker 34 (10.7) 7 (2.1) 41 (6.3) <0.0001 
Medications 
 
Digoxin 140 (44.0) 23 (7.0) 163 (25.2) <0.0001 
Warfarin 192 (60.4) 61 (18.5) 253 (39.0) <0.0001 
Aspirin 129 (40.6) 233 (70.6) 362 (55.9) <0.0001 
Clopidogrel 43 (13.5) 72 (21.8) 115 (17.7) 0.0057 
Anti-arrhythmic 9 (2.8) 26 (7.9) 35 (5.4) 0.0045 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference 
between the groups. 
 
CAD = coronary artery disease (defined as >50% stenosis in ≥ 1 major epicardial vessel, 
denominator is number of patients who have undergone angiography) 
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There was no difference in LVEF according to MTWA eligibility, mean LVEF 39% versus 
41% for eligible versus ineligible, respectively (p=0.11). There was also no difference in 
the proportions of patients with HF-REF compared to HF-PEF according to eligibility for 
MTWA testing (50.4% and 51.1% eligibility for HF-PEF and HF-REF, respectively 
[p=0.89]).  
 
There were no differences in routine physiological findings or BMI measurements between 
the two groups. Table 6-3 displays the clinical examination, ECG and blood parameters 
that differed according to MTWA eligibility. Peripheral oedema was the only clinical 
examination sign that differed between the two groups. The presence of ankle (p<0.0001) 
and knee oedema (p=0.029) was more common amongst patients ineligible for MTWA 
testing.  
 
ECG parameters that differed between the two groups were sinus rhythm, AF, a paced 
rhythm and Q waves (p<0.0001 for all four parameters). The greater proportion of eligible 
patients in sinus rhythm is unsurprising given that this rhythm is mandatory for the spectral 
method of MTWA testing. AF and paced rhythms were more common amongst ineligible 
patients, unsurprising as MTWA testing is not possible in either of these conditions. 
Proportionately more eligible patients had Q waves present on their ECG, consistent with 
the greater prevalence of a previous MI amongst this group.  
 
There were biochemical and haematological parameters that differed between the two 
groups of patients (Table 6-3). Log B-type natriuretic peptide (BNP) concentration was 
higher amongst patients ineligible for MTWA testing (p=0.0045). Eligible patients had a 
greater decline in median BNP, from hospitalisation to study visit, than ineligible patients 
(p=0.046). Renal function differed between the two groups of patients. Those ineligible for 
MTWA testing had proportionately more patients with renal impairment and fewer patients 
with normal renal function, than eligible patients (p=0.0039). Bilirubin (p<0.0001), 
alkaline phosphatase (p=0.0098) and GGT (p<0.0001) concentrations were higher amongst 
patients ineligible for MTWA testing. Higher urate levels were also present amongst 
ineligible patients (p<0.0001). Haemoglobin concentration was slightly lower amongst 
those eligible for MTWA (p=0.034), although there was no difference in the prevalence of 
anaemia between the two groups. Lymphocyte concentration was lower amongst ineligible 
patients (p=0.02). 
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Table 6-3: Clinical examination, ECG and blood parameters stratified by MTWA  
eligibility (significant results). Data are number (%), mean (SD) or median [IQR].  
 
* Inter-group comparisons using Student’s t-test (continuous variables) and χ2 test 
(categorical variables), p value < 0.05 indicates a significant difference between the groups. 
Parameter Ineligible 
(n=318) 
Eligible  
(n=330) 
Overall     
(n=648) 
p value* 
Clinical examination 
Peripheral oedema – ankle 146 (45.9) 92 (27.9) 238 (36.7) <0.0001 
Peripheral oedema – knee 28 (8.8) 15 (4.5) 43 (6.6) 0.029 
ECG 
Sinus rhythm 43 (13.5) 328 (99.4) 371 (57.3) <0.0001 
AF 242 (76.1) 0 (0.0) 242 (37.3) <0.0001 
Paced rhythm 33 (10.4) 2 (0.6) 35 (5.4) <0.0001 
Q waves 14 (4.4) 47 (14.2) 61 (9.4) <0.0001 
Blood tests 
Log (BNP) 6.1 (1.0) 5.9 (1.1) 6.0 (1.1) 0.0045 
∆ BNP (hosp – study visit) 
(pg/ml) 
208              
[12.0-704.0] 
301             
[32.5-858.5] 
240.5            
[17.8-771.3] 
0.046 
eGFR (ml/min/1.73m2) 54.6 (18.6) 58.7 (19.8) 56.7 (19.3) 0.007 
eGFR  <30 
            30-60 
            60-90 
             ≥90 
27 (8.5) 
183 (57.6) 
100 (31.4) 
8 (2.5) 
24 (7.3) 
149 (45.1) 
140 (42.4) 
17 (5.2) 
51 (7.9) 
332 (51.2) 
240 (37.0) 
25 (3.9) 
0.0039 
Bilirubin (µmol/l) 13.1 (8.7) 10.1 (6.8) 11.6 (7.9) <0.0001 
GGT (U/l) 57 [32-110] 39 [25-66] 45 [28-88] <0.0001 
Alk Phos (U/l) 94 [75-121] 91 [73-112] 92 [74-118] 0.0098 
Urate (mmol/l) 0.49 (0.1) 0.44 (0.1) 0.47 (0.1) <0.0001 
Haemoglobin (g/dl) 12.7 (2.1) 12.4 (1.9) 12.5 (2.0) 0.034 
Lymphocytes (x109/l) 1.8 (0.8) 2.0 (1.6) 1.9 (1.3) 0.02 
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6.2.3 Automated computer-generated report 
 
A computer generated report is automatically produced following the completion of each 
MTWA test. An example is shown in Figure 6.5. Each report contains the following; a 
graph of heart rate trend, artefacts that may be potentially obscuring true alternans (for 
example ectopic activity or noise), measurement of alternans activity in individual vector 
and praecordial leads, artefacts that may be potentially creating false alternans and the 
alternans classification (positive, negative or indeterminate). Each report contains two 
pages, the first displaying data for the four vector leads (VM, X, Y and Z) and the second 
displaying data for praecordial leads V1-6.  
 
The heart rate trend contains two lines; an uneven line that corresponds to the 
instantaneous heart rate, or ‘real time’ heart rate, and a smooth line that corresponds to the 
‘epic’ heart rate present over time. The instantaneous heart rate provides information about 
sudden variations in heart rate or the occurrence of ectopic beats. The ‘epic’ heart rate is 
the average heart rate in each of the epics and is produced by using an enhanced ECG 
noise reduction algorithm. Each epic consists of 128 consecutive beats selected for analysis. 
The beats are aligned and each T wave in the epic is analysed at the same relative point in 
time. All alternans parameters are measured against the epic, or smoothed, heart rate.  
 
Ectopic beats and noise are the two main artefacts that can obscure the presence of true 
physiological alternans. If the number of ectopic beats, displayed in the report as ‘bad 
beats’, in each epic exceeds the threshold of 15% then the detection of true alternans 
cannot be performed and the trend will be shaded grey in the corresponding areas. Figure 
6.5 shows almost undetectable levels of ectopic beats. The noise trend represents the noise 
level in the VM vector lead, a measure of overall noise in the system. Like ectopic beats, 
the presence of excessive noise can prevent the detection of true physiological alternans. If 
the noise level exceeds the threshold of 1.8 microvolts then the detection of true alternans 
cannot be performed and the trend will be shaded grey in the corresponding areas. The 
noise level in Figure 6.5 is <1 microvolt and within acceptable limits.   
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Figure 6.5: Example of a MTWA test report (a negative MTWA test) 
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Each alternans trend on the report displays alternans voltage, alternans noise and alternans 
ratio. This information is illustrated in Figure 6.5. For each of the ten leads, the timing of 
alternans activity is charted along the bottom of the report. Each square on the Y axis 
represents 2 microvolts of alternans. The solid line outlining the grey shaded areas signifies 
the alternans voltage and the dotted line represents the alternans noise. The shaded grey 
area indicates the presence of statistically significant alternans, present for brief periods in 
leads X, Z and V6 in Figure 6.5. The thicker black horizontal line below the shaded grey 
areas represents artefact-free periods and signifies intervals where no artefacts are present 
that could potentially cause alternans.  
 
The main artefacts that can potentially create false alternans are displayed in three rows 
along the bottom of the first page of the report, below the vector leads. These artefacts are; 
respiration, heart rate delta and RR alternans. Trends of these artefacts are shaded in grey, 
highlighting if acceptable levels have been exceeded. Premature ventricular beats can also 
cause false alternans but these are usually short-lived and would not meet criteria for 
sustained alternans. 
 
Finally, at the bottom of both pages of the MTWA report is the automated interpretation of 
whether or not sustained alternans is present and a clinical classification of the alternans 
result (positive, negative or indeterminate). The report also suggests how a determinate test 
may be achieved on retesting, if the result is indeterminate. Previous clinical studies have 
suggested that immediately repeating indeterminate MTWA tests due to noise reduces the 
rate of indeterminate tests by at least 50% (123). 
 
6.2.4 MTWA Classification 
 
Significant alternans is present when the following criteria are met; the voltage of alternans 
is equal to or exceeds 1.9 microvolts, alternans activity is present in any of the vector leads 
or a praecordial lead and an adjacent lead, and the alternans is sustained. The latter occurs 
when alternans is consistently present above a patient-specific onset heart rate, the duration 
of alternans is at least one minute and there is a period of artefact-free data. A positive test 
occurs when sustained alternans occurs at rest or at an onset heart rate ≤ 110 bpm. Criteria 
for a negative test are met when there is no sustained alternans and the maximum negative 
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heart rate is ≥ 105 bpm.  Sustained alternans at an onset heart rate of > 110 bpm but with a 
maximum negative heart rate > 105 bpm is also classified as a negative result. An 
indeterminate test is one where the test does not fulfil either positive or negative test 
criteria, due to physiological (for example insufficient heart rate, ectopic activity or noise) 
or user reasons (for example poor skin preparation prior to application of the proprietary 
electrodes). Nonsustained alternans activity would also be classified as an indeterminate 
result. 
 
An example of a positive MTWA test for a patient in this study is shown in Figure 6.6. 
This test fulfils the criteria for a positive result. Alternans activity is present at the start of 
exercise with an onset heart rate of 96 bpm and the voltage of alternans often exceeds the 
required 1.9 microvolts. When the heart rate drops below 96 bpm, alternans activity is not 
always present but does always occur above the onset heart rate of 96 bpm. Alternans 
activity is always present in at least one vector or praecordial lead and adjacent praecordial 
lead. There are many periods of artefact-free data, represented by the solid black horizontal 
line below each shaded grey area, and the duration of alternans is greater than one minute. 
Thus, this MTWA test is positive. Of note, there are few ectopic beats present in this test. 
Noise levels are often high but do not exceed levels that prevent interpretation of this test. 
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Figure 6.6: The automated MTWA test report for a study patient with a positive 
MTWA result 
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An example of a negative MTWA test for a patient in this study is shown in Figure 6.7. 
There is brief evidence of alternans activity in vector lead X at the start of the test, prior to 
commencing exercise, but this is not sustained. There is also alternans activity in 
praecordial lead V6 but not in an adjacent praecordial lead. Furthermore, the alternans 
activity in lead V6 is not sustained. There is evidence of alternans activity in the vector 
leads towards the end of the test but this is not significant as alternans is not consistently 
present above this heart rate. The maximum negative heart rate attained is 112 bpm.  
 
 
 
Figure 6.7: The automated MTWA test report for a study patient with a negative 
MTWA result 
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6.2.5 Prevalence Study 
 
Of 648 patients attending the post-discharge study visit, 330 (50.9%) had MTWA exercise 
tests performed. The results are displayed in Figure 6.8. As outlined earlier in this chapter 
(section 6.2.1), 43 patients were unable to exercise for at least two minutes.  
 
A positive MTWA result occurred in 100 patients (30.3%). Of these patients, 93 had no 
evidence of alternans activity at rest and sustained alternans occurred during exercise at an 
onset heart rate <110 bpm. The remaining 7 patients with positive MTWA tests had 
evidence of sustained alternans present at rest. Only 1 positive result occurred in a patient 
unable to perform exercise due to physical frailty. The remaining 6 patients with sustained 
alternans at rest were able to exercise satisfactorily and had sustained alternans present 
throughout the period of exercise.  
 
A negative MTWA result occurred in 78 patients (23.6%). Of these patients, 75 had no 
evidence of sustained alternans activity and had a maximum negative heart rate >105 bpm. 
Only 3 patients had sustained alternans with an onset heart rate >110 bpm but with a 
maximum negative heart rate >105 bpm.  
 
An indeterminate MTWA result occurred in 152 patients (46.1%). The reasons for an 
indeterminate result are described later in this section. 
 
When analysed in the contemporary way as non-negative versus negative; 252 (76.4%) of 
all MTWA exercise tests were non-negative (Figure 6.9).  
 
Of the 43 MTWA tests performed in patients unable to exercise (either unsatisfactory 
exercise or no exercise at all), only 1 patient had sustained MTWA alternans at rest. The 
remaining 42 patients had no evidence of sustained alternans at rest, the results of which 
are not included in the subsequent figures or analyses.  
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Figure 6.8: MTWA test results for 330 patients of the post-discharge cohort 
 
 
 
 
 
 
Figure 6.9: MTWA tests for the post-discharge cohort; non-negative versus negative 
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Almost half of all MTWA exercise test results were indeterminate. The reasons for an 
indeterminate MTWA test are displayed in Figure 6.10. The majority of these tests were 
indeterminate because of a failure to achieve the required heart rate of 110bpm (75% of all 
indeterminate tests). There were two principal reasons patients had an insufficient heart 
rate. Firstly, some patients had a low resting heart rate, due to being on maximal dose of 
beta-blocker therapy. These patients were often physically able to exercise for a sufficient 
period of time, exceeding 10 minutes in many cases, but unable to elevate their heart rate 
and it was clear that prolonging exercise would not achieve the desired heart rate of 110 
bpm (represented as ‘chronotropic incompetence’ in Figure 6.11). The other reason for an 
insufficient heart rate was exercise intolerance preventing attainment of a heart rate of 
110bpm (represented as ‘physical limitations’ in Figure 6.11). The remaining MTWA tests 
were indeterminate due to the presence of one of the following; ectopic activity (16.4%), 
noise (5.9%), non-sustained alternans (2%) or a rapid rise in heart rate (0.7%).   
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Figure 6.10: Classification of reasons for an indeterminate MTWA test result in the 
post-discharge cohort. 
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Figure 6.11: Classification of reasons for an indeterminate MTWA test result in the 
post-discharge cohort; highlighting the two reasons for an insufficient heart rate. 
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6.2.6 Functional capacity of study cohort 
  
Assessing the cohort’s ability to complete the MTWA treadmill test was important for the 
evaluation of the suitability of this test for a cohort of patients with HF.  
 
Table 6-4 displays details of the exercise performed by those who managed MTWA 
exercise testing for at least 2 minutes. The mean duration of exercise was 6.7 minutes and 
patients achieved, on average, almost 70% of their predicted heart rate. The expenditure of 
energy for each patient was calculated in metabolic equivalents of task (METs). Exercise 
capacity is often reported in METs. MET capacity is the body’s ability to expend energy 
compared to what it expends at rest. One MET is equivalent to the body’s metabolism at 
rest. MET capacity is used as a prognostic indicator in patients with coronary artery 
disease, an exercise capacity of at least 10 METs being associated with a good prognosis. 
The mean METs for the patients who performed MTWA exercise testing in this study was 
2.5. 
 
There were several reasons why patients discontinued exercise (Table 6-4). The most 
common reason was achievement of a peak heart rate. This encompassed patients who 
reached the target heart rate for completing the MTWA test (110 bpm) and also those who 
attained a maximum heart rate (below 110 bpm) that failed to rise with further exercise. 
The latter consisted largely of patients on maximal dose beta-blockers who were unable to 
elevate their heart rate to 110 bpm despite prolonged exercise with increases in both the 
speed and gradient of the treadmill machine. However, the majority of patients 
discontinued exercise because of various physical limitations (Table 6-4). 
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Table 6-4: Exercise parameters and reasons for terminating exercise for 330 patients  
 
 
Exercise parameter Mean (SD) or n (%) 
Duration of exercise (mins) 6.7 (3.9) 
% predicted heart rate 69.5 (10.8) 
Max exercise (METS) 2.5 (1.2) 
Reason exercise stopped 
     Peak HR achieved 
     Fatigue 
     Breathless 
     Joint / muscle pain 
     Claudication 
     Pre-syncope 
     Chest pain 
 
138 (41.8) 
85 (25.8) 
55 (16.7) 
34 (10.3) 
13 (3.9) 
3 (0.9) 
2 (0.6) 
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6.2.7 Optimal heart failure therapy 
 
An assessment of whether or not patients were prescribed optimal HF therapy was made 
for all patients undergoing a MTWA test (Figure 6.12). Optimal therapy for patients with 
reduced left ventricular systolic function was defined as being prescribed the target dose of 
at least two HF disease modifying agents, including a beta-blocker. The target dose was the 
dosage used in the pivotal HF clinical trials. A past history of intolerance to specific HF 
medications or being prescribed a sub-optimal dose, because of intolerance to higher doses, 
was also classed as optimal medical therapy. In many cases it was unclear whether patients 
were not prescribed optimal HF therapy because of previous intolerance or because of 
failure to prescribe – these cases were recorded as ‘unknown’. Overall, 138 patients 
(41.8%) completing MTWA exercise testing were prescribed optimal HF therapy. The 
prescribing was sub-optimal in 93 patients (28.2%), and in 99 patients (30.8%) it was 
unknown whether or not they were being optimally managed. Patients with indeterminate 
MTWA test results were more likely to be on optimal medical therapy, than the other two 
groups (p<0.0001). The corollary of this was also true; those with indeterminate MTWA 
tests were less likely to be prescribed sub-optimal HF therapies than the other two groups. 
The difference between the three groups in the proportions of patients with unknown 
optimal HF therapy regimes was less striking. 
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Figure 6.12: Rate of prescribing of optimal heart rate therapy for patients undergoing MTWA exercise tests* 
 
 
* Inter-group comparisons using χ2 test, p value < 0.0001 indicates a significant difference between the groups. 
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6.2.8 Adjudication of MTWA test results 
 
All automated computer-generated MTWA test results were interpreted by a single clinician 
(Dr Rachel Myles) experienced in reviewing MTWA reports. The clinician was blinded to 
both the patient details and the automated computer-generated result. Of 373 MTWA tests 
(330 on exercise and 43 at rest), 358 automated results matched the interpreted results (96%). 
For the 15 cases where a discrepancy existed between the clinician’s interpretation and the 
computer-generated result, the clinician’s analysis was used for the results. All 15 
discrepancies were from exercise MTWA tests. Of the 43 MTWA tests at rest, one test was 
reported positive by both the clinician and the computer. The remaining 42 tests at rest were 
reported as ‘MTWA not present at rest’ by both reporting modes.  
 
6.2.9 Comparison with other MTWA clinical studies 
 
The results of MTWA exercise testing for this study were compared to the major LVSD and 
HF MTWA clinical studies that have been performed to date. Two comparisons were 
performed; firstly the proportions of positive, negative and indeterminate results, (Figure 6.13), 
and then the proportion of non-negative to negative results (Figure 6.14). In both figures, my 
study is referred to as ‘Glasgow MTWA’.  
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Figure 6.13: Comparison of Glasgow MTWA study to other major clinical MTWA 
studies to date (102;107;109;113;118;119) – positive, negative and indeterminate results  
 
 
 
 240 
 
 
Figure 6.14: Comparison of Glasgow MTWA study to other major clinical MTWA 
studies to date (102;107;109;113;118;119) – non-negative and negative results  
 
 
6.3 Discussion 
 
Chapter 6 has described the practical application of the MTWA exercise test in an unselected 
cohort of patients with HF. Eligibility of the post-discharge cohort was similar to the potential 
eligibility of the hospitalised cohort.  
 
A significant number of patients were ineligible for MTWA testing. This is the first 
observational prospective study to describe the reasons for ineligibility in a ‘real-life’ HF 
population. The majority of patients were ineligible due to permanent AF. A small proportion 
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were ineligible due to pacemaker dependency, this may be greater in a well treated cohort with 
a higher percentage of CRT implantation. A significant number of patients were physically 
unable to perform this sub maximal treadmill test.  The clinical value of any test is limited if 
nearly half of the patients are ineligible for the test. 
 
Many of the characteristics of the ineligible patients in my study suggested they had a poor 
prognosis, including the highest log (BNP) concentration. BNP is also an independent 
predictor of sudden cardiac death (53), suggesting that the patients at the highest arrhythmic 
risk may in fact not be eligible for MTWA testing. These findings suggest the utility of the 
MTWA test as a means of detecting those at highest risk of sudden death is likely to be limited 
as many such patients are ineligible for the test. Patients ineligible for MTWA testing were 
older than patients eligible for testing and a higher proportion had a history of pre-admission 
HF. Ineligible patients also had more evidence of persisting or advanced HF, with a higher 
proportion having NYHA functional class III or IV symptoms and a greater frequency of 
peripheral oedema. Those ineligible for MTWA testing also had a greater prevalence of renal 
dysfunction, liver enzyme abnormalities, hyperuricaemia and lymphopenia. There was, 
however, no difference in LVEF according to MTWA eligibility and the use of HF medication 
was similar between the groups.  
 
An indeterminate MTWA test was the most common result in this study with a positive 
MTWA test was found in only 30% and a negative test in 24%. The majority of indeterminate 
tests were because of failure to elevate the heart rate to 110 bpm. This was due to chronotropic 
incompetence or physical limitations, with similar proportions of each. The majority of 
chronotropic incompetence was secondary to beta-blocker therapy. Many other clinical 
MTWA studies have discontinued beta-blockers prior to MTWA testing in order to achieve 
determinate results. However a primary aim of this study was to evaluate the use of MTWA 
on optimal HF therapy, including beta-blockers. This was to determine both the prevalence of 
an abnormal MTWA result on beta-blocker therapy and assess the prognostic value of this test 
for patients on optimal HF therapy. Other reasons for an indeterminate MTWA test were 
outlined. This is the first prospective study to characterise the types of indeterminate result, 
particularly detailing the two types of insufficient heart rate, and highlight how common a 
result this is in an unselected HF population on optimal HF therapy.   
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The functional capacity of the cohort was poor. There was no significant difference in the 
duration of exercise or energy expended during exercise (measured in METS), between the 
three groups. The majority of patients discontinued the MTWA test because of physical 
limitations, with only 42% achieving the target heart rate of 110bpm required for completion 
of the MTWA test.  This is perhaps unsurprising as many of the patients were elderly with 
multiple comorbidities. However this does question the general usefulness of this test in ‘real-
life’ HF patients. 
 
The automated computer-generated results were highly accurate when adjudicated against the 
blinded clinician interpretation. The automated result matched the clinician’s interpretations in 
over 95% of cases. This is the first study to present results of the accuracy of the automated 
report. 
 
The prevalences of positive, negative and indeterminate results in my study were different to 
other clinical MTWA studies. One of the major differences was the number of indeterminate 
results (Figure 6.13). The other studies had proportionately fewer indeterminate results than 
my study. The reasons for this are likely multifactorial and may be explained by many of the 
limitations of the current studies to date, addressed in section 1.3 of chapter 1. One of these is 
patient selection. My study was performed in an unselected cohort of patients with recent 
decompensated HF. This cohort had a higher mean age with extensive medical comorbidity 
and a significant proportion of physically frail patients, compared to the other MTWA studies.  
 
My study shared some similar and contrasting results to the other MTWA HF studies. The 
ALPHA study (118) had proportionately more negative and positive results and fewer 
indeterminate results than my study. These differences may be explained by the types of 
cohorts studied. The ALPHA study was performed exclusively in non-ischaemic heart failure 
patients with reduced left ventricular systolic function, defined as ejection fraction ≤ 40%, and 
the mean age was only 59 years. On the other hand, the SCD-HeFT MTWA study (119) 
exhibited a similar pattern of the three test results to the Glasgow MTWA study, an 
indeterminate result being most common followed by positive then negative. The proportions 
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of negative results in the two studies were similar whereas the SCD-HeFT MTWA study had 
proportionately more positive results and fewer indeterminate results than the Glasgow 
MTWA study. One possible explanation for the similarities between these two studies may be 
inclusion of both ischaemic and non-ischaemic aetiologies of heart failure. Moreover, both 
studies contained similar proportions of beta-blocker prescribing (74% in the SCD-HeFT 
MTWA study and 64% in the Glasgow MTWA study), although the SCD-HeFT MTWA study 
withheld these medications for at least 24 hours prior to MTWA testing.  
 
Analysis of the Glasgow MTWA study results in the contemporary way of non-negative and 
negative yielded similar proportions to the majority of other clinical studies (Figure 6.14). In 
most studies a non-negative MTWA result was prevalent in at least two-thirds of the cohort. 
The exception to this was the study performed by Ikeda et al (102) in which over two-thirds of 
the cohort had a negative MTWA result. This study was performed in a cohort of post 
myocardial infarction patients. The high proportion of negative MTWA results may be 
explained by all patients having preserved left ventricular systolic function, as well as few 
patients being prescribed beta-blocker therapy.  
 
In summary, almost half of all patients in the post-discharge cohort were ineligible for MTWA 
testing. Of the original 1003 patients enrolled in this study, only 330 underwent MTWA 
exercise testing. Of the 330 patients who were eligible, many were unable to complete the test 
due to chronotropic incompetence, secondary to beta blocker therapy, or physical limitations. 
These issues show that MTWA treadmill testing is not widely applicable to an unselected, 
real-life HF population. Finally, the most common result was an indeterminate one, the 
clinical associates of which will be explored in the Chapter 7.  
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CHAPTER SEVEN 
 
CLINICAL ASSOCIATES OF 
MICROVOLT T-WAVE ALTERNANS 
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7.1 Introduction 
 
This chapter will describe the clinical characteristics of the post-discharge cohort stratified by 
MTWA result. The clinical characteristics discussed in chapter 5 will be analysed to determine 
if any of these characteristics differ between the three groups of patients according to their 
MTWA results (positive, negative and indeterminate). Analyses will also be performed to 
determine if any differences exist when the MTWA groups are classified as negative and non-
negative. A probability value of p<0.05 will be considered significant for statistical analyses. 
The characteristics that differ between the three groups of MTWA results will then be 
analysed separately, in three pairs, using logistic regression analyses. These pairs will 
comprise; positive versus negative, positive versus indeterminate and negative versus 
indeterminate. A probability value of p<0.1 in the former analyses will be used for selecting 
variables for inclusion in the logistic regression.  These analyses will reveal the main 
associates of each MTWA result.   
 
7.2 Results 1: Differences in clinical characteristics according to MTWA 
result 
 
7.2.1 Demographics 
 
Table 7-1 displays the demographics of the post-discharge cohort, stratified by MTWA result. 
The overall results for all patients completing the MTWA test are also displayed. Patients with 
a negative MTWA result were younger than those with a positive or indeterminate result 
(p=0.00013). Patients with an indeterminate result were older than those with a positive result. 
There was no difference between the three groups in the proportion of patients with a history 
of chronic HF prior to enrolment into the MTWA study. Few patients who underwent MTWA 
exercise testing were readmitted to hospital with decompensated HF following recruitment. 
Readmission rates were similar in all three groups. 
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Table 7-1: Demographics stratified by MTWA result. Data are expressed as number (%) or mean (SD).   
               
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Male sex  65  
(65) 
44  
(56.4) 
89  
(58.6) 
198  
(60) 
0.45 
Mean age, years 68.1 
(12.5) 
64.9  
(12.0) 
71.4  
(9.3) 
68.8  
(11.3) 
0.00013 
Age ≥ 75 years 36  
(36) 
17 
(21.8) 
53  
(34.9) 
106  
(32.1) 
0.081 
Diagnosed HF before enrolment into study 31  
(31) 
25  
(32.1) 
64 
(42.1) 
120 
(36.4) 
0.13 
Re-admission since recruitment 3  
(3) 
4  
(5.1) 
14  
(9.2) 
21  
(6.4) 
0.12 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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7.2.2 Symptoms of heart failure 
 
Table 7-2 shows the HF symptoms stratified by MTWA result. The majority of patients 
who underwent MTWA exercise testing experienced an overall improvement in their HF 
symptoms since discharge from hospital. There was no difference between the three groups 
in the number of patients who experienced deterioration in their overall symptom status. 
This was also reflected in the proportions of patients in each of the four NYHA classes. 
There were no differences between the three groups in the proportions of patients in each 
NYHA category. Of the five principal symptoms recorded at the study visit (Table 7-2), 
only palpitations differed between the groups (p=0.021). Fewer patients with an 
indeterminate MTWA result experienced palpitations compared with those with positive 
and negative results.  
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Table 7-2: Current heart failure symptoms stratified by MTWA result. Data are expressed as number (%).   
                                                                                                                                                                                                                    
Symptom Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Deterioration in HF symptoms 
since discharge 
10 (10) 5 (6.4) 17 (11.2) 32 (9.7) 0.51 
NYHA Class   I 
                        II 
                        III 
                        IV 
3 (3) 
66 (66) 
31 (31) 
0 (0) 
7 (9.0) 
56 (71.8) 
15 (19.2) 
0 (0) 
6 (3.9) 
99 (65.1) 
46 (30.3) 
1 (0.7) 
16 (4.9) 
221 (66.9) 
92 (27.9) 
1 (0.3) 
 
0.24 
Paroxysmal nocturnal dyspnoea 13 (13) 13 (16.7) 16 (10.5) 42 (12.7) 0.41 
Orthopnoea 27 (27) 12 (15.4) 38 (25) 77 (23.3) 0.15 
Ankle swelling 23 (23) 13 (16.7) 37 (24.3) 73 (22.1) 0.4 
Palpitations 29 (29) 22 (28.2) 24 (15.8) 75 (22.7) 0.021 
Wheeze 18 (18) 21 (26.9) 33 (21.7) 72 (21.8) 0.36 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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7.2.3 Common medical comorbidity 
 
The common medical comorbidities, stratified by MTWA result, are shown in Table 7-3. 
The prevalences of most comorbidities were similar in all three groups. The exceptions to 
this were MI and AF.  
 
Patients with an indeterminate or positive MTWA result were more likely to have had a 
previous MI than those with a negative test, those in the indeterminate group having the 
highest prevalence of this condition (p=0.016). The prevalences of angina, PCI and CABG 
were also lowest amongst those with a negative result, although these were not statistically 
significant.  
 
Sinus rhythm is mandatory for the spectral method of MTWA exercise testing used in this 
study. Thus all patients who underwent MTWA testing were in sinus rhythm at the time of 
the study visit. A history of AF for these patients meant either past AF, paroxysmal AF or 
permanent AF at the time of enrolment into the study. All patients with permanent AF 
during hospitalisation, and subsequently eligible for MTWA testing, would have 
spontaneously cardioverted to sinus rhythm by the study visit. A history of AF was more 
common amongst those with an indeterminate result than the other two groups (p=0.015).  
 
Anaemia was more common amongst patients with an indeterminate result than the other 
two groups, although this difference only showed a trend towards being statistically 
significant (p=0.08). 
 
The prevalences of hypertension, cerebrovascular disease, diabetes mellitus, cancer, 
peripheral arterial disease and osteoarthritis were all greatest amongst patients with an 
indeterminate MTWA result, although the differences were not statistically significant. 
COPD was more common amongst patients with a negative result, although the difference 
between the three groups was not statistically significant.  
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Table 7-3: Common medical comorbidities stratified by MTWA result. Data are expressed as number (%).   
 
Condition Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
MI 50 (50) 29 (37.2) 87 (57.2) 166 (50.3) 0.016 
History of angina 62 (62) 39 (50) 95 (62.5) 196 (59.4) 0.15 
PCI 18 (18) 11 (14.1) 31 (20.4) 60 (18.2) 0.5 
CABG 19 (19) 10 (12.8) 25 (16.4) 54 (16.4) 0.53 
Hypertension 62 (62) 44 (56.4) 102 (67.1) 208 (63.0) 0.27 
TIA/CVA 15 (15) 14 (17.9) 39 (25.7) 68 (20.6) 0.099 
History of AF 14 (14) 16 (20.5) 54 (35.5) 84 (25.5) 0.015 
Prosthetic heart valve 7 (7) 4 (5.1) 8 (5.3) 19 (5.8) 0.81 
Pacemaker 4 (4) 1 (1.3) 2 (1.3) 7 (2.1) 0.48 
Prior arrhythmia 4 (4) 7 (9.0) 11 (7.2) 22 (6.7) 0.39 
Diabetes mellitus 26 (26) 21 (26.9) 56 (36.8) 103 (31.2) 0.12 
Anaemia 39 (39) 30 (38.5) 78 (51.3) 147 (44.5) 0.08 
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Condition Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Depression 19 (19) 21 (26.9) 33 (21.7) 73 (22.1) 0.44 
History of cancer 9 (9) 10 (12.8) 23 (15.1) 42 (12.7) 0.31 
COPD 24 (24) 27 (34.6) 44 (28.9) 95 (28.8) 0.3 
PAD 16 (16) 11 (14.1) 32 (21.1) 59 (17.9) 0.36 
Osteoarthritis 18 (18) 15 (19.2) 38 (25) 71 (21.5) 0.36 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
PAD = peripheral arterial disease 
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7.2.4 Medications 
 
The prescribing of HF medications, stratified by MTWA result, is shown in Table 7-4. 
Optimal therapy for patients with HF-REF was as previously defined in Chapter 6 (section 
6.2.7). Patients with an indeterminate MTWA test were most likely to be prescribed 
optimal therapy, with more than double the proportion of patients on optimal therapy than 
either the positive or negative groups (p<0.0001).  
 
Consequently there were significant differences between the three groups in the 
proportions of patients prescribed beta-blocker therapy (p<0.0001). As expected, the 
pattern was similar to optimal therapy prescribing, those with an indeterminate MTWA test 
having the highest prescribing of beta-blocker therapy - almost 80%. Significantly fewer 
patients with a positive MTWA test were prescribed beta-blockers with the lowest 
prescribing amongst those with a negative test. The proportion of patients prescribed 
diuretics showed a trend towards greater prevalence amongst those with a positive or 
indeterminate MTWA result, although the difference was not statistically significant 
(p=0.059). The proportion of patients prescribed ACE inhibitors showed a trend towards 
greater prevalence amongst those with a positive MTWA result (p=0.066). The prescribing 
of ARBs, aldosterone antagonists and digoxin was similar in all three groups.  
 
The frequencies of prescribing of common cardiovascular medications, stratified by 
MTWA result, are shown in Table 7-5. The only significant difference between the three 
groups was the prescribing of statin therapy (p=0.029). Three-quarters of all patients who 
underwent MTWA exercise testing were taking statins. Statins were used most commonly 
in patients with an indeterminate MTWA result; over 80% were prescribed this therapy. 
This finding is consistent with a greater prevalence of coronary heart disease amongst this 
group of patients. Statin prescribing was similar in the positive and negative groups. The 
frequencies of prescribing of common non-cardiovascular medications, stratified by 
MTWA result, are shown in Table 7-6. The prescribing of bronchial inhalers was highest 
amongst the negative group, consistent with a greater prevalence of COPD in this group, 
although not a statistically significant difference. The proportions of patients prescribed 
other non-cardiovascular medications were similar in all three groups.  
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Table 7-4: Frequency of heart failure medication prescribing stratified by MTWA result. Data are expressed as number (%).   
 
Heart failure medication Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Optimal therapy 23 (23) 19 (24.4) 89 (58.6) 131 (39.7) <0.0001 
Diuretics 97 (97) 71 (91.0) 148 (97.4) 316 (95.8) 0.059 
ACE inhibitor 80 (80) 52 (66.7) 103 (67.8) 235 (71.2) 0.066 
Beta-blocker 56 (56) 39 (50) 118 (77.6) 213 (64.5) <0.0001 
ARB 7 (7) 13 (16.7) 21 (13.8) 41 (12.4) 0.12 
Aldosterone blocker 16 (16) 10 (12.8) 19 (12.5) 45 (13.6) 0.71 
Digoxin 7 (7) 3 (3.8) 13 (8.6) 23 (7.0) 0.41 
 
 
 * Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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Table 7-5: Frequency of cardiovascular medication prescribing stratified by MTWA result. Data are expressed as number (%).   
  
Cardiovascular medication Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Statin 69 (69) 55 (70.5) 125 (82.2) 249 (75.5) 0.029 
Aspirin 70 (70) 55 (70.5) 108 (71.1) 233 (70.6) 0.98 
Clopidogrel 24 (24) 13 (16.7) 35 (23.0) 72 (21.8) 0.44 
Aspirin or clopidogrel 75 (75) 56 (71.8) 120 (78.9) 251 (76.1) 0.4 
Warfarin 16 (16) 17 (21.8) 28 (18.4) 61 (18.5) 0.61 
Calcium channel blocker 15 (15) 15 (19.2) 30 (19.7) 60 (18.2) 0.61 
Anti-arrhythmic 5 (5) 4 (5.1) 17 (11.2) 26 (7.9) 0.12 
Long-acting nitrates 14 (14) 10 (12.8) 30 (19.7) 54 (16.4) 0.3 
Nicorandil 17 (17) 9 (11.5) 27 (17.8) 53 (16.1) 0.45 
Oral hypoglycaemic agents 19 (19) 14 (17.9) 35 (23.0) 68 (20.6) 0.45 
Insulin 10 (10) 5 (6.4) 18 (11.8) 33 (10.0) 0.43 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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Table 7-6: Frequency of prescribing of common non-cardiovascular medications stratified by MTWA result. Data are expressed as number (%).    
 
Non-cardiovascular medication Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Bronchial inhalers 22 (22) 27 (34.6) 40 (26.3) 89 (27) 0.17 
Antidepressants 11 (11) 9 (11.5) 23 (15.1) 43 (13) 0.57 
Vitamins (B1 & B complex) 11 (11) 10 (12.8) 16 (10.5) 37 (11.2) 0.87 
NSAIDs 0 (0) 5 (6.4) 0 (0) 5 (1.5) NA 
Antihistamines 3 (3) 3 (3.8) 8 (5.3) 14 (4.2) 0.67 
Incontinence meds 0 (0) 0 (0) 6 (3.9) 6 (1.8) NA 
 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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7.2.5 Clinical examination 
 
7.2.5.1 Routine physiological measurements 
 
Table 7-7 displays the routine physiological findings stratified by MTWA result. Patients 
with an indeterminate result were more likely to have a lower resting heart rate, consistent 
with the higher rate of beta-blocker prescribing (p<0.0001). Those with a negative result 
had the highest resting heart rates. Patients with an indeterminate result were also more 
likely to have lower diastolic blood pressure than patients in the other two groups 
(p<0.0001). Those with a negative result had highest diastolic blood pressure. Although 
there was no difference in systolic blood pressure between the three groups, there was a 
difference in pulse pressure. Patients with a negative MTWA result were more likely to 
have a normal pulse pressure whilst those with a positive or indeterminate MTWA result 
were more likely to have an elevated pulse pressure (defined as greater than 60mmHg) 
[p=0.016]. Temperature and respiratory rate at rest were similar in all three groups. 
 
7.2.5.2 Body mass index measurements 
 
The BMI measurements stratified by MTWA result are shown in Table 7-8. These 
measurements were similar in all three MTWA groups. 
 
7.2.5.3 Cardiovascular examination signs 
 
Table 7-9 shows the frequencies of cardiovascular examination signs, focusing on signs of 
HF, stratified by MTWA result. The number of patients with clinical signs of HF was 
much less than during hospitalisation. There were no differences between the three groups 
in the prevalences of any of these signs.  
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Table 7-7: Physiological findings stratified by MTWA result. Data are expressed as mean (SD) or number (%).   
 
Variable Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Heart rate (bpm) 80 (13.2) 84 (11.8) 72 (13.5) 77 (14) <0.0001 
SBP (mmHg) 133 (25.3) 129 (21.5) 131 (23.2) 131 (23.5) 0.56 
DBP (mmHg) 68 (12.6) 72 (10.9) 64 (12.5) 67 (12.5) <0.0001 
Pulse pressure (mmHg) 65 (25.1) 57 (19.3) 67 (21.8) 64 (22.5) 0.016 
Temperature (°C) 36.2 (0.6) 36.2 (0.5) 36.2 (0.6) 36.2 (0.6) 0.64 
Respiratory rate  
(breaths per minute) 
19 (3.8) 19 (3.6) 19 (3.4) 19 (3.6) 0.2 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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Table 7-8: BMI measurements stratified by MTWA result. Data are expressed as mean (SD) or number (%).   
 
Measurement Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Mean height (cm) 165 (9.4) 163 (10.3) 163 (10.3) 164 (10.0) 0.31 
Mean weight (kg) 76.3 (19) 76.1 (19.4) 77.1 (19.6) 76.6 (19.3) 0.92 
Mean BMI (kg/m2) 27.9 (6.0) 28.3 (6.1) 28.9 (6.8) 28.5 (6.4) 0.46 
Mean BMI class 
       < 18.5 (underweight) 
      18.5 – 24.9 (normal weight) 
      25 – 30 (overweight) 
      > 30 (obese) 
 
4 (4) 
27 (27) 
37 (37) 
32 (32) 
 
1 (1.3) 
25 (32.1) 
26 (33.3) 
26 (33.3) 
 
4 (2.6) 
44 (28.9) 
46 (30.3) 
58 (38.2) 
 
9 (2.7) 
96 (29.1) 
109 (33.0) 
116 (35.2) 
 
0.79 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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Table 7-9: Cardiovascular examination findings stratified by MTWA result. Data are expressed as number (%). 
 
  Clinical sign Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Third heart sound 2 (2) 1 (1.3) 1 (0.7) 4 (1.2) 0.63 
Pulmonary crackles 
         None 
         Basal 
         Mid-zones 
 
72 (72) 
27 (27) 
1 (1) 
 
59 (75.6) 
19 (24.4) 
0 (0) 
 
116 (76.3) 
34 (22.4) 
2 (1.3) 
 
247 (74.9) 
80 (24.2) 
3 (0.9) 
0.79 
Pleural effusion (s) 1 (1) 0 (0) 4 (2.6) 5 (1.5) NA 
Peripheral oedema – ankle 28 (28) 21 (26.9) 43 (28.3) 92 (27.9) 0.98 
Peripheral oedema – knee 4 (4) 4 (5.1) 7 (4.6) 15 (4.5) 0.94 
Peripheral oedema – thigh 0 (0) 0 (0) 2 (1.3) 2 (0.6) 0.31 
Ascites 0 (0) 1 (1.3) 1 (0.7) 2 (0.6) 0.55 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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7.2.6 Electrocardiography  
 
The frequencies of resting electrocardiograph (ECG) findings, stratified by MTWA result, 
are shown in Table 7-10. The proportion of patients with LVH showed a trend towards 
greater prevalence amongst those with a positive result (p=0.07). Patients with an 
indeterminate result were more likely to have a longer QTc interval than patients in the 
other two groups (p=0.0035). Patients with a negative result were more likely to have 
shorter QTc intervals than patients with a positive result. There were no differences 
between the three MTWA groups in the prevalence of other recorded ECG parameters. 
 
7.2.7 Exercise parameters 
 
The frequencies of exercise parameters recorded during the MTWA test, stratified by 
MTWA result, are shown in Table 7-11. Patients with positive and negative MTWA results 
were more likely to achieve higher predicted heart rates than those with indeterminate 
results (p<0.0001). Maximum ST depression was recorded during the MTWA test. Those 
with a positive result were more likely to have deeper ST depression than the other two 
groups (p=0.02). Those with an indeterminate result had the least ST depression. These 
findings are consistent with the trend for the percentage predicted heart rate for the three 
groups.  
 
There was no difference between the three groups in the duration of exercise, although 
patients with an indeterminate result had the shortest time. Maximum exercise expended 
was similar in all three groups.  
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Table 7-10: Electrocardiographic parameters stratified by MTWA result. Data are expressed as number (%), mean (SD) or median [IQR]. 
 
ECG  Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
RBBB 
LBBB 
9 (9) 
21 (21) 
4 (5.1) 
20 (25.6) 
5 (3.3) 
27 (17.8) 
18 (5.5) 
68 (20.6) 
0.19 
Pathological Q waves 15 (15) 9 (11.5) 23 (15.1) 47 (14.2) 0.74 
LVH 23 (23) 9 (11.5) 21 (13.8) 53 (16.1) 0.07 
Ischaemic ST depression 5 (5) 2 (2.6) 3 (2.0) 10 (3.0) 0.38 
Median QRS (ms) 104 [91.5-134.5] 100 [88-129.5] 102 [92-120] 102 [90-125.5] 0.52 
QRS duration (ms)  <120 
                                120-150 
                                 ≥ 150 
68 (68) 
16 (16) 
16 (16) 
52 (66.7) 
18 (23.1) 
8 (10.2) 
112 (73.7) 
30 (19.7) 
10 (6.6) 
232 (70.3) 
64 (19.4) 
34 (10.3) 
0.15 
Mean QTc (ms) 437 (27.6) 432 (29.6) 446 (36.3) 440 (32.8) 0.0035 
QTc ≥ 440 46 (46) 32 (41) 86 (56.6) 164 (49.7) 0.056 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant 
difference between the groups. 
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Table 7-11: Exercise parameters stratified by MTWA result. Data are expressed as mean (SD) or median [IQR]. 
 
Exercise Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Duration of exercise (mins) 6.0 
[3.5-9.9] 
7.1 
[4.0-9.0] 
5.8 
[3.8-8.1] 
6.0 
[3.8-8.7] 
0.43 
Max ST depression (mm) 0.66 
(0.67) 
0.63 
(0.42) 
0.47 
(0.41) 
0.57 
(0.51) 
0.02 
% predicted HR 74.9 
(8.3) 
74.8 
(6.6) 
63.1 
(10.7) 
69.5 
(10.8) 
<0.0001 
Max exercise (METS) 2.5 
(1.3) 
2.6 
(1.4) 
2.4 
(1.0) 
2.5 
(1.2) 
0.56 
 
* Inter-group comparisons using ANOVA F-test (continuous variables), p value < 0.05 indicates a significant difference between the groups. 
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7.2.8 Ejection fraction by echocardiography 
 
The mean left ventricular ejection fractions (LVEF) for the three groups of patients are 
illustrated in Figure 7.1. Patients with a positive test were more likely to have a lower 
LVEF than patients in the other two groups (p=0.022). The mean LVEF for patients with a 
positive result was 36.6%. Those with indeterminate and negative results had similar mean 
LVEF, 40.8% and 40.4%, respectively. 
 
 
  
 
 
 
Figure 7.1: LVEF stratified by MTWA result. Data are expressed as mean (SD)* 
 
* Inter-group comparison using ANOVA F test, p value <0.05 indicates a significant 
difference between the groups. 
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7.2.9 Heart failure with reduced versus preserved ejection fraction 
 
The proportions of patients with HF-REF and HF-PEF, stratified by MTWA results are 
shown in Figure 7.3. Patients with HF-REF had proportionately more patients with a 
positive MTWA result, and similar proportions of patients with negative and indeterminate 
results, compared to patients with HF-PEF.  
 
 
 
 
Figure 7.2: Proportions of patients with HF-REF and HF-PEF, stratified by MTWA 
result 
 
Inter-group comparison using χ2 test, p value <0.05 indicates a significant difference 
between the groups. 
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7.2.10 Haematology 
 
Table 7-12 shows the full blood count parameters stratified by MTWA result.  
 
Haemoglobin concentration was lower in patients with an indeterminate result than those 
with a positive or negative result (p=0.0053). Furthermore patients with an indeterminate 
result had the greatest proportion of patients meeting WHO criteria for anaemia (139). Of 
152 patients with an indeterminate result, 96 (63.2%) were anaemic, approximately 20% 
more than those with positive or negative results (p=0.0009).   
 
Total white blood cell count, red cell distribution width and lymphocyte concentration 
were similar in the three groups. However, the proportion of patients who were 
lymphopenic (defined as lymphocyte concentration <1x109/l) showed a trend towards a 
difference between the three groups (p=0.07). Over 10% of patients with an indeterminate 
result were lymphopenic, more than double the proportion of patients with a positive result 
and almost three times the proportion of patients with a negative result.  
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Table 7-12: Full blood count parameters stratified by MTWA result. Data are expressed as mean (SD), number (%) or median [IQR]. 
 
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
WBC count (x109/l) 8.1 (2.1) 7.8 (2.0) 7.9 (2.9) 7.9 (2.5) 0.58 
Haemoglobin (g/dl) 12.8 (1.8) 12.5 (2.0) 12.0 (1.8) 12.4 (1.9) 0.0053 
Haemoglobin <13 M; <12 F 41 (41) 35 (44.9) 96 (63.2) 172 (52.1) 0.0009 
RDW (%) 14.9 [13.9-16.3] 14.8 [13.7-15.9] 14.9 [14-16.2] 14.8 [13.9-16.2] 0.79 
RDW ≥15 50 (50) 36 (46.2) 75 (49.3) 161 (48.8) 0.86 
Lymphocytes (x109/l) 1.9 [1.5-2.5] 1.9 [1.4-2.4] 1.8 [ 1.4-2.3] 1.8 [1.4-2.4] 0.91 
Lymphocytes <1 5 (5) 3 (3.8) 17 (11.2) 25 (7.6) 0.07 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant 
difference between the groups. 
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7.2.11 Biochemistry 
 
The biochemical tests results stratified by MTWA result are shown in Tables 7-13 to 7-16. 
The BNP and troponin I results are displayed in Table 7-13. Log BNP levels were highest 
in patients with an indeterminate result whilst those with a negative result had the lowest 
log BNP levels (p=0.035). The proportions of patients with an elevated troponin result 
(defined as ≥ 0.04 µg/l) were similar in all three groups.  
 
Table 7-14 displays the renal function parameters. Hyponatraemia (defined as a sodium 
concentration <135mmol/l) was more common in patients with an indeterminate test, 
double the prevalence of patients with a positive result and four times the prevalence of 
those with a negative result (p=0.05). Patients with an indeterminate result also had higher 
urea concentrations than patients in the other two groups (p=0.041), and consequently the 
greatest proportion of patients with an elevated urea concentration (defined as urea equal to 
or above 7.5mmol/l) [p=0.013]. Those with a positive result had fewest patients with an 
elevated urea concentration, yet this was still more than half of this group. Creatinine 
concentration also differed between the three groups. Creatinine concentration was higher 
in patients with an indeterminate result, whilst patients with positive or negative results had 
similar concentrations (p=0.012). There was a significant difference between the three 
groups in the prevalence of moderate, or worse, renal dysfunction (defined as eGFR 
<60ml/min/1.73m2) [p=0.00011]. Patients with indeterminate MTWA results had 
proportionately more patients with moderate, or worse, renal dysfunction.  
 
The liver function parameters are displayed in Table 7-15. Albumin was the only 
parameter that differed between the groups. Patients with indeterminate MTWA results had 
lower albumin concentrations than those with positive or negative results (p=0.016). Other 
biochemical test parameters stratified by MTWA result are displayed in Table 7-16. Free 
T4 differed between the three groups, a higher concentration occurring amongst those with 
indeterminate results (p=0.0084). Patients with an indeterminate result were more likely to 
have a higher urate concentration than the other two groups (p=0.038). Total cholesterol 
and HDL concentration differed between the groups (p=0.00059 and p=0.0064, 
respectively), patients with an indeterminate MTWA result having the lowest 
concentration of both parameters, whilst those with a positive result had the highest.  
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Table 7-13: BNP and troponin I results stratified by MTWA result. Data are expressed as median [IQR], mean (SD) or number (%). 
 
 
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
BNP (pg/ml) 316 
[186-689] 
291 
[114-542] 
408 
[175-945] 
356 
[160-793] 
0.11 
Log BNP 5.9 
(1.0) 
5.6 
(1.2) 
6.0 
(1.2) 
5.9 
(1.1) 
0.035 
TnI ≥ 0.04 (µg/l) 19 
(19) 
12 
(15.4) 
24 
(15.8) 
55 
(16.7) 
0.75 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant 
difference between the groups. 
 
 
 
 
 269
Table 7-14: Renal function results stratified by MTWA result. Data are expressed as mean (SD), number (%) or median [IQR]. 
 
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Sodium (mmol/l) 139.5 (3.0) 139.4 (2.7) 138.7 (3.7) 139.1 (3.3) 0.12 
Sodium <135  5 (5) 2 (2.6) 16 (10.5) 23 (7.0) 0.05 
Potassium (mmol/l) 4.0 (0.5) 4.1 (0.5) 4.1 (0.5) 4.1 (0.5) 0.14 
Urea (mmol/l) 7.6 [5.7-10.3] 8.0 [5.8-11] 9.3 [6.6-12.8] 9.5 [4.8-8.1] 0.041 
Log (urea) 2.08 (0.43) 2.09 (0.45) 2.21 (0.49) 2.14 (0.46) 0.052 
Urea ≥ 7.5 51 (51) 45 (57.7) 105 (69.1) 201 (60.9) 0.013 
Creatinine (µmol/l) 99 [88-120.3] 99 [84.3-118.8] 109.5 [89-142.5] 102.5 [87-131.8] 0.012 
Log (creatinine) 4.7 (0.3) 4.6 (0.3) 4.7 (0.4) 4.7 (0.3) 0.011 
eGFR (ml/min/1.73m2) 61.8 [49.1-73.5] 63.5 [46.5-76.3] 52.9 [40.8-67.0] 58.3 [43.4-72.0] 0.002 
eGFR < 60ml/min/1.73m2 41 (41) 33 (42.3) 99 (65.1) 173 (52.4) 0.00011 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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Table 7-15: Liver function test results stratified by MTWA result. Data are expressed as median [IQR], number (%) or mean (SD). 
 
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Bilirubin (µmol/l) 8 [6-13] 7 [5-10] 8 [6-12] 8 [6-12] 0.46 
Bilirubin > 22 7 (7) 5 (6.4) 8 (5.3) 20 (6.1) 0.84 
AST (U/l) 22 [18-26] 19 [16-26] 21 [16-25] 21 [16-26] 0.69 
ALT (U/l) 17 [12-25] 17 [13-24] 18 [13-25] 17 [13-25] 0.54 
GGT (U/l) 36 [25-61] 38 [25-60] 43 [24-75] 39 [25-66] 0.64 
Alk Phos (U/l) 90 [72-106] 93 [76-119] 91 [75-110] 91 [73-112] 0.8 
Albumin (g/l) 39.7 (3.9) 39.4 (4.0) 38.4 (3.6) 39.0 (3.8) 0.016 
Albumin < 35 7 (7) 8 (10.3) 21 (13.8) 36 (10.9) 0.23 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
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Table 7-16: Other biochemical test results stratified by MTWA result. Data are expressed as median [IQR] or mean (SD). 
 
Parameter Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
TSH (mU/l) 1.3 [0.8-2.2] 1.6 [1.0-2.2] 1.5 [0.9-2.4] 1.5 [0.9-2.2] 0.63 
T4 (pmol/l) 13.6 (2.1) 14.0 (2.6) 14.8 (4.1) 14.3 (3.3) 0.0084 
HBA1c (%) 6.4 (1.3) 6.2 (1.4) 6.5 (1.4) 6.4 (1.4) 0.35 
Urate (mmol/l) 0.43 (0.1) 0.42 (0.2) 0.46 (0.1) 0.44 (0.1) 0.038 
Chol (mmol/l) 4.6 (1.3) 4.2 (1.0) 4.1 (1.1) 4.3 (1.1) 0.00059 
Chol : HDL 4.0 (1.5) 3.9 (1.3) 3.9 (1.3) 3.9 (1.4) 0.73 
HDL (mmol/l) 1.25 (0.46) 1.18 (0.39) 1.1 (0.31) 1.16 (0.38) 0.0064 
Triglycerides (mmol//l) 1.8 [1.2-2.4] 1.4 [1.0-2.0] 1.6 [1.1-2.2] 1.6 [1.1-2.3] 0.48 
Phosphate (mmol/l) 1.16 (0.21) 1.21 (0.22) 1.19 (0.21) 1.19 (0.21) 0.34 
 
* Inter-group comparisons using ANOVA F-test (continuous variables) and χ2 test (categorical variables), p value < 0.05 indicates a significant difference 
between the groups. 
 272 
7.2.12 Aetiology of heart failure 
 
The primary aetiologies of HF (Figure 7.4) differed according to MTWA result (p=0.034). 
Patients with an indeterminate or positive MTWA result were more likely to have an 
established ischaemic cause of HF than those with a negative result. Patients without a 
prior MI or a coronary angiogram performed by the time of the study visit were classed as 
‘unknown’ primary aetiology of HF. This applied to approximately one-quarter of all 
patients who completed a MTWA exercise test. There were only small proportions of 
patients with non-ischaemic causes of HF.  
 
There were no significant differences between the three MTWA groups in contributing 
causes of HF, although those with an indeterminate MTWA test had the highest 
proportions of hypertension, paroxysmal AF and diabetes mellitus (Table 7-17). Patients 
with a positive MTWA test had the highest proportions of both valvular heart disease and 
alcohol as contributing causes of HF.  
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Figure 7.3: Primary aetiologies of heart failure stratified by MTWA result (inter-group comparisons using χ2 test, p value < 0.05 indicates a 
significant difference in proportions of positive, negative or indeterminate MTWA results between the seven groups) 
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Table 7-17: Contributing aetiologies of heart failure stratified by MTWA result. Data are expressed as number (%). 
 
Contributing aetiology Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
Hypertension 62 (62) 43 (55.1) 104 (68.4) 209 (63.3) 0.13 
Valvular heart disease 37 (37) 21 (26.9) 44 (28.9) 102 (30.9) 0.27 
Paroxysmal atrial fibrillation 6 (6) 5 (6.4) 19 (12.5) 30 (9.1) 0.14 
Diabetes mellitus 26 (26) 21 (26.9) 55 (36.2) 102 (30.9) 0.16 
Alcohol 24 (24) 17 (21.8) 30 (19.7) 71 (21.5) 0.72 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
275 
7.3 Results 2: Differences in clinical characteristics - negative and non-
negative MTWA results 
 
Every clinical parameter examined in Section 7.2 was analysed to determine if there were any 
differences between the MTWA groups when classified as negative and non-negative. Only 
the parameters where a significant difference (p<0.05) existed are displayed in Table 7-18. 
Patients with a negative result were approximately 5 years younger than those with a non-
negative result. Consequently, there was a notable difference in the proportion of patients aged 
75 years or older, over 35% of those with a non-negative result compared to 21% with a 
negative result. More patients with a non-negative MTWA result had a prior MI. No other 
medical comorbidities were differed between the two groups.  
 
As mentioned in the previous section, only a quarter of patients with a negative test were on 
optimal HF therapy, nearly half the proportion of patients with a non-negative result. This is 
likely explained by the significant difference in proportions prescribed beta-blockers, only half 
of patients with a negative test compared to almost 70% of patients with a non-negative test. 
The difference in beta-blocker prescribing is also a likely explanation for the significant 
difference in resting heart rate between the two groups. Patients with a negative test had a 
higher resting heart rate than those with a non-negative result. Patients with a non-negative 
test had a lower mean DBP and an elevated pulse pressure, compared to patients with a 
negative result. 
 
QTc was the only ECG parameter that differed between the two groups, patients with a non-
negative result being more likely to have a longer QTc. There was no difference between the 
two groups in the proportion of patients with HF-REF and HF-PEF. Patients with a negative 
test achieved a higher percentage of their predicted heart rate during MTWA exercise testing.   
Finally, log BNP and moderate, or worse, renal dysfunction (defined as eGFR 
<60ml/min/1.73m2) were the only blood parameters that differed significantly between the two 
groups. Patients with a non-negative result were more likely to have a higher log BNP and 
more patients with moderate, or worse, renal dysfunction. 
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Table 7-18: Clinical variables stratified by negative and non-negative MTWA 
classification (significant results only). Data are mean (SD) or number (%). 
 
Variable Negative 
(n=78) 
Non-negative 
(n=252) 
Overall 
(n=330) 
p value* 
 
Age (years)  65 (12.1) 70 (10.8) 69 (11.3) 0.00041 
MI 29 (37.2) 137 (54.4) 166 (50.3) 0.008 
Optimal therapy 19 (24.4) 112 (44.4) 131 (39.7) 0.0012 
Diuretics 71 (91.0) 245 (97.2) 316 (95.8) 0.018 
Beta-blockers 39 (50) 174 (69.0) 213 (64.5) 0.0021 
Heart rate (bpm) 84 (11.8) 75 (14.0) 77 (14.0) <0.0001 
Diastolic BP (mmHg) 71.6 (10.9) 65.9 (12.7) 67.3 (12.5) 0.0004 
Pulse pressure (mmHg) 57.8 (19.3) 65.9 (23.1) 64.0 (22.5) 0.0053 
QTc (ms) 432 (29.6) 442 (33.4) 440 (32.8) 0.012 
% predicted HR 74.8 (6.6) 67.8 (11.4) 69.5 (10.9) <0.0001 
Log (BNP) 5.6 (1.2) 6.0 (1.1) 5.9 (1.1) 0.015 
eGFR < 60ml/min/1.73m2 33 (42.3) 139 (55.2) 172 (52.1) 0.04 
 
* Inter-group comparisons using Student’s t-test (continuous variables) and χ2 test (categorical 
variables), p value < 0.05 indicates a significant difference between the groups. 
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7.4 Results 3: Differences in clinical characteristics for the three MTWA 
pairings 
 
7.4.1 Negative versus positive MTWA 
 
All clinical characteristics where a statistically significant difference existed between the three 
MTWA groups were evaluated by logistic regression analysis to determine if certain variables 
were associated with a specific MTWA result.  
 
The results for the comparison of negative versus positive MTWA are displayed in Table 7-19. 
Overall there were three parameters where a significant difference (p<0.05) existed between 
negative and positive MTWA results. Patients with a negative result were less likely to be 
treated with an ACE inhibitor and more likely to have a higher LVEF, than patients with a 
positive result. These differences were of borderline statistical significance. Those with a 
negative test were also more likely to have a lower cholesterol concentration than patients with 
a positive result. Fewer patients with a negative result had electrocardiographic evidence of 
LVH and a lower pulse pressure was more common amongst those with a negative result, 
these differences only showed a trend towards statistical significance.   
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Table 7-19: Logistic regression analysis for negative versus positive MTWA results 
 
Parameter Odds Ratio 95% Confidence Interval p value* 
Age (by 10 years) 0.81 0.64 - 1.04 0.095 
Palpitations 0.96 0.5 - 1.85 0.91 
MI 0.59 0.32 - 1.08 0.089 
TIA / CVA 1.24 0.56 - 2.75 0.6 
Previous AF 1.59 0.72 - 3.49 0.25 
HR (per 10bpm) 1.27 1 - 1.61 0.054 
DBP (per 10mmHg) 1.25 0.97 - 1.61 0.088 
Pulse pressure  0.99 0.97 - 1.0 0.051 
Optimal HF therapy 0.92 0.43 - 1.98 0.42 
Diuretics 0.31 0.08 - 1.26 0.1 
ACE inhibitors 0.5 0.25 - 0.99 0.046 
β-blockers 0.79 0.43 - 1.42 0.43 
Statins 1.07 0.56 - 2.05 0.83 
LVH 0.44 0.19 - 1.01 0.052 
QTc 0.99  0.98 - 1.0 0.25 
Max ST depression  0.86 0.5 - 1.56 0.57 
% predicted HR  1.0  0.96 - 1.04 0.88 
LVEF (by 5%) 1.13 1.0 - 1.27 0.049 
Log (BNP) 0.78 0.59 - 1.04 0.09 
Sodium < 135mmol/l 0.5 0.09 - 2.65 0.41 
Log (Urea) 1.1 0.56 - 2.17 0.78 
Log (Creatinine) 0.81 0.29 - 2.2 0.67 
eGFR (per ml/min/1.73m2) 1.0 0.99 - 1.02 0.73 
eGFR <60 ml/min/1.73m2 1.06 0.58 - 1.92 0.86 
Albumin (g/l) 0.98 0.91 - 1.06 0.68 
T4 (pmol/l) 1.09 0.96 - 1.24 0.21 
Urate (mmol/l) 0.41 0.05 - 3.59 0.42 
Cholesterol (total) (mmol/l) 0.71 0.54 - 0.94 0.016 
HDL (mmol/l) 0.67 0.33 - 1.37 0.27 
Haemoglobin (g/dl) 0.93 0.79 - 1.09 0.36 
Lymphocytes <1x109/l 0.76 0.18 - 3.28 0.71 
* p value < 0.05 indicates a significant difference 
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7.4.2 Indeterminate versus positive MTWA 
 
The results for the comparison of indeterminate versus positive MTWA are displayed in Table 
7-20. Overall there were twenty-two parameters where a significant difference (p<0.05) 
existed between indeterminate and positive MTWA results. 
 
Patients with an indeterminate result were older and more likely to have a history of AF and 
cerebrovascular disease, than patients with a positive result. Those with an indeterminate 
result were less likely to experience palpitations than patients with a positive result. Patients 
with an indeterminate result had a lower resting heart rate and DBP. In terms of HF 
medications, patients with an indeterminate result were more likely to be on optimal HF 
therapy, with a higher rate of beta-blocker prescribing but lower rate of ACE inhibitor 
prescribing than those with a positive result. Patients with an indeterminate result were more 
likely to be taking statins. Patients with an indeterminate result had a longer QTc interval, than 
patients with a positive result. During MTWA exercise testing, patients with an indeterminate 
result achieved a lower percentage of their predicted heart rate than those with a positive result. 
Patients with an indeterminate test had a higher LVEF than patients with a positive result. 
There were several significant biochemical differences between the two groups of patients. 
Those with an indeterminate test had a higher proportion of patients with elevated log (urea) 
and log (creatinine) concentrations and lower eGFR concentrations. Consequently more 
patients with indeterminate results had at least moderate chronic kidney disease (defined as 
eGFR < 60 ml/min/1.73m2). They also had lower albumin concentrations and higher free T4 
levels, than patients with a positive result. Total cholesterol and HDL levels were lower 
amongst those with an indeterminate result than patients with positive results. Finally, patients 
with an indeterminate result were more likely to be anaemic.  
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Table 7-20: Logistic regression analysis for indeterminate versus positive MTWA results 
 
Parameter Odds Ratio 95% Confidence Interval p value 
Age (by 10 years) 1.34 1.05 - 1.7 0.019 
Palpitations 0.46 0.25 - 0.85 0.013 
MI 1.34 0.81 - 2.22 0.26 
TIA / CVA 1.96 1.01 - 3.78 0.046 
Previous AF 3.38 1.76 - 6.52 0.00027 
HR (per 10bpm) 0.62 0.5 - 0.75 <0.0001 
DBP (per 10mmHg) 0.76 0.62 - 0.93 0.0093 
Pulse pressure 1.0 0.99 - 1.02 0.49 
Optimal HF therapy 6.13 3.08 - 12.17 <0.0001 
Diuretics 1.14 0.25 - 5.23 0.86 
ACE inhibitors 0.53 0.29 - 0.95 0.035 
β-blockers 2.73 1.57 - 4.72 0.00034 
Statins 2.08 1.15 - 3.77 0.016 
LVH 0.54 0.28 - 1.03 0.063 
QTc 1.01 1.0 - 1.02 0.03 
Max ST depression  0.62 0.37 - 1.02 0.062 
% predicted HR  0.88 0.85 - 0.91 <0.0001 
LVEF (by 5%) 1.16 1.04 - 1.29 0.0088 
Log (BNP) 1.11 0.88 - 1.4 0.19 
Sodium < 135mmol/l 2.24 0.79 - 6.31 0.13 
Log (Urea) 1.86 1.06 - 3.26 0.03 
Log (Creatinine)  2.68 1.17 - 6.11 0.019 
eGFR (per ml/min/1.73m2) 0.98 0.97 - 0.99 0.0046 
eGFR < 60ml/min/1.73m2 2.69 1.6 - 4.52 0.00019 
Albumin (g/l) 0.91 0.85 - 0.98 0.0085 
T4 (pmol/l) 1.19 1.06 - 1.33 0.0026 
Urate (mmol/l) 6.22 0.83 - 46.46 0.075 
Cholesterol (total) (mmol/l) 0.66 0.53 - 0.83 0.0004 
HDL (mmol/l) 0.34 0.17 - 0.68 0.0023 
Haemoglobin (g/dl) 0.79 0.69 - 0.92 0.0017 
Lymphocytes <1x109/l 2.39 0.85 - 6.71 0.097 
* p value < 0.05 indicates a significant difference 
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7.4.3 Indeterminate versus negative MTWA 
 
The results for the comparison of indeterminate versus negative MTWA are displayed in 
Table 7-21. Overall there were nineteen parameters where a significant difference (p<0.05) 
existed between indeterminate and negative MTWA results. 
 
Patients with an indeterminate result were older and more likely to have had a previous 
myocardial infarction and a history of AF, than those with a negative result. They were less 
likely to be symptomatic from palpitations than patients with a negative result. Those with an 
indeterminate result had a lower resting heart rate and diastolic blood pressure but a higher 
pulse pressure than patients with a negative result. In terms of heart failure medications, 
patients with an indeterminate result were more likely to be on optimal heart failure therapy. 
These patients had significantly more prescribing of both beta-blockers and diuretics than 
those with a negative result. Patients with an indeterminate result were also more likely to be 
prescribed statins. Patients with an indeterminate result had longer QTc intervals. During 
MTWA exercise testing those with an indeterminate result achieved a lower percentage of 
their predicted heart rate, than patients with a negative result. LVEF was similar in patients 
with indeterminate and negative results. There were several significant biochemical 
differences between these two groups. Patients with an indeterminate test had higher log BNP 
concentration, higher log (creatinine) concentration and lower eGFR concentration. 
Consequently, they were more likely to have at least moderate chronic kidney disease than 
patients with a negative result. They were also more likely to be hypoalbuminaemic and have 
higher urate levels than patients with a negative result.  
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Table 7-21: Logistic regression analysis for indeterminate versus negative MTWA results 
 
Parameter Odds Ratio 95% Confidence Interval p value 
Age (by 10 years) 1.81 1.36 - 2.41 <0.0001 
Palpitations 0.48 0.25 - 0.92 0.028 
MI 2.26 1.29 - 3.96 0.0043 
TIA / CVA 1.58 0.8 - 3.12 0.19 
Previous AF 2.14 1.12 - 4.06 0.021 
HR (per 10bpm) 0.48 0.38 - 0.62 <0.0001 
DBP (per 10mmHg) 0.6 0.48 - 0.77 <0.0001 
Pulse pressure 1.02 1.01 - 1.03 0.0034 
Optimal HF therapy 6.64 3.23 - 13.63 <0.0001 
Diuretics 3.65 1.03 - 12.87 0.044 
ACE inhibitors 1.05 0.59 - 1.88 0.87 
β-blockers 3.47 1.93 - 6.23 <0.0001 
Statins 1.94 1.02 - 3.67 0.043 
LVH 1.23 0.53 - 2.83 0.63 
QTc 1.01 1.0 - 1.02 0.0036 
Max ST depression  0.65 0.35 - 1.21 0.18 
% predicted HR  0.87 0.84 - 0.91 <0.0001 
LVEF (by 5%) 1.01 0.9 - 1.14 0.85 
Log (BNP) 1.35 1.06 - 1.71 0.015 
Sodium < 135mmol/l 4.47 1.19 - 9.7 0.05 
Log (Urea) 1.66 0.93 - 2.98 0.089 
Log (Creatinine)  2.85 1.21 - 6.7 0.016 
eGFR (per ml/min/1.73m2) 0.98 0.97 - 0.99 0.0044 
eGFR < 60ml/min/1.73m2 2.55 1.46 - 4.46 0.0011 
Albumin (g/l) 0.92 0.86 - 1.0 0.046 
T4 (pmol/l) 1.09 0.98 - 1.2 0.1 
Urate (mmol/l) 9.81 1.34 - 72.14 0.025 
Cholesterol (total) (mmol/l) 0.9 0.69 - 1.16 0.41 
HDL (mmol/l) 0.49 0.22 - 1.1 0.082 
Haemoglobin (g/dl) 0.87 0.75 - 1.01 0.064 
Lymphocytes <1x109/l 3.15 0.89 - 11.09 0.074 
* p value < 0.05 indicates a significant difference 
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7.5 Discussion 
 
This chapter has described the clinical characteristics associated with specific MTWA results.  
When the patients were analysed in three separate groups, according to the MTWA result, 
there were 27 clinical characteristics that differed significantly (p<0.05) between the groups of 
patients. A large amount of clinical data was included in these analyses and the limitations of 
multiple testing are recognised. However, 12 of the 27 characteristics that differed between the 
three groups had p values <0.01. When analysis was performed according to the 
contemporarily accepted classification of non-negative and negative (85), only 12 clinical 
characteristics differed significantly between the two groups (p<0.05), with 8 having p values 
<0.01. This novel finding highlights that the patients with non-negative MTWA results are a 
heterogeneous group of patients, in terms of clinical characteristics, and may explain the 
observation in other studies that patients with an indeterminate test result had a higher all-
cause mortality rate than those with a positive result (84;94;100;102;116). Pair-wise analysis 
of MTWA results (negative versus positive; indeterminate versus positive; indeterminate 
versus negative) revealed notable differences also. In particular, this analysis exposed major 
difference between the indeterminate group and the other two groups of patients (and fewer 
differences between those with positive and negative tests). There were 22 clinical 
characteristics that significantly differed (p<0.05) between the indeterminate and positive 
groups, 14 with p values <0.01. There were almost as many significant differences between 
the indeterminate and negative groups, with 11 differences having a p value <0.01. 
Interestingly, there were only 3 clinical characteristics with significant differences between the 
negative and positive groups and none of these had a p value <0.01.  
 
In summary, this chapter has highlighted that patients with indeterminate MTWA results are a 
distinct group of patients with more abnormal clinical characteristics than patients with 
positive or negative results. This novel finding argues against the current classification of 
patients into two groups, as non-negative and negative, and proposes that MTWA results 
should be considered as three separate groups: positive, negative and indeterminate. Whether 
or not this translates into a difference prognostically, thereby influencing how MTWA results 
should be classified for risk stratification purposes will be the focus of Chapter 8. 
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8.1 Introduction 
 
This chapter will describe the outcomes of the post-discharge cohort, focusing on the patients 
who underwent MTWA testing. The unadjusted mortality rates for each MTWA result will be 
illustrated. The most powerful predictors of prognosis will be determined using a three stage 
multivariable model. Finally the incremental prognostic value of MTWA will be assessed in 
the multivariable model. 
 
8.2 Results 
 
8.2.1 Overall survival of post-discharge cohort 
 
The follow-up duration was calculated from the date of the study visit (first appointment 16th 
January 2007) to the date of death or censoring at 31st July 2009. The mean follow-up was 526 
days (SD 243) or 18 months (SD 8.1) with a range 52-973 days. Median follow-up was 494 
days. Of the 648 patients in the post-discharge cohort, 131 died during the follow-up period. 
Median survival was not calculable as 50% had not died by the censor date. Of 131 deaths, 20 
were SCD and 63 cardiovascular deaths (excluding SCD). The remaining 48 patients died 
from non-cardiovascular causes. Table 8-1 shows unadjusted one and two year survival rates 
for the 648 patients. Almost one quarter of the post-discharge cohort were deceased by 2 years 
of follow-up. Of the original 1003 patients enrolled in the study, 329 patients (33%) died 
during the follow-up period. 
 
Table 8-1: Overall survival for 648 patients in the post-discharge cohort 
 
 Survival (%) 95% Confidence Interval 
1 year 86.6 83.9 – 89.3 
2 year 75.3 71.4 – 79.4 
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8.2.2 Survival stratified by MTWA eligibility  
 
Of the 648 patients attending the post-discharge study visit, there were proportionately more 
deaths amongst those ineligible for MTWA exercise testing (Table 8-2). The difference in all 
cause mortality showed a trend towards statistical significance (p=0.057). There were no 
significant differences in the rates of SCD or resuscitated cardiac arrest and cardiovascular 
death (excluding sudden) between the two groups (Table 8-2). 
 
Table 8-2: Mortality outcomes for the post-discharge cohort, stratified by eligibility for 
MTWA testing. Data are expressed as number (%). 
 
Outcome Eligible 
(n=330) 
Ineligible 
(n= 318) 
Overall 
(n=648) 
p value* 
All cause mortality 57 
(17.3) 
74 
(23.3) 
131 
(20.2) 
0.057 
SCD or resuscitated cardiac arrest 9 
(2.7) 
11 
(3.5) 
20 
(3.1) 
0.59 
Cardiovascular death  (excluding sudden) 27 
(8.2) 
36 
(11.3) 
63 
(9.7) 
0.18 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference 
between the groups. 
 
Table 8-3 shows one and two year survival rates for patients stratified by MTWA eligibility at 
the study visit. The one year unadjusted case survival rates were 88.8% and 79.4% for eligible 
and ineligible groups, respectively. The two year unadjusted case survival rates were 79.4% 
and 71.4% for eligible and ineligible groups, respectively. The differences were not 
statistically significant.  
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Table 8-3: Overall unadjusted survival for 648 patients in the post-discharge cohort, 
stratified by MTWA eligibility 
 
Eligible 
(n=330) 
Ineligible 
(n=318) 
 
Survival (%) 95% CI Survival (%) 95% CI 
1 year  88.8 85.3 – 92.5 84.3 80.3 – 88.5 
2 year  79.4 74.4 – 84.6 71.4 65.6 – 77.7 
 
8.2.3 Survival stratified by LVEF 
 
Table 8-4 shows one and two year survival rates for patients stratified by LVEF. The one year 
unadjusted case survival rates were 86.3% and 86.4% for HF-PEF and HF-REF groups, 
respectively. The two year unadjusted case survival rates were 83.3% and 72.8% for HF-PEF 
and HF-REF, respectively. The differences were not statistically significant but the confidence 
intervals only just overlap by two year survival, suggesting the two groups may have 
significantly different survival rates with follow-up beyond two years. Unadjusted Kaplan-
Meier curves for all-cause mortality graphically demonstrate no significant difference in 
survival between the two LVEF groups, with the curves crossing early on in follow-up (log 
rank test p= 0.172) (Figure 8.1).  
 
Table 8-4: Overall unadjusted survival for 648 patients in the post-discharge cohort, 
stratified by LVEF 
 
 
HF-PEF 
(n=127) 
HF-REF 
(n=521) 
 
Survival (%) 95% CI Survival (%) 95% CI 
1 year  86.3 80.4 – 92.6 86.4 83.3 – 89.5 
2 year  83.3 76.8 – 90.3 72.8 68.1 – 77.8 
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Figure 8.1: Kaplan-Meier survival curves for HF-PEF and HF-REF (curves were 
compared using the log rank test, where p<0.05 indicates a significant difference between 
the two groups). 
 
 
 
8.2.4 Unadjusted outcomes for MTWA result 
 
The breakdown of causes of death according to MTWA classification is displayed in Table 8-5. 
Of 100 patients with a positive MTWA result, 12 (12%) died during the follow-up period. Of 
78 patients with a negative MTWA result, 16 (20.5%) died during the follow-up period. Of 
152 patients with an indeterminate MTWA result, 29 (19.1%) died during the follow-up 
period. The difference in all cause mortality rates was not statistically significant. Unadjusted 
Kaplan-Meier curves for all-cause mortality demonstrated no significant difference in survival 
between the three MTWA groups (log rank test p= 0.1989) (Figure 8.2). The survival curve 
analyses for the secondary outcome measures are displayed in Figures 8.3 and 8.4. There were 
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no significant differences in the rates of secondary outcome measures between the three 
MTWA groups (Table 8-5) [p=0.82 and p=0.077, respectively].  
 
Table 8-6 shows one and two year survival rates for patients stratified by MTWA result. 
Patients with a positive or indeterminate MTWA result did not have a higher all-cause 
mortality rate than those with a negative result. The one year unadjusted case survival rates 
were 85.7%, 94.5% and 86.7% for negative, positive and indeterminate results, respectively. 
The two year unadjusted case survival rates were 74.7%, 83.6% and 79.2% for negative, 
positive and indeterminate results, respectively. The differences were not statistically 
significant. 
 
Figure 8.2: Kaplan-Meier survival curves for all-cause mortality for negative, positive 
and indeterminate MTWA results (curves were compared using the log rank test, where 
p<0.05 indicates a significant difference between the three groups). 
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Figure 8.3: Kaplan-Meier survival curves for sudden cardiac death or resuscitated 
cardiac arrest for negative, positive and indeterminate MTWA results 
 
Figure 8.4: Kaplan-Meier survival curves for cardiovascular death (excluding sudden) 
for negative, positive and indeterminate MTWA results 
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Table 8-5: Unadjusted mortality outcomes stratified by MTWA result. Data are expressed as number (%) 
 
Outcome Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate 
(n=152) 
Overall 
(n=330) 
p value* 
All-cause mortality 12 
(12) 
16 
(20.5) 
29 
(19.1) 
57 
(17.3) 
0.24 
SCD or resuscitated cardiac arrest 2 
(2) 
2 
(2.6) 
5 
(3.3) 
9 
(2.7) 
0.82 
Cardiovascular death (excluding sudden) 3 
(3) 
8 
(10.3) 
16 
(10.5) 
27 
(8.2) 
0.077 
 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the groups. 
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Table 8-6: Unadjusted survival rates for patients with negative, positive and indeterminate MTWA results 
 
Negative 
(n=78) 
Positive 
(n=100) 
Indeterminate 
(n=152) 
 
Survival (%) 95% CI Survival (%) 95% CI Survival (%) 95% CI 
1 year 85.7 77.8 – 94.4 94.5 89.9 – 99.3 86.7 81.3 – 92.5 
2 year 74.7 64.4 – 86.6 83.6 75.4 – 92.8 79.2 72.1 – 87.0 
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Mortality outcomes were also analysed in accordance with accepted practice as non-
negative and negative MTWA results (85). This did not alter the outcome; a non-negative 
MTWA result was not significantly different to a negative MTWA result in determining 
all-cause mortality (Figure 8.5 and Table 8-7) or the secondary outcome measures (Table 
8-8). Table 8-8 shows one and two year case survival rates for MTWA result dichotomised 
to negative and non-negative. The one year unadjusted case survival rates were 85.7% and 
89.8%, for negative and non-negative results, respectively. The two years unadjusted 
survival rates were 74.7% and 80.9%, for negative and non-negative, respectively. The 
differences were not statistically significant. 
 
 
Figure 8.5: Kaplan-Meier survival curves for negative and non-negative MTWA 
results (curves were compared using the log rank test, where p<0.05 indicates a 
significant difference between the two groups). 
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Table 8-7: Unadjusted mortality outcomes stratified by negative and non-negative 
MTWA result. Data are expressed as number (%) 
 
Outcome Negative 
(n=78) 
Non-negative 
(n=252) 
Overall 
(n=330) 
p value* 
All-cause mortality 16 
(20.5) 
41 
(16.3) 
57 
(17.3) 
0.39 
SCD or resuscitated cardiac 
arrest 
2 
(2.6) 
7 
(2.8) 
9 
(2.7) 
0.92 
Cardiovascular death 
(excluding sudden) 
8 
(10.3) 
19 
(7.5) 
27 
(8.2) 
0.44 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference 
between the groups. 
 
Table 8-8: Survival rates for patients with negative and non-negative MTWA results 
 
Negative 
(n=78) 
Non-negative 
(n=252) 
 
Survival 
(%) 
95% CI Survival 
(%) 
95% CI 
1 year 85.7 77.8 – 94.4 89.8 86.0 – 93.8 
2 year 74.7 64.4 – 86.6 80.9 75.4 – 86.8 
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The indeterminate MTWA results were further analysed according to the classification 
illustrated in Figure 6.11 (page 233). This was to determine if the different types of 
indeterminate result had different outcomes, particularly the two main indeterminate 
results. As previously described in chapter 6, the majority of indeterminate tests were 
because of a failure to achieve the required heart rate of 110bpm (75% of all indeterminate 
tests). There were two principal reasons for this. Firstly, some patients had a low resting 
heart rate, due to being on maximal dose of beta-blocker therapy. These patients were often 
physically able to exercise for a long period of time but unable to elevate their heart rate 
and it was clear that prolonging exercise would not achieve the desired heart rate of 110 
bpm (represented as ‘insufficient HR – chronotropic incompetence’ in Table 8-9). The 
other reason for an insufficient heart rate was exercise intolerance preventing attainment of 
a heart rate of 110bpm (represented as ‘insufficient HR – physical limitations’ in Table 8-
9). The remaining MTWA tests were indeterminate due to the presence of ectopic activity 
(16.4%), noise (5.9%), non-sustained alternans (2%) or a rapid rise in heart rate (0.7%).  
These are represented as ‘Indeterminate – Other’ in Table 8-9.  
 
Patients with indeterminate results due to an insufficient heart rate secondary to physical 
limitations had proportionately more events for all three outcomes, compared to other 
MTWA results, although these differences were not statistically significant. There was no 
significant difference in any of the three outcomes according to the type of indeterminate 
MTWA result. There were too few events to permit survival curve analyses. 
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Table 8-9: Mortality outcomes stratified by type of indeterminate MTWA result. Data are expressed as number (%) 
 
Outcome Positive 
(n=100) 
Negative 
(n=78) 
Indeterminate – 
insufficient HR       
due to physical 
limitation (n=59) 
Indeterminate – 
insufficient HR due to 
chronotropic 
incompetence (n=55) 
Indeterminate 
Other 
(n=38) 
Overall 
(n=330) 
p value* 
All-cause mortality 12 
(12) 
16 
(20.5) 
14 
(23.7) 
9 
(16.4) 
6 
(15.8) 
57 
(17.3) 
0.15 
SCD or resuscitated 
cardiac arrest 
2 
(2) 
2 
(2.6) 
3 
(5.1) 
2 
(3.6) 
0 
(0) 
9 
(2.7) 
0.65 
Cardiovascular death 
(excluding sudden) 
3 
(3) 
8 
(10.3) 
8 
(13.6) 
5 
(9.1) 
3 
(7.9) 
27 
(8.2) 
0.11 
 
* Inter-group comparisons using χ2 test, p value < 0.05 indicates a significant difference between the five groups. 
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8.2.5 Comparison of mortality rates to other LVSD and HF MTWA studies 
 
The mortality rates of LVSD and HF MTWA studies are shown in Table 8-10. All-cause 
mortality and SCD rates, if available, are presented. My study is displayed in the last row. 
Only studies with at least 10 deaths during their follow-up period are displayed in this table.  
 
There are several reasons limiting direct comparisons between these studies. Firstly, the 
wide range of follow-up durations prevents direct comparisons of overall event rates. Thus 
approximate mortality rates per 100 patient-years of follow-up were calculated (Table 8-
11). Secondly, the differences in the patient population included in each study limits 
comparisons between studies, for example some studies are exclusively ischaemic or non-
ischaemic HF patients whilst others include both. Also some studies are post-MI LVSD, 
likely containing patients asymptomatic of HF. Finally, some studies do not present the 
numbers for all-cause mortality or sudden cardiac death according to the MTWA result. 
Several studies only present results for non-negative patients, preventing comparison of 
positive and indeterminate results separately. Some studies only present actuarial mortality 
rates according to MTWA result rather than absolute numbers of death according to 
MTWA result, preventing direct comparison with other studies. Many studies do not 
present the numbers of patients who succumbed to SCD. 
 
Approximate mortality rates per 100 patient-years of follow-up were calculated to allow a 
comparison of all-cause mortality between studies (Table 8-11). The higher mortality rate 
of my study may reflect the unselected nature of my cohort, including more elderly 
patients with comorbidity.  
 
The proportion of all deaths that were SCD is displayed in the last column of Table 8-10. 
The range of this proportion is wide, from 17-58%. The limitations in the definition of 
SCD used in my study, addressed in chapter 2 (section 2.6.3, page 89), likely account for 
the low proportion of all deaths that were sudden in my study. This prevents meaningful 
comparisons to the other MTWA studies, all of which used a more robust definition 
(section 2.6.3, page 89). 
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Table 8-10: Distribution of all-cause mortality and sudden cardiac death in LVSD and HF MTWA studies* 
 
All Cause Mortality, N (%) Sudden Cardiac Death, N (%) Study N Population Mean FU  
(SD) Pos Ind N-N Neg Total Pos Ind N-N Neg Total % ACM 
Chow (107) 768 Ischaemic LVSD 18 (10) 44/355 (12) 34/159 (21) 78/514 (15) 21/254 (8) 99 (13) 17 (5) 16 (10) 33 (6) 9 (4) 42 (5) 42 
Gold (119) 490 HF -  LVSD   30 [-] 33/182 (18)  32/173 (19) 65/355 (18) 16/135 (12) 81 (17) 12 (7) 6 (4) 18 (5) 8 (5) 26 (5) 32 
Chow (104) 575 Post-MI  LVSD 25 (11) - - 46/361 (13) 13/214 (6) 59 (10) - - 7 (2) 3 (1) 10 (2) 17 
Bloomfield (109) 549 LVSD  20 (6) - - 38/360 (11) 2/189 (1) 40 (7) - - - 1 (<1) - - 
Huikuri (105) 312 Post-MI LVSD 22 (6) - - - - 38 (12) - - - - 8 (3) 21 
Grimm (113) 263 HF –DCM 52 (12) - - - - 33 (13) - - - - 17 (7) 52 
Salerno-Uriarte 
(118) 
446 HF – DCM 19 [18-24] - - 25/292 (9) 3/154 (2) 28 (6) - - 7/282 (2) 0 7 (2) 25 
Hohnloser (103)  129 Post-MI  LVSD 17 (8) - - 16/94 (17) 4 (11) 20 (16) - - 8/94 (9) 0 8 (6) 40 
Bloomfield (85) 177 Post-MI  LVSD 20 (6) - - - - 20 (11) - - - - - - 
Rashba (106) 144 Ischaemic LVSD 17 (13) - - - - 14 (10) - - - - - - 
Klingenheben 
(116) 
107 HF – LVSD 15 (-) - - - - 12 (11) - - - - 7 (7) 58 
Jackson 330 HF 18 (8) 12/100 (12) 29/152 (19) 41/252 (16) 16/78 (21) 57 (17) 2 (2) 5 (3) 7 (3) 2 (3) 9 (3) 16 
 
* Studies with ≤ 10 deaths during follow-up not included in this table (108;111;112;114;115). Order is according to number of deaths during follow-up. 
N = number; FU = follow-up (months);  pos = positive; ind = indeterminate; N-N = non-negative; neg = negative; DCM = dilated cardiomyopathy (non-
ischaemic); - = data not presented 
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Table 8-11: Approximate mortality rates per 100-patient years of follow-up for studies in Table 8-10  
 
Study N Population Mean FU (months) 
 
All-cause mortality,    
N (%) 
Mortality rate per 
100-patient years 
Chow (107) 768 Ischaemic LVSD 18  99 (13) 8.6 
Gold (119) 490 HF -  LVSD   30  81 (17) 6.6 
Chow (104) 575 Post-MI  LVSD 25  59 (10) 4.9 
Bloomfield (109) 549 LVSD  20 40 (7) 4.4 
Huikuri (105) 312 Post-MI LVSD 22 38 (12) 6.6 
Grimm (113) 263 HF -DCM 52 33 (13) 2.9 
Salerno-Uriarte (118) 446 HF - DCM 19 28 (6) 4.0 
Hohnloser (103) 129 Post-MI  LVSD 17  20 (16) 10.9 
Bloomfield (85) 177 Post-MI  LVSD 20 20 (11) 6.8 
Rashba (106) 144 Ischaemic LVSD 17 14 (10) 6.9 
Klingenheben (116) 107 HF - LVSD 15 12 (11) 9.0 
Jackson 330 HF 18 57 (17) 11.5 
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8.2.6 Stepwise multivariable models without MTWA 
 
A detailed description of the variables selection and the statistical analyses employed in the 
multivariable models is given in chapter 2 (section 2.6, page 86). Multivariable analysis 
was carried out using a Cox proportional hazards regression three stage model. The 
multivariable models were created using the significant univariate variables at each stage. 
These analyses are for all-cause mortality only. There were too few events to allow 
analyses for the secondary outcome measures. 
 
The univariate and multivariable analysis for stage one is presented in Table 8-12. 
Increasing age, lower LVEF, lower BMI, NYHA class III or IV, a diagnosis of HF for 
more than two years and a history of a previous MI were univariate predictors of all-cause 
mortality. After adjusting for the variables in the Cox regression model, lower BMI, 
NYHA class III or IV and previous MI were found to be independent predictors of all-
cause mortality.  
 
 
The univariate and multivariable analysis for stage two is presented in Table 8-13. Lower 
eGFR, higher RDW, higher bilirubin and lower haemoglobin concentrations were 
univariate predictors of all-cause mortality. After adjusting for the variables in the Cox 
regression model, lower eGFR, higher bilirubin and lower haemoglobin concentration were 
found to be independent predictors of all-cause mortality.  
 
 
The univariate and multivariable analysis for stage three is presented in Table 8-14. This 
showed elevated levels of both novel biomarkers BNP and troponin I to be independent 
predictors of all-cause mortality. 
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Table 8-12: Univariate and multivariable analysis for stage 1 variables 
 
Univariate Multivariable1 Multivariable2 Stage 1 Variable 
HR 95% CI p value HR 95% CI p value HR 95% CI p value 
Age (per year) 1.03 1.01 - 1.04 0.0057 1.01 0.99 - 1.03 0.17 - - - 
LVEF (per 5% increase) 0.91 0.84 - 0.97 0.0062 0.94 0.87 - 1.02 0.13 - - - 
DM  - No 
         - Insulin  
         - Other  
1.0 
1.25 
1.05 
 
0.68 - 2.29 
0.7 - 1.57 
0.7749 - - - - - - 
BMI (per kg/m2 increase) 0.95 0.92 - 0.98 0.0008 0.96 0.93 - 0.99 0.0072 0.95 0.92 - 0.98 0.0005 
Sex (Female) 1.0 0.71 - 1.42 0.99 - - - - - - 
NYHA  - I / II 
              - III /IV 
1.0 
2.23 
 
1.58 - 3.14 
<0.0001  
2.07 
 
1.45 - 2.97 
 
<0.0001 
 
2.1 
 
1.48 - 2.96 
 
<0.0001 
Bundle branch block 1.36 0.94 - 1.97 0.1 - - - - - - 
Cardiomegaly 1.1 0.74 - 1.63 0 - - - - - - 
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Univariate Multivariable1 Multivariable2 Stage 1 Variable 
HR 95% CI p value HR 95% CI p value HR 95% CI p value 
SBP (per 10 mmHg increase) 0.99 0.99 - 1.0 0.21 - - - - -  
Chronic HF > 2 years 1.51 1.06 - 2.14 0.022 1.27 0.88 - 1.84 0.2 - - - 
Previous MI 1.99 1.4 - 2.82 0.0001 1.67 1.15 - 2.41 0.0066 1.82 1.28 - 2.59 0.0009 
Dependent oedema 1.3 0.92 - 1.83 0.14 - - - - - - 
HR (per 10bpm) 1.0 0.99 - 1.01 0.57 - - - - - - 
AF 0.88 0.61 - 1.26 0.49 - - - - - - 
 
1 = Multivariable analysis containing significant (p < 0.05) univariate variables only 
2 = Multivariable analysis after removing non significant (p ≥ 0.05) variables 
HR = hazard ratio; CI = confidence interval 
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Table 8-13: Univariate and multivariable analysis for stage 2 variables 
 
Univariate Multivariable1 Multivariable2 Stage 2 Variable 
HR* 95% CI p value HR* 95% CI p value HR* 95% CI p value 
eGFR (ml/min/1.73m2) 0.99 0.98 - 0.99 0.0071 0.99 0.98 - 0.99 0.027 0.99 0.98 - 0.99 0.026 
Log (RDW)  3.33 1.17 - 9.5 0.025 1.84 0.58 - 5.88 0.3 - - - 
Log (Bilirubin)  1.58 1.16 - 2.14 0.0034 1.6 1.15 - 2.22 0.0052 1.71 1.26 - 2.3 0.0005 
Haemoglobin (g/dl) 0.89 0.82 - 0.97 0.0077 0.93 0.85 - 1.03 0.15 0.91 0.84 - 0.99 0.037 
Log (Lymphocytes)  0.62 0.43 - 0.9 0.011 0.89 0.58 - 1.37 0.61 - - - 
Urate (mmol/l) 2.42 0.74 - 7.95 0.14 - - - - - - 
Phosphate (mmol/l) 1.25 0.56 - 2.75 0.59 - - - - - - 
HBA1c (%) 0.97 0.38 - 2.51 0.95 - - - - - - 
 
1 = Multivariable analysis containing significant (p < 0.05) univariate variables only 
2 = Multivariable analysis after removing non significant (p ≥ 0.05) variables 
* = Hazard ratio is per unit increase for all variables 
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Table 8-14: Univariate and multivariable analysis for stage 3 variables 
 
Univariate Multivariable Stage 3 Variable 
HR* 95% CI p value HR* 95% CI p value 
Log (BNP)  1.68 1.41 - 2.0 <0.0001 1.54 1.27 - 1.85 <0.0001 
Troponin I ≥ 0.04 (µg/l) 2.51 1.73 - 3.65 <0.0001 1.733 1.16 - 2.6 0.0079 
 
* Hazard ratio is per unit increase for log (BNP) 
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The multivariable analysis for the significant variables from all three stages is shown in 
Table 8-15. All predictors from the multivariable analysis for stages 1 and 3 remained 
independent predictors of all-cause mortality. None of the predictors from the stage 2 
multivariable analysis were predictive after adjusting for variables from stage 1 and 3. The 
independent predictors of all-cause mortality were lower BMI, NYHA class III or IV, 
previous myocardial infarction, elevated log (BNP) concentration and raised troponin I. 
 
Table 8-15: Multivariable analysis for variables from stages 1, 2 and 3 
 
Multivariable1 Multivariable2 Variable 
HR* 95% CI p value HR* 95% CI p value 
Stage 1 
BMI (kg/m2) 0.96 0.93 - 0.99 0.0073 0.96 0.93 - 0.99 0.01 
NYHA  
(III/IV v I/II) 
1.71 1.19 - 2.45 0.0038 1.72 1.2 - 2.47 0.0032 
Previous MI 1.68 1.18 - 2.4 0.004 1.68 1.18 -  2.4 0.0039 
Stage 2 
eGFR  
(ml/min/1.73m2 ) 
0.99 0.98 - 1.0 0.15 - - - 
Log (Bilirubin)  1.36 0.97 - 1.89 0.074 - - - 
Haemoglobin (g/dl) 0.94 0.85 - 1.03 0.15 - - - 
Stage 3 
Log (BNP)  1.26 1.03 - 1.54 0.026 1.36 1.12 - 1.65 0.0019 
Troponin I  (≥ 0.04 µg/l) 1.49 0.99 - 2.26 0.058 1.57 1.04 - 2.37 0.033 
 
1 = Multivariable analysis with significant (p < 0.05) variables from stages 1-3 
2 = Multivariable analysis after removing non significant (p ≥ 0.05) variables  
* Hazard ratio is per unit increase for continuous variables (BMI, eGFR, log [bilirubin], 
haemoglobin, log [BNP]) 
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8.2.7 Multivariable models with MTWA 
 
The results of the univariate analysis for MTWA are displayed in Table 8-16. As already 
described in section 8.2.3, the unadjusted MTWA result did not predict all-cause mortality. 
 
Table 8-16: Univariate analysis for MTWA 
 
MTWA result HR 95% CI p value* 
Negative 1.0  
Positive 0.56 0.27 : 1.18 
Indeterminate 0.96 0.52 : 1.76 
0.1989 
Non-negative 0.79 0.44 : 1.41 0.43 
 
* p value <0.05 indicates significant difference between the MTWA groups. 
 
The additional prognostic value of MTWA was evaluated by fitting it into each stage of the 
multivariable models. MTWA result (negative, positive or indeterminate) was not an 
independent predictor of all-cause mortality at any stage after adjusting for other 
significant variables, with overall p values of 0.0578, 0.2242 and 0.1496 for stages 1, 2 and 
3, respectively (data from individual stages not shown). MTWA was added to the final 
multivariable model with significant predictors of mortality from all three stages (Table 8-
17). Again, at this stage after adjusting for significant variables, MTWA had no additional 
explanatory value for all-cause mortality. 
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Table 8-17: Multivariable analysis for final model with MTWA 
 
Multivariable analysis with MTWA in 3 categories Multivariable analysis with MTWA in 2 categories Variable 
HR 95% CI p value* HR 95% CI p value* 
BMI (per 1kg/m2 increase) 0.96 0.92 : 1.01 0.11 0.96 0.92 : 1.01 0.14 
NYHA (III/IV v I/II) 2.09 1.2 : 3.65 0.0094 2.06 1.19 : 3.59 0.01 
Previous MI 1.85 1.05 : 3.26 0.033 1.89 1.07 : 3.33 0.028 
Log (BNP) (per unit increase) 1.39 1.05 : 1.85 0.021 1.45 1.09 : 1.91 0.01 
Troponin I (≥ 0.04 µg/l) 1.5 0.79 : 2.85 0.22 1.41 0.75 : 2.69 0.29 
MTWA 3 Categories 
     Negative 
     Positive 
     Indeterminate 
1.0 
0.41 
0.69 
 
0.19 : 0.87 
0.36 : 1.3 
0.0608 
NA 
MTWA 2 Categories 
     Negative 
     Non-negative 
NA 
1.0 
0.56 
 
0.31 : 1.03 
0.06 
* p value <0.05 indicates significant difference between the MTWA groups. 
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8.3 Discussion 
 
This chapter has described the outcomes for the 648 patients in the post-discharge cohort. 
Mortality rates were high, almost one quarter of all patients were deceased by two years 
follow-up. This is an expected finding given all patients had recently been hospitalised with 
decompensated HF. The overall mortality for the 1003 enrolled patients was 33%, comparable 
with recently published mortality rates for Scottish patients hospitalised for HF (147).  
 
There were proportionately more deaths amongst the patients ineligible for MTWA testing 
than those eligible. Many of the reasons for being ineligible for MTWA testing (AF, 
pacemakers and medical comorbidities preventing exercise) are also risk factors for adverse 
outcomes in HF. This is the first study to describe outcomes in patients ineligible for MTWA 
testing and highlights the adverse mortality rates of these patients. 
 
There was no significant difference in mortality rates between patients with HF-REF and HF-
PEF in this study. This finding is consistent with recent studies reporting no significant 
difference in survival between the two groups of patients (19;23). However the number of 
patients in this study is relatively small, with even fewer deaths and the Kaplan-Meier curves 
and two year unadjusted survival figures suggest that differences in survival between those 
with HF-REF and HF-PEF may emerge with longer term follow-up. 
 
MTWA did not predict any of the study’s prespecified outcomes. The failure to predict SCD 
can be partly explained by the small numbers of patients with this outcome. However, it was 
expected that an abnormal MTWA result (positive or indeterminate) may predict all-cause 
mortality (99;100;102;104;105;111). In fact patients with a positive result had proportionately 
fewest events overall with patients with indeterminate and negative results having 
proportionately similar mortality rates, although there was no significant difference in 
mortality rates between the three groups. This result was surprising. Indeed, the results from 
Chapter 7 had demonstrated that patients with positive and negative results were more similar, 
in terms of clinical characteristics, than those with indeterminate results. However, this did not 
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translate prognostically. Also patients with indeterminate results because physical limitations 
prevented elevation of their heart rate had proportionately more events than patients with other 
indeterminate results, although these differences were not statistically significant. MTWA was 
also analysed in the accepted way of non-negative (positive and indeterminate) and negative 
(85), but this did not alter the results. Moreover the very different mortality rates for those 
patients with positive and indeterminate results challenges the use of this ‘non-negative’ 
classification. In the original study that classified patients with positive and indeterminate as 
‘non-negative’, patients with positive and indeterminate MTWA results had two year actuarial 
mortality rates of 14.5% and 20.1%, respectively. The authors of this small (n=177) study of 
patients with ischaemic LVSD concluded that these were similar mortality rates and positive 
and indeterminate tests should be classified as ‘non-negative’. Many studies since have only 
reported ‘non-negative’ mortality rates, preventing an understanding of the exact risk 
conferred by a positive or indeterminate test. The findings of my study strongly suggest this 
approach is incorrect. 
 
The mortality rate (expressed as an approximate event rate per 100 patient-years of follow-up) 
was higher in my study than in prior LVSD and HF MTWA studies (Table 8-11, page 298). 
This likely reflects the unselected nature of my cohort, including more elderly patients with 
comorbidity. One noticeable difference between my study and the other studies presented in 
Table 8-10 (page 297) is the mortality rates for the patients with negative MTWA results. Of 
the studies that presented mortality rates according to the MTWA result, all had a lower 
mortality rate for patients with a negative MTWA result compared with the overall mortality 
rate for each study. By contrast, my study demonstrated the exact opposite; the mortality rate 
was 21% for patients with negative MTWA results compared to an overall mortality rate of 
17% for all patients undergoing MTWA testing. The exact reason for this unexpected finding 
is unclear. This may reflect the different population enrolled, compared with previous studies. 
Perhaps the MTWA test does not identify those at greatest risk when used in unselected 
cohorts with more elderly patients and patients with more comorbidity. The lower rate of beta-
blocker prescribing amongst patients with negative MTWA results, compared to patients with 
indeterminate results, may be a contributory factor to the unexpected higher mortality amongst 
patients with negative results. Patients with indeterminate MTWA results were more than 
three times more likely to be prescribed a beta-blocker than those with negative results                
(OR 3.47, p<0.0001).  
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However this does not explain the higher mortality of patients with negative MTWA results 
compared to those with positive results. Although beta-blocker prescribing was less common 
amongst those with a negative MTWA result, compared to those with a positive result, this 
difference was not significant (OR 0.79, p 0.43). Higher beta-blocker prescribing amongst 
patients with an indeterminate result may have been expected to confer a prognostic advantage. 
The high mortality of the patients with indeterminate results is likely multifactorial and 
explained by the multiple risk factors for poor prognosis present in this group, including 
advancing age, diabetes, anaemia and renal dysfunction. 
  
The proportion of all deaths that were SCD was reported by most LVSD and HF MTWA 
studies and varied from 17-58%. The limitations in the definition of SCD used in my study 
(section 2.6.3, page 89) likely account for the low proportion of all deaths that were sudden in 
my study and thus further comparisons to the other studies were not made. The MASTER 
study (104) had a noticeably lower proportion of SCD compared to the other studies in Table 
8-10. All patients in this study fulfilled MADIT-II criteria and underwent ICD implantation 
following MTWA testing. During the follow-up period 9% of negative patients and 12% of 
non-negative patients received appropriate ICD therapy, many of which may have resulted in 
SCD if an ICD had not been implanted.  Furthermore, although the proportions of events for 
positive and indeterminate patients are not reported separately in this study, the proportion of 
indeterminate results is low in this study (12%). One reason for this may be the use of 
pharmacological means of stress or pacing for patients who were unable to exercise. The low 
rate of indeterminate results together with a low proportion of SCD highlights a possible 
relationship between an indeterminate result and risk of sudden cardiac death. Few studies 
have reported the numbers of SCD, thus it is difficult to extrapolate a potential link between 
indeterminate results and SCD. I could not explore a potential relationship between 
indeterminate results and SCD in my study due to the limitations acknowledged above. 
However, in the largest study to date of MTWA in patients with LVSD, patients with an 
indeterminate result had the highest proportion of SCD and SCD accounted for 42% of all-
cause mortality in this study (107). Another possible explanation for the MASTER study (104) 
having a lower proportion of SCD may be the high rate of beta-blocker prescribing (87%). 
Excluding the MASTER study, there is still a wide range in the proportion of all deaths that 
were sudden in the other studies presented in Table 8-10 (21-58%), likely reflective of the 
inherent difficulties in determining SCD.  
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MTWA had no incremental prognostic value in my study when added to a multivariable 
model containing the strongest predictors of mortality in this study. The independent 
predictors of all-cause mortality following stepwise multivariable modelling were; lower BMI, 
NYHA III/IV, previous MI, elevated log (BNP) concentration and raised troponin (defined as 
≥ 0.04 µg/l). The small number of independent predictors may be explained by the relatively 
small number of events that occurred during the follow-up period for those who underwent 
MTWA testing. 
 
In summary, MTWA had no prognostic value in my cohort of unselected patients with HF. 
There was no evidence to suggest that this test is of benefit in the risk stratification of ‘real-
life’ patients with HF. The independent predictors of mortality in this study included BNP and 
cardiac troponin, a novel biomarker in HF. Both are simple, cheap biochemical tests to 
perform. The other three independent predictors of mortality were clinical variables that are 
readily available. This straightforward model containing only five simple variables identified 
the patients at most risk in my study.  
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CHAPTER NINE 
 
DISCUSSION 
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9.1 Major findings of the study 
 
HF is a major health concern internationally and associated with considerable morbidity and 
mortality. Despite advances in the management of HF in recent decades, the prognosis 
remains poor for many patients (147). This emphasises the importance of prognostication in 
HF, particularly when several therapies available for the management of this condition are 
expensive and require accurate targeting to optimise their use. However the solution to risk 
stratification in HF remains elusive. There are many established predictors of mortality in HF, 
as outlined in Chapter 1, but few have been shown to predict cause-specific death. This is 
particularly important in HF where many deaths may be attributed to SCD caused by VTE, 
which may be prevented by appropriate selection of patients for primary prevention ICDs. 
MTWA has recently been proposed as a potential tool for assisting in the selection of patients 
for primary prevention ICD therapy by identifying those at risk of SCD. As outlined in 
Chapter 1, there are many unresolved issues regarding the clinical utility of MTWA testing in 
HF.  
 
This study has provided a comprehensive evaluation of the use of MTWA in a real-life, near-
consecutive and well-defined population of patients with HF, accounting for aetiology and 
LVEF. The proportion of patients eligible for MTWA testing has been demonstrated. The 
prevalence of positive, negative and indeterminate results and the tolerability of the exercise 
protocol have been assessed. The clinical characteristics associated with each MTWA result 
have been determined. The predictive value of MTWA testing for all-cause mortality has been 
evaluated alongside established predictors of outcome, including BNP, and more novel 
biomarkers, such as cardiac troponin. This study has achieved its main aim of determining if 
MTWA testing has a role in the risk stratification of patients with HF. 
 
Of 2361 patients with suspected decompensated HF screened for inclusion in the study, 1003 
were recruited. The majority of the cohort was elderly with multiple medical co-morbidities 
and LVSD. Of those recruited, 648 patients (65%) attended the study visit approximately 4 
weeks after discharge from hospital. The most common reason for failing to attend the study 
visit was refusal to participate (n=167, 17%). A significant proportion of patients died prior to 
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the study visit appointment (n=115, 11%) and many patients were unable to attend because of 
deterioration in their health (n=73, 7%). The patient’s clinical characteristics recorded during 
hospitalisation were analysed according to whether or not they subsequently completed the 
study visit. Patients attending the study visit were similar, in terms of clinical characteristics, 
to the group of patients who withdrew from participating in the study visit. The groups who 
failed to complete the study visit due to deteriorating health or death had proportionately more 
patients with markers of adverse prognosis in HF. The clinical characteristics recorded during 
hospitalisation were updated at the study visit. Many of the symptoms, signs and laboratory 
values showed an improvement, as expected, compared with the findings recorded during 
hospitalisation.  
 
In patients evaluated after discharge, the clinical characteristics of those with HF-REF and 
HF-PEF were compared. The majority of these characteristics were similar between the two 
groups, consistent with previous reports that patients with HF-PEF cannot readily be 
distinguished from those with HF-REF on the basis of symptoms and signs, CXR or ECG 
findings (19). However, there were some notable differences between the two groups. Patients 
with HF-PEF were older, more likely to be female, more likely to have hypertension and less 
likely to have had a MI, in comparison to those with HF-REF. These findings are consistent 
with previous studies of HF-PEF (22;24;155). Prescribing of recommended pharmacological 
treatments for HF was greater amongst patients with HF-REF, an unsurprising result given the 
evidence-base for the use of these medications exists only for patients with HF-REF and no 
treatment is of proven benefit in HF-PEF. Prescribing of calcium channel blockers was more 
common amongst those with HF-PEF, perhaps reflecting the use of these agents as 
antihypertensive treatment. Apart from SBP and pulse pressure, there were no differences in 
clinical examination findings between the two groups. There were also no differences in the 
proportions in sinus rhythm or AF between the two groups. QRS duration and QTc interval 
were longer amongst patients with HF-REF. The majority of biochemical and haematological 
test findings were similar in the two LVEF groups. The major exception was BNP and here 
the differences in average concentrations between the two groups were striking, both on 
admission to hospital and at the post-discharge study visit. Median BNP concentrations in 
patients with HF-REF were almost twice those of patients with HF-PEF at both time points.  
Previous studies in patients with decompensated HF have demonstrated similar findings (156). 
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Anaemia was more common amongst patients with HF-PEF, consistent with previous reports 
(23).   
 
Of 648 patients who completed the study visit, 330 (51%) were eligible for MTWA testing. 
Thus, almost half were ineligible for MTWA testing. The clinical value of any test is limited if 
nearly half of the patients are ineligible for the test. This is the first prospective observational 
study to describe the reasons for ineligibility in a ‘real-life’ HF population. Patients were 
ineligible because of conditions commonly associated with HF, such as AF, ventricular pacing 
and an inability to exercise. AF accounted for three-quarters of those who were ineligible in 
my study i.e. 38% of all patients. This is higher than the ~23% reported in two earlier studies, 
although those studies enrolled only patients with HF of non-ischaemic aetiology (113;118). 
Although only a small proportion of patients (7% overall) were ineligible because of physical 
inability to attempt the sub-maximal treadmill test, this is an underestimate of this problem as 
many patients simply did not attend for the test because of poor health. Furthermore, as 
discussed later, many of those who did attempt the test could not perform satisfactorily.  
 
Many of the characteristics of the ineligible patients in my study suggested they had a poor 
prognosis, including the highest log (BNP) concentration. BNP is also an independent 
predictor of sudden cardiac death (53), suggesting that the patients at the highest arrhythmic 
risk may in fact not be eligible for MTWA testing. These findings suggest the utility of the 
MTWA test as a means of detecting those at highest risk of sudden death is likely to be limited 
as many such patients are ineligible for the test. Patients ineligible for MTWA testing were 
older than patients eligible for testing and a higher proportion had a history of pre-admission 
heart failure. Ineligible patients also had more evidence of persisting or advanced heart failure, 
with a higher proportion having NYHA functional class III or IV symptoms and a greater 
frequency of peripheral oedema. Those ineligible for MTWA testing also had a greater 
prevalence of renal dysfunction, liver enzyme abnormalities, hyperuricaemia and lymphopenia. 
There was, however, no difference in LVEF according to MTWA eligibility and the use of HF 
medication was similar between the groups.  
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An indeterminate MTWA test was the most common result in this study (46%), with a positive 
MTWA test found in only 30% and a negative test in 24%. This is the first prospective study 
to demonstrate how common an indeterminate result is in an unselected HF population – the 
majority of which were on optimal medical therapy. This is also the first study to characterise 
the causes of indeterminate results in detail. The majority of indeterminate test results were 
due to failure to elevate the heart rate to 110bpm. This was due to chronotropic incompetence 
or physical limitations, with similar proportions of each. Other reasons for an indeterminate 
MTWA test included ectopy, noise, nonsustained alternans and a rapid rise in heart rate. Most 
cases of chronotropic incompetence were due to beta-blocker therapy. Importantly, this is the 
first study to identify two types of insufficient heart rate response. As discussed in Chapter 1, 
beta-blocker treatment was discontinued prior to MTWA testing in many previous studies in 
order to avoid indeterminate tests occurring due to heart rate limitation 
(98;106;107;113;114;119). There is evidence that acute beta-blockade can reduce the 
magnitude of MTWA, potentially converting a positive to a negative test (122). Omission of 
beta-blockers may increase the number of positive tests as well as reducing the number of 
indeterminate tests. However a primary aim of this study was to evaluate the use of MTWA as 
a predictor of the residual risk of SCD in patients on optimal therapy, including a beta-blocker 
(as beta-blockers reduce the risk of SCD). ICDs are only indicated in patients remaining at 
substantial risk of SCD, despite optimal medical therapy. It is hard to see the value of a test 
that predicted SCD in patients not optimally treated. Thus the high proportion of indeterminate 
results in my study, compared with most prior studies (Figure 6.13, page 239), may, in part, 
reflect the high rate of use of beta-blockers in our patients. This further highlights the 
potentially limited value of MTWA testing as a generally applicable tool for risk-stratification 
in HF.  
 
Beta-blocker use may not be the whole explanation for the high proportion of indeterminate 
results in our study. In one other large study in which patients with ischaemic and non-
ischaemic HF were tested off beta-blockers, the prevalence of a positive, negative and 
indeterminate result was 37%, 22% and 41% (119), respectively, very similar to the 
distribution observed in my study. This suggests that cessation of beta-blockers may not be an 
effective means of limiting the number of indeterminate tests in HF patients. This is especially 
pertinent given that there is also a potential risk to HF patients in the withdrawal of beta-
blockers. In addition, the value of a test that is positive off-treatment, but negative or 
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indeterminate on-treatment, in targeting ICD therapy is unclear; a test that remains positive on 
optimal therapy should be more useful in clinical decision-making.  
 
The high proportion of indeterminate tests in our study may also reflect the patient population 
studied and not just discontinuation of beta-blocker therapy, as already discussed. My study 
was carried out in an unselected cohort of patients who had recently been hospitalised with 
decompensated HF. Many of these patients were elderly with extensive medical comorbidities 
and physical frailty. The majority of other MTWA studies have been cohorts of younger 
patients with less comorbidity (Table 1-4, page 54).  
 
The functional capacity of the cohort was poor. There was no significant difference in the 
duration of exercise or energy expended during exercise (measured in METS) according to 
MTWA result. The majority of patients discontinued the MTWA test because of physical 
limitations, with only 42% achieving the target heart rate of 110bpm required for completion 
of the MTWA test. This is perhaps unsurprising as many of the patients were elderly with 
multiple comorbidities. However, this does question the general usefulness of this test in ‘real-
life’ HF patients.  
 
When the patients were analysed according to their MTWA result (positive, negative or 
indeterminate), there were 27 clinical characteristics that differed (p<0.05) between the groups 
of patients. A large amount of clinical data was included in these analyses and the limitations 
of multiple testing are recognised. However, 12 of the 27 characteristics that differed between 
the three groups had p values <0.01. Yet when analysis was performed according to the 
contemporarily accepted classification of non-negative and negative (85), only 12 clinical 
characteristics differed significantly between the two groups (p<0.05), with 8 having p values 
<0.01. These results demonstrate that patients with an indeterminate test result are different to 
those with a positive test. Patients with an indeterminate result were older and more likely to 
have a history of HF, diabetes, AF, anaemia and renal dysfunction (as well as a higher BNP); 
characteristics known to be predictive of poor outcome. These findings may explain the 
observation in other studies that patients with an indeterminate test result had a higher all-
cause mortality rate than those with a positive result (85;101;107;109;123). My novel findings 
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about patients with non-negative MTWA results highlight how heterogeneous this group is, in 
terms of clinical characteristics, and argues against this binary classification of MTWA test 
results. Moreover, pair-wise analysis of MTWA results (negative versus positive; 
indeterminate versus positive; indeterminate versus negative) revealed notable differences in 
clinical characteristics. In particular, this analysis exposed major difference between the 
indeterminate group and the other two groups of patients (and, remarkably, fewer differences 
between those with positive and negative tests). There were 22 clinical characteristics that 
differed (p<0.05) between the indeterminate and positive groups, 14 with p values <0.01. 
There were almost as many differences between the indeterminate and negative groups, with 
11 differences having a p value <0.01. Interestingly, there were only 3 clinical characteristics 
that differed significantly between the negative and positive groups and none of these had a p 
value <0.01. Patients with indeterminate MTWA results are a distinct group of patients with 
more abnormal clinical characteristics than those with positive or negative results. This novel 
finding suggests that patients should not be classified as non-negative and negative. I propose 
that MTWA results should only be considered as three separate groups: positive, negative and 
indeterminate. 
 
The overall mortality rate by two years of follow-up for the 1003 enrolled patients was 33%, 
comparable with recently published mortality rates for Scottish patients hospitalised for HF 
(147). The overall mortality for the 648 patients in the post-discharge cohort was also high 
with almost one-quarter of patients deceased by two years follow-up.  
 
There were proportionately more deaths amongst the patients ineligible for MTWA testing 
than those eligible. Thus, being ineligible for MTWA testing was a better predictor of an 
adverse prognosis than the MTWA result itself. Many of the reasons for being ineligible for 
MTWA testing (AF, pacemakers and medical comorbidities preventing exercise) are also risk 
factors for adverse outcomes in HF. This is the first study to describe outcomes in patients 
ineligible for MTWA testing and highlights the adverse mortality rates of these patients. 
 
There was no significant difference in mortality rates between patients with HF-REF and HF-
PEF in this study. This finding is consistent with some recent studies reporting no significant 
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difference in survival between the two groups of patients (19;23). However the number of 
patients in this study is relatively small, with even fewer deaths and both the Kaplan-Meier 
curves and two year unadjusted survival figures suggest that differences in survival between 
those with HF-REF and HF-PEF may emerge with longer term follow-up. 
 
MTWA did not predict any of the study’s prespecified outcomes. The failure to predict SCD 
in this study can be partly explained by the small numbers of patients with this outcome. 
However, it was expected that an abnormal MTWA result may predict all-cause mortality 
(106;107;109;111;111;112;118). Patients with a positive result had proportionately fewest 
events overall with patients with indeterminate and negative results having proportionately 
similar mortality rates, although there was no statistically significant difference between the 
three groups. This result was surprising. Indeed, the results from Chapter 7 had demonstrated 
that patients with positive and negative results were more similar, in terms of clinical 
characteristics, than those with indeterminate results. However, this did not translate 
prognostically. Also patients with indeterminate results because physical limitations prevented 
elevation of their heart rate had proportionately more events than patients with other MTWA 
results, although this difference was not statistically significant. MTWA was also analysed in 
the contemporary way of non-negative (positive and indeterminate) and negative, but this did 
not alter the conclusions. Moreover, the very different mortality for those patients with 
positive and indeterminate results challenges the use of this ‘non-negative’ classification. 
Indeed it is interesting to review the original study that combined positive and indeterminate 
results into a single ‘non-negative’ category. Although the authors of that small study (n=177) 
of patients with ischaemic LVSD concluded that the mortality rates for patients with positive 
and indeterminate tests were similar, the two year actuarial mortality rates were 14.5% and 
20.1%, respectively, a trend similar to that apparent in my study. Many studies have since only 
reported ‘non-negative’ mortality rates, preventing, I suggest, a proper understanding of the 
different risks conferred by positive and indeterminate tests. My findings strongly suggest this 
approach is incorrect. 
 
The mortality rate (expressed as an approximate event rate per 100 patient-years of follow-up) 
was higher in my study than in prior LVSD and HF MTWA studies (Table 8-11, page 309). 
This finding was expected and likely reflects the nature of my patient cohort, consisting of 
 320 
unselected and recently discharged subjects, including more elderly individuals and patients 
with comorbidity, compared with prior studies. Unexpectedly, however, I found a higher 
mortality rate among patients with a negative MTWA result, compared with the mortality rate 
in the overall cohort. Of the studies that reported mortality rates according to the MTWA 
result, all described a lower mortality rate in patients with a negative MTWA result, compared 
with the rate in the overall cohort or in patients with a ‘non-negative’ MTWA result. By 
contrast, I found the exact opposite; the mortality rate was 21% for patients with a negative 
MTWA result compared with the overall rate of 17% in all patients undergoing MTWA 
testing, although the differences between the groups were not statistically significant. The 
exact reason for this unexpected finding is unclear. It may reflect the different population 
enrolled, compared with previous studies. Perhaps the MTWA test does not identify those at 
greatest risk when used in unselected cohorts with more elderly patients and patients with 
more comorbidity. The lower rate of beta-blocker prescribing amongst patients with negative 
MTWA results, compared to patients with indeterminate results, may be a contributory factor 
to the unexpected higher mortality amongst patients with negative results. Patients with 
indeterminate MTWA results were more than three times more likely to be prescribed a beta-
blocker than those with negative results (OR 3.5, p<0.0001). However this does not explain 
the higher mortality of patients with negative MTWA results compared to those with positive 
results. Although beta-blocker prescribing was less common amongst those with a negative 
MTWA result, compared to those with a positive result, this difference was not significant 
(OR 0.79, p=0.43). Higher beta-blocker prescribing amongst patients with an indeterminate 
result may have been expected to confer a prognostic advantage. The high mortality of the 
patients with indeterminate results is likely multifactorial and explained by the multiple risk 
factors for poor prognosis present in this group, including advancing age, diabetes, anaemia 
and renal dysfunction. 
  
There is wide variation in the proportion of all deaths considered sudden in the LVSD and HF 
MTWA studies, although only one prior study reported a proportion as low as in my study (I 
discuss this exception, the MASTER study (104), in more detail below). The low proportion 
of SCD in my study is likely accounted for by the limitations in the definition I had to use due 
to the nature of my dataset (section 2.6.3, page 91) and this really precludes further 
comparison with other studies. However, as noted above, among the other studies, the 
MASTER study (104) described a notably lower proportion of SCD. All patients in the 
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MASTER study fulfilled MADIT-II criteria and underwent ICD implantation following 
MTWA testing. During the follow-up period 9% of negative patients and 12% of non-negative 
patients received appropriate ICD therapy, some of which may have resulted in SCD if an ICD 
had not been implanted.  Furthermore, although the proportions of events for positive and 
indeterminate patients are not reported separately in this study, the proportion of indeterminate 
results is low in this study (12%). One reason for this may be the use of pharmacological 
means of stress or pacing for patients who were unable to exercise. The low rate of 
indeterminate results together with a low proportion of SCD highlights a possible relationship 
between an indeterminate result and risk of SCD. Few studies have reported the numbers of 
SCD, thus it is difficult to extrapolate a potential link between indeterminate results and SCD. 
I could not explore a potential relationship between indeterminate results and SCD due to the 
limitations acknowledged above. However, in the largest study to date in patients with LVSD, 
patients with an indeterminate result had the highest proportion of SCD and SCD accounted 
for 42% of all-cause mortality in that study (107). Another possible explanation for the 
MASTER study (104) having a lower proportion of SCD may be the high rate of beta-blocker 
prescribing (87%). After excluding the MASTER study and my study, there was still a wide 
range in the proportion of all deaths that were sudden in the other LVSD and HF studies (21-
58%), likely reflective of the inherent difficulties in determining SCD.  
 
MTWA had no incremental prognostic value when added to a multivariable model containing 
the strongest predictors of mortality in my study. The independent predictors of all-cause 
mortality following stepwise multivariable modelling were; lower BMI, NYHA III/IV, 
previous MI, BNP and troponin. The small number of independent predictors may be 
explained by the relatively small number of events that occurred during the follow-up period 
for those who underwent MTWA testing. 
 
9.2 Strengths  
 
The major strength of this study is the unselected nature of the patients studied and the 
consequent high mortality rate compared with other studies (Table 8-11, page 298). This study 
represented a ‘real-life’ cohort of patients, prospectively studied following hospitalisation with 
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decompensated HF. The unselected approach to enrolment meant that patients were recruited 
irrespective of age, gender, LV dysfunction and comorbidities. All patients had a validated 
diagnosis of HF and all fulfilled ESC criteria for HF. The nature of this cohort allows 
extrapolation of these results to ‘real-life’ HF patients and not the minority who may fulfil 
clinical trial inclusion criteria. Previous MTWA clinical studies have enrolled highly selective 
cohorts.  
 
The second major strength is the extensive phenotyping of all enrolled patients. The patients 
enrolled in this cohort are similar in many ways to those included in large epidemiological 
studies of HF. Moreover, this extensive phenotyping has allowed multiple detailed 
comparisons of the clinical characteristics of the patients. Firstly, those completing the study 
visit were compared to those who failed to attend due to death, deteriorating health or 
withdrawal from the study. The patients attending the study visit were then stratified according 
to eligibility for MTWA testing and the clinical characteristics of the two groups compared. 
Finally the characteristics were compared according to MTWA result, identifying the distinct 
clinical characteristics relating to positive, negative and indeterminate MTWA results.   
 
All enrolled patients consented to be “flagged” with the Information Services Division of the 
Scottish Health Service. This allowed accurate mortality follow-up data to be obtained by 
linking the study database to information on deaths, held by the General Register’s Office for 
Scotland. Another strength of this study was the creation of an electronic database, held in the 
Robertson Centre for Biostatistics at the University of Glasgow. Data were manually entered 
into the electronic database and verified by two independent database managers. All data were 
subject to manual and prespecified electronic data validation checks. This robust system 
ensured quality control of the data processed.  
 
9.3 Limitations  
 
Recruitment at the Royal and Western Infirmaries was not completely consecutive because of 
staff holidays. Clinical research nurses recruited patients from the Royal Alexandra Hospital 
but staff shortages prevented daily recruitment from this site.  
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Many enrolled patients were unable to return for MTWA testing one month after discharge 
from hospital. This, however, is an inevitable consequence of both the effects of HF and 
participation in a clinical study. Indeed the rate of follow-up was probably greater than in 
‘real-life’ due to the encouragement I gave patients to attend and the fact that transport was 
provided for them. MTWA testing during hospitalisation for decompensated HF would have 
been impractical and possibly dangerous.  
 
The large number of inter-group tests for differences in the clinical characteristics of the 
various groups may have led to chance findings where the p value is not <0.01.  
 
There were limitations in defining events and outcomes. The mortality data provided by ISD 
are restricted to information documented on the death certificates. Deaths were not adjudicated 
and medical records and information from next of kin were not available to improve the 
accuracy of the attributed cause of death. The definition of SCD used in this study may have 
been pragmatic but is suboptimal nonetheless. Deaths occurring outside hospital and certified 
as due to acute MI were included as SCD but may have been deaths due to MI. This approach 
was taken because the majority of SCD occurs outside hospital and is commonly certified as 
acute MI and verified acute MI is a relatively uncommon event in patients with HF 
(121;157;158). Unfortunately there was no way of distinguishing between the two causes with 
the information available. Classifying SCD using only death certificate information is 
extremely limited and, one could argue, futile. This secondary analysis was included because 
the biomarker of interest was MTWA.  
 
Information regarding appropriate ICD discharges for ventricular tachyarrhythmias was not 
available but probably would not have altered the results given the low rate of implantation of 
these devices in the cohort I recruited. 
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9.4 Future research analyses 
 
All of the outcome analyses will be repeated with a minimum follow-up of 1 year for every 
patient. Extending follow-up will help me determine whether my conclusions about the 
usefulness of MTWA testing will alter upon reanalysis using a larger number of deaths. I think 
this is unlikely. Instead, I think alternative and more effective investigations are warranted to 
identify patients with HF at risk of potentially lethal ventricular arrhythmias.  
 
The multivariable models described in chapter 8 were only created in the 330 patients who 
underwent MTWA testing, as the prognostic value of MTWA was the focus of this study. My 
next analysis will be to evaluate these models in all 648 patients in the post-discharge cohort 
to determine whether or not the same variables are independent predictors of mortality, 
regardless of eligibility for MTWA testing. Identification of the independent predictors of 
mortality in the entire post-discharge cohort may help create a simple way of risk stratifying 
patients recently hospitalised with decompensated HF. Ideally I would then externally validate 
this model in an independent cohort of patients recently hospitalised with decompensated HF. 
 
My future research plans also include using the data from the 1003 patients enrolled in this 
study to create a simple, prognostic model to help risk stratify in-patients hospitalised with 
decompensated HF. Clearly, the use of individual risk markers in isolation has limited 
prognostic utility, as the absence or presence of a single risk marker does not necessarily 
convey good or bad prognosis. Multiple individual risk markers may be present in any given 
patient and combining these to form an accurate, individualised prognosis is the current 
challenge. Established prognostic models exist and are used in clinical practice for acute 
coronary syndromes, such as the Global Registry of Acute Coronary Events (GRACE) (159) 
and the Thrombolysis In Myocardial infarction (TIMI) risk scoring systems (160). These are 
practical, simple to use in the clinical setting and have also been validated to prospectively 
demonstrate that they accurately predict mortality and the risk of recurrent ischaemic events. 
An equivalent risk stratification tool is not currently used in HF clinical practice. Combining 
the most powerful markers of risk in the form of a prognostic model may be a strategy to 
improve prognostication in HF.  Prognostic models predicting mortality risk and risk of 
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rehospitalisation have been developed in patients with acute decompensated HF and chronic 
HF, but these have largely remained research tools (76;126;158;161-165). These models have 
some common shortfalls. Most have been derived from clinical trial populations, which are 
necessarily selective and limit extrapolation to ‘real-life’ HF patients. Some have used 
complex formulae to calculate an individual’s risk, reducing the likelihood of use in clinical 
practice. Only two models have included patients with HF-PEF (76;126); one was derived 
from a clinical trial population (126), whilst the other has not yet been externally validated 
(76). Only two models have incorporated BNP into the risk score (76;158). Only one has 
included cardiac troponin and this model, derived from patients with chronic HF, has not been 
externally validated (76). The Heart Failure Survival Score (HFSS) has been used in the 
management of advanced heart failure, particularly for assisting in the selection of appropriate 
candidates for cardiac transplantation (166). The shortcomings of the HFSS are, however, 
increasingly recognised (167). Furthermore NT-pro-BNP alone has been shown to be a 
stronger predictor of death than the HFSS (168). 
 
The ideal prognostic model for assessing prognosis in HF would comprise simple, readily 
available variables and involve straightforward calculations. I plan to build a simple 
prognostic risk scoring tool using the independent predictors identified in this study. This 
model will be validated internally in the original 1003 enrolled patients. If this is a powerful 
tool for identifying those at highest risk in my cohort the next step would be to externally 
validate the model in an independent cohort of patients with decompensated HF.  
 
9.5 Conclusion 
 
Of the 1003 patients enrolled into this study during hospitalisation with decompensated HF, 
648 completed the study visit approximately 4-6 weeks following discharge. Only 330 patients 
were eligible for MTWA testing and almost half of all MTWA tests were indeterminate. Many 
patients were unable to complete the test due to chronotropic incompetence, secondary to beta-
blocker therapy or physical limitations. These results show that MTWA treadmill testing is not 
widely applicable to an unselected real-life HF population.  
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MTWA had no prognostic value in our cohort of unselected patients with HF. There was no 
evidence to suggest that this test is of benefit in the risk stratification of ‘real-life’ patients 
with HF. The independent predictors of mortality in this study included BNP and cardiac 
troponin, a novel biomarker in HF. Both are simple, cheap biochemical tests to perform. The 
other three independent predictors of mortality were clinical variables that are readily 
available (lower BMI, NYHA class III/IV and previous myocardial infarction). This 
straightforward model containing only five simple variables identified the patients at most risk 
in our study. At present MTWA cannot be endorsed as a tool for risk stratification for patients 
with HF. 
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Appendix I: Screening Sheet 
 
DATE OF SCREENING 
       /  /  
Hospital 
   GRI   WIG  RAH  
Ward  
Name  
Hospital number  
Date of birth 
        /  /  
 
SCREENING CRITERIA Yes No 
Admitted with symptoms of HF   
Admitted with signs of HF   
Radiological evidence of pulmonary oedema   
Response to IV diuretics   
 
CHECKLIST Yes No 
Stage 1 consent obtained   
BNP sent   
BNP result pg/ml  
Recruited into study (if no, complete exclusion 
criteria 
  
 
EXCLUSION CRITERIA Yes No 
BNP <100pg/ml   
Cognitive impairment   
Serious concurrent systemic disease   
ACS complicated by pulmonary oedema   
Geographical or social factors preventing 
participation 
  
Refusal to participate   
Already enrolled in study   
Other (specify)   
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Appendix II 
 
NHS Greater Glasgow & Clyde Health Board 
 
Glasgow Royal Infirmary and  
Western Infirmary Glasgow  
Cardiology Departments 
 
Enquiries to Dr Colette Jackson  
 
Tel:  0141 330 2064 
Fax: 0141 330 6955 
 
 
PATIENT INFORMATION SHEET- STAGE 1 
 
You are being invited to take part in a research study involving a gentle walking test (known 
as microvolt T-wave alternans).  Before you decide whether or not to take part it is important 
you understand why the research is being done and what it involves. Thank you for reading 
this. 
 
The first part of this study involves having a blood test done and agreeing to the doctors and 
nurses involved in the study looking at your medical notes and obtaining information about 
your future progress. This form explains why we want to do this and how it happens.  
 
When you read this you will be in hospital and may have been admitted with shortness of 
breath or swollen legs. These are symptoms which sometimes indicate a condition called heart 
failure. Heart failure is a condition where the heart is not pumping blood around the body as 
well as it should be. As a result fluid often accumulates in the lungs or the legs.  Possible 
causes include previous heart attacks, high blood pressure or damage to the heart valves. 
 
Patients with heart failure are at risk of dying earlier than those without heart failure. This risk 
can be reduced in some patients by using a special pacemaker known as a cardiac defibrillator.  
Doctors are currently trying to work out which patients with heart failure should have these 
pacemakers implanted.  Microvolt T-wave alternans testing is a new investigation that may 
help identify which patients might benefit from this pacemaker.  Our study aims to provide 
more information about this test by studying a large group of patients, and looking at their 
progress over the following years. 
 
The way that we follow a patient’s progress for a study like this is by entering their details into 
a national database, which uses hospital notes to record when you come into hospital. This 
database is run by the Scottish Health Service and is confidential. Any information gathered is 
only available to the doctors running this study. It does not require any participation from you, 
and no one will contact you or your family as part of this process. If you agree to take part in 
the study at this stage, we will enter your details into this database. 
 
If you agree to take part, you will have a blood test for B-type natriuretic peptide (BNP), this 
tests how well the heart is pumping.  Approximately 10 mls (two teaspoons) of blood will be 
taken. Having blood taken is uncomfortable and some people may feel faint. There is a small 
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risk of bleeding, bruising or infection at the puncture site following the blood test. This blood 
test is exactly the same as other blood tests that you will have had taken before.   
 
If the blood test is positive then either a doctor or nurse that is involved in this study will visit 
you before you are discharged from hospital to discuss whether or not you would like to take 
part in stage 2 of the research study. 
 
 
Thank you for taking the time to read this patient information leaflet. 
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Appendix III 
NHS Greater Glasgow & Clyde Health Board 
 
Glasgow Royal Infirmary and  
Western Infirmary Glasgow  
Cardiology Departments 
 
Enquiries to Dr Colette Jackson  
 
Tel:  0141 330 2064 
Fax: 0141 330 6955 
  
 
 
PATIENT INFORMATION SHEET- STAGE 2 
 
 
1.  Study title 
 
Microvolt T-Wave Alternans in Chronic Heart Failure 
 
A study investigating a walking test in patients with chronic heart failure:  Microvolt T-Wave 
Alternans (MTWA) test. 
 
2.  Invitation to take part 
 
You are being invited to take part in a research study involving a gentle walking test.  This is 
called the Microvolt T-Wave Alternans test.  Before you decide whether or not to take part it 
is important you understand why the research is being done and what it involves. Please read 
the following information carefully and discuss it with others if you wish. Please ask us if 
anything is not clear or you would like more information. Take time to decide whether or not 
you wish to take part. You are not obliged to take part.  If you decide to participate in the 
study you will be given a copy of this information sheet and a signed consent form to keep. 
Thank you for reading this. 
 
3.  What is the purpose of the study? 
 
Heart failure is a condition where the heart is not pumping blood around the body as well as it 
should be. As a result fluid often accumulates in the lungs or the legs.  Possible causes include 
previous heart attacks, high blood pressure or damage to the heart valves. 
 
Patients with heart failure are at risk of dying earlier than those without heart failure.  One of 
the most common causes of dying is a rapid speeding of the heart rate.  These problems with 
heart rhythm are known as arrhythmias.  These arrhythmias can be controlled in some patients 
by placing a special pacemaker known as a cardiac defibrillator under the skin below the 
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collarbone.  Doctors are currently trying to work out which patients with heart failure should 
have these pacemakers implanted.  Microvolt T-wave alternans testing is a new investigation 
that may help identify patients that are at risk of developing arrhythmias in the future.  Our 
investigation aims to provide more information about this test by studying a large group of 
patients.   
 
The study will involve a total of around 600 patients and is expected to last 3 years. 
 
4.  Why have I been chosen? 
 
You are being invited to consider taking part in this study as you have been admitted to 
hospital with heart failure.  
 
 
5.  Do I have to take part? 
 
Taking part in this study is entirely voluntary and your decision. If you take part you will 
receive this information sheet to keep and be asked to sign a consent form. If you take part you 
are free to withdraw at any time and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
 
6.  What will happen to me if I take part? 
 
When you read this you will be in hospital and may have been admitted with shortness of 
breath or swollen legs.  You will have been asked in stage 1 of the study whether or not you 
would be willing to have a special blood test.  If this blood test shows your heart is not 
pumping as well as it should be then you will be invited to attend the new British Heart 
Foundation Glasgow Cardiovascular Research Centre (next to Western Infirmary Glasgow) 
once approximately four weeks after you get out of hospital. This visit is in addition to your 
normal hospital and General Practitioner appointments. Your treatment will continue to be 
supervised by your own hospital doctors and General Practitioner. We will pay your travelling 
expenses for the visit. 
 
Your visit to the research centre will last approximately 90 minutes. 
 
This visit will involve : 
 
• Medical history - speaking to a doctor about your symptoms and previous illnesses 
 
• Physical examination - you will be examined and your height and weight will be 
measured. 
 
• Echocardiogram – this is an ultrasound scan of the heart, it is sometimes just called 
an ‘echo’.  For this test you will be asked to lie on a bed and a probe will be placed 
gently on to your chest to allow pictures of the heart to be taken. 
 
• Blood test - a blood sample will be taken from a vein in your arm. This blood test is 
exactly the same as other blood tests that you will have had taken before.  
Approximately 20 mls (4 teaspoons) of blood will be taken. Having blood taken is 
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uncomfortable and some people may feel faint. There is a small risk of bleeding, 
bruising or infection at the puncture site following the blood test.  We are checking the 
blood for a substance called b-type natriuretic peptide (BNP), which tells us how well 
the heart is pumping.  We will also use this blood sample to check your kidneys and 
liver and your blood cell counts. 
 
• Electrocardiogram (ECG) – this is a recording of the electrical activity of the heart.  
You will probably have had this test before.  To take the recording, you will be asked 
to lie on a bed while stickers are placed on to their chest wall.  This test does not 
involve discomfort. 
 
• Microvolt T-Wave Alternans test (MTWA) – this involves walking at a slow pace 
on a treadmill for up to 12 minutes while a computer monitors the heart rhythm.  This 
test will not be carried out if you have an irregular pulse or if you already have a type 
of pacemaker.  If you cannot walk well enough we will not ask you to perform this test.   
 
7.  What do I have to do? 
 
You will be asked to attend for one visit to the research centre as outlined above. 
Taking part in the study should not interfere with your normal lifestyle. You will continue to 
take all your regular medications as directed by your doctors. 
 
8.  What is the investigation that is being studied/tested? 
 
The investigation being tested is called Microvolt T-wave Alternans (MTWA).   This is a test 
that looks at changes in the heart rhythm whilst you raise your heart rate by walking on a 
treadmill.  This test is new and not routinely used in the United Kingdom.  It is currently being 
used in many countries including the United States of America as a test to decide whether or 
not patients should have special pacemakers implanted. 
 
9.  What are the alternatives for investigation? 
 
At present there is no alternative test for assessing who should and who should not have these 
special pacemakers put in.   
 
10. What are the possible disadvantages and risks of taking part? 
 
Having your blood taken is occasionally uncomfortable and some people may feel faint.  
There is a small risk of bleeding, bruising or infection at the puncture site following the blood 
test.    
 
Exercise testing in general carries an extremely small risk of life-threatening complications 
(about 1 in 5000). The risks will be even lower for MTWA testing, since only gentle exercise 
is required for this test. Many patients with heart failure have had these walking tests with no 
serious problems.  An experienced doctor and nurse will be present to ensure that any possible 
problem is dealt with expertly. 
 
11. What are the possible benefits of taking part? 
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You may not benefit directly from taking part in the study; however the information we get 
from this study may help us to give better treatment to patients with heart failure in the future. 
 
If the research doctor discovers during the study that you have another medical condition of 
which you were previously unaware you will be referred to the appropriate doctor for 
treatment of this condition. 
 
12. What if new information becomes available? 
 
If any new information becomes available that is relevant to your care we will inform you. 
 
13. What happens when the research study stops? 
 
There will be no further participation required. 
 
14. What if something goes wrong? 
 
There are no special compensation arrangements if taking part in this research project harms 
you. If you are harmed due to someone’s negligence, then you may have grounds for legal 
action but you may have to pay for it. The normal National Health Service complaints 
mechanisms are available if you wish to complain or have any concerns. 
 
15. Will my taking part in this study be kept confidential? 
 
If you consent to take part in the study, the research doctor may inspect your medical records 
for purposes of analysing the results. Only government regulatory authorities and the research 
doctor will have access to your medical notes.  Your General Practitioner will be informed of 
your participation in this study. 
 
All information collected about you during the course of the research will be kept strictly 
confidential. Any information about you, which leaves the hospital, will have your name and 
address removed so that you cannot be recognised from it. Reports or publications resulting 
from the study will not contain any personal details.  
 
16. What will happen to the results of the research study? 
 
The results of the research study will be stored on a computer database and are likely to be 
published in cardiology journals. Reports or publications resulting from the study will not 
contain any personal details. The research doctor will provide a copy of the results on request. 
 
17. Who is organising and funding the research? 
 
We are seeking funding from the British Heart Foundation.  Glasgow University and the 
Departments of Cardiology in Glasgow Royal Infirmary and the Western Infirmary of 
Glasgow are performing the study. 
 
18. Who has reviewed the study? 
 
 334 
This study has been reviewed and approved by West Glasgow Research Ethics Committee, 
which is an independent panel. 
 
19. Contact for further information 
 
You are encouraged to ask questions at any time during the study. 
 
Please contact :- 
 
Study Doctor :   Dr Colette E Jackson 0141 330 2064 
 
Supervisor :   Prof Stuart M Cobbe 0141 211 4722 
 
Independent Doctor :  Dr Adrian JB Brady 0141 211 4727 
 
   
 
 
Thank you for taking the time to read this patient information leaflet. 
 
Please let Dr Jackson know if you are admitted to hospital for any reason. 
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Appendix IV 
 
CONSENT FORM – Stage 1 
 
Title of Project: Microvolt T-Wave Alternans in Chronic Heart Failure 
Name of researcher: Dr C. Jackson 
 
1. I agree to a blood sampling to assess how well my heart is pumping.    □ 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.  □ 
 
3. I understand that my medical records may be looked at by the research doctor or medical 
staff coordinating the study and this may also involve linkage to a national database. I give 
permission for these individuals to have access to my records.    □ 
 
Name of patient: 
Signature: 
Date: 
 
Name of person taking consent: 
Signature: 
Date: 
 
1 copy for patient; 1 copy for researcher; 1 copy for hospital notes 
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CONSENT FORM – Stage 2 
 
Title of Project: Microvolt T-Wave Alternans in Chronic Heart Failure 
Name of researcher: Dr C. Jackson 
 
1. I confirm that I have read and understand the information sheet dated 04/01/07 (version 3) 
for the above study and have had the opportunity to ask questions.    □ 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.  □ 
 
3. I agree to take part in the above study.       □ 
 
 
Name of patient: 
Signature: 
Date: 
 
Name of person taking consent: 
Signature: 
Date: 
 
1 copy for patient; 1 copy for researcher; 1 copy for hospital notes 
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Appendix V: Case notes sheet 
Cardiology Research Study: Microvolt T-Wave Alternans 
(MTWA) and Chronic Heart Failure 
    Patient ID     
 
 
 
 
 
This patient has kindly agreed to participate in a cardiology research 
study. The first stage of this study involves a blood test for B-type 
natriuretic peptide (BNP). 
 
A blood sample for BNP was sent on:…………………………….. 
 
If the BNP is positive (>100pg/ml) then either a research Doctor or 
Nurse will visit the following day to explain the results and discuss 
their involvement in the second stage of the study. If the BNP test is 
negative then there will be no further contact with the patient but their 
BNP result will be available via the hospital biochemistry database, as 
for routine samples. 
 
Further information : Dr Colette Jackson 0141 330 2064 
Project supervision : Prof  S Cobbe, Prof J McMurray, Dr M Petrie 
Name 
 
DOB 
 
Hospital number 
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Appendix VI: Appointment card 
 
 
 
MTWA Study in Patients  
with Heart Failure  
 
BHF Glasgow Cardiovascular Research Centre 
126 University Place 
University of Glasgow 
G12 8TA 
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Dear          
Thank you for agreeing to take part in the Heart Failure study. 
An appointment has been made for you at the BHF Glasgow Cardiovascular Research Centre 
on 
              …………………. at ……………….  
Transport will be organised by us. If you are arriving with your own transport please see the 
map below for directions. When you arrive please report to reception and someone will take 
you through to the clinic area. The visit should last no more than 90 minutes. Please bring a 
list of your medications and comfortable shoes. For appointment queries or to change the date 
or time please contact the research team on 0141 330 2064 
 
Kind regards 
Dr Colette Jackson 
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Appendix VII 
 
 
Letter to Patient’s GP and Consultant 
 
 
 
 
 
Dear Dr. 
 
Re : ________________________________________________________________ 
 
 
Your patient has been admitted to Glasgow Royal Infirmary / Western Infirmary / Royal 
Alexandra Hospital with heart failure.  This has been confirmed by B-type natriuretic peptide 
(BNP) testing.  
 
I am currently carrying out a research project in patients admitted to hospital with heart failure.  
Your patient has kindly agreed to take part in this study. 
 
This will involve one visit to the British Heart Foundation Glasgow Cardiovascular Research 
Centre, adjacent to the Western Infirmary, approximately 4 weeks after discharge from 
hospital.  Their participation will involve blood sampling, echocardiography and a 
submaximal exercise treadmill test called microvolt t-wave alternans testing. The exercise test 
only involves gentle walking to raise the heart rate to 110bpm and they will not participate in 
this if they have AF, ventricular pacemaker or are physically unable to. 
 
Yours sincerely, 
 
 
 
 
Dr C Jackson 
Cardiology Research Fellow 
Tel. 0141 330 2064 
 
Project Supervision : Prof S Cobbe, Prof J McMurray and Dr M Petrie 
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Appendix VIII: Hospital visit case record form 
 
Section 1 : Patient Identification & Contact Information 
Study Patient ID 
 --  
Hospital GRI   WIG  RAH  
Date of recruitment 
 /  /  
 
Name  
Hospital Number 
 
CHI number 
 
Date of birth (dd/mm/yy) 
 /  /  
 Address 
 
Postcode  
Home phone number  
Mobile phone number  
Work phone number  
Holiday home phone number  
Next of kin (or friend/carer)  
Next of kin phone number  
 Next of kin (or friend/carer) 
address 
 
GP name  
 GP address 
 
GP number  
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Section 2 : Demographics 
 
Study number 
 --  
Hospital GRI   WIG  RAH  
Gender Male  Female  
Date of birth (dd/mm/yy) 
 /  /  
White                     
Black                       
South Asian           
Arab/Middle East   
Oriental                   
Malay                      
Race 
Other                     ______________           
(specify) 
Date of Admission 
 /  /  
Date of recruitment 
 /  /  
Date of Discharge  OR death 
 /  /  
Symptoms YES NO 
Orthopnoea   
Paroxysmal nocturnal dyspnoea   
Ankle swelling   
Palpitations   
NYHA class pre-admission  
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Section 3 : Medical History 
 
 
YES NO 
Myocardial Infarction 
  
History of Angina 
      If yes, current 
      If current, stable 
 
 
 
 
 
 
Coronary Angiography 
             If yes, year _________________ 
  
Percutaneous Coronary Intervention (PCI) 
  
Coronary Artery Bypass Graft (CABG) 
  
Treated Hypertension 
  
Cerebrovascular disease (CVA/TIA) 
  
Atrial Fibrillation 
      If yes, past 
                 paroxysmal 
                 persistent (potential restoration SR) 
                 permanent 
 
 
 
 
 
 
 
 
 
 
Chronic Heart Failure 
   If yes, previous admission with decompensated heart failure 
   Diagnosis > 2 years ago 
   Healthcare professionals involved____________________ 
 
 
 
 
 
 
 
Valvular Heart Disease 
 AS 
 AR 
 MS 
 MR 
Specify severity : Mild / Moderate / Severe  
 
 
 
 
 
 
 
 
---------- 
---------- 
---------- 
---------- 
Valve replacement   
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 YES NO 
Pacemaker 
 Conventional 
 CRT-P 
 CRT-D 
 
 
 
 
 
 
Primary Prevention ICD   
Syncope (brief loss of consciousness) 
    If yes, how many episodes  
  
Prior arrhythmia     
If yes, 
 SVT 
 Ventricular tachycardia 
1. Sustained 
2. Nonsustained 
 SSS 
 AV block 
1. 1st degree 
2. 2nd degree 
3. 3rd degree  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Mellitus 
 Diet Controlled 
 Oral Hypoglycaemic 
 Insulin 
 
 
 
 
 
 
Chronic Renal Failure   
Involuntary weight loss (>5% in 6 months) 
  
Depression 
      If yes, current 
 
 
 
 
Cancer 
 Current (specify site on dotted line) 
 Previous (specify site) 
 
 
 
 
--------- 
--------- 
COPD 
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 YES NO 
Peripheral Vascular Disease   
Asthma   
Neuropathy 
  
Hypothyroidism 
  
Hyperthyroidism 
  
Rheumatoid Arthritis 
  
Osteoarthritis 
  
Anaemia 
  
Urinary incontinence 
  
Smoker 
 If yes, current 
 Ex (<12 months) 
 Ex (>12 months) 
 
 
 
 
 
 
Alcohol 
 If yes XS 
 Previous XS 
 
 
 
 
Family history heart disease 
 If yes, coronary heart disease 
 Cardiomyopathy 
 Other____________________ (specify) 
 
 
 
 
 
 
Any other significant medical history (specify) 
1. 
2. 
3. 
4. 
5. 
6. 
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Section 4 : Medications Pre-Admission 
Cardiovascular Medication YES NO 
Diuretics (if yes specify type & total daily dose) 
 
 Furosemide 
 Other loop 
 Spironolactone 
 Other K+ sparing 
 Thiazide 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
ACE-Inhibitor (if yes specify type & total daily dose) 
 
 Captopril 
 Enalapril 
 Fosinopril 
 Lisinopril 
 Perindopril 
 Quinapril 
 Ramipril 
 Trandolapril 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Beta-blocker (if yes specify type & total daily dose) 
 
 Atenolol 
 Bisoprolol 
 Carvedilol 
 Metoprolol 
 Nebivolol 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Aldosterone Blocker (if yes specify type & daily dose) 
 
 Spironolactone 
 Eplerenone 
 
 
 
 
 
 
_______mg 
_______mg 
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YES 
 
NO 
 
ARB (if yes specify type & daily dose) 
 
 Candesartan 
 Irebesartan 
 Losartan 
 Olmesartan 
 Telmisartan 
 Valsartan 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Digoxin (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Aspirin (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Clopidogrel (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Warfarin 
 
 
 
 
Nicorandil (if yes, specify total daily dose)  
 
 
 
______mg 
Calcium channel-blocker (if yes specify type & total 
daily dose) 
 
 Amlodipine 
 Diltiazem 
 Nifedipine 
 Verapamil 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Anti-arrhythmic (if yes specify type & total daily dose) 
 
 Amiodarone 
 Other (name)__________________ 
 
 
 
 
 
 
_______mg 
_______mg 
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Non-Cardiovascular Medication 
 
Bronchodilator (if yes specify type & daily dose) 
 
 Beta-agonist tablets 
 Steroid tablets 
 Beta-agonist inhalers 
 Anti-cholinergic inhalers 
 Steroid inhalers 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
 
YES 
 
NO 
 
Long-acting nitrates (not s/c or short acting GTN) 
 
 ISDN 
 ISMN 
 GTN patch 
 Other (name)_________________ 
 
 
 
 
 
 
 
 
 
 
 
 
Statin (if yes, specify type & daily dose) 
 
 Atorvastatin 
 Pravastatin 
 Rosuvastatin 
 Simvastatin 
 Other________________________ 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Other lipid-lowering drug   
Diabetic Meds (if yes, specify type & daily dose) 
 
 Insulin 
 Sulphonylurea (eg gliclazide) 
 Biguanide (eg metformin) 
 Glitazone 
 Other (specify)____________ 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
 349 
Antidepressants (if yes specify type & daily dose) 
 
 SSRI 
 TCA 
 MAOI 
 Other (specify)_____________ 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
NSAIDs   
Vitamins    
Incontinence meds 
 
  
Antihistamines   
 
List any prescribed medications in addition to above 
prior to admission (state total daily dose) 
 
• .…………………………………………………… 
 
 
• ......................................................................... 
 
 
• .…………………………………………………… 
 
 
• .…………………………………………………… 
 
 
• ......................................................................... 
 
 
• .…………………………………………………… 
 
 
• .…………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
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Section 5 : HF Medications in first 24 hours 
 
YES NO 
Furosemide  
 
 Intravenous once-off 
 Intravenous regular 
 Oral once-off 
 Oral regular 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
IV nitrate   
 
IV dobutamine   
 
IV dopamine   
 
IV other (name) 
                        ______________________________ 
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Section 6 : Examination During Admission 
 
 
VITAL SIGNS 
 
Height 
 
.  cm 
Weight 
 
. kg 
SpO2 
 % Air  O2  
 
Waist circumference 
 
.  cm 
Blood pressure 
 /  mmHg 
 
Heart rate 
 
 bpm 
Temperature 
 .  ºC 
 
Respiratory rate 
 
 bpm 
 
CARDIOVASCULAR EXAMINATION 
  
 
YES 
 
NO 
 
Elevated JVP (>4cm)  
 
 
 
Palpable Apex  
 
 
 
Displaced Apex 
 
 
 
 
 
Third Heart Sound 
 
 
 
 
 
Murmur 
 AS 
 AR 
 MR  
 MS 
 TR 
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YES 
 
NO 
Pulmonary crackles 
 
If yes 
 Basal 
 Middle 
 Apex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral oedema 
 
If yes 
 Ankle 
 Knee 
 Thigh 
 Sacrum 
 Abdomen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ascites 
 
 
 
 
 
Carotid Bruit 
 Specify:  Right / Left / Bilateral (circle) 
 
 
 
 
 
 
Killip Class               I              II                   III                   IV   
 
(I = No clinical signs heart failure, II = lung crackles / gallop rhythm / S3, 
III = frank pulmonary oedema, IV = cardiogenic shock) 
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Section 7 : Investigations during hospital admission 
(a) ECG 
  
 YES NO 
Performed  
 
 
 
Hard copy obtained for study  
 
 
 
If yes, 
 SR 
 AF/flutter 
 BBB     (  right / left  ) Specify 
 Paced 
 Pathological Q waves 
 LVH 
 QRS duration __________ms 
 QTc duration __________ ms 
 Other _________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) CXR 
  
 YES NO 
Performed  
 
 
 
If yes, 
 Cardiomegaly (CTR>0.5) 
 Upper lobe venous diversion 
 Interstitial oedema (kerley B lines) 
 Alveolar oedema (patchy consolidation) 
 Pleural effusions 
                     - Specify:  Right / Left / Bilateral (circle) 
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(c) ECHO 
  
 YES NO 
Previous echo 
If yes, year ________________________ 
 
 
 
 
Performed in last year 
If yes, complete following, 
 
 
 
 
Dilated left ventricle 
LVEDD __________________ (cm) 
 
 
 
 
Left ventricular systolic dysfunction 
 
        Mild 
        Moderate 
        Severe 
 
 
 
 
 
 
 
 
Valvular heart disease (if yes, circle severity) 
 
        AS   :    Mild / Moderate / Severe 
        AR   :    Mild / Moderate / Severe 
        MS   :    Mild / Moderate / Severe 
        MR   :   Mild / Moderate / Severe 
        TR    :   Mild / Moderate / Severe 
 
Other_________________ (specify) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other relevant echo findings   
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 Biochemistry 
 
BNP level  pg/ml 
TnI  µg/l 
 
Sodium  mmol/l 
Potassium  mmol/l 
Chloride  mmol/l 
Urea  mmol/l 
Creatinine  µmol/l 
eGFR  ml/min 
 
Bilirubin  mmol/l 
AST  mmol/l 
ALT  mmol/l 
GGT  mmol/l 
Alk Phos  mmol/l 
Albumin  mmol/l 
 
TSH  mU/l 
Free T3  nmol/l 
T4  mmol/l 
Glucose  mmol/l 
Glycosylated haemoglobin  % 
Urate  mmol/l 
CRP  mg/l 
Phosphate  mmol/l 
 (d) Admission Blood Results 
(1st available result during admission) 
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 Lipid Profile         Fasting              Non-fasting      
 
Chol (total)  mmol/L 
C/HDL  mmol/L 
LDL  mmol/L 
HDL  mmol/L 
Triglycerides  mmol/L 
 
 Haematology 
 
WCC  x109/l 
Haemoglobin  g/dl 
MCV  fl 
RDW  % 
Platelets  x109/l 
Lymphocytes  x109/l 
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Appendix IX: Study visit case record form 
 
Section 1 : STUDY VISIT 
 
 YES 
 
NO 
Attended 
 
 
 
 
If no 
 Failed/refused to attend 
 Deteriorating health 
 Deceased 
 
 
 
 
 
 
 
 
If deceased, date of death / /  
Date of study visit / /  
 
Section 2 : CHANGES IN MEDICAL CONDITION 
 
 YES 
 
NO 
Any changes in health since discharge from hospital 
Specify_____________________________________ 
 
Deterioration in HF symptoms post-discharge 
MI since enrolment 
Coronary angiography since enrolment 
New arrhythmia (specify_______________) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptoms YES NO 
Orthopnoea   
Paroxysmal nocturnal dyspnoea   
Ankle swelling   
Palpitations   
NYHA class _________________________   
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Section 3 : CURRENT MEDICATIONS 
Cardiovascular Medication YES NO 
Diuretics (if yes specify type & total daily dose) 
 
 Furosemide 
 Other loop 
 Spironolactone 
 Other K+ sparing 
 Thiazide 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
ACE-Inhibitor (if yes specify type & total daily dose) 
 
 Captopril 
 Enalapril 
 Fosinopril 
 Lisinopril 
 Perindopril 
 Quinapril 
 Ramipril 
 Trandolapril 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Beta-blocker (if yes specify type & total daily dose) 
 
 Atenolol 
 Bisoprolol 
 Carvedilol 
 Metoprolol 
 Nebivolol 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
 
Aldosterone Blocker (if yes specify type & daily dose) 
 
 Spironolactone 
 Eplerenone 
 
 
 
 
 
 
_______mg 
_______mg 
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 YES NO 
ARB (if yes specify type & daily dose) 
 
 Candesartan 
 Irebesartan 
 Losartan 
 Olmesartan 
 Telmisartan 
 Valsartan 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Digoxin (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Aspirin (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Clopidogrel (if yes, specify daily dose) 
 
 
 
 
 
_______mg 
Warfarin 
 
 
 
 
Nicorandil (if yes, specify total daily dose)  
 
 
 
______mg 
 
   
Calcium channel-blocker (if yes specify type & total 
daily dose) 
 
 Amlodipine 
 Diltiazem 
 Felodipine 
 Nifedipine 
 Verapamil 
 Other (name)__________________ 
 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Anti-arrhythmic (if yes specify type & total daily dose) 
 
 Amiodarone 
 Other (name)__________________ 
 
 
 
 
 
 
_______mg 
_______mg 
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Non-Cardiovascular Medication YES NO 
Bronchodilator (if yes specify type & daily dose) 
 
 Beta-agonist 
 Anti-cholinergic 
 Inhalers 
 
 
 
 
 
 
 
_______mg 
_______mg 
Antidepressants (if yes specify type & daily dose) 
 
 SSRI 
 TCA 
 MAOI 
 Other (specify)_____________ 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
NSAIDs   
Long-acting nitrates (not s/c or short acting GTN) 
  
 ISDN 
 ISMN 
 GTN patch 
 Other (name)_________________ 
 
 
 
 
 
 
 
 
 
 
 
 
Statin (if yes, specify type & daily dose) 
 
 Atorvastatin 
 Pravastatin 
 Rosuvastatin 
 Simvastatin 
 Other________________________ 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
Other lipid-lowering drug   
Diabetic Meds (if yes, specify type & daily dose) 
 
 Insulin 
 Sulphonylurea (eg gliclazide) 
 Biguanide (eg metformin) 
 Glitazone 
 Other (specify)____________ 
 
 
 
 
 
 
 
 
 
_______mg 
_______mg 
_______mg 
_______mg 
_______mg 
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Vitamins    
Incontinence meds   
 
Antihistamines   
 
List any prescribed medications in addition to above 
(state total daily dose) 
 
• .…………………………………………………… 
 
 
• ......................................................................... 
 
 
• .…………………………………………………… 
 
 
• .…………………………………………………… 
 
 
• ......................................................................... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
 
_______mg 
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Section 4 : PHYSICAL EXAMINATION – STUDY VISIT 
 
 
VITAL SIGNS 
 
Height 
 
.  cm 
Weight 
 
. kg 
SpO2 
 % Air  O2  
 
Waist circumference 
 
.  cm 
Blood pressure 
 /  mmHg 
 
Heart rate 
 
 bpm 
Temperature 
 .  ºC 
 
Respiratory rate 
 
 bpm 
 
CARDIOVASCULAR EXAMINATION 
  
 Yes No 
Elevated JVP (>4cm)  
 
 
 
Palpable Apex  
 
 
 
Displaced Apex 
 
 
 
 
 
Third Heart Sound 
 
 
 
 
 
Murmur 
 AS 
 AR 
 MR  
 MS 
 TR 
 
 
 
 
 
 
 
 
 
 363 
 
 
 
 YES NO 
 
Pulmonary crackles 
 
If yes 
 Basal 
 Middle 
 Apex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral oedema 
 
If yes 
 Ankle 
 Knee 
 Thigh 
 Sacrum 
 Abdomen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ascites 
 
 
 
 
 
Carotid Bruit 
 Specify:  Right / Left / Bilateral (circle) 
 
 
 
 
 
 
Section 5 : Investigations at study visit 
 
(a) ECG  
  
 Yes No 
Performed  
 
 
 
Hard copy obtained for study  
 
 
 
If yes, 
 SR 
 AF/flutter 
 BBB 
 Paced 
 Pathological Q waves 
 LVH 
 QRS duration __________ms 
 QTc duration __________ ms 
 Other _________________ 
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 Biochemistry 
 
BNP level  pg/ml 
TnI  µg/l 
 
Sodium  mmol/l 
Potassium  mmol/l 
Chloride  mmol/l 
Urea  mmol/l 
Creatinine  µmol/l 
Egfr  ml/min 
 
Bilirubin  mmol/l 
AST  mmol/l 
ALT  mmol/l 
GGT  mmol/l 
Alk Phos  mmol/l 
Albumin  mmol/l 
 
TSH  mU/l 
Free T3  nmol/l 
T4  mmol/l 
Glycosylated haemoglobin  % 
Urate  mmol/l 
Phosphate  mmol/l 
 
(b) BLOOD RESULTS  
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 Lipid Profile         Fasting              Non-fasting      
 
Chol (total)  mmol/L 
LDL  mmol/L 
HDL  mmol/L 
Triglycerides  mmol/L 
 
 Haematology 
 
WCC  x109/l 
Haemoglobin  g/dl 
MCV  fl 
RDW   
Platelets  x109/l 
Lymphocytes  x109/l 
 
(c) ECHO – LVEF (Simpson’s) 
  
 YES 
 
NO 
 
Preserved ( > 50% )  
 
 
 
Reduced (≤ 50% )  
 
 
 
Value  % 
 
LVEF incalculable 
If yes, 
 Estimated preserved 
 
 Estimated reduced 
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Section 6 : MTWA TEST  
 
(a) ELIGIBILITY 
 
 
YES 
 
NO 
 
Eligible for MTWA treadmill testing  
(if yes, proceed to test result) 
 
 
 
 
 
 
If no, please specify:  
 AF 
 Ventricular pacing 
 Severe AS 
 Unable to exercise 
 
 
 
 
 
 
 
 
 
 
 
If unable to exercise please give 
reason: ……………………………………………………. 
 
 
If unable to exercise was MTWA assessed at rest 
If yes,  
 Was MTWA present at rest 
 Resting heart rate   bpm 
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(b) MTWA TEST - RESULT 
  
Positive  
 
 
 
Indeterminate  
 
 
 
Negative  
 
 
 
 
If positive  
 Sustained alternans at rest 
 
 Sustained alternans onset HR <110bpm 
 
 
 
 (Class I) 
 
(Class 2) OHR= 
             
bpm 
 
 
If negative  
 No sustained alternans and max negative 
HR >105bpm 
 
 Sustained alternans OHR >110bpm and 
max NHR>105bpm 
 
 
 
 (Class 5) NHR=
              
bpm 
 
 (Class 3) OHR=
              
bpm 
 
 
If indeterminate  
 Sustained alternans OHR >110bpm and 
max NHR <105bpm  
 
 
 Bad beats, noise or nonsustained 
alternans 
 
 Insufficient HR 
 
 Other/comments…………………………… 
      
     ……………………………………………….. 
 
 
 
 (Class 4) OHR=
              
bpm 
                    NHR= 
              
bpm 
 (Class 6) 
 
 
 (Class 4) 
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If indeterminate, repeat MTWA test Yes  
 
No  
 
If positive  
 Sustained alternans at rest 
 
 Sustained alternans onset HR <110bpm 
 
 
 (Class I) 
 
(Class 2) OHR=
             
bpm 
 
If negative  
 No sustained alternans and max negative 
HR >105bpm 
 
 Sustained alternans OHR >110bpm and 
max NHR>105bpm 
 
 
 (Class 5) NHR=
              
bpm 
 
 (Class 3) OHR=
              
bpm 
 
If indeterminate  
 Sustained alternans OHR >110bpm and 
max NHR <105bpm  
 
 
 Bad beats, noise or nonsustained 
alternans 
 
 Insufficient HR 
 
 Other/comments…………………………… 
      
     ……………………………………………….. 
 
 (Class 4) OHR=
              
bpm 
                    NHR=
              
bpm 
 (Class 6) 
 
 
 (Class 4) 
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Section 7 : AETIOLOGY OF HEART FAILURE 
 
 YES NO 
Known HF prior to enrolment in this study  
 
 
 
If yes, which healthcare professionals are involved 
 GP 
 General physician 
 Cardiologist 
 HF specialist 
 HF liaison nurse 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Aetiology   
 
Ischaemic 
If yes, must have  
 
 Definite previous MI     
                  or 
 Angio. CHD (>50% stenosis in ≥ 1 
vessel) 
 
Yes 
 
 
 
 
 
 
 
No  
 
 
 
 
 
 
 
Unknown 
 
 
Idiopathic DCM 
 
 
 
 
 
Hypertension (if all other causes excluded)  
 
 
 
Alcohol (if all other causes excluded)  
 
 
 
 
Contributing Aetiologies   
Valvular 
If yes, 
 AS 
 AR 
 MS 
 MR 
 
 
 
 
 
 
 
 
Diabetes Mellitus   
Atrial Fibrillation   
Hypertension    
Alcohol    
Other (specify)  
………………………………………………………………………………………………… 
 
Unknown 
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